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Primary care electronic health records (EHR) capture real life patterns of healthcare utilisation 
over time. This provides the opportunity to estimate the effect of allopurinol on long term 
outcomes in people with gout. However, use of such data gives rise to confounding by 
indication which may change over time, a major impediment in treatment effect estimation. 
Methods 
A cohort of patients consulting for gout between 1997-2002 and not previously prescribed 
urate-lowering drugs were identified from the Clinical Practice Research Datalink GOLD and 
were followed up until the end of 2014. Effect of allopurinol vs. non-use was evaluated on 
reaching target serum urate (SU) level ≤360μmol/L, mortality, healthcare utilisation, vascular 
and renal diseases.  
Three statistical approaches with differing complexities and assumptions imposed were 
considered: (1) baseline measurement of allopurinol and covariates with confounding 
controlled for using propensity score (PS) subclassification; (2) extending the methods in (1) 
to repeated measures where allopurinol and covariates were measured yearly; (3) using 
marginal structural models (MSM) within the repeated measures set-up. Survival models 
estimated hazard ratios with 95% confidence intervals. Robustness of estimated treatment 
effects to unmeasured confounding was evaluated.   
Results 
16,876 patients were eligible for analysis (mean age (standard deviation) 62 (14.1) years, 77% 
male). Baseline analysis found allopurinol was associated with higher chance of reaching 
target SU level (2.32 (1.97, 2.74)) and fewer gout consultations (0.70 (0.65, 0.75)), and with 
ii 
 
increased risk of mortality (1.10 (1.03, 1.17)), gout hospitalisation (1.82 (1.64, 2.02)), coronary 
heart disease (1.11 (1.02, 1.21)), and renal disease (1.19 (1.10, 1.28)).  
In the repeated measures setting, issues with poor performance of PS estimation were 
identified in both time-varying PS subclassification and MSM. These were resolved by allowing 
associations between covariates and initiation and continuation of allopurinol to differ in 
MSM; larger treatment effect estimates were obtained for most outcomes compared with 
baseline analysis and statistical significance was lost for mortality. The treatment effect 
estimates for target SU level and gout hospitalisation were likely to be robust to unmeasured 
confounding however, unmeasured confounding may explain away the treatment effects for 
coronary heart disease and renal disease. 
Conclusion 
Fitting complex models to EHR is challenging and consideration needs to be given to both 
clinical and statistical assumptions made during data preparation and analysis. Associations of 
allopurinol with adverse outcomes persisted, regardless of statistical approach used. This may 
be due to remaining residual confounding and/or because allopurinol dosage and adherence 
is suboptimal in primary care. Nevertheless, the treatment effect estimates obtain are 
relevant to UK primary care and provide evidence that managing gout in the long term needs 
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1 Introduction and aims 
1.1 Estimation of treatment effect: RCTs versus observational 
studies 
Randomised controlled trials (RCTs) are considered to be the gold standard to infer causal 
effectiveness of treatment on outcome. Randomisation ensures observed and unobserved 
patient characteristics are balanced across treatment groups thus, any differences observed 
in outcome may be attributed to treatment. RCTs however often face a range of limitations 
and restrictions. They cannot address clinical questions where randomisation is unfeasible or 
interventions are potentially harmful; they typically specify strict inclusion and exclusion 
criteria, meaning that clinically important subgroups (such as those with comorbidity or the 
oldest age) may be ignored; they may be inappropriate for assessment of rare events or long-
term outcomes, for example death; furthermore they may be subject to financial constraints 
and other practical and ethical issues (Sanson-Fisher et al., 2007, Black, 1996). Therefore, RCTs 
cannot support all treatment decisions and consequently many decisions are based on sub-
optimal evidence or clinical based practice, knowledge and consensus (Frieden, 2017). 
Another drawback of RCTs is their reliance on the intention-to-treat principle which assumes 
that once patients are randomly assigned to treatment, they actually received that treatment 
as intended and patient characteristics remained balanced across the treatment groups 
(Hernán and Hernández-Díaz, 2012). However, in practice, observing treatment on a single 
occasion (or time-invariant treatment) does not match real life clinical management where 
treatment varies over time. For example, the treatment given at presentation of a symptom 
or morbidity may be varied later as the condition progresses or improves, or side effects arise 
which may lead to non-compliance with the treatment. 
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Observational data collected on large populations over a long period of time have the 
potential to overcome such shortfalls of RCTs and provide estimates of benefits and harms of 
treatment in real life clinical settings. The increasing availability of data gathered and coded 
electronically in the course of routine health care contacts, provides the opportunity to follow 
a patient’s course of illness from first presentation to long-term outcome and to assess the 
effect of treatment on outcome. For example, the Clinical Practice Research Datalink (CPRD), 
a database of primary care electronic health records (EHR), provides clinical records for up to 
30 years for approximately 8.5 million patients; it has been used to estimate treatment 
outcomes for a range of health conditions such as assessing the effect of metformin use on 
risk of developing cancer (Farmer et al., 2019) and kidney morbidity on adverse cardiovascular 
events (Currie et al., 2019). Therefore, EHR potentially allow us to study the outcomes of real-
life patterns of healthcare use and prescribing that varies over time; they further allow us to 
study both rare and long-term outcomes, thus increasing generalisability particularly as 
diverse patient populations and wider spectrum of disease severity that may otherwise be 
excluded are available. Furthermore, using EHR in research is a relatively cheap way to study 
treatment effect without investing considerable time collecting data (Patorno et al., 2013). 
 
1.2 Confounding by indication 
Confounding, defined as a spurious association between treatment and outcome due to a 
third variable that is associated with both, is prevented through randomisation in RCTs 
however, it is a major area of concern for researchers using observational data to estimate 
outcomes of healthcare. Treatment decisions may be influenced by many pre-treatment 
characteristics (covariates), such as severity of the disease or comorbidity, which may also be 
associated with subsequent outcomes, in which case such covariates are termed confounders. 
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RCTs remove this “confounding by indication” by ensuring treatment allocation cannot be 
influenced by such prognostic covariates beyond chance hence enabling outcomes to be 
directly comparable between treatment groups, with any differences attributable to effects 
of treatment. In observational studies, in contrast, any systematic differences in covariates 
between treatment groups mean that differences in outcome could be the result of either 
treatment effect or differences in covariates, or both. 
Conducting observational studies to the same level of academic rigor as RCTs by minimising 
confounding effects can lead to comparable treatments effects with RCTs. Anglemyer et al. 
(2014) conducted a Cochrane review of 14 systematic reviews and methodological reviews of 
reviews published between 1990 and 2013; each review compared the effect of treatment 
between RCTs and observational studies (cohort and case-control studies). On average, no 
significant differences in treatment effect were found, even when separately comparing 
cohort and case-control studies with RCTs, and when stratifying by non-pharmacological and 
pharmacological interventions. Discrepancies in treatment effect were found between RCTs 
and observational studies included in three reviews, two of which may be due to insufficient 
control of confounding. Similar findings was observed in an earlier review that found little 
evidence that treatment effect estimates differed between observational and RCTs (Benson 
and Hartz, 2000). 
Multivariable regression modelling, which involves fitting a statistical model to estimate the 
association between a dependent variable (outcome) and one or more independent variables 
(treatment and covariates), is a popular approach used to account for observed confounders, 
but this approach has various drawbacks. For example, different regression models are subject 
to specific model assumptions which often go untested in practice. Furthermore, the 
estimated treatment effect would be biased if there is major imbalance in covariates between 
treatment groups and/or treatment effect varies across values of covariates (D'Agostino and 
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Kwan, 1995). Often, no attempt is made to ensure treatment groups are comparable by 
assessing whether the distribution of covariates is similar (adequate overlap) between 
treatment groups. Regression models will extrapolate data to cover areas where there is no 
overlap in incomparable groups. Matching may somewhat alleviate this problem by pairing 
treated patients with untreated patients on one or more covariates. This ensures adequate 
overlap between treatment groups as unmatched patients are excluded from analysis. 
However, matching may be limited as the number of covariates it is possible to match for is 
restricted by sample size.  
As was stated earlier, in real life treatment is likely to vary over time. Furthermore, the 
covariates that influence choice of treatment and outcome may also change over time, giving 
rise to time-varying confounding as time-varying covariates are associated with both outcome 
and time-varying treatment. Estimating the overall treatment effect whilst accounting for 
time-varying covariates is complex. The key issue is that time-varying covariates also behave 
as mediators as they are affected by past treatment and are therefore on the causal pathway 
between treatment and outcome. This is illustrated in Figure 1.1 with treatment 𝐴 and a single 
covariate 𝑋 measured at three time points, assuming no unmeasured (or unobserved) 
covariates. The red arrows indicate when covariates act as mediators. At time point 1, 
covariates are adjusted for in regression modelling ensuring treatment groups are 
comparable. However, at time point 2, covariates and treatment are updated modifying the 
risk of outcome across treatment groups, meaning that treatment groups are now 
incomparable thus introducing residual confounding. A dilemma arises whether covariates at 
time point 2 need to be adjusted for, as this adjustment would remove the effect of treatment 
at time point 1 on outcome. The same issue applies at time point 3 when adjusting for these 
covariates would remove the effect of treatment at time point 2. Use of standard regression 
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models, for example the time-varying Cox model, in such instances may yield biased treatment 
effects thus their use is not recommended (Hernan et al., 2000, Robins et al., 2000). 
Figure 1.1: Time-varying covariates affected by past treatment use 
 
 
1.3 Estimation of treatment effect: Propensity score 
An approach that avoids issues encountered in multivariable regression, and has gained 
widely in popularity over the last two decades, is propensity score (PS) methodology, originally 
formulated by Rosenbaum and Rubin (1983). The approach has been recommended for use 
in observational studies using EHR estimating effectiveness of treatment (Stuart et al., 2013a, 
Brookhart et al., 2010b). The attractiveness of this approach lies in the PS acting as a balancing 
score so that treatment groups homogeneous in PS have similar distribution of covariates, 
thus removing some of the bias due to confounding by indication before considering outcome 
and estimating treatment effect. Information from several covariates is collapsed into a single 
𝐴𝑡: Treatment; 𝑋𝑡: Observed covariates; 𝑌: Outcome; where time t=1, 2, 3 
 Associations between 𝐴𝑡, 𝑋𝑡, and 𝑌 



















score (the PS) which reflects the probability of a patient receiving treatment given these 
covariates. Once PS has been adjusted for in the analysis of treatment effect via matching, 
subclassification or weighting, any differences in outcome can be attributed to treatment 
assuming there is no unmeasured confounding.  
The PS approach has widely been investigated and applied, however predominantly in 
scenarios where treatment is observed only once. In this instance, two systematic reviews 
have found that there was no difference in findings relating to effect of type of surgery on a 
range of outcomes between RCTs and PS-based analyses using observational data (Kuss et al., 
2011, Lonjon et al., 2014).  
In repeated measures design, a common approach to estimating effect of time-varying 
treatment is via one of Robins’ G-methods  (Robins, 1986, Robins et al., 2000, Robins et al., 
1992), for example G-computation formula, however this approach assumes specification of 
the entire covariate history. Alternatively, one may use inverse probability of treatment (i.e., 
inverse PS) weighting (IPTW) of marginal structural models (MSM) (Robins 2000). Similar to 
PS, the probability of receiving treatment is estimated over time given treatment and 
covariate histories which are then converted to time-varying inverse probability of treatment 
weights. The weights reflect by how much observations are under-represented or over-
represented in the study sample compared to the pseudo-population where there are no 
confounding effects. The treatment effect is then estimated in the pseudo- (or weighted) 
population. MSM are being increasingly used in EHR in various clinical areas such as diabetes 
(Gamble et al., 2017, Farmer et al., 2019), chronic kidney disease (Anderson et al., 2015) and 
gout (Desai et al., 2018). 
In terms of more direct extension of the PS methodology as originally specified, Leon (2011b) 
estimated PS over time accounting for changing treatment status and covariates. 
Observations are then stratified into subclasses based on the PS, with treatment groups 
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comparable within each subclass. Treatment effects are estimated within each subclass and 
are then pooled. The authors mostly applied this method to the evaluation of ordinal doses of 
antidepressants in mental illness using a small number of time points (Leon et al., 2001, Leon 
et al., 2003); there are very few applications in other settings.  
However, most of these approaches have been restricted in complexity to the case where all 
patients are observed at common discrete time points. This of course may be unrealistic in 
many clinical set-ups and is suboptimal for exploring treatment behaviour of individuals as 
represented by continually collected data such as that in CPRD where covariate and treatment 
observation time points differ between patients. Therefore, on one hand, EHR provide real 
life patterns of covariate, treatment and outcome data, but on the other hand lead to 
potentially complex analyses.  
Performance and comparison of the different PS methods could be assessed under various 
scenarios via a simulation study. Some examples of existing simulation studies in this field 
include identifying the optimal PS matching approach (Austin, 2009b, Austin, 2011b, Austin, 
2014), assessment of performance of time-varying PS subclassification in the estimation of 
treatment effect on different types of outcome data (Leon and Hedeker, 2005, Leon and 
Hedeker, 2007a, Leon, 2011b), and assessment of performance of different types of weights 
in reducing variability in the estimated treatment effect in MSM (Xiao et al., 2010). Ideally, the 
data generated in a simulation study should reflect the type of data observed in real life to 
assess how statistical models may perform in practice. Most existing relevant simulation 
studies have explored model performance under simple study designs with typically a small 
number of repeated measures or considered treatment at one time point. It is currently 
unclear what sort of data management and computational challenges may be encountered 
when applying PS based methods in large and complex observational studies, such as those 
based on EHR data. In order to design an informative simulation study, it would be necessary 
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to know what these challenges may be. This could be investigated by first applying different 
PS based approaches in analysis of real data, to give an indication of the model 
implementation challenges, types of observed treatment patterns, strength of plausible 
associations between covariates and treatment/outcome etc, all of which could subsequently 
inform a thorough simulation study. A simulation study was therefore considered to be 
outside the scope of this PhD project.  
This PhD project will use gout as an exemplar to explore these issues.  
 
1.4 Effectiveness of allopurinol in gout 
Gout is the most common type of inflammatory arthritis. In the UK population, prevalence 
and incidence is reported to be 2.49% and 1.77 cases per 1,000 person-years respectively in 
2012. Both prevalence and incidence increase with age and is higher in males than in females 
(Kuo et al., 2015b). 
The key risk factor for gout is persistent hyperuricaemia causing monosodium urate (MSU) 
crystals to form and deposit in and around the joints; this leads to various clinical 
manifestations. The most common manifestation is the self-limiting painful flares of joint 
inflammation and swelling, typically seen in the first metatarsophalangeal joint, that lasts up 
to two weeks. If hyperuricaemia is not treated, subsequent flares often become more 
frequent, last longer, and may affect different joints. Over a long period of time, chronic gouty 
arthritis develops where joint inflammation becomes persistent due to recurrent flares; 
subcutaneous tophaceous deposits, crystals compressed with debris from the inflammatory 
response, harden and cause further joint damage. Consequently, all this leads to irreversible 
joint damage, pain, and disability (Roddy et al., 2013, Chandratre et al., 2018, NICE, 2018a). 
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Gout is often treated in primary care. The British Society for Rheumatology (BSR) (Jordan et 
al., 2007b, Hui et al., 2017) and the European League Against Rheumatism (EULAR) (Zhang et 
al., 2006a, Richette et al., 2017) have published guidelines for the management of gout. Long-
term management involves urate-lowering therapy (ULT) with a treat-to-target strategy to 
lower serum urate (SU) levels to below the threshold of urate saturation to prevent the 
formation of new crystals and allow deposited crystals to dissolve and tophi to shrink; the aim 
of ULT is to prevent flares and ‘cure’ the patient of gout. The BSR guidelines recommend an 
initial target SU level ≤300µmol/L that can be relaxed to ≤360µmol/L once the patient no 
longer has tophi and flares; the same target levels are recommended by the EULAR guidelines 
but those with severe gout are recommended to have a lower target of ≤300µmol/L. ULT 
involves addressing modifiable risk factors for hyperuricaemia, for example diet and 
medication use, and taking urate-lowering drugs. Allopurinol, a xanthine oxidase inhibitor, 
works by decreasing SU production and is the first line drug treatment. The BSR guidelines 
state patients with comorbidities associated with gout (renal impairment and hypertension) 
and those with more severe gout (recurrent flares, tophi, chronic gouty arthritis, and joint 
damage) should be offered allopurinol. Allopurinol treatment is recommended to be life-long. 
Allopurinol was developed for the treatment of gout over 50 years ago however, only a few 
RCTs have investigated its effectiveness. Seth et al. (2014) conducted a Cochrane review in 
2014 evaluating the effect and safety of allopurinol in chronic gout. Eleven RCTs were 
identified with eight studies comparing allopurinol with other urate-lowering or uricosuric 
drugs. The review highlighted a lack of high quality RCTs due to small samples and attrition 
bias. Studies were limited up to 52 weeks follow-up and employed strict inclusion and 
exclusion criteria, for example only including patients with severe hyperuricaemia or excluding 
patients with renal impairment, which may limit their generalisability to the majority of 
patients with gout (Becker et al., 2005, Schumacher et al., 2008, Becker et al., 2010). More 
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recently, larger RCTs with more than 6,000 participants have been undertaken, however, strict 
inclusion and exclusion criteria were still used (White et al., 2018, MacDonald et al., 2014), 
and length of follow-up remained limited to around three years. One RCT generalisable to the 
UK gout population compared the efficacy of nurse-led care with usual general practitioner 
(GP)-led care on reaching primary outcome, target SU level ≤360µmol/L, with ULT; within 
nurse-led care, all participants were treated with allopurinol at baseline and had reductions in 
number and size of tophi, number of flares, reduction in SU level with increased number of 
patients reaching target SU level (≤300µmol/L and ≤360µmol/L), and improved physical health 
over two years (Doherty et al., 2018).   
Despite the availability of guidelines, management of gout is often suboptimal and that 
uptake, adherence, and persistence to ULT are often poor. Various studies have shown only 
30-40% of patients with gout were ever prescribed ULT, of which the majority were prescribed 
allopurinol dose ≤300mg/day (Cottrell et al., 2013, Roddy et al., 2007b, Clarson et al., 2017). 
The majority of patients with indications for ULT were not prescribed ULT; at diagnosis 44% of 
patients had indications for ULT of whom <1% were prescribed ULT (Kuo et al., 2014). Once 
patients had started allopurinol, 39% stopped treatment after a year; 64% of these restarted 
treatment within five years. Median patient time of allopurinol adherence (time covered with 
a prescription) was 67% (Scheepers et al., 2018). Consequently, only up to 40% of patients 
reach target SU level (Cottrell et al., 2013) hence approximately <1 in 10 patients are `cured’. 
Gout is managed ineffectively for a number of reasons including lack of GP training, focus on 
treating flares only, underestimation of the long-term effects of gout, lack of patient and 
practitioner understanding of gout pathogenesis, and the benefits and role of ULT (Doherty et 
al., 2012). 
Estimating the effect of allopurinol using EHR is challenging. Confounding by indication is likely 
to be present as guidelines suggest patients with poorer health should be prescribed 
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allopurinol however, in practice this is often not realised. Allopurinol treatment is time-varying 
with patients often stopping and restarting treatment over time, with each treatment choice 
being influenced by time-varying and time-invariant covariates measured up to that time 
point. 
Around the time when this PhD project was conceptualised in 2013, there were a few existing 
EHR based studies evaluating the effect of allopurinol in gout using PS methodology; 
compared with those not using allopurinol, allopurinol users were found to have an increased 
risk of severe cutaneous adverse reactions although the study was not limited to patients with 
gout (Kim et al., 2013a); Wei et al. (2011) reported no difference in risk of cardiovascular 
events between allopurinol users and non-users of ULT however, this study too was not 
restricted to gout. There was a general lack of consideration of a wider range of outcomes, in 
particular renal and cardiovascular diseases. 
Since then, EHR observational studies evaluating the effect of allopurinol on different 
outcomes have been on the increase, for example mortality (Dubreuil et al., 2015, Kuo et al., 
2015a), chronic kidney disease (Roughley et al., 2018, Vargas-Santos et al., 2018), and vascular 
diseases (Sultan et al., 2019); three of these studies used PS matching (Dubreuil et al., 2015, 
Kuo et al., 2015a, Vargas-Santos et al., 2018). However, these studies evaluated the effect of 
initiating allopurinol treatment thus ignoring time-varying confounding.  
One issue frequently encountered in EHR studies using time-to-outcome data is immortal time 
bias, defined as, a period of follow-up time during which outcome cannot occur. This can arise 
during the period from study entry to prescription of treatment. The landmark method 
overcomes this issue by designating a period of time from study entry (the landmark period) 
to determine treatment status; follow-up commences after the landmark period in patients 
who did not have outcome up until then. This method has frequently been used in EHR studies 
in the evaluation of effectiveness of allopurinol (Sultan et al., 2018, Kuo et al., 2015a, Roughley 
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et al., 2018). However, the disadvantage of the landmark method is that it can potentially 
misclassify treated patients as untreated if the landmark period is too short, or exclude too 
many patients who had outcome occurring early on if the landmark period is too long (Dafni, 
2011). Alternatively, to reduce misclassification bias from patients starting allopurinol many 
years from the start of follow-up, follow-up may instead be assumed to start when allopurinol 
was first prescribed (Sultan et al., 2019, Vargas-Santos et al., 2018, Dubreuil et al., 2015). 
However, these studies assumed patients did not change treatment status during follow-up.  
Some studies may alternatively perform per-protocol analysis where analysis only includes 
patients who adhered to treatment. For example, Vargas-Santos et al. (2018) censored patient 
follow-up time when allopurinol treatment had stopped or changed. However, this may 
introduce selection bias if the reasons for stopping or changing allopurinol treatment, for 
example may have potentially experienced an adverse reaction to allopurinol or no longer had 
gout flares, is associated with outcome (Hernán and Hernández-Díaz, 2012).  
None of these studies evaluated the effect of allopurinol on outcome when patients initiate, 
stop and restart treatment in the presence of time-varying confounding. Therefore, an 
observational study based on EHR is both needed and timely to investigate the realistic effect 
of allopurinol use versus non-allopurinol use over a long period of time on a range of 
outcomes. CPRD is one of the largest UK databases of primary care EHR and is thus an ideal 
data-source given that gout is generally diagnosed and managed in primary care.   
As explained above, bias due to confounding by indication is a major impediment to valid 
assessment of treatment effect based on observational data. Use of PS and MSM 
methodologies will allow causal inferences to be made provided careful consideration is given 
to the study design, data manipulation and choice of covariates to adjust for. Naturally, not all 
important covariates will be measured or even observable, such as adherence of allopurinol 
uptake and genetic factors, thus some residual confounding will remain. Often, no attempts 
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are made to understand the extent to which residual confounding can impact treatment effect 
estimation.  
To our knowledge, these methodologies have rarely been used to estimate effect of time-
varying allopurinol use and never in EHR setting in the UK.  
 
1.5 Thesis aims and overview 
This PhD aims to approach estimation of allopurinol effect using observational EHR data in a 
comprehensive and thorough manner. From a clinical aspect, this will be achieved by 
considering a wide range of outcomes in patients with gout, relaxing exclusion criteria, and 
stratifying analyses on severity of SU levels and renal disease.  
From a statistical aspect, allowance will be made for time-varying allopurinol use and time-
varying covariates thus giving rise to repeated measures data structure within which both PS 
and inverse probability treatment weights and subsequently treatment effect will be 
estimated. Robustness of allopurinol treatment effect estimates to missing data and omission 
of important covariates will be tested. Comparisons of methodology and results will be made 
between PS and MSM.  
The clinical objectives are:  
1) To examine the effect of allopurinol versus not taking allopurinol on reaching target 
SU level ≤360µmol/L, the primary outcome. Secondary outcomes are all-cause 
mortality; gout hospital admission; joint replacement; and gout comorbidities 
(cerebrovascular, coronary heart, peripheral vascular diseases and renal disease). 
2) Repeat objective 1 stratified on baseline levels of SU level (above and below 
480μmol/L) and on presence of renal disease to assess whether effect of allopurinol 
varies by severity of SU level or renal disease. 
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The statistical objectives which will be addressed within objectives 1 and 2 above are to 
compare and contrast: 
3) The effect of including time-varying covariates in addition to baseline covariates in PS 
subclassification on treatment effect. 
4) Compare and contrast estimation of treatment effect from time-varying PS 
subclassification from objective 3 to MSM. 
5) To examine the sensitivity of treatment effect estimates obtained in objective 1 to 
missing data and omission of covariates (with varying degree of strength of association 
with outcome and/or treatment) from modelling of treatment assignment to address 
the impact of unobserved covariates. 
A brief description of each chapter is given below. 
Chapter 2: Gout 
A description of the clinical characteristics, risk factors, prognosis, and diagnosis of gout is 
given. Short- and long-term management of gout is discussed and the extent to which patients 
are prescribed allopurinol and remain on treatment.  
Chapter 3: A narrative review of observational studies evaluating the effect of allopurinol in 
gout 
A systematic search to identify all published observational studies evaluating the effect of 
allopurinol in gout. A narrative review of the eligible studies summarised the study design, 
adjustment for confounding, sources of data, definition of allopurinol exposure, and outcomes 
used. The findings from the review will identify the extent of use of EHR in evaluation of 
allopurinol effect as well as highlight methodological limitations of existing studies and where 
possible methodological improvements can be made.  
Chapter 4: Data source and study sample 
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How the population-based cohort study is set up, how the study sample is defined, and the 
definitions for allopurinol use, covariates, and outcomes from electronic primary care medical 
records in CPRD are provided. 
Chapter 5: Propensity scores and marginal structural models 
The concept of the casual inference framework and advantages and disadvantages of common 
methods used to control for confounding are discussed. Reasons why PS and MSM 
methodologies are chosen to control for confounding is justified. Further details on how to fit 
such models are described.      
Chapter 6: Statistical analysis plan 
The four methods applied to CPRD data in estimating treatment effect of allopurinol are 
described. The first two methods focussed on PS subclassification performed at a single point 
in time and then repeatedly over time; description of covariate selection for PS estimation, 
how the number of subclasses are determined, and assessment for balance and treatment 
effect estimation are provided. The third and fourth methods focussed on MSM and the 
assumption regarding associations between treatment and covariates are stated; initially it is 
assumed that the reasons for prescription of treatment are the same amongst patients 
initiating and continuing with treatment, and subsequently these reasons are then allowed to 
differ.  
Chapters 7: Effect of allopurinol: time-invariant PS subclassification 
Treatment effect estimates are presented after using PS subclassification at a single time point 
to control for confounding. This chapter addresses all the clinical objectives.  
Chapter 8: Effect of allopurinol: time-varying PS subclassification 




Chapter 9: Modelling simple mechanisms of allopurinol via MSM 
Reasons for treatment are assumed not to differ between patients initiating and continuing 
treatment. This assumption led to unreliable treatment effect estimates. Results from various 
methods employed to improve weight estimation are presented. Outcome considered is all-
cause mortality.   
Chapter 10: Modelling complex mechanisms of allopurinol via MSM 
Treatment effect estimates are presented after using MSM allowing reasons for prescription 
of treatment to differ amongst patients initiating and continuing with treatment.  
Chapter 11: Discussion 
The final chapter describes the overall conclusions, strengths and limitations of the 





The aim of this chapter is to provide background information about gout that is of relevance 
to this thesis. An overview of clinical manifestations, risk factors, and poor outcomes is 
provided. Diagnosis of gout, management, and implementation of management for gout is 
described.  
 
2.1 Hyperuricaemia, crystal formation and clinical presentation 
The development and progression of gout is viewed as three overarching disease states 
(Bursill et al., 2019). These include the pre-clinical state, gout flare and advanced gout 
manifestations, which are now briefly described. 
Pre-clinical state 
Asymptomatic hyperuricaemia with monosodium urate (MSU) crystal deposition precedes 
gout (Choi et al., 2005). Uric acid is the end product of the degradation of purines, nucleotide 
bases which are a key component of DNA. Uric acid largely exists in its ionised form, urate, at 
physiological pH and temperature. Urate level is dependent upon endogenous purine 
metabolism, dietary intake of purine rich food, and rate of excretion via the kidneys and gut. 
In 90% of cases hyperuricaemia results from renal under-excretion of urate, and in the 10% of 
cases a combination of urate underexcretion and overproduction (Choi et al., 2005). MSU 
crystal formation occurs when the urate level persistently exceeds 380μmol/L; the synovial 
fluid becomes supersaturated with urate causing MSU crystals to form and deposit in the 






The most common clinical manifestation of gout is occurrence of episodic flares. Gout flares 
occur from shedding of crystals from the deposits into the joint space eliciting an inflammatory 
response at the joint site. The gout flare has distinct characteristics of reaching peak 
inflammation within 24 hours of onset accompanied by swelling, tenderness, and excruciating 
pain in the affected joint that resolves itself within one to two weeks (Roddy et al., 2013). Gout 
is frequently monoarticular and typically affects the lower limb with the majority of flares 
occurring in the first metatarsophalangeal joint. Other joints frequently involved include the 
mid-foot, ankle and knee, and less frequently the upper limbs and fingers (Roddy, 2011). 
After the gout flare has resolved, the patient enters the inter-critical period and generally 
remains symptom free until the next flare. Despite being symptom free, if hyperuricaemia is 
not treated, crystals continue to form and cause low persistent inflammation with the majority 
of patients having a second flare within two years (Yu and Gutman, 1961). Subsequent flares 
become more frequent, last longer, and more joints become involved (oligoarticular (affecting 
2-4 joints) or polyarticular gout (≥5 joints)), and may affect also the upper limbs (Dalbeth et 
al., 2016). 
Advanced gout manifestations 
Untreated hyperuricaemia over a number of years may lead to chronic gouty arthritis, tophi, 
and bone erosion in some patients. Joint inflammation becomes persistent due to crystals 
causing inflammation from recurrent flares and low-level inflammation during the inter-
critical period.  
Crystals harden and compress forming tophaceous deposits mainly in subcutaneous and 
periarticular areas such as fingers, toes, knees, olecranon processes, Achilles’ tendons, and 
36 
 
helix of the ears. Subcutaneous tophi are typically pain free. They may have a white to yellow 
appearance and are asymmetrically shaped (Roddy, 2011, Dalbeth et al., 2016).  
A combination of synovial hypertrophy from chronic inflammation, gout flares, and tophi 
presence and size leads to irreversible structural joint damage (Wu et al., 2019) and poor 
health-related quality of life (Khanna et al., 2012c). Bone erosion is dominantly due to tophi 
infiltrating into the bone (Dalbeth et al., 2016). 
 
2.2 Diagnosis 
The European League Against Rheumatism (EULAR) have published guidelines on how gout 
should be diagnosed (Zhang et al., 2006b, Richette et al., 2020). The definitive diagnosis of 
gout involves joint aspiration of synovial fluid or tophi for microscopic examination of MSU 
crystals. The procedure can be performed during a gout flare or during the inter-critical period 
between flares (Roddy et al., 2013). Joint aspiration is rarely performed in primary care which 
may be due to lack of facilities or expertise (Underwood, 2006, Kienhorst et al., 2014).  
In practice, diagnosis is often based on clinical signs and symptoms. Clinical features of gout 
and hyperuricaemia are highly suggestive but not specific for gout. Consequently, gout can be 
misdiagnosed. Gout can be mistaken for a flare of osteoarthritis in the 1st MTP joint in the 
presence of hyperuricaemia or pseudo-gout, a type of arthritis resulting from deposits of 
calcium pyrophosphate crystals (Sturrock, 2000). Joint aspiration should be undertaken if 





2.3 Risk factors for gout 
2.3.1 Hyperuricaemia 
Longitudinal population-based studies have long established the association between 
hyperuricaemia (elevated serum urate (SU) level) and gout. These studies have shown higher 
levels of SU are associated with greater risk of incident gout (Campion et al., 1987), with 
incidence being higher in men compared to women (Bhole et al., 2010). Similarly, 
hyperuricaemia was found to increase the risk of recurrent gout flares (Trifiro et al., 2013). 
More recently, Dalbeth et al. (2018) pooled participants from four large cohort studies, and 
showed the cumulative incidence of gout over 15 years was 1.1% in patients with SU <6mg/dL 
but 49% in patients with SU level ≥10mg/dL. Figure 2.1 illustrates the percentage of patients 
remaining gout free over time based on different SU categories (Dalbeth et al., 2018). 
Figure 2.1: Kaplan-Meier plot showing the percentage of participants who were gout-free 
over the follow-up period, based on baseline SU categories in mg/dL 
 
Reproduced from Relationship between serum urate concentration and clinically evident incident gout: an 
individual participant data analysis, Dalbeth et al, vol. 77, pg. 1048-1052, 2018, with permission from BMJ 
Publishing Group Ltd. The American system measured SU level as mg/dL; 6.0mg/dL is equivalent to 360μmol/L; 
7.0mg/dL is equivalent to 420μmol/L; 8.0mg/dL is equivalent to 480μmol/L; 9.0mg/dL is equivalent to 
540μmol/L; 10.0mg/dL is equivalent to 600μmol/L. 
 
Not all individuals with hyperuricaemia go on to develop gout with prevalence of 
hyperuricaemia (20%) being higher than the prevalence of gout (3.9%) (Chen-Xu et al., 2019).  
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2.3.2 Demographics  
In the UK population in 2012, both prevalence and incidence of gout increased with increasing 
age, and were higher in males than in females (Figure 2.2) (Kuo et al., 2015b). 
Figure 2.2: Age-specific prevalence (A) and incidence (B) of gout in 2012  
 
Reproduced from Rising burden of gout in the UK but continuing suboptimal management: a nationwide 
population study, Kuo et al, vol. 74, pg. 661-667, 2015, with permission from BMJ Publishing Group Ltd. (Blue: 
men; red: women; green: total; dotted lines show 95% confidence bounds) 
 
Gout has historically been associated with male sex however prevalence and incidence of gout 
has increased over time in both males and females. In females, prevalence and incidence rises 
after menopause. Hak et al. (2010) found amongst menopausal women, that those taking 
hormone replacement therapy had lower risk of gout than non-users. Oestrogen aids urate 
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renal excretion (Nicholls et al., 1973) and once women stop producing oestrogen, SU levels 
begin to rise and consequently the risk of gout increases.  
Historically, gout was perceived to be associated with socioeconomic privilege and frequently 
referred to as the ‘disease of kings’. Contemporary studies have otherwise shown the opposite 
to be true; gout is both more common and more severe with greater deprivation. Prevalence 
of gout was higher in a more deprived English town (4.8%) compared with an English town 
that was considered less deprived (3.9%) (Gardner et al., 1982). Further education (odds ratio 
(OR) 0.54 (95% CI: 0.36, 0.81)) and low area-level deprivation determined by the Index of 
Multiple Deprivation (OR 0.71 (95% CI: 0.51, 0.98)) were associated with lower risk of having 
≥2 flares in the preceding 12 months. Although deprivation does not have a direct impact on 
SU levels, it is linked to poorer health and greater number of visits to the general practitioner 
(GP), and may contribute to delayed consultation and reluctance to acknowledge having gout 
(Bowen-Davies et al., 2018). 
 
2.3.3 Diet 
Most urate is produced due to the process of aging and the associated increased cell death in 
the human body however, urate is also produced by the metabolism of purines found in the 
diet.  
Li et al. (2018) performed a systematic review and meta-analysis of dietary factors and risk of 
incident gout (19 prospective cohort and cross-sectional studies). Red meat, seafood, alcohol 
consumption, and fructose sweetened soft drinks increased risk of incident gout. On the other 
hand, dairy products, soy foods, high-purine vegetables, and coffee consumption were 
protective against gout. Another study had shown higher vitamin C consumption yielded 
lower risk of gout (Choi et al., 2009).  
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Studies have also investigated whether dietary factors trigger recurrent gout flares. Two case-
cross over studies had found greater alcohol consumption was associated with greater odds 
of flares (Neogi et al., 2014), whereas greater cherry consumption was associated with lower 
odds (Zhang et al., 2012).  
 
2.3.4 Genetics 
Gout tends to cluster within families, implying that it may be related to lifestyle and genetic 
factors. Genome-wide association studies had found a large number of genes involved in the 
development of hyperuricaemia and gout. The majority of these genes are involved with renal 
function where urate is under excreted. The heritability, defined as the percentage variance 
of phenotype that is explained by inherited genetic variants, can be estimated by studying the 
phenotypic correlation between related individuals (Major et al., 2018). The heritability of SU 
levels and gout in Europeans was estimated to be between 27% and 41% (Köttgen et al., 2013) 
and approximately 30% (Cadzow et al., 2017), respectively.  
 
2.3.5 Metabolic syndrome 
The association between gout and the metabolic syndrome is well known with several large 
studies evaluating these associations (Roddy and Choi, 2014). There are various definitions for 
the metabolic syndrome but they all share the same comorbidities of obesity, hypertension, 
dyslipidaemia, and either or both hyperinsulinaemia or hyperglycaemia (Eckel et al., 2005).  
Prevalence of the metabolic syndrome and its individual components was higher in patients 
with gout compared with those without (Choi et al., 2007). 
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A systematic review and meta-analysis of 11 cohort studies found obesity (risk ratio (RR) 2.24 
(95% CI: 1.76, 2.86)) and hypertension (RR 2.11 (95% CI: 1.64, 2.72)) doubled the risk of 
incident gout (Evans et al., 2018).  
Risk of gout differs in patients pre- and post-diagnosis of diabetes. Studies have shown SU 
level is higher in prediabetes vs. non-diabetics (Herman and Goldbourt, 1982) and increases 
with HbA1c levels (Choi and Ford, 2008); this is explained by high insulin levels impairing renal 
urate excretion leading to hyperuricaemia (Ter Maaten et al., 1997). Conversely, analysis of 
primary care medical records has shown uncomplicated and complicated diabetes lowers the 
risk of incident gout (OR 0.90 (95% CI: 0.85, 0.96) and (OR 0.87 (95% CI: 0.76, 1.00), 
respectively) compared with not having diabetes (Kuo et al., 2016b), and lowers the risk of 
recurrent flare (hazard ratio (HR) 0.92 (95% CI: 0.85, 0.99)) (Rothenbacher et al., 2011). The 
negative association between diabetes and gout may be explained by high glucose levels in 
the urine (glycosuria) leading to increased urine volume (polyuria) and  enhanced urate 
excretion, lowering SU levels (Cook et al., 1986).  
 
2.3.6 Chronic kidney disease 
The association between chronic kidney disease (CKD) and gout is well established. A Clinical 
Practice Research Database (CPRD) study found renal disease was associated with incident 
gout (OR 6.63 (95% CI: 5.18, 8.48) (Kuo et al., 2016b). This is due to impaired kidney function 
leading to reduced urate excretion and increased risk of hyperuricaemia and gout.  
Conversely, various studies have shown that gout is associated with incident CKD. A meta-
analysis study of three cross-sectional studies found that compared to patients without gout, 
those with gout had increased odds (OR 2.41 (95% CI: 1.86, 3.11)) of CKD stage ≥3 (Roughley 
et al., 2015); two studies in CPRD found gout was associated with increased risk of advanced 
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CKD (HR 1.29 (95% CI: 1.23, 1.35)) and its components including end stage kidney disease, 
estimated glomerular filtration rate <10 mL/min/1.73m2, and doubling of serum creatinine 
from baseline (Stack et al., 2019), and incident renal disease (Kuo et al., 2016b). The risk of 
renal disease is higher in patients with gout than those without due to comorbid hypertension 
and diabetes, hyperuricaemia, chronic inflammation, and non-steroidal anti-inflammatory 
drug (NSAID) use (Roughley et al., 2018). 
Although high SU levels have been shown to be associated with kidney disease (Li et al., 2014), 
recent studies have suggested SU level may not have a causal relationship. Randomised 
controlled trials (RCTs) have demonstrated urate-lowering therapies (ULTs) do not slow the  
rate of kidney function decline (Badve et al., 2011, Badve et al., 2020, Kimura et al., 2018, 
Doria et al., 2020) whilst Mendelian randomisation studies have shown no effect of SU level 
on CKD (Jordan et al., 2019).    
 
2.3.7 Osteoarthritis 
There is limited evidence osteoarthritis is a possible risk factor for gout, under the mechanism 
that MSU crystals deposit more easily in osteoarthritic joints (Ma and Leung, 2017). A cross-
sectional study found flares at a particular joint were associated with presence of 
osteoarthritis within that joint (OR 7.94 (95% CI: 6.27, 10.05)), with statistically significant 
associations found at the 1st metatarsophalangeal joint, mid-foot, knee and distal 
interphalangeal joints in those with gout (Roddy et al., 2007a). An analysis of CPRD data found 
osteoarthritis was associated with incident gout (OR 1.27 (95% CI: 1.20, 1.34)) (Kuo et al., 
2016b).  
As stated in Section 2.1, joint damage may occur in gout. A small cross-sectional study had 
found presence of tophi over 5mm at a particular joint was associated with bone erosion 
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within that joint, and there is a positive strong correlation between tophi size and the degree 
of erosion (McQueen et al., 2014). A cohort study using data from CPRD had shown prevalence 
of total joint replacement was higher in people with gout than those without (2.61% vs. 1.76%) 
(Kuo et al., 2018). Given osteoarthritis is the largest risk factor for joint replacement and 
predisposes gout, gout is therefore a risk factor for joint replacement.   
 
2.3.8 Medications 
Antihypertensives are widely used to treat hypertension and thus have protective effects 
against myocardial infarction and strokes. However, diuretics (thiazides and loop diuretics), 
used to treatment hypertension and heart failure, commonly cause hyperuricaemia and gout 
(Pascual and Perdiguero, 2006). A systematic review and meta-analysis of three cohort studies 
found diuretic use increased the risk of developing gout (RR 2.39 (95% CI: 1.57, 3.65)) (Evans 
et al., 2018). Choi et al. (2012) evaluated the risk of various antihypertensives on incident gout 
in a large case-control study using primary care electronic health records (EHR) from The 
Health Improvement Network (THIN) database. Current prescriptions of calcium channel 
blockers and losartan had lower odds of gout yielding OR 0.87 (95% CI: 0.82, 0.93) and 0.81 
(95% CI: 0.70 to 0.94) respectively. On the other hand, diuretics (OR 2.36 (95% CI: 2.21, 2.52)), 
beta-blockers (OR 1.48 (95% CI: 1.40, 1.57)), angiotensin converting enzyme inhibitors (OR 
1.24 (95% CI: 1.17, 1.32)) and other non-losartan angiotensin II receptor blockers (OR 1.29 
(95% CI: 1.16 to 1.43)) had greater odds of gout compared with non-use.  
Aspirin, a blood thinning drug, lowers urate excretion when used in lower cardioprotective 
doses whereas high anti-inflammatory doses have the opposite effect of increasing urate 
excretion. A case-crossover study found low dose aspirin increased odds of recurrent gout 
flares compared with no use in the last two days (OR 1.81 (95% CI: 1.20, 2.51)). The odds of 
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recurrent gout flares were higher with lower aspirin doses compared with non-aspirin use 
(Zhang et al., 2014). However, since gout is associated with cardiovascular disease, the 
cardioprotective effects of low dose aspirin are thought to outweigh its slight effect to 
increase urate levels.  
 
2.4 Long-term outcomes from gout 
Gout increases the risk of poor outcomes over a long period of time, particularly 
cardiovascular and renal diseases. This may partly be attributed to poor management of 
hyperuricaemia, as hyperuricaemia has been verified as an independent risk factor of 
cardiovascular and renal diseases (Gaffo et al., 2009). Persistent inflammation may also play 
a role.  
Several studies analysing primary care medical records from CPRD have shown gout increased 
the risk of various vascular diseases, genitourinary diseases, and comorbidities (Table 2.1). 
Gout is associated with many poor outcomes and unsurprisingly, is also associated with a 
greater risk of premature mortality. Using Swedish medical records, compared with non-gout 
patients, those with gout were found to be at increased risk of death due to cardiovascular 
disease (HR 1.27 (95% CI: 1.22, 1.33)), renal disease (HR 1.78 (95% CI: 1.34, 2.35)), and diseases 








Table 2.1: Summary of the findings from previous studies of gout outcomes undertaken in 
CPRD 
Outcomes Overall 
HR (95% CI) 
Men 
HR (95% CI) 
Women 
HR (95% CI) 
Vascular diseases    
Any vascular disease (Clarson et al., 2015) -  1.06 (1.01, 1.12)  1.25 (1.15, 1.35) 
   Any coronary heart disease -  1.08 (1.01, 1.15)  1.25 (1.12, 1.39) 
      Angina  -  1.02 (0.92, 1.13)  1.28 (1.09, 1.51) 
      Myocardial infarction -  1.12 (1.00, 1.27)  0.97 (0.77, 1.22) 
   Any cerebrovascular disease -  0.95 (0.83, 1.09)  1.17 (0.99, 1.38) 
      Transient ischaemic attack -  1.02 (0.88, 1.18)  1.26 (1.05, 1.53) 
      Cerebrovascular attack -  0.93 (0.81, 1.06)  1.34 (1.15, 1.57) 
      Peripheral vascular disease -  1.18 (1.01, 1.38)  1.89 (1.50, 2.38) 
Atrial fibrillation (Kuo et al., 2016a)  1.09 (1.03, 1.16) 1.09 (1.01, 1.16) 1.12 (1.02, 1.24) 
Venous thromboembolism (Sultan et al., 2019)  1.25 (1.15, 1.35)  1.20 (1.09, 1.33)  1.32 (1.14, 1.52) 
Cardiac arrhythmias (Kuo et al., 2016b) 1.59 (1.48, 1.70) - - 
Congestive heart failure (Kuo et al., 2016b) 1.81 (1.65, 1.98) - - 
Valvular heart disease (Kuo et al., 2016b) 1.80 (1.60, 2.04) - - 
Chronic pulmonary disease 1.10 (1.02, 1.18) - - 
Genitourinary diseases    
Chronic kidney disease (Roughley et al., 2018)  1.78 (1.70, 1.85)  1.78 (1.69, 1.87)  1.79 (1.66, 1.93) 
Renal disease (Kuo et al., 2016b) 3.18 (2.88, 3.50) - - 
Urolithiasis (Kuo et al., 2016b) 1.26 (1.02, 1.55) - - 
Comorbidities    
Hypertension (Kuo et al., 2016b) 1.51 (1.43, 1.58) - - 
Hyperlipidaemia (Kuo et al., 2016b) 1.40 (1.31, 1.50) - - 
Hypothyroidism (Kuo et al., 2016b) 1.46 (1.32, 1.61) - - 
Osteoarthritis (Kuo et al., 2016b) 1.45 (1.35, 1.54) - - 
Depression (Kuo et al., 2016b) 1.19 (1.12, 1.26) - - 
Other    
Erectile dysfunction (Abdul Sultan et al., 2017) -  1.31 (1.24, 1.40) - 
Joint replacement (Kuo et al., 2018) 1.14 (1.05, 1.22) - - 
Fractures (Sultan et al., 2018) 0.97 (0.92, 1.02) - - 
HR: Hazard ratio; CI: Confidence interval 
 
 
2.5 Management of gout 
Various organisations had published guidelines on the management of gout flares and chronic 
gouty arthritis. The British Society of Rheumatology (BSR) published guidelines in 2007 (Jordan 
et al., 2007b) and later updated the guidelines in 2017 (Hui et al., 2017). The European League 
Against Rheumatism (EULAR) published guidelines in 2006 (Zhang et al., 2006a) and updated 
them in 2016 (Richette et al., 2017). The American College of Rheumatology (ACR) published 
guidelines in 2012 (Khanna et al., 2012a, Khanna et al., 2012b) and updated in 2020 (FitzGerald 
et al., 2020).  
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The more recent guidelines (BSR 2017, EULAR 2016 and ACR 2020) emphasised the need to 
educate patients to understand the causes and consequences of gout and hyperuricaemia, 
the importance of ULT, associated comorbidities, and required lifestyle changes.  
 
2.5.1 Treatment of gout flares 
Treatment of flares aims to rapidly reduce pain and swelling. Commonly prescribed 
pharmacological treatments are NSAIDS, colchicine, and corticosteroids. Choice of treatment 
is dependent upon comorbidity, risk of side effects, and patient preference. 
NSAIDS are the most frequently prescribed medication for flares (Roddy et al., 2010). All 
guidelines recommend quick-acting NSAIDS at full dose, co-prescribed with gastro-protective 
drugs. Several RCTs have demonstrated the efficacy of NSAIDS in the treatment of flares 
(Khanna et al., 2014). There is little difference in anti-inflammatory effect between NSAIDS 
and there is no evidence any one NSAID is superior to another (Roddy et al., 2013). NSAIDS 
are prescribed with caution in patients with vascular diseases, impaired renal or liver function, 
and gastro-intestinal problems (for example, ulceration and haemorrhage) (NICE, 2019). 
Low dose colchicine, the second most used drug (Roddy et al., 2010), is an effective treatment 
that rapidly reduces pain and inflammation. Despite its effectiveness, adverse events of 
diarrhoea, nausea and vomiting are common (Terkeltaub et al., 2010, Ahern et al., 1987). 
A RCT compared the effect of naproxen versus low-dose colchicine on treating flares. No 
difference in change of pain scores over seven days were found between the two treatments 
although, naproxen use had fewer side effects, less analgesic use, and lower overall cost 
(aggregate of drug, GP, nurse, emergency GP, A&E and intervention costs) than colchicine use 
(Roddy et al., 2019).  
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Corticosteroids are not often used in primary care (Roddy et al., 2010) but they are an 
alternative in patients who have contraindications to NSAIDS and colchicine. In RCTs, 
prednisolone, an oral corticosteroid, was equally effective as NSAIDS in reducing pain scores 
(Janssens et al., 2008, Man et al., 2007). More recent guidelines (ACR 2012, BSR 2017, and 
EULAR 2016) recommended the use of combination therapy of NSAIDS, colchicine with 
corticosteroids when monotherapy was not sufficient to resolve a severe flare or flares 
affected were polyarticular. 
Similarly, analgesics such as paracetamol and codeine are not often prescribed to treat flares 
(Roddy et al., 2010) but are recommended to be used as clinical adjuncts if pain is not 
adequately controlled when taking NSAIDS or colchicine (Jordan et al., 2007b). 
   
2.5.2 Urate-lowering drugs 
Gout is a consequence of crystal deposition due to hyperuricaemia. The plausible treatment 
of gout is to lower SU level below the urate saturation threshold of 380μmol/L (Roddy et al., 
2013, Seegmiller, 1965, Loeb, 1972). This allows deposited MSU crystals and tophi to dissolve 
away and prevent new crystals from forming, thus preventing flares. A patient is considered 
‘cured’ of gout if they are crystal and tophi free and had no flares, typically after two years of 
treatment (Roddy et al., 2013). The management guidelines for ULT are summarised in Table 
2.2. 
The treat-to-target concept is the cornerstone of ULT and has been adopted across most 
guidelines. EULAR 2006 and 2016 guidelines recommend SU level should be lowered to a 
target of ≤360μmol/L, with the 2016 guidelines stating a lower target of <300μmol/L may be 
needed in those with severe gout. BSR 2007 opted for a stricter target of <300μmol/L which 
was upheld in the 2017 guidelines, but with a further recommendation that once the patient 
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is in clinical remission, the target can be relaxed and SU maintained below ≤360μmol/L. This 
target allows SU level to be well below the saturation point allowing for fluctuations in SU 
level without increasing the risk of flares. Similarly, ACR 2012 opted for target SU level 
≤360μmol/L but also recommended a lower target of <300μmol/L that may be needed to 
rapidly improve signs and symptoms in those with severe gout. 
Xanthine oxidase inhibitors target the metabolism of purine by preventing the degradation of 
hypoxanthine to uric acid, thus lowering SU level. Allopurinol is the most commonly used 
xanthine oxidase inhibitor in ULT. Another xanthine oxidase inhibitor febuxostat, was 
approved by NICE in 2009 for use in patients who are intolerant of allopurinol.  
Uricosuric drugs raise excretion of uric acid in the urine thus lowering SU level. Guidelines 
recommend using either benzbromarone, sulfinpyrazone and probenecid. Off-label drugs with 
mild uricosuric properties for gout are also considered in patients with comorbidities. These 
drugs include fenofibrate and losartan for the treatment of hyperlipidaemia and hypertension, 
respectively. Recently, a new uricosuric drug, lesinurad, co-prescribed with a xanthine oxidase 
inhibitor has marketing authorisation for treating hyperuricaemia in adults with gout provided 
the standalone xanthine oxidase inhibitor failed to lower SU level to target, however the drug 
does not have approval for use in the UK from the National Institute for Health and Care 
Excellence (NICE, 2018b).  
The initial phases of ULT and titration increases the risk of flares. Although such flares are 
unwanted, they are an indication that SU level is decreasing and crystal dissolution occurring, 
and are markers of successful treatment (Roddy et al., 2013). To prevent such flares, anti-
inflammatory prophylaxis can be co-prescribed with ULT. Guidelines recommend to either 
prescribe low dose colchicine or NSAIDS if not contradicted.  
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Uricosurics are uncommonly used in the UK and account for <1% of patients prescribed gout 
treatment in primary care practices (Annemans et al., 2008). Scarce use of uricosurics may be 
because allopurinol is an effective drug, allopurinol intolerance is uncommon, and febuxostat 
is available as an alternative when allopurinol is not tolerated. Probenecid and 
benzbromarone are unlicensed drugs and are only prescribed by rheumatologists within 
secondary care. Uricosurics should not be prescribed for over-producers of urate or in CKD, 
and benzbromarone carries a severe risk of hepatotoxicity (Hui et al., 2017). 
Checking whether patients reach and maintain SU target, particularly during ULT initiation and 
titration, requires frequent SU monitoring. BSR 2007 guidelines state SU level should be 
monitored monthly during allopurinol titration and then yearly after SU target has been 
obtained. However in practice, measuring SU level is variable; an audit of a UK primary care 
practice found only 22% of patients with gout had SU measured in the last year, with that 
figure rising to 34% amongst allopurinol users (Cottrell et al., 2013).   
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Table 2.2: Comparison of guidelines in the long-term management of gout 
BSR 2007  
(Jordan et al., 2007b) 
BSR 2017  
(Hui et al., 2017) 
EULAR 2006  
(Zhang et al., 2006a) 
EULAR 2016  
(Richette et al., 2017) 
ACR 2012  
(Khanna et al., 2012a) 
ACR 2020 
(FitzGerald et al., 2020) 
Who to start treatment in  
No comorbidities and had 
first flare, consider ULT 
after recurrence of flares 
within 1 year 
 
In patients with 
comorbidity, consider ULT: 
• Visible tophi 
• Renal insufficiency 
• Uric acid stones 
• Prescribed diuretics 
ULT offered to all patients & 
particularly advised in those 
with: 
• ≥2 flares in a year 
• Tophi 
• Chronic gouty arthritis 
• Joint damage 
• Renal impairment 
• History of urolithiasis 
• Diuretic use 
• Young age 
Severe established gout: 
• Recurrent flares 
• Gouty arthropathy  
• Tophi 
• Radiographic changes of 
gout 
• Multiple joint 
involvement 
• Uric acid nephrolithiasis  
Considered and discussed in 
all patients, particularly if:  
• ≥2 flares per year 
• Tophi 
• Urate arthropathy 
and/or renal stones 
• Young age <40 years 
• SU level >480μmol/L 
• Renal impairment 
• Hypertension 
• Ischaemic heart disease 
• Heart failure 
ULT indicated in:  
• ≥2 flares annually 
• Tophi 
• CKD stage 2 or worse 
• Past urolithiasis 
ULT indicated in: 
• ≥2 flares annually 
• ≥1 subcutaneous tophi 
• Radiographic damage 
• Previously experienced 
>1 flare but had 
infrequent flares (<2 
flares per year) 
• First flare and CKD stage 
≥3, SU >9mg/dL, or 
urolithiasis 
SU level 
• Target and maintain at 
<300μmol/L 
• Target SU level should be 
reached within 4 weeks 
• Measure SU every 3 
months for the first year, 
then annually including 
creatinine level 
• Target <300μmol/L 
• Maintain <360μmol/L 
once SU level is stable 
• Target and maintain at 
≤360μmol/L 
• Target and maintain at 
<360μmol/L 
• <300μmol/L in severe 
gout (tophi, chronic 
arthropathy, frequent 
flares) 
• <3mg/dL not 
recommended in the 
long term 
• Minimum target 
≤360μmol/L 
• Lower target of <5mg/dL 
may be needed to 
improve signs and 
symptoms of gout 
• Treatment is indefinite 
 
 
• Target and maintain at 
<6mg/dL 
When to start treatment 
1-2 weeks after flare has 
ended 
• After flare has ended 
• Can start during a flare if 
appropriate timing 
cannot be found 
Not stated Not stated Can start during a flare 
provided anti-inflammatory 
medication has already 
been initiated 




BSR 2007  
(Jordan et al., 2007b) 
BSR 2017  
(Hui et al., 2017) 
EULAR 2006  
(Zhang et al., 2006a) 
EULAR 2016  
(Richette et al., 2017) 
ACR 2012  
(Khanna et al., 2012a) 
ACR 2020 
(FitzGerald et al., 2020) 
Allopurinol  
First line drug 
• Start at 50-100mg/day 
• Increase by 50-100mg 
every few weeks until 
target SU level reached 
• Maximum dose 900mg 
• Lower dose according to 
impaired renal function 
• Rare life-threatening side 
effects 
• Co-prescribe with 
benzbromarone to 
reduce SU level further 
First line drug 
• Start at 50-100mg/day 
• Increase by 100mg every 
4 weeks until target SU 
level reached 
• Maximum dose 900mg 
• Increase by 50mg in 
patients with renal 
impairment 
• Associated with rare side 
effects 
• Should not be given to 
patients with a positive 
screening for HLA-
B*5801 
• Co-prescribe with 
uricosuric if target SU 
level not reached 
Appropriate long term ULD 
• Starting dose of 
100mg/day 
• Increase by 100mg every 
2-4 weeks if needed 
• Adjust dose in renal 
impaired patients 
• May cause life-
threatening AHS 
First line ULT 
• Start at low dose 
100mg/day 
• Titrate upwards by 
100mg every 2-4 weeks 
until target SU level 
reached 
• Adjust dose according to 
renal function 
• Co-prescribe with 
uricosuric if allopurinol 
alone is unsuccessful in 
reaching SU target 
First line drug 
• Start at ≤100mg OD 
• Start at 50mg in CKD 
stage 4 or worse 
• Titrate every 2-5 weeks 
• Maximum dose 
800ng/day 
• Monitored every 2-5 
weeks during titration 
• Once SU level achieved, 
monitored every 6 
months 
• Risk of AHS 
• Prescribe in patients 
intolerant to febuxostat 
• If target SU level not 
met, co-prescribe with 
one uricosuric as second 
line approach 
First line drug 
• Starting dose 
≤100mg/day, and at 
lower doses for those 
with CKD stage ≥3 
• Subsequent titration 
• In patients with prior 
allergic response to 
allopurinol and cannot be 
treated with other ULT, 
allopurinol 
desensitisation is an 
option 
• Screen for HLA-B*5801 in 
patients of Southeast 




 Second line drug in patients 
• Contraindicated to 
allopurinol 
• Renal impairment that 
prevents increased 
allopurinol dose to reach 
SU level 
• Starting dose 80mg/day, 
increase after 4 weeks to 
120mg/day if necessary 
to reach target SU level  
 Prescribe febuxostat if 
patients: 
• Cannot achieve SU target 
• Intolerant to allopurinol, 
especially in patients 
with impaired renal 
function 
First line drug  
• Upward titration 
• Maximum dose 
80mg/day 
• Prescribe in patients 
intolerant to allopurinol 
• If target SU level not 
met, co-prescribe with 
one uricosuric as second 
line approach 
Second line drug 
• Cannot achieve target 
using allopurinol 
• Starting dose ≤40mg/day 
and subsequent titration 
• Not to be prescribed in 
patients with a new or 




BSR 2007  
(Jordan et al., 2007b) 
BSR 2017  
(Hui et al., 2017) 
EULAR 2006  
(Zhang et al., 2006a) 
EULAR 2016  
(Richette et al., 2017) 
ACR 2012 
(Khanna et al., 2012a, 
Khanna et al., 2012b) 
ACR 2020 
(FitzGerald et al., 2020) 
Uricosurics  
Prescribed in patients: 
• Intolerant to allopurinol 
• Under-excretes urate 
• Not over producers of 
urate 








Prescribed in patients: 
• Intolerant to allopurinol 
and febuxostat 
• With normal-mild 
impaired renal function, 
prescribe sulfinpyrazone 
or probenecid 
• With mild-moderate 
impaired renal function, 
prescribe benzbromarone 
• Contraindicated in those 
with urolithiasis or 
severe renal impairment 
Uricosuric drugs are an 
alternative:  




• with mild-to-moderate 
renal insufficiency , 
prescribe 
benzbromarone  
• Contraindicated in 
patients with urolithiasis 
 
Uricosuric drugs are an 
alternative: 
• If target SU level not 
reached on allopurinol 
alone 
• If intolerant to 
allopurinol 
• Benzbromarone is more 
potent than probenecid 
• Benzbromarone 
prescribed in patients 
with renal impairment 
Prescribed in patients:   
• Intolerant to allopurinol 
or febuxostat 
• With normal renal 
function, prescribe 
probenecid 
• Contraindications in 
patients who 
overproduce urate or 
have a history of 
urolithiasis 
• Consider fenofibrate and 
losartan 
Alterative in patients who 
cannot have allopurinol or 
febuxostat: 




Following initiation of 
allopurinol or uricosuric 
drugs, consider: 
• Colchicine 0.5mg BD for 
maximum 6 months 
• NSAID or coxibs in those 
intolerant of colchicine, 
provided no 
contraindications, for a 
maximum of 6 weeks 
Following ULT initiation or 
up-titration, consider: 
• Colchicine 500μg BD up 
to 6 months 
• Low dose NSAID or 
coxibs with gastro-
protection if there are no 
contraindications 
• Lose-dose colchicine 
adjusted for renal-
disease is safer than low 
dose NSAID 
During the first months of 
ULT, consider: 
• Colchicine 0.5-1mg/day 
• NSAID with gastro-
protection if required 
• Benefits and harms need 
to be considered for both 
drugs 
In the first 6 months of ULT, 
consider: 
• Colchicine 0.5-1mg/day 
• Reduce dose in patients 
with renal impairment 
• Potential neurotoxicity 
and/or muscular toxicity 
in renal impairment or 
statin treatment 
• Alternatively use low 
dose NSAID 
After initiating ULT, 
consider: 
• Colchicine 0.5-0.6mg/day 
• Low dose NSAID with 
gastro-protection 
• Prescribe prednisolone If 
NSAID and colchicine not 
tolerated/indicated  
• Continue for >6 months, 
or 3/6 months once SU 




prophylaxis for 3-6 months 
• Colchicine 
• NSAIDS 
• Prednisolone   
CKD: Chronic kidney disease; Coxibs: Cyclooxygenase II inhibitors; NSAIDS: Non-steroidal anti-inflammatory drugs; SU: Serum urate; ULT: Urate-lowering therapy
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Modification of lifestyle and diet, and the management of comorbidities are adjunct measures 
in ULT. Patient education is required to improve diet and lifestyle. Guidelines recommend that 
patients should reduce consumption of alcohol and foods rich in purine and fructose, where 
excessive, although the evidence that these are effective management strategies is sparse. 
 
2.5.3 Indications for urate-lowering therapy 
Indication for ULT differs across guidelines (Table 2.2). Early guidelines (BSR 2007, EULAR 
2006) recommended that allopurinol should be used in patients with established gout. Despite 
these guidelines, uptake of ULT is poor. Analysis of primary care medical records from CPRD 
of patients with incident gout in 1997-2010 found 44% of patients at diagnosis had indications 
for ULT of whom, <1% were prescribed ULT. At 5 years from diagnosis, 86% of patients were 
indicated for treatment but only 30% were prescribed ULT (Kuo et al., 2014). This builds upon 
previous estimates that between 25% and 56% of patients were on ULT (Kuo et al., 2015b, 
Roddy et al., 2007b, Cottrell et al., 2013, Annemans et al., 2008). The majority of patients on 
ULT would be prescribed allopurinol (Cottrell et al., 2013). 
ULT prescription was more common in people with indications for ULT (recurrent flares, tophi, 
CKD, diuretic use etc.) apart from urolithiasis. Other factors associated with receiving ULT 
were male sex, higher deprivation, and higher Charlson comorbidity score (a summary 
measure of 17 diagnostic categories representing a person’s severity of health) (Charlson et 
al., 1994, Deyo et al., 1992, Kuo et al., 2014). 
Clarson et al. (2017) investigated factors influencing initiation of allopurinol. Only 40% of 
patients were prescribed allopurinol. Median time to first allopurinol prescription was 8 
months. Similarly to Kuo et al. (2014), CKD, diuretic use, and tophi were associated with 
increased likelihood of allopurinol prescription. In addition, patients with urolithiasis, two or 
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more gout consultations in the preceding 12 months, and who were overweight were more 
likely to be prescribed allopurinol. Conversely, males and those with increased Charlson 
comorbidity score were less likely to be prescribed allopurinol. Charlson score at diagnosis 
was higher in those who received allopurinol suggesting that people with comorbidity were 
more likely to receive allopurinol. 
Allopurinol is recommended across all guidelines to be taken daily starting at the low dose of 
up to 100mg and to be titrated upwards by 100mg every 2-4 weeks until target SU level is 
reached. This approach is not applied in most allopurinol users. Cottrell et al. (2013) found 
only 62% of allopurinol users were correctly prescribed a starting dose of 100mg, with 32% 
prescribed 300mg, and titration was not performed in 57% of allopurinol users. Annemans et 
al. (2008) found the most common average daily dose was 200-300mg in 63% of patients 
followed by 50-100mg in 21% of patients; only a minority of patients (2%) were prescribed 
>300mg.  
 
2.5.4 Adherence to allopurinol 
Allopurinol treatment is intended to be life-long however it is well known prescribing of 
allopurinol is suboptimal.  
Kuo et al. (2015b) evaluated the proportion of days (covered) (PDC) patients were prescribed 
ULT during each year of follow-up from diagnosis within CPRD. Adherence to treatment (PDC 
≥80%) improved over time from 28% in 1997 to 39% in 2012, although overall adherence was 
still poor.  
Also within CPRD, Scheepers et al. (2018) published a more comprehensive study evaluating 
persistence and adherence to allopurinol among patients diagnosed between 1987-2014 with 
gout. Median time to non-persistence (defined as no allopurinol prescription for at least 90 
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days) was 1,029 days. Non-persistence increased over time (Figure 2.3) with 39% stopping 
allopurinol at 1 year and 57% at 5 years. PDC was moderate with median 67% of patient 
observation time had a prescription for allopurinol. Of patients who stopped allopurinol, 57% 
restarted treatment and median time to restarting treatment was 643 days (Figure 2.4). Non-
persistence (52%) and PDC (mean 49%) was poor in this group of patients (Scheepers et al., 
2018).  
Figure 2.3: Kaplan-Meier curve for persistence (90-day gap) to treatment with allopurinol 
medication in the total study sample 
 
Scheepers et al, Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in 
the Clinical Practice Research Datalink (CPRD), Rheumatology, 2018, vol. 57, issue no. 9, pgs. 1641-1650, by 
permission of Oxford University Press 
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Figure 2.4: Probability of restarting treatment over time 
 
Scheepers et al, Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in 
the Clinical Practice Research Datalink (CPRD), Rheumatology, 2018, vol. 57, issue no. 9, pgs. 1641-1650, by 
permission of Oxford University Press 
  
A systematic review conducted in 2013 evaluated adherence to allopurinol (De Vera et al., 
2014). The systematic review found non-adherence was high in other countries (US, New 
Zealand, Israel, Netherlands and Spain); PDC ranged from 17-36% in three studies which were 
lower than 39-57% in the UK studies.  
Scheepers et al. (2018) found factors associated with non-persistence and non-adherence 
(PDC <80%) were female sex, smoking, and greater number of primary care consultations. 
Whereas factors associated with persistence and adherence of allopurinol use were older age, 
higher BMI, ex-smoking, alcohol consumption, more recent initiation of allopurinol, initiation 
of treatment within 90 days of diagnosis, prescribed anti-hypertensive treatment, diagnosis 
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of dementia, diabetes, and dyslipidaemia. This is comparable to the systematic review which 
found among the six included studies that older patients and those with hypertension were 
consistently reported to have higher adherence. Furthermore, occurrence of flares, absence 
of tophi and incident gout were associated with lower adherence (De Vera et al., 2014). An 
analysis of Swedish health records further found reduced kidney function was associated with 
non-adherence (Dehlin et al., 2017).   
 
2.6 Summary  
This chapter introduced gout, the condition of interest for this thesis. Epidemiological research 
has identified risk factors for gout and long-term consequences of gout. Organisations had 
published how gout should be diagnosed and managed.  
Since the main aim of this thesis is to investigate the effectiveness of allopurinol using 
observational EHR data, the next chapter will describe a narrative review which will examine 
how published observational studies of the effectiveness of allopurinol have accounted for 
confounding in their analysis.   
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3 A narrative review of observational studies evaluating 
the effect of allopurinol in gout  
3.1 Objectives 
The objective of this chapter was to perform a narrative review of observational studies 
assessing the effects of allopurinol in the treatment of gout, and to establish the range of 
study designs and statistical methods used to control for confounding variables in the 
published literature. 
 
3.2 Literature search strategy and data extraction 
A literature review protocol (Appendix A) was developed specifying details relating to search 
strategy and study selection process in order to optimise identification of relevant studies.  
Throughout the literature review process, assistance was sought from the designated 
departmental systematic literature review support team when needed, and attendance of the 
departmental systematic literature review workshop.  
Search terms were compiled from guidance from the supervisory team and the search was 
conducted in five databases (AgeLine, CINAHL, EMBASE, MEDLINE, and Web of Science) from 
the date of inception to 4th October 2014, for full-text articles published in English. The search 
terms ‘Gout’ and ‘Allopurinol’ or equivalent e.g., ‘podagra’ and brand names for allopurinol, 
were searched for in the title and abstract; the full search strategy for MEDLINE is given in 
Appendix B. The search strategy was broad to include any outcome and any comparator group 
including different drugs, dosage of allopurinol, or a non-pharmacological intervention.  
The inclusion criteria were:  
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• articles evaluating the effectiveness of allopurinol (versus any comparator group) on 
any outcome in patients with gout  
• observational studies of any design including: cross-sectional, cohort, case-control, 
and case-crossover studies 
The exclusion criteria were:  
• studies without a comparator group 
• randomised controlled trials 
• studies undertaken exclusively in children aged <18 years 
• non-published material/grey literature 
Screening of search results (titles, abstracts, and full texts) using pre-defined inclusion and 
exclusion criteria, was performed independently by one reviewer (T Rathod-Mistry (TRM)) 
with a subsample screened by two independent reviewers (M Blagojevic-Bucknall (MBB)/E 
Roddy (ER)). Originally, articles not published in English were included however approximately 
half of eligible titles with no abstracts (n≅200) came from non-English journals. Due to time 
constraints, articles not published in English were excluded. Further articles were excluded if 
the entire study sample under analysis did not have gout, for example studies with mixed 
populations where people with hyperuricaemia but not gout were included alongside people 
with gout, or if there was contamination of treatment groups such that the exposure group 
contained participants taking any anti-gout medication, for example allopurinol or 
probenecid. To ensure eligible articles were not missed from the search strategy, the 
references of the eligible articles were manually screened. Reviewers ER and MBB screened 




Data extracted from eligible articles were: study design that may have been used to control 
for confounding; setting and source of data; sample size used in analysis and length of follow-
up period; gout outcomes; how exposure to allopurinol, dosage, and treatment duration were 
recorded and analysed; statistical models used to adjust for confounding variables; how 
unmeasured confounding and missing data were handled. Treatment effect estimates were 
not extracted as meta-analysis and meta-regression were not performed as the aim was to 
conduct a narrative review of the methods that were used to control for confounding. 
Extracted data was entered into a pre-tested Excel spreadsheet devised with supervisors’ 
guidance. Data extraction was performed independently by TRM. Uncertainties concerning 
data extraction were discussed with ER and MBB. The following characteristics of the included 
studies were described narratively: study design, methods used to adjust for confounding, 
exposure to allopurinol, data sources, and gout outcomes. 
 
3.3 Description of included articles 
The search of databases yielded 8,195 records, 2,562 of which were duplicates. The exclusion 
criteria were applied to the remaining 5,633 titles, and subsequently to 1,153 abstracts, and 
then 209 full-text articles. Reasons for exclusion can be found in Figure 3.1. Thirty-five studies 
met the inclusion criteria. Manual reference checks of eligible articles yielded no further 
articles. One known eligible article was not identified by the database search as it was 
published ahead of print and was included. A total of 36 articles were therefore reviewed. 
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Figure 3.1 Systematic review flow chart 
 
Appendix C summarises the data extracted of the 36 articles. Study designs used to estimate 
the effects of allopurinol were: 
• Cohort studies (n=20) 
• Cross-sectional studies (n=11) 
• Case-control studies (n=3) 




5,633 records for title 
screening 
1,153 records for 
abstract screening 
209 records for full 
text screening 
36 eligible articles 
Title screening exclusions (N=4,480) 
 
Non-English (1,253) 
Animal studies (105) 
Children studies (50) 
Not on the gout population (1,821)  
Narrative reviews (466)  
Randomised controlled trials (86)  
Case reports/qualitative studies (204)  
Not evaluating the effectiveness of allopurinol (495) 
 
Abstract screening exclusions (N=944) 
 
Conference abstracts (177) 
Animal studies (7) 
Children studies (1) 
Not on the gout population (34) 
Narrative reviews (266) 
Randomised controlled trials (85) 
Case reports (164) 
Not evaluating the effectiveness of allopurinol (210)  
 
Full-text screening exclusions (N=174) 
 
Non-English (1) 
Not on the gout population (27) 
Narrative reviews (16) 
Randomised controlled trials (13) 
Case reports (18) 
Not evaluating the effectiveness of allopurinol (99) 
 
2,562 duplicate records 
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3.4 Accounting for confounding in study design 
Cohort study  
Cohort design, which has the potential to infer causality as the temporal ordering of treatment 
and outcome is known, was the most popular study design. Two studies controlled for 
covariates via the study design. Kok et al. (2014) created a matched cohort between 
allopurinol users and non-users matching on seven baseline variables to make the two 
treatment groups similar. Despite initially finding 12,563 allopurinol users, only 20% were 
matched to a non-user. The number of valid matches was limited by its sample size and the 
number of covariates to match on. The incident user cohort study design of Dubreuil et al. 
(2015) improved upon the previous study by using propensity score (PS) matching that was 
conditional on a greater number of covariates (24), and more allopurinol users were matched 
to non-users (85%). One cohort study was nested within a case-control study design although 
no further details were given on how matching was performed (Alvarez-Nemegyei et al., 
2005). The other 16 studies did not use matching and simply assembled a cohort of patients 
with gout to follow-up. 
Cross sectional study  
Cross-sectional was the second most commonly used study design. As exposure to allopurinol 
and outcome is collected at a single time-point or over a short period of time, causality cannot 
be inferred as the temporal order between exposure and outcome is unknown, therefore only 
an association can be estimated. 
Case-control study  
A common misconception within case-control studies is that matching removes confounding 
of the matched covariates. Matching ensures outcome groups, rather than treatment groups, 
are comparable on the matching covariates however this may underestimate the treatment 
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effect as cases and controls may become too similar with regards to the distribution of 
treatment. The primary reason to match on covariates is to improve precision in the effect 
estimates upon adjustment for the matched covariates (Pearce, 2016).Three studies used a 
case-control study design however none of these studies adjusted for the matching covariates 
in treatment effect estimation. Thanassoulis et al. (2010) case-control study was nested within 
a cohort study, with cases and controls matched on calendar day of admission to the cohort 
allowing equal follow-up periods between matched sets of cases and controls. Both Hutton et 
al. (2009) and Stamp et al. (2012) had matched on demographics, with Stamp et al. (2012) also 
matching on diuretics and renal function.  
Case-crossover study  
Two studies, Zhang et al. (2012) and Neogi et al. (2014), used a case-crossover study design. 
Case-crossover studies are typically used to investigate intermittent exposures with short-
term effects on the risk of an acute outcome. The key advantage of case-crossover studies is 
that they allow cases to serve as their own control with individuals crossing between periods 
of exposure and non-exposure, thus eliminating confounding of individual characteristics that 
remain constant over time e.g., sex. However, within-individual confounding can remain when 
individual characteristics change over time e.g., medication use, thus requiring further 
analysis. Case-crossover studies are ideally used for a short follow-up period to minimise time-
varying confounding. 
 
3.5 Sources of data 
Data was collected from three sources: national administrative databases of routinely 
collected electronic health records (EHR) (n=9); medical record data collected from individual 
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or few rheumatology clinics and hospitals (n=22); recruiting patients from the general 
population (n=5).  
Administrative databases 
National administrative health care databases contain EHR for claims for services, procedures, 
and drugs for health insurance programs. Studies based on such data were most frequently 
based in the USA (Halpern et al., 2009, Hatoum et al., 2014, Kim et al., 2013b, Pandya et al., 
2011), with three other studies conducted in Taiwan (Kok et al., 2014), Canada (Thanassoulis 
et al., 2010) and New Zealand (Stamp et al., 2012). Use of such data allow large longitudinal 
studies to be conducted; six studies had sample sizes ranged from 1,768 to 35,577 patients 
and median follow-up ranged from 0.2 to 5.25 years. Furthermore, such data allowed one 
study to evaluate the effect of allopurinol on a rare outcome, allopurinol hypersensitivity 
syndrome (Stamp et al., 2012). Although administrative databases can be largely 
representative of the general population, there is less detailed clinical information in the form 
of free text, and generalisability may be limited if health care systems only cover those with 
health insurance; such patients may be healthier, more affluent, and more likely to be 
employed (Schneeweiss and Avorn, 2005).  
Two studies used data from The Health Improvement Network database (THIN) which hold 
records of 11.1 million patients from 562 primary care practices in the UK, covering 6.2% of 
the population. Dubreuil et al. (2015) and Rothenbacher et al. (2011) were able to analyse a 
large sample of 9,590 and 6,795 patients respectively however, the associated length of follow 
up was short (2.9 years and 6 months respectively).  
Rheumatology clinics and hospitals 
Twenty-two studies either reviewed medical records or recruited patients who underwent 
clinical assessments to collect data from rheumatology clinics or hospitals. These studies 
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tended to be small with sample sizes ranging from 31 to 1,288. Patients attending 
rheumatology clinics or hospitals may be more likely to have severe gout and more 
comorbidities, therefore results obtained from these studies may not be generalisable to the 
general population; on the other hand, diagnosis of gout is more likely to have been definite 
and may allow more covariates to be measured that may not be available in administrative 
databases.   
General population  
These studies recruited gout patients from the general population and collected data from 
questionnaires, medical record review and/or clinical assessment. Alternative study designs 
were used such as the case-crossover design used in two studies (Neogi et al., 2006, Zhang et 
al., 2012). These studies tended to be small with sample sizes ranged from 57 to 290 
participants although two studies were quite large with up to 724 participants. A disadvantage 
of using questionnaire data is that responses may be inaccurate if participants do not respond 
with introspective ability and honesty.  
 
3.6 Gout outcomes 
The 36 eligible studies reported association of allopurinol with various outcomes. Shown in 
Table 3.1, outcomes considered could be grouped into seven categories with the most number 
of studies frequently reporting SU level (n=14), gout flare (n=6), and cardiovascular outcome 
(n=4). Although many of the key outcomes relevant to gout were considered, actual time to 
occurrence of outcome was only taken into account in four studies (SU level <360µmol/L; 











Outcome (number of times analysed) 
SU level 14 
SU level (11); time to or attained SU level <360µmol/L (9); 
clearance or urinary excretion of urate/uric acid level (7) 
Gout flare 6 
Frequency of gout flares (3); occurrence of gout flare (3); time to 




Cardiovascular event or sudden death due to cardiac causes (1); 
heart failure re-admission or all-cause mortality (1); myocardial 
infarction (1). 
 
Time to cardiovascular outcome requiring hospitalisation (1); 
coronary heart disease (1); stroke (1), hypertensive heart disease 




Adverse event (1); allopurinol hypersensitivity syndrome (1); 
oxypurinol level (3); 
Renal disease 5 
Chronic kidney disease (1); clearance of creatinine (2); renal failure 
(1); Serum cystatin C concentration (1) 
Tophi 3 
Diameter of tophi (1); presence of tophi (2); time until tophi 
resolution (1); velocity of reduction in tophi (1) 
Urolithiasis 2 Stone composition (11); stone formation (1); 
Other 4 
Hospital admission (1); MSK physical disability (1); time to all-cause 
mortality (1); urinary pH (1); urinary volume (1)  
MSK: Musculoskeletal; SU: Serum urate.  
 
3.7 Exposure to allopurinol 
All 36 studies recorded allopurinol use at baseline therefore estimating the effect of initiating 
treatment. Five studies had taken into account the duration spent on allopurinol in different 
ways. Dubreuil et al. (2015) performed sensitivity analyses truncating follow-up at 1, 2 and 3 
years of follow-up to address the potential of patients discontinuing treatment although that 
study did not report the number of patients who actually discontinued treatment. Kim et al. 
(2013b) censored follow-up time when patients discontinued allopurinol use which was 
accounted for in modelling effect of allopurinol, and also stratified analysis by the number of 
days (<30, 31-90, 91-120 days) spent on allopurinol. Mak et al. (2009) adjusted for number of 
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years allopurinol was taken for in a regression model. Thanassoulis et al. (2010) compared 
outcome amongst non-users to those on allopurinol for less or more than 30 days in regression 
modelling. 
Eighteen studies modelled the effect of allopurinol dose on outcome in different ways. Five 
studies evaluated the effect of giving a higher or lower than recommended dose of allopurinol 
on outcome based on creatinine level (Dalbeth et al., 2006, Stamp et al., 2000, Stamp et al., 
2011b, Stamp et al., 2012, Vazquez-Mellado et al., 2001). One study stratified analysis by dose 
(Perez-Ruiz et al., 1998). The remaining studies adjusted for dose in regression models or 
compared the distribution of dose between those who had or did not have outcome.  
Zhang et al. (2012) and Neogi et al. (2014) were the only two studies to have collected 
information on allopurinol use every three months however, allopurinol use was not modelled 
as time-varying as conditional logistic regression was performed. Hatoum et al. (2014) 
reported the number of patients who changed treatment from allopurinol to febuxostat and 
vice versa however treatment was not modelled as time-varying. Six studies stated not 
accounting for adherence or compliance to allopurinol was a study limitation. 
 
3.8 Adjustment for confounding variables in analysis 
Apart from controlling for covariates via the study design (described in Section 3.4), covariates 
can also be adjusted for in subsequent analysis via the outcome model. Twenty studies did 
not adjust for confounding variables in their analysis whereas 13 studies did; three studies 







Statistical tests used to determine if an association between allopurinol exposure and 
outcome exists without adjusting for covariates were:   
• Analysis of variance, Mann Whitney U test, Wilcoxon independent groups test, and T-
test (n=17 studies) 
• Chi-square test/Fisher’s test (n=14 studies) 
• Regression models, more specifically linear regression, Cox regression and mixed 
effects linear model (n=3 studies) 
• Likelihood ratio test (n=1 study) 
• Mantel-Haenszel odds ratio (n=1 study) 
The chi-square test/Fisher’s test, Mann Whitney-u test, analysis of variance, and the likelihood 
ratio test only determine if a treatment effect between allopurinol exposure and outcome 
exists at a pre-defined significance level, typically at 5%. These statistical tests do not inform 
the magnitude and direction of the treatment effect. On the other hand, the t-test, regression 
models, and the Mantel-Haenszel odds ratio estimates the magnitude and direction of the 
actual treatment effect and the associated standard error. Treatment effect estimates were 
expected to be biased due to no adjustment for covariates.  
Adjusted analyses 
Types of regression models used to determine if an association between allopurinol exposure 
and outcome existed whilst adjusting for covariates were:   
• Logistic regression (n=5 studies) 
• Conditional logistic regression (n=4 studies) 
• Cox regression (n=3 studies) 
• Linear regression (n=3 studies) 
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• Poisson regression (n=1 study)  
The disadvantages of using regression models are that the number of covariates that can be 
adjusted for may be limited by the study sample size, and model regression assumptions are 
imposed.  
A wide range of covariates that were controlled for are listed in Table 3.2. The covariates 
encountered can be grouped into five general categories: demographics, medication use, 
comorbidities, health care utilisation, and lifestyle factors. The most commonly controlled 
confounding variables were age (n=13), sex (n=12), and SU level (n=9). The median number of 
confounding variables adjusted or matched on was seven, ranging between one and 29. 
The majority of studies had at least controlled for demographics and comorbidities, with 
lifestyle factors rarely being adjusted for. Cardiovascular and renal diseases, either measured 
in the form of biomarkers, use of medications, or diagnosis, were often adjusted for in 
analysis. It is possible that adjusting for information on gout and healthcare utilisation may 
have indirectly adjusted for severity of gout and general health. 
All studies but two adjusted for confounding variables at baseline with the assumption that 
covariates were time-invariant. This assumption may not hold especially if the follow-up 
period is long, as patients may have new diagnoses, severity of gout may worsen or lessen, or 
there may be changes in lifestyle and other covariates. Although the two case-crossover 
studies by Zhang et al. (2012) and Neogi et al. (2014) collected information on confounding 
variables every three months for a year, subsequent analysis did not take this into account. 
All studies performed complete case analysis i.e., patients with missing covariate data were 
excluded from analysis, as their primary analysis; no studies looked at the sensitivity of missing 




Table 3.2: Confounding variables controlled for via the study design or statistical analysis   
Category 
(no. of studies) 
Sub-category 
(no. of studies) 
 









NSAIDS (6); colchicine (2); benzbromarone (1); 
corticosteroids (1); coxibs (1); intra-articular steroids 





ACE inhibitors (4); ARBs (3); aspirin (2); beta-blockers 
(4); calcium channel blockers (2); diuretics (8); 
fibrates (2); hydrochlorothiazide (3); losartan (2); 
statins (3); antiplatelet agents (1); anticoagulants (1); 








Atrial fibrillation (1); cardiovascular disease (3); 
diseases of the heart (1); heart failure (1); 
hypertension (7); ischaemic heart disease (2); 
myocardial infarction (1); stroke (1) 
 
Biomarkers: C-reactive protein (1); erythrocyte 




Disorders of lipid metabolism (1); dyslipidaemia (1); 
hyperlipidaemia (3) 
 
Biomarkers: Cholesterol (2); high density lipoprotein 




Chronic kidney disease (2); chronic renal failure (2); 
diseases of the urinary system (1); renal function (1); 
renal stones (1); stage of chronic kidney disease (1); 
stage of renal function (1); uremia (1); confidence to 
keep SU under control (1) 
 
Biochemical tests/biomarkers of renal function: 
Creatinine clearance (2); glomerular filtration rate 
(2); serum creatinine level (1) 
Other 
(n=8) 
Body mass index (4); COPD (1); Charlson comorbidity 
index (4); comorbidity index (1), diabetes (6); gastric 
ulcer (1); non-traumatic joint disorders (1); obesity 
(1) 
 




Duration of gout (1); tophi (2); year of gout diagnosis 
(1) 




Cardiac procedures (1); emergency room visits (1); 
hospitalisations (1); prescription drugs (1); office 
visits (1); primary care practice visits (4); gout 
consultations (1) rheumatology visits (1); speciality of 




Alcohol consumption (3); cherry intake (1);  
purine intake (2); smoking status (1) 
ACE: Angiotensin-converting enzyme; ARBs: Angiotensin II receptor blockers; COPD: Chronic obstructive 
pulmonary disorder; NSAIDS: Non-steroidal anti-inflammatory drugs. 
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3.9 Implications for the PhD project 
This narrative review systematically identified and assessed 36 observational studies that had 
evaluated the effect of allopurinol on gout outcomes.  
 
3.9.1 Strengths and limitations 
The key strengths of this literature review were that a systematic search was performed and 
in addition the references of eligible articles were manually checked to identify all 
observational studies evaluating the treatment effect of allopurinol in gout. Additional 
reviewers had screened a subsample of the search results and reviewed data extraction 
separately.  
It is possible that eligible articles could have been missed if they were published ahead of print 
but not identified by the database search; regression analysis adjusted for allopurinol but was 
not reported in the abstract due to lack of association with outcome; treatment effectiveness 
analysis was performed in a different population, say hyperuricaemia, and as a sensitivity 
analysis restricted analysis to patients with gout but this not reported in the abstract. 
Furthermore, some articles may have been eligible from the 1,253 articles published in 
languages other than English that were excluded. Cross validation was not performed, 
potentially increasing the chance of missing eligible articles and data extraction errors. 
This literature review highlighted possible improvements that can be made in the approach 






3.9.2 Time-varying confounding 
Control for confounding could be improved in the majority of studies. Under half of the 36 
eligible studies controlled for baseline confounding; the remaining studies ignored 
confounding issues thus potentially yielding biased treatment effect estimates. Confounding 
was mostly controlled for using regression models. Only one study used PS matching to create 
comparable treatment groups. No studies attempted to model for time-varying treatment or 
covariates although few studies acknowledged that ignoring time-varying allopurinol use, 
adherence and compliance to treatment were limitations of the study. Fifteen studies 
acknowledged that residual confounding was likely owing to unmeasured confounding 
variables and lack of randomisation however, no attempt was made to revise the estimated 
treatment estimates to take this into account. Across studies, a wide range of covariates were 
considered however within studies, the median number of confounding variables adjusted or 
matched on was seven and ranged between one and 29. 
As explained in Section 2.5.4, adherence to allopurinol is poor and changes over time. In 
addition to time-varying treatment, time-varying confounding will also exist. Indications for 
allopurinol are likely to vary over time as flares become more frequent and may last longer 
and affect more joints, chronic gouty arthritis, tophi and bone erosion may develop in 
untreated patients.  
None of these studies have assessed such time-varying nature of indication for allopurinol nor 
its effect on outcome.  
 
3.9.3 Electronic health records 
Large EHR databases are increasingly being used for health research (Schneeweiss and Avorn, 
2005). Several studies analysed data from administrative databases for health insurance 
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programs mostly based in the USA. Only two studies had used primary care data from THIN 
that represents 6.2% of the UK population. As stated in Section 1.1, the advantages of using 
such data are that their large size is generalisable to the population of interest and represents 
routine primary care.  
No study had evaluated the effect of allopurinol on gout outcomes using primary care medical 
records from the Clinical Practice Research Datalink (CPRD). CPRD is comparable with THIN as 
both databases recruit practices that use the management software Vision (that records 
medical record data) thus there is considerable overlap in their patient pools. CPRD is 
representative of 8% of the UK population and allows linkage to more secondary databases 
such as Hospital Episode Statistics data. Since gout is primarily managed in primary care it was 
surprising to not see more studies using this data source. 
 
3.9.4 Allopurinol exposure 
Exposure to allopurinol was measured in different ways. Studies had either compared the 
effect of allopurinol use vs. non-use, amount of time taking allopurinol, or differing allopurinol 
doses. 
In practice, the recommended starting dose of allopurinol is 100mg daily which is gradually 
titrated upwards by 100mg every 2-4 weeks in order to lower SU levels below 360µmol/L 
(Zhang et al., 2006a); dosages greater than 300mg are needed to meet this target in over half 
of patients (Khanna et al., 2012a). Furthermore, allopurinol dosage needs to be adjusted for 
in patients with renal impairment (Khanna et al., 2012a). In practice, allopurinol dose is often 
not titrated and patients may remain on their starting dose (Cottrell et al., 2013). As stated 
above in Section 3.9.2, in addition to dose potentially changing over time, indications for 
treatment, and adherence to treatment may also change over time.  
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Definition of allopurinol will be dependent upon how in practice one could model time-varying 
treatment in the presence of time-varying confounding.  
 
3.9.5 Outcomes 
Gout is widely known to be associated with comorbidity particularly with vascular and renal 
diseases. Unsurprisingly, studies evaluating the effectiveness of allopurinol have considered a 
wide range of outcomes however only mortality and gout flares have been considered so far 
in studies undertaken using data from primary care medical records. Primary care EHR provide 
an opportunity to observe a wide range of outcomes that can take many years after diagnosis 
to develop. Therefore, a high quality observational study using data from a large primary care 
EHR database, such as CPRD, to evaluate the effect of allopurinol on such outcomes is needed. 
A retrospective cohort study is the ideal observational study design to evaluate effectiveness 
of allopurinol using EHR data as it would allow calculation of incidence rates or the relative 
risk of multiple outcomes between the treatment groups. The advantage of using EHR data is 
that the outcomes of interest are routinely collected and available for analysis; prospectively 
collecting data is not feasible due to very long follow-up required for some outcomes, such as 
death, to occur.  
Outcomes of interest in this thesis are target SU level, mortality, vascular and renal diseases, 
health care contacts for gout in primary and secondary care, and joint replacement. Reasons 
why these outcomes were chosen, and limitations of existing studies identified from this 
review are described below. 
Target SU level 
As explained in Section 2.3.1, hyperuricaemia is a primary risk factor for gout and reducing SU 
level is the most important treatment objective (Section 2.5.2). Thus, reaching target SU level 
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≤360μmol/L, as recommended by EULAR (Zhang et al., 2006a), was considered the primary 
outcome. 
This review identified SU level as the most frequently evaluated outcome. Eight studies had 
evaluated the effect of allopurinol on attaining target SU ≤360μmol/L. Studies had found the 
median time to achieve target was 37 weeks (Lim et al., 2012), target SU level was reached by 
29-41% of allopurinol users by 6 months and 48-72% by 12-24 months (Lim et al., 2012, 
Hatoum et al., 2014), and attaining target was more commonly achieved in those taking 
allopurinol than non-users (Dalbeth et al., 2006, Roddy et al., 2007b) and in those with higher 
doses (Pandya et al., 2011).   
No high quality study exists comparing the effects of allopurinol use with non-use on the time 
to achieve target SU level using primary care EHR databases. Only cross-sectional studies had 
compared allopurinol use vs. non-use but cannot infer causal effects (Dalbeth et al., 2006, 
Dalbeth et al., 2012, Roddy et al., 2007b), whilst cohort studies had used febuxostat or 
uricosuric drugs as the comparator group (Hatoum et al., 2014, Perez-Ruiz et al., 1998, Stamp 
et al., 2011b). Two studies that had used EHR from large administrative databases were based 
in the USA (Hatoum et al., 2014, Pandya et al., 2011), with the majority of studies conducted 
in non-UK rheumatology/hospitals; only one small cross-sectional study had recruited people 
from the general UK population (Roddy et al., 2007b). Few studies had adjusted for baseline 
covariates (Dalbeth et al., 2012, Hatoum et al., 2014, Pandya et al., 2011) however no studies 
had modelled time-varying treatment or covariates.  
All-cause mortality 
Gout is known to be associated with premature mortality (Lottmann et al., 2012) with 
common causes of death being vascular disease (particularly from coronary heart disease, 
stroke and heart failure), endocrine and metabolic diseases (mostly diabetes), and kidney 
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disease (Kuo et al., 2011). Interest is in whether allopurinol use is protective against premature 
morality in people with gout. 
This review identified one high quality cohort study using data from THIN (a UK primary care 
EHR database) that had evaluated the effect of allopurinol on time to all-cause mortality and 
had shown allopurinol use was protective. Although this study had used PS matching to create 
comparable treatment groups on several covariates, information was lacking on how PS was 
performed and the assessment of comparability of treatment groups. To address the potential 
for allopurinol users to discontinue treatment, that study had used a suboptimal approach 
censoring patient follow-up at 1, 2, and 3 years after treatment initiation (Dubreuil et al., 
2015), when a better approach would have been to model allopurinol use as time-varying.  
Further investigation is needed whether modelling allopurinol as time-varying yields similar 
conclusions, and to perform statistical analysis in a more rigorous manner ensuring PS analysis 
performed well.  
Vascular diseases 
Gout has been shown to be associated with coronary heart disease and peripheral vascular 
disease among men and women, and associated with cerebrovascular disease among women 
(Clarson et al., 2015). A systematic review conducted in 2013 had shown there is limited 
evidence allopurinol reduces risk of cardiovascular disease (Fleeman et al., 2014) thus a need 
for higher quality studies is needed.  
The second most commonly evaluated outcome as identified by the review in this chapter was 
vascular disease which covered a range of conditions such as myocardial infarction and stroke. 
Two studies had used administrative databases of EHR to evaluate effectiveness of allopurinol. 
One matched cohort study found allopurinol users had an overall increased risk of any 
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cardiovascular event, and had separate increased risks for coronary heart disease, 
hypertensive heart disease and heart failure than non-users but no association was observed 
for stroke (Kok et al., 2014). Conversely, a case-control study nested within a cohort found 
allopurinol use had reduced odds of heart failure readmission/death than non-users 
(Thanassoulis et al., 2010). Despite using EHR data, median follow-up was short ranging from 
2 to 5 years in the two studies. Two other studies had considered myocardial infarction and 
cardiovascular event or death however they were of cross-sectional design and did not adjust 
for any covariates. 
No studies had evaluated effect of treatment on vascular disease including peripheral vascular 
disease using UK primary care EHR data especially modelling allopurinol and covariates as 
time-varying.  
Renal disease 
As seen in Section 2.3.6, the association of renal disease and gout is widely known to be bi-
directional. Few studies had evaluated the effectiveness of allopurinol on renal disease using 
various outcome definitions, with one systematic review showing there is limited evidence 
allopurinol reduces risk of renal disease (Fleeman et al., 2014).  
Five small studies based in rheumatology clinics or hospitals, had evaluated the effect of 
allopurinol on renal disease were identified in this review. Various definitions for renal disease 
were used including chronic kidney disease and creatinine clearance. Four of these studies 
had found no association between allopurinol use and renal disease (Alvarez-Nemegyei et al., 
2005, Cheyoe et al., 2012, Perez-Ruiz et al., 1998, Perez-Ruiz et al., 2010). One study had found 
allopurinol users had worse renal function than non-users, and was the only study to use non-
allopurinol use as the comparator group (Choe et al., 2010). Follow-up in the two cohort 
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studies were short of approximately one year and did not adjust for any covariates (Perez-Ruiz 
et al., 1998, Perez-Ruiz et al., 2010). 
Overall effectiveness of allopurinol on renal disease is limited with mixed results on presence 
of association being reported, suboptimal methods, did not model allopurinol and covariates 
as time-varying, and not had used UK primary care EHR data.  
Health care contacts for gout 
Few studies had evaluated frequency of gout flares within EHR data and hospital admissions. 
A large cohort study of an administrative data containing health insurance claims found 
allopurinol users had a higher (adjusted) rate of claims of gout flares than colchicine users 
over a short follow-up period of less than a year; follow-up was short as it was censored when 
patients discontinued treatment (Kim et al., 2013b). A small hospital based cohort study used 
clinical interviews to ascertain the frequency of flares treated with either colchicine or 
corticosteroids over a 15 month period; that study found longer periods of allopurinol use was 
not associated with the number of gout flares (Mak et al., 2009). One small case-control study 
found allopurinol use compared with non-use, and lower doses were associated with 
recurrent hospital admission during a 12-month period over five years (Hutton et al., 2009). 
Evidence is lacking on whether allopurinol use leads to reduced number of primary care 
consultations for gout-related hospitalisations.   
Joint replacement 
As described in Section 2.3.7, osteoarthritis has been shown to be associated with gout flares 
within a joint. People with gout may be at an increased risk of joint replacement as 
osteoarthritis is the main reason for patients to undergo this procedure. This review had found 
no studies had evaluated whether allopurinol use was associated with joint replacement.  
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3.9.6 Effectiveness of allopurinol in subgroups 
One of the clinical objectives of this PhD project is to evaluate effectiveness of allopurinol 
stratified by presence of renal disease and severity of hyperuricaemia. No studies have 
evaluated effectiveness of allopurinol within these clinically important subgroups. 
 
3.10 Conclusions 
To conclude, this chapter presents a narrative review of observational studies of the 
effectiveness of allopurinol. Common limitations of these studies were that none modelled 
allopurinol use as time-varying, and often studies did not even control for baseline covariates. 
The majority of studies were non-UK based and frequently set in rheumatology clinics and 
hospitals. Only a few studies were based in the UK and used primary care data. The next 
chapter will describe how a UK EHR database (CPRD) will be used to address some of the 




4 Data source and study sample 
Preparing electronic primary care medical records for research is a complex task. This chapter 
describes the data source used in this PhD project as well as data preparation and 
management procedures. More specifically, the objectives for this chapter are to: 
1) Describe the data source, namely the Clinical Practice Research Datalink (CPRD). 
2) Define and describe how the study sample was derived. 
3) Define the start and end dates of follow-up. 
4) Define outcomes, treatment, and covariates. 
 
4.1 Primary care electronic health record databases 
In the UK, gout is largely managed in primary care with annual consultation prevalence of 
4.7/1,000 in 2007 (Elliot et al., 2009). As identified from Chapter 3, there are a lack of studies 
using large EHR databases evaluating effectiveness of allopurinol in gout. For this PhD project, 
data from CPRD was utilised, as CPRD is the largest, well established UK primary care database, 
has been validated the most, and has been used in over 2,500 publications.  
CPRD (GOLD) contains anonymised, routinely collected research quality medical records 
spanning from 1987 to the present time, jointly supported by the Medicines and Healthcare 
products Regulatory Agency and National Institute for Health Research. The database holds 
medical records on over 11.3 million residents registered with over 674 UK primary care 
practices. Over 95% of the population is registered with a primary care practice (Lawrenson 
et al., 1999). Active patients who are alive and currently registered, represent 6.9% (4.4 million 
patients) of the UK general population and are similar in terms of age (although there may be 
some under-representation in younger age groups), sex, and ethnicity. However, CPRD may 
not be representative of all practices as CPRD practices tend to be larger than the national 
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average (Herrett et al., 2015, Campbell et al., 2013). CPRD GOLD collects data from practices 
that use the management software Vision which records medical record data however, Vision 
is only used by 9% of English practices compared to more popular systems such as EMIS (56%) 
and SystmOne (34%). There are geographical differences; Vision practices are predominantly 
based in London, South of England, greater Manchester, and Birmingham and are under-
represented in the North and East of England (Kontopantelis et al., 2018). Furthermore, many 
Vision practices have migrated to EMIS from 2014 resulting in patient follow-up being 
censored. 
Data available in CPRD include demographic details, lifestyle factors, consultations, 
prescriptions, referrals, death, and other data available via linked datasets, such as the Index 
of Multiple Deprivation (IMD) data, Office of National Statistics (ONS) mortality data, and 
Hospital Episode Statistics (HES) records. Data entries such as diagnoses, symptoms and 
processes of care are recorded and stored as Read codes and prescribed drugs stored 
according to their British National Formulary equivalent product code. The Quality and 
Outcomes Framework (QOF) was introduced in 2004 and aimed to improve quality of care by 
financially incentivising general practitioners (GPs) to record and monitor patient health, thus 
patient data had become more complete over time, for example, smoking status (Doran et al., 
2011). The accuracy and completeness of the CPRD data has been validated extensively 
(Herrett et al., 2010). In the UK, the GP is responsible for the majority of patients’ medical 
care, including referral to specialist care, illness prevention and co-ordination of healthcare 
following hospitalization, and other medical events, making CPRD an ideal data source for 
assessing the impact of allopurinol on long term outcomes in patients with gout. 
Approval for access to anonymised medical records was obtained by the Independent 
Scientific Advisory Committee (ISAC). The ISAC approval number is 14_163 and the ISAC 
application form is in Appendix D. Primary care medical records were obtained in January 2015 
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with linkage obtained in July 2015. Details of the relevant data required for this thesis are 
given in Table 4.1.  
All patients were assigned a unique patient identification number thus linking each patient’s 
medical history across different aspects of care. Dates were provided when patients first 
registered with the practice, at each point of contact with primary care, and if applicable when 
the patient left the practice.   
Table 4.1: Relevant information obtained from CPRD 
Category Data collected 
Patient details Demographics: Year of birth, sex, primary care practice 
Registration details: date of first registration, date and reason of transfer out 
of primary care practice, date of death 
Primary care practice details Region where the primary care practice is located, date of last data collection, 
last known date data is checked to be of research quality 
Clinical details Recorded medical codes and date of symptoms, signs, and diagnoses and the 
date they occurred 
Referrals Recorded medical codes and date of patient referrals to secondary care such 
as hospitals and specialist care centres 
Additional information Various information supporting medical codes on height, weight, body mass 
index, alcohol consumption and smoking status 
Test results Results of pathology tests ordered. Serum urate levels were of interest only.  
Prescriptions Recorded product codes and date of prescription including schedules and 
issues for repeat prescriptions, dosage, and instructions on how to take the 
therapy 
Index of multiple deprivation Categorisation of the Index of Multiple Deprivation 2004 into quintiles, deciles 
and twentiles where the patient resides 
ONS mortality Date and cause of death 
Hospital episode statistics Recorded ICD-10 codes of reason for inpatient and day case admissions to 
hospital and date of discharge 
ONS: Office of National Statistics 
Details of the patient consultation were recorded in various formats. Clinical symptoms, signs, 
and diagnoses were entered via Read codes. The Read code system is a standard clinical coding 
system used by GPs where a Read code describes the clinical (or Read) term of the main reason 
for the patient’s consultation. Read codes have a hierarchical structure where the first 
character indicates the chapter, for example a class of conditions, and subsequent characters 
are subchapters, grouping similar conditions, until the disease itself has been specified. For 
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example, the Read code for Gout is C34 where ‘C’ denotes all endocrine, nutritional, metabolic 
and immunity disorders; within this, ‘3’ denotes other metabolic and immunity disorders; 
within this, ‘4’ denotes gout. Subchapters of C34 identify different types and causes of gout; 
for example, C345 identifies gout due to impairment of renal function. For certain Read codes, 
additional information may be entered into the structured data area in to provide complete 
information; for example, the Read term 'O/E Blood Pressure Reading', the actual blood 
pressure reading needs to be recorded. Each distinct Read code was assigned a unique 
numeric medical code derived by CPRD in order to retrieve necessary details.  
Gemscript is a coding system based on the NHS dictionary of medicine and devices used by 
GPs to manage prescription of therapies. Each distinct Gemscript therapy was assigned a 
unique numerical product code within CPRD, which were used to retrieve therapy events.  
ONS mortality and HES data were coded using the International Classification of Diseases (ICD) 
system version 10. Similar to the Read code system, the ICD-10 codes have a hierarchical 
structure. For example, the ICD-10 code for gout is M10; the first character ‘M’ refers to 
conditions of the musculoskeletal system and connective tissue and the number ‘10’ refers to 
gout. 
Primary care medical records are considered to be accurate in terms of the information they 
contain. A systematic review of 212 publications validated 183 different diagnoses in CPRD 
(formally known as the General Practice Research Datalink (GPRD)) and had shown the median 
89% of cases were confirmed using additional internal or external information (Herrett et al., 
2010). With regards to a diagnosis of gout, a GPRD study has shown that among patients 
recorded as having gout and were prescribed gout medication (allopurinol, colchicine, 
probenecid, indomethacin, or other NSAIDS), 86% were confirmed as having gout; in addition 
if a patient had a high serum urate (SU) level, 100% were confirmed as having gout (Meier and 
Jick, 1997). Data are also considered complete with 87% of diagnoses recorded on the 
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database from 58 UK primary care practices (Jick et al., 1991). Disadvantages of using primary 
care medical records are that patients only present the illness they want to treat to their GP 
thus mild cases may not present, data quality across GPs and practices may vary although 
practices are required to have good quality data in order to contribute to CPRD, variable 
recording of lifestyle factors such as body mass index (BMI), alcohol consumption, diet, and 
smoking status, and loss of follow-up if patients moved practice.  
 
4.2 Study design and population 
A retrospective cohort study design was used. The study sample consisted of patients 
consulting for gout between the 1st January 1997 and the 31st December 2002. Patients who 
were under 18 years of age at their first gout consultation within this period were excluded. 
This would have resulted in minimal exclusions as gout is rare in patients younger than 20 
years with 5.11 patients consulting for gout per 100,000 patients in this age group (estimate 
was derived from CPRD) (Kuo et al., 2015b). This five-year period was chosen as CPRD linkage 
to HES was available from 1997 onwards and allowed patients to have a sufficiently long 
follow-up period of a maximum of 18 years. This five-year period was chosen as there was a 
sufficient number of consulters for gout needed to adequately power analyses to detect 
treatment effect (see Section 4.5). 
For each patient, the date of start of the follow-up (known as the index date), was defined as 
the first consultation for gout in the period 1st January 1997 to 31st December 2002 and had 
no prescription for allopurinol or uricosuric drugs in the two years prior to consultation. If the 
patient was prescribed allopurinol or uricosuric drugs (sulfinpyrazone, probenecid or 
benzbromarone, definitions can be found in Section 4.4.4) in the two years prior to their gout 
consultation, a cycle occurred where the subsequent gout consultation, up until the end of 
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2002, was identified and checked for any prescription (regardless of dosage and duration) for 
allopurinol and uricosuric drugs in the two years beforehand. This was repeated until a gout 
consultation was identified as the index date or the patient was excluded if no index date was 
found. The study sample contained a mixture of prevalent and incident consulters for gout. 
This was to ensure previous effects of allopurinol and uricosuric prescription did not have an 
impact on estimating treatment effect. Febuxostat was licensed for use in 2009 hence it was 
not required to consider this drug when selecting the index date. Figure 4.1 illustrates this 
process. 
Practices had to have consented to linkage to the HES, ONS mortality, and IMD databases to 
be included in this study. Patient-level IMD measured in 2004 was available for England-based 
practices but was not available for Wales, Scotland, and Northern Ireland. Therefore, patients 
registered to non-England based practices were excluded and findings may not be 
generalisable to the rest of the UK. Patients had to have been registered with their practice 
for at least two years prior to their gout consultation and had to have at least one year of 
follow-up time. 
The latest date of follow-up was defined as the minimum of the date of transfer out of the 
practice, practice last data collection (December 2014), CPRD derived date of death and ONS 
date of death (see Section 4.4.1 for further details on recording of death).  
Patients were followed up from their index date and follow-up ended if one of the five 
scenarios occurred first: (1) the outcome of interest, (2) prescribed sulfinpyrazone, 
probenecid, benzbromarone or febuxostat; this allowed one to evaluate the effect of 
allopurinol without interference from the effect of these drugs, (3) transferred out of practice, 
(4) last data collection (31st December 2014), or (5) death.  
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Figure 4.1: Selection of the index date 
 
The code lists identifying gout is listed in Section 4.4.4, allopurinol is listed in Section 4.4.2, 
and uricosuric drugs and febuxostat are listed in Section 4.4.4.  
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1st gout consultation = index date 
Scenario A: No allopurinol and uricosuric drugs were prescribed in the two years prior to 
the 1st gout consultation. The 1st gout consultation date was taken as the index date. 





Scenario B: Allopurinol and uricosuric drugs was prescribed in the two years prior to the 1st 
gout consultation. A cycle occurred where the next gout consultation was identified and 
checked if allopurinol and uricosuric drugs were prescribed in the two years beforehand. 
The first gout consultation date with no allopurinol and uricosuric drugs prescribed in the 
last two years was taken as the index date. 
2 year period, 
prescribed drugs 
Prescribed drugs Prescribed drugs 
Scenario C: Allopurinol and uricosuric drugs were prescribed in the two years prior to all 
gout consultations between 1997 and 2002. This patient was excluded.  
31/12/200
2 
nth gout consultation  
= index date 
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4.3 The landmark method 
4.3.1 Time-invariant treatment and covariates 
In practice, allopurinol can be prescribed many years after a gout diagnosis (Kuo et al., 2014). 
The time period prior to prescription of allopurinol needs to be adequately handled in analysis 
otherwise the treatment effect may suffer from immortal time bias. Immortal time bias is 
defined as a period of follow-up where outcome cannot be considered to occur. For example, 
using death as a outcome, for allopurinol users survival time would commence upon 
prescription for allopurinol thus death cannot be considered to occur prior to date of 
prescription and patients are considered ‘immortal’; in non-users such a requirement that 
does not apply as survival time starts from study entry. Allopurinol users would accrue survival 
time waiting for treatment and consequently appear to live longer than non-users biasing 
treatment effect (Lévesque et al., 2010, Dafni, 2011). 
To overcome this issue, one approach is the landmark method that was implemented for this 
study. A time point after the index date (i.e., the landmark date) was chosen allowing 
allopurinol treatment to be determined using prescriptions from the index date up until and 
including, the landmark date (i.e., the landmark period). Follow-up commenced from the 
landmark date for both allopurinol users and non-users ensuring that outcome was dependent 
on treatment status at the landmark date. Patients who had the outcome during the landmark 
period were excluded and non-users who were prescribed allopurinol after the landmark date, 
a change in treatment status, was ignored in the analysis. 
The landmark method is best used in situations where outcome is unlikely to occur early on 
during follow-up but the likelihood of being treated early on was high. Given the range of 
outcomes with some likely to occur early on, for example gout consultation, and some likely 
to occur later, for example cerebrovascular disease, the primary analysis was conducted using 
88 
 
a one-year landmark period. Sensitivity analysis using a two-year landmark period was then 
performed to evaluate robustness of treatment effects against misclassification of treatment. 
There is a balance between lessening misclassification of treatment status and excluding too 
many patients who had the outcome prior to the landmark date leading to a loss of power. 
Furthermore, Kuo et al. (2014) had shown of the patients who received urate-lowering 
therapy (ULT), most had received treatment within 5 years. The landmark method is illustrated 
in Figure 4.2. Patients prescribed three or more months of allopurinol were deemed 
allopurinol users (treatment definition can be found in Section 4.4.2). To ensure temporal 
ordering, covariates were measured in the interval prior to the index date (the baseline 
period).  
Figure 4.2: The landmark method at 1 and 2 years 
 
Several studies had used the landmark method for treatment effect estimation. For example, 
Kuo et al. (2015a) evaluated the effect of allopurinol on all-cause mortality in the gout 

















Start of follow-up 
Within each landmark period, if a patient was prescribed ≥3 months of allopurinol, they would be classed 
as an allopurinol user otherwise classed as a non-user. Follow-up would commence from the landmark 
date. As the length of the landmark period increases, more patients would be classified as allopurinol 




4.3.2 Time-varying treatment and covariates 
To capture changes in treatment and covariates over time, follow-up time was divided into 
discrete intervals. As medical record collection is not set-up for research, data will not be 
measured repeatedly at set time periods that one may be able to control in a prospective 
cohort study. Data is only collected when patients need to consult their GP, and data of 
interest will be measured at different times. For example, a patient presenting with gout for 
the first time may be recorded as gout, but SU level measurements and screening for 
comorbidities may occur later. It is anticipated there will be missing data over time.   
The length of intervals needs to capture how frequently data is recorded but not to have too 
many intervals such that analyses are not cumbersome and computationally intensive. SU 
level is the key confounding variable as it is a strong indication for allopurinol use. Guidelines 
suggest this should be measured every 6 months from treatment and thereafter yearly (Jordan 
et al., 2007b). Initial interval length considered was 6 months however when proceeding with 
time-varying PS subclassification analysis (Section 6.3), fitting of multi-level logistic models did 
not converge or had taken a long time to converge. Given SU level was mostly missing and had 
to be treated as time-invariant, and the majority of covariates whose status could only change 
once thus repeated measures were mostly static (see Section 4.4.3), one-year intervals were 
instead chosen.  
Within each interval during follow-up, covariates, treatment, and outcome were repeatedly 
measured. Patients had a baseline interval (the period prior to the index date) with follow-up 
represented by at least two intervals. The number of intervals did not succeed the maximum 
follow-up time. 
To establish temporal ordering between covariates, treatment, and outcome, covariates 
measured in the previous interval were used to predict treatment in the current interval. Then 
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treatment was used to predict outcome in the subsequent interval. This is illustrated in Figure 
4.3; covariates measured in the last two intervals and treatment measured in the last interval 
of follow-up were not required as outcome was not recorded in subsequent intervals. This is 
an extension of the landmark method with the interval for covariates and treatment 
repeatedly created over time.  
Figure 4.3: Temporal ordering of covariates, allopurinol treatment and outcome 
 
Longer intervals were considered as a sensitivity analysis, for example two years. However, 
due to the way temporal ordering was imposed, covariates used to predict treatment may 
have occurred at the most four years ago; covariates measured in the same interval as 
treatment were more likely to have stronger associations. Therefore, longer intervals as a 
sensitivity analysis was not considered.  
 
4.4 Definitions of outcomes, treatment, covariates and other 
Definitions for most outcomes, covariates, and treatment were based on Read codes or 
Gemscript codes. To identify all relevant codes a process was undertaken: 
1) Code lists were identified from previous published work using medical record data 
undertaken in Primary Care Centre Versus Arthritis, Keele University. 
t-1 year 1 year 2 year 3 year… 
Covariates Covariates Covariates Covariates 
Allopurinol Allopurinol Allopurinol Allopurinol 









2) An online clinical codes repository (clinicalcodes.org (Springate et al., 2014)) was 
used to identify further codes. 
3) Read codes under the highest subchapter from codes identified in (1) and (2) were 
searched for using the CPRD medical browser; the drug substance names were 
searched for using CPRD product browser. 
4) The lists of consolidated codes were then reviewed and finalised by two GPs and a 
rheumatologist where applicable.  
In some instances, vascular and renal diseases were both covariates and outcome; the same 
Read codes were used to define both in this instance. Table 4.2 lists the source of studies 
whose Read code lists were available and were potentially used in this PhD project.   
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Table 4.2: Source of Read codes and Gemscript codes 
Comorbidities Source for Read codes 
Anxiety Burton et al. (2013), Prior et al. (2015), Walters et al. (2012) 
Depression Kontopantelis et al. (2012), Burton et al. (2013), Prior et al. (2015), Rait et al. 
(2009) 
Cerebrovascular disease PCC (2012), Reilly et al. (2015), Kontopantelis et al. (2014), Khan et al. (2010), 
Clarson et al. (2015) 
Coronary heart disease Bhattarai et al. (2012), Doran et al. (2011), Hawkins et al. (2013), Horsfield 
(2004), PCC (2012), Khan et al. (2010), Reeves et al. (2014), Reilly et al. (2015), 
Parisi et al. (2015), Kontopantelis et al. (2015b), Kontopantelis et al. (2015a), 
Kontopantelis et al. (2014), Clarson et al. (2015), Roughley et al. (2018) 
Type I and II diabetes Khan et al. (2010), Kontopantelis et al. (2014), Kontopantelis et al. (2015b), 
Kontopantelis et al. (2015a), PCC (2012), Reilly et al. (2015), Reeves et al. 
(2014), Clarson et al. (2015), Roughley et al. (2018), Horsfield (2004) 
Gout consultation Clarson et al. (2015), Chandratre et al. (2018) 
Hyperlipidaemia Clarson et al. (2015), Roughley et al. (2018) 
Hypertension Horsfield (2004), PCC (2012), Doran et al. (2011), Kontopantelis et al. (2015b), 
Kontopantelis et al. (2015a), Reeves et al. (2014), Clarson et al. (2015), 
Roughley et al. (2018) 
Hip or knee joint replacement Culliford et al. (2015) 
Osteoarthritis  Kontopantelis et al. (2015a), Reilly et al. (2015) 
Peripheral vascular disease Doran et al. (2011), Khan et al. (2010), PCC (2012), Clarson et al. (2015), 
Roughley et al. (2018) 
Renal disease Doran et al. (2011), Reilly et al. (2015), PCC (2012), Kontopantelis et al. 
(2015b), Khan et al. (2010), Clarson et al. (2015), Roughley et al. (2018) 
Lifestyle factors  
Body mass index (Clarson et al., 2015, Doran et al., 2011, Reeves et al., 2014, Stocks et al., 2015, 
Fairhurst et al., 2014); 
Alcohol consumption Fairhurst et al. (2014). 
Smoking status (Clarson et al., 2015, Doran et al., 2011, Fairhurst et al., 2014, Kontopantelis 
et al., 2014, Kontopantelis et al., 2015b, Reeves et al., 2014, Springate et al., 
2015, Stocks et al., 2015). 
Medications Source for Gemscript codes 
Allopurinol Clarson et al. (2017) 
Analgesics Bedson et al. (2013) 
Colchicine Clarson et al. (2015) 
Diuretics Clarson et al. (2015), Kontopantelis et al. (2015b), Springate et al. (2015), 
Stocks et al. (2015) 
NSAIDS Bedson et al. (2013), Clarson et al. (2015) 
NSAIDS: Non-steroidal anti-inflammatory drugs 
 
4.4.1 Outcomes 
The choice of which outcomes to analyse was previously described in Section 3.9.5. The 
primary outcome was time taken to reach target SU level ≤360µmol/L for the first time. 
Patients were eligible for this analysis if they had a baseline measurement (as defined in 
Section 4.4.3.3) that was above target (>360μmol/L), and SU level was measured during 




The range of time to first secondary outcomes measured during follow-up that were 
considered is listed in Table 4.3. With the exception of repeated gout consultations, patients 
were excluded from analysis if they had outcome in the baseline period or if follow-up ended 
during the landmark period. For repeated gout consultations, consultations that occurred 
during the landmark period were ignored as it was expected a large proportion of patients 
would consult during this period.  
Table 4.3: Primary and secondary outcomes 
Primary outcome 
   Target SU level ≤360µmol/L 
Secondary outcomes 
   All-cause mortality 
   Repeated gout consultations 
   Gout hospitalisation 
   Hip or knee joint replacement 
   Cerebrovascular disease 
   Coronary heart disease 
   Peripheral vascular disease 
   Renal disease 
SU: Serum urate 
The definition of outcomes is described below.  
Target SU level 
SU level and its units were not consistently recorded as implausible values, duplicate entries, 
and a range of units used were observed in the data. Based on the raw data, the following 
process was undertaken to remove implausible data and to standardise it to one set of units, 
μmol/L, that is commonly used in the UK.  
1) Only one SU level per date per patient was allowed: 
i. Duplicates in terms of patient identifier, SU level, unit of measurement, and 
date of measurement were removed. 
ii. If there were two or more different measurement recorded on the same date, 
implausible values were removed. If the different measurements appeared to 
be plausible, one measurement was retained at random. 
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2) To standardise SU measurements, for each recorded unit of measurement: 
i. The distribution of the SU levels was checked. 
ii. SU levels were then categorised based on the location of the gaps in the 
distribution.  
iii. If it was believed the wrong units was recorded within a category, a more 
appropriate unit was chosen based on the distribution of SU levels recorded in 
other units. 
iv. If there were less than 20 observations within a category, the patient’s history 
of SU level was checked to determine plausibility of SU levels and its units.  
The results of standardising SU levels can be found in Appendix E. 
All-cause mortality 
Date of death was recorded in two ways within CPRD, (1) date the patient transferred out of 
the practice due to death and (2) CPRD derived date of death based on an algorithm. When 
the practice is notified that a patient had died, the relevant Read code for death is entered in 
the patient’s medical history alongside with information on date and cause of death. The 
patient’s registration status would be changed to ‘transferred out’ with death being the 
reason; the date of transfer is often after the actual date of death. Due to this delay, CPRD 
developed an algorithm to identify records of death to estimate the date the patient had died. 
Date of death was defined to be the earliest of (1) the transferred out of practice date due to 
death, (2) date of death or date of recording information on death, and (3) date when Read 
code for death was recorded.  
A more accurate date of death was obtained from ONS mortality data. It is a legal requirement 
to register all deaths in England to the General Register Office with a medical certificate 
completed by the medical practitioner establishing the cause of death. Deaths should be 
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registered within five days from the date of death however late registration can occur for up 
to a number of years if the cause of death is not known, for example, deaths referred to 
coroners. Data is validated to ensure data is entered correctly. Death registration data was 
collected from 01/01/1998 up until 30/04/2014.  
Most deaths recorded in the ONS are also recorded in CPRD however, there may be small 
differences in the recording of the exact date of death in CPRD; this difference had become 
smaller over time (Gallagher et al., 2019).   
Date of death was defined as the earliest date recorded from either CPRD based on its 
algorithm or from ONS. 
Gout hospitalisation 
A hospitalisation due to a gout was defined using HES via ICD-10 codes. The list of codes is 
shown in Table 4.4. As not all patients would have a record for any hospitalisation, it was 
assumed they were not hospitalised due to gout.  
Table 4.4: ICD-10 codes for gout hospitalisation 
ICD-10 code Description 
M10 Gout 
M10.0 Idiopathic gout 
M10.1 Lead-induced gout 
M10.2 Drug-induced gout 
M10.3 Gout due to impairment of renal function 
M10.4 Other secondary gout 
M10.9 Gout, unspecified 
 
Repeated gout consultations 
This was defined as any consultation for gout. The Read codes used to define gout in Section 






Coronary heart disease, also known as ischaemic heart disease or coronary artery disease, is 
caused by build-up of fatty deposits in the arteries around the heart and restricting blood flow 
to the heart. Common symptoms are angina (chest pain) and myocardial infarction (heart 
attack). Read codes identified patients with angina and myocardial infarction, as well as 
surgery for treatment such as angioplasty and coronary artery bypass graft. 
Cerebrovascular disease refers to disorders of the brain where the blood flow is affected. Read 
codes identified the different types of cerebrovascular disease including stroke (such as 
haemorrhage and transient ischaemic attack), aneurysm, embolism, thrombosis, and carotid 
artery stenosis.  
Peripheral vascular (or arterial) disease is caused by fatty deposits in the arteries restricting 
blood supply to the leg muscles. Read codes identified symptoms include intermittent 
claudication and ischaemic legs, foot and toes, and surgical treatment including peripheral 
bypass surgery.  
Renal disease 
The ability of kidneys to filter and excrete waste (for example creatinine) and excess fluids 
from the blood becomes impaired over time. Read codes identified those with chronic kidney 
disease (stages 1-5), or acute or chronic renal failure.   
Joint replacement 
Read codes identified total hip and knee joint replacement (arthroplasty), a major surgery that 






All prescriptions for allopurinol during follow-up were identified along with date of 
prescription, drug quantity, numeric daily dose, and number of days of prescription. 
Allopurinol was analysed as a binary variable (allopurinol use vs. non-use). Various definitions 
of allopurinol use had been used in medical record studies. Kuo et al. (2015a) had used a six-
month prescription of allopurinol during the one-year landmark period; Dubreuil et al. (2015) 
had used any prescription for allopurinol during a six-month period; Rothenbacher et al. 
(2011) had used any prescription of allopurinol within 30 days of gout diagnosis.  
Choice of length of allopurinol prescription is dependent on how long patients adhered with 
treatment. Kuo et al. (2015b) defined adherence as the proportion of days covered (PDC) with 
a prescription of ULT (majority of prescriptions is for allopurinol) over a one-year period using 
data from CPRD. In 2012, 39% adhered with treatment (PDC >80%), 42% partially adhered 
(PDC 20-79%), and 17% were not adherent (PDC <20%). In 1997, 28% of ULT patients adhered 
with treatment and approximately 50% were partially adherent. 
For this PhD project, it was assumed non-adherent allopurinol users were unlikely to observe 
treatment effects on long-term outcomes, whereas partially and adherent patients are more 
likely to observe treatment effects. Given 20% PDC is equivalent to 73 days in a year, and 
prescription of allopurinol is either given for one, two, or three months, patients with a total 
of three or more non-consecutive months of allopurinol prescription were deemed allopurinol 
users, whereas those with no prescription or had less than three months of allopurinol 
prescription were deemed non-users.  
When allopurinol use was time-invariant, prescriptions of allopurinol during the one-year 
landmark period was used to determine treatment status. For the two-year landmark period, 
patients were required to have a three-month prescription in the first year or second year of 
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follow-up to be deemed as an allopurinol user. When allopurinol use was time-varying, 
prescriptions within a one-year intervals was used to determine treatment status. Repeatedly 
measuring allopurinol status in this way captured when patients were prescribed and not 
prescribed allopurinol. Hypothetical scenarios where patients were classed as allopurinol or 
non-users within a time interval is illustrated in Figure 4.4.  
Figure 4.4: Examples of how patients were classed as allopurinol users and non-users within 
an interval 
 





Scenario A: Patient was prescribed allopurinol at 2 months for a duration of three months 
with no further prescriptions. Classed as an allopurinol user for this time interval. 
Scenario B: Patient was prescribed allopurinol at 2 and 9 months for a duration of 2 
months each. The total time period on allopurinol was 4 months. Classed as an allopurinol 
user for this time interval. 
Scenario C: Patient was prescribed allopurinol at 2 months for a duration of 2 months. As 
the period being on allopurinol was less than 3 months, this patient was classed as a non-
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The Gemscript code and its associated product codes for prescription of allopurinol were 
obtained from Clarson et al. (2015) study. To identify any further relevant codes, using the 
product browser supplied by CPRD, search terms of ‘allopurinol’ and brand names for 
allopurinol were searched for. The list of product codes used to identify prescription of 
allopurinol is given in Table 4.5. 
Table 4.5: Products codes for prescription of allopurinol 
Product code Gemscript code Product name 
76 59735020 Allopurinol 300mg tablets 
368 52350020 Zyloric 100mg tablets (Aspen Pharma Trading Ltd) 
413 59734020 Allopurinol 100mg tablets 
5182 74888020 Xanthomax 100 tablets (Ashbourne Pharmaceuticals Ltd) 
7805 53508020 Zyloric 300mg tablets (Aspen Pharma Trading Ltd) 
11975 88998020 Allopurinol 100mg/5ml sugar free oral suspension 
13467 48562020 Caplenal 300mg tablets (Teva UK Ltd) 
17255 58338020 Hamarin 300 Tablet (Roche Products Ltd) 
19037 74889020 Xanthomax 300 tablets (Ashbourne Pharmaceuticals Ltd) 
19201 48380020 Allopurinol 100mg tablets (IVAX Pharmaceuticals UK Ltd) 
23368 58335020 Hamarin 100 Tablet (Nicholas Laboratories Ltd) 
24215 48561020 Caplenal 100mg tablets (Teva UK Ltd) 
30768 48366020 Allopurinol 100mg tablets (A A H Pharmaceuticals Ltd) 
33484 56807020 Allopurinol 100mg tablets (Actavis UK Ltd) 
34005 53683020 Allopurinol 300mg tablets (Teva UK Ltd) 
34278 48367020 Allopurinol 300mg tablets (A A H Pharmaceuticals Ltd) 
34566 60172020 Allopurinol 300mg tablets (Generics (UK) Ltd) 
34573 48371020 Allopurinol 300mg tablets (Wockhardt UK Ltd) 
34711 60171020 Allopurinol 100mg tablets (Generics (UK) Ltd) 
34930 48370020 Allopurinol 100mg tablets (Wockhardt UK Ltd) 
34947 55358020 Allopurinol 100mg Tablet (Lagap) 
41520 48381020 Allopurinol 300mg tablets (IVAX Pharmaceuticals UK Ltd) 
41541 53684020 Allopurinol 100mg tablets (Teva UK Ltd) 
41612 56808020 Allopurinol 300mg tablets (Actavis UK Ltd) 
41664 48362020 Allopurinol 100mg Tablet (Celltech Pharma Europe Ltd) 
44239 60082020 Cosuric 100mg Tablet (DDSA Pharmaceuticals Ltd) 
44240 60083020 Cosuric 300mg Tablet (DDSA Pharmaceuticals Ltd) 
45352 48390020 Allopurinol 300mg tablets (Ranbaxy (UK) Ltd) 
46941 55359020 Allopurinol 300mg Tablet (Lagap) 
52409 18891020 Allopurinol 100mg/5ml oral suspension 
54139 18907020 Allopurinol 300mg/5ml oral suspension 
 
To calculate the duration of time the patient was on allopurinol, the start and end date of 
prescription needed to be determined. The start date of prescription was assumed to be the 
date when prescription was entered into the Vision system, however the end date of 
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prescription was not recorded. Although number of days related to each prescription can be 
recorded, this is not a required field thus was mostly missing (94% of all prescriptions).  
Duration was therefore calculated by dividing drug quantity by daily dose which was more 
complete. For example, if the prescription quantity is 56 tablets and the daily dosage is 2, then 
duration of prescription would be 28 days. However, it was observed daily dose and quantity 
may also be missing as some patients may be instructed to take treatment ‘as needed’ or ‘as 
directed’ and values were found to be implausible.  
Based on the observed data, rules were derived how to impute missing and implausible data. 
Implausible daily dose was defined as those with values <0.5 and >6, or equal to 0.75 and 2.25 
after seeking guidance from a GP. Implausible drug quantity was defined as a prescription that 
would last less than a month (for example quantities less than multiples of 28 and 30) with 
the exception of values 7, 14 and 100 as they appeared to be frequently used.   
Imputation of missing and implausible values across all patients 
1) If daily dose was missing, the most common daily dose was taken for that particular 
drug quantity only if it was extremely unlikely another daily dose could have been 
used.   
2) If daily dose was missing, daily dose from the previous prescription was used if drug 
quantity was the same.  
3) If drug quantity was missing, drug quantity from the previous prescription was used if 
daily dose was the same. 
4) If drug quantity and daily dose were both missing, the duration of the previous 
prescription was taken. 
5) If duration was still missing or greater than 30 days (as the majority of durations was 
for a month), it was assumed duration was for 28 days instead.  
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The distribution of quantity of drugs and numeric daily dose before and after imputing data is 
shown in 0. The date the prescription stopped was thus calculated by adding the duration of 
prescription to the start date of the prescription. Using this information, patients were 
determined as either allopurinol user or non-user as described above. The distribution of 
numeric daily dose and quantity of drugs before and after imputing for missing data is shown 
in Appendix F.  
 
4.4.3 Covariates 
Covariates considered for time-invariant and time-varying analyses is listed in Table 4.6 and 
covered a range of demographics, comorbidities, medication usage and lifestyle factors.  




Demographics   
Age X Time-varying: increased yearly 
Sex X Time-invariant 
Deprivation X Time-invariant 
Comorbidities   
Anxiety X Time-varying: status changed once 
Depression X Time-varying: status changed once 
Cerebrovascular disease X Time-varying: status changed once 
Coronary heart disease X Time-varying: status changed once 
Type II and I diabetes X Time-varying: status changed once 
Gout consultation N/A Time-varying: status may change multiple times 
Hyperlipidaemia X Time-varying: status changed once 
Hypertension X Time-varying: status changed once 
Osteoarthritis  X Time-varying: status changed once 
Peripheral vascular disease X Time-varying: status changed once 
Renal disease X Time-varying: status changed once 
Lifestyle   
Alcohol consumption X Time-varying: status changed once 
Body mass index X Time-varying: status may change multiple times 
Smoking status X Time-varying: status changed once 
Serum urate X Time-invariant 
Medication use   
Analgesics X Time-varying: status may change multiple times 
Colchicine X Time-varying: status may change multiple times 
Diuretics X Time-varying: status may change multiple times 
NSAIDS X Time-varying: status may change multiple times 
Cumulative allopurinol use (years) N/A Time-varying: status can only increase in value 
Year of follow-up N/A Time-varying: increased yearly 
NSAIDS: Non-steroidal anti-inflammatory drugs 
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All time-invariant covariates, with the exception of lifestyle factors (see below), were 
measured in the two years prior to the index date.  
With the exception of sex, deprivation and SU level, covariates were then considered time-
varying measured in the two years prior to the index date (with the exception of lifestyle 
factors, see below) and then in one-year intervals after the index date until follow-up ended.  
Selection of covariates were chosen on the basis that they are indications for treatment and 
risk factors for gout or poor outcomes due to gout. Genetics and diet is not recorded in CPRD 
hence is considered as unmeasured confounders.  
Definition of covariates is described below. 
 
4.4.3.1 Demographics 
Only the patient’s year of birth was obtained from CPRD. It was therefore assumed patients 
were born on the 1st January. Time-invariant age was calculated on the index date. Time-
varying age was calculated at the start of each interval. Age was treated as a continuous 
covariate.  
The IMD measures relative deprivation for small areas (known as lower layer super output 
areas) in England at the patient level. Each area is ranked from 1 being the most deprived area 
to 32,844 being the least deprived area with the ranking based on seven domains: income; 
employment; health deprivation and disability; education, skills and training; barriers, housing 
and services; crime; living environment. IMD is updated every few years and CPRD provided 
deprivation measure based on quintile, deciles and twentile scores based on the rank; 
deprivation measures were published in 2004 that had used data between 1997 and 2003. 
Deprivation measured in 2004 was used as this measure was the closest time point to the 
baseline period. Twentile scores were used for analysis rather than deciles and quintiles as it 
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retained the most information after categorisation of ranks. Deprivation was treated as a 
continuous covariate.  
 
4.4.3.2 Comorbidities and medication use 
For comorbidities defined by Read codes, absence of the code was assumed to imply absence 
of the relevant diagnosis. Thus, by default there were no missing data in these measures. 
Similarly, for drug use covariates, defined via Gemscript codes, absence of the code implied 
that a patient had not been prescribed the relevant medication. Thus, in this instance too, 
missing data were non-applicable. 
For all time-varying comorbidities, except for gout consultation, once the patient was 
diagnosed with the comorbidity, they were assumed to have that comorbidity for the rest of 
follow-up. 
In defining analgesics, topical analgesics were excluded as it was believed they have little pain-
relieving effects for the gout flare. NSAIDS were also not included as they were considered as 
a separate covariate.  
In defining NSAIDS, topical NSAIDS were excluded as it was believed they have little pain-
relieving effects for the gout flare. Unlicensed NSAIDS were also considered s drugs can fall in 
and out of fashion for treating gout flares.  
Time-invariant gout consultation was not considered as adjustment for this covariate may 
partially adjust out the treatment effect. Patient index date was based on consulting for gout 
between 1997 and 2002 and was not prescribed allopurinol in the two years prior to 
consultation. In prevalent gout cases, adjusting for previous gout consultation may introduce 
the effect of allopurinol as that previous gout consultation was not chosen due to being 
prescribed allopurinol in the last two years. In treatment effect estimation, part of the effect 
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would be adjusted for. Therefore, it was assumed patients did not consult for gout in the two 
years prior to index date.  
 
4.4.3.3 Lifestyle factors 
As part of management of gout, GPs give general advice regarding making healthier lifestyle 
choices (stop smoking and reduce alcohol intake) and to lose weight. This information may be 
missing as consultations tend to be short (approximately 10 minutes) thus not all relevant data 
may be entered with the most important aspects of the consultation recorded. As the study 
sample contains prevalent and incident patients with gout, it is possible in prevalent cases the 
two-year period prior to the index date may not be long enough to capture these details when 
they may have been recorded when the patient was first diagnosed with gout. Patients with 
more severe gout may be more likely to have lifestyle factors recorded than less severe cases. 
Missingness may arise as healthier patients are less likely to consult their GP if they do not 
have gout flares.  
Body mass index 
Measurements of weight, height and BMI were obtained. For time-invariant BMI, initially the 
most recent BMI was taken in the two years prior to the index date however there was 
substantial missing data with only 30% of patients with a record. On further investigation, a 
total of 10,660 patients (63%) had a measurement recorded prior to the index date however 
some measurements were recorded up to 13 years prior. To minimise missing data, the most 
recent measurement was taken during this 13-year period (Table 4.7); the median (IQR) 
number of years prior to the index date in which weight or BMI was recorded was 2.13 (0.65, 
4.51) years; 50% of measurements were recorded within five years of the index date.  
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Table 4.7: Number of eligible patients (n=16,876) with recorded weight and BMI prior to the 
index date 
Period prior to index date N (%) 
2 years 4,981 (30) 
5 years  8,356 (50) 
10 years 10,519 (62) 
13 years 10,669 (63) 
 
Height, weight and BMI underwent a process of cleaning outlined by Bhaskaran et al. (2013) 
to remove implausible values and to calculate BMI. Further details of this process can be found 
in Appendix G. BMI was then categorised as normal weight (BMI<25), overweight (BMI 25-30), 
and obese (BMI 30+).  
To further minimise missing data Read codes for BMI were utilised. The Read codes had to 
differentiate between BMI of normal weight (<25kg/m2), overweight (25-30kg/m2), and obese 
(≥30kg/m2). 
Alcohol consumption 
Alcohol consumption was recorded as non-, current- or ex- drinker; additional information on 
start and stop dates of drinking and units of alcohol consumed per week were recorded as 
well. Recording of alcohol consumption in CPRD is a blunt measure as it is often recorded as 
non-, current- or ex-drinker. The number of units consumed is not often recorded (Stewart et 
al., 2017) and thus it was not possible to accurately distinguish between light, moderate and 
heavy drinkers. 
Similarly to BMI, missing data was substantial in the two years prior to the index date (Table 
4.8), therefore the most recent record was taken over the 13 year period prior to the index 
date. The median (IQR) number of years in which alcohol consumption was recorded prior to 




Table 4.8: Number of eligible patients (n=16,876) with recorded alcohol consumption prior 
to the index date 
Period prior to index date N (%) 
2 years 3,467 (21) 
5 years  7,222 (43) 
10 years 10,131 (60) 
13 years 10,344 (61) 
 
To further minimise missing data, Read codes for alcohol consumption were obtained. The 
relevant Read Codes contained information on the patient’s drinking status if they are a 
current, ex-, or non-drinker. 
When considering alcohol consumption as a time-varying covariate, a record of ex-drinker was 
only plausible after a record of current drinker however GPs interchangeably use ex-drinkers 
and non-drinkers. Therefore, alcohol consumption was categorised as never- and ever- 
drinkers. The never drinkers consisted of non-drinkers provided there was no earlier record of 
ex- or current drinker. The ever-drinkers consisted of current- and ex- drinkers. This 
classification can be used over time as patients can switch from never drinker to ever drinker 
but not from ever drinker to never drinker.  
Smoking status 
Similarly to alcohol consumption, smoking status was recorded as either non-, current- or ex-
smoker with additional information on how many cigarettes smoked per day and the start and 
stop dates of smoking. Substantial missing data was observed in the two years prior to the 
index date (Table 4.9), therefore the most recent record was taken over the 13-year period 
prior to the index date. The median (IQR) number of years in which smoking status was 





Table 4.9: Number of eligible patients (n=16,876) with recorded smoking status prior to the 
index date 
Period prior to index date N (%) 
2 years 4,590 (27) 
5 years  8,336 (49) 
10 years 11,068 (66) 
13 years 11,283 (67) 
 
To further minimise missing data, Read codes for smoking status was obtained. The relevant 
Read Codes contained information on the patient’s smoking status if they are a current 
smoker, ex-smoker, or non-smoker. 
Recording of ex-smokers is under-utilised by GPs (Booth et al., 2013) and ex-smokers and non-
smokers may be used interchangeably. Therefore, smoking status was categorised as never 
smoker and ever smoker. Never smokers consisted of non-smokers who did not have a 
previous record of ex- or current smoker. Ever-smokers consisted of non- and ex- smokers. 
This classification can be used over time as patients can switch from never smoker to ever 
smoker but not from ever smoker to never smoker.  
SU level 
The cleaning of SU level was already described above in Section 4.4.1. 
Preference was for SU to be measured as a time-varying covariate as SU level is a strong 
indication for treatment and is associated with various outcomes such as vascular and renal 
diseases. On inspection of data, missing data was substantial in the two years prior to the 
index date which remained consistent over time. Therefore, SU was only considered time-
invariant.  
SU recorded more than two years prior to the index date could not be used as patients may 
have been prescribed allopurinol or uricosuric drugs which may have influenced SU level.  
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Therefore, within allopurinol users (identified in the one-year landmark period), the most 
recent SU level was taken prior to prescription of allopurinol up to one year after the index 
date. In non-users, the most recent SU level was taken up to one year after the index date.  
In the primary outcome analysis (time to achieve target SU level ≤360 µmol/L), SU level was 
considered as a continuous covariate as there was no missing data. In the analysis of 
secondary outcomes, SU level was dichotomised such that patients with SU ≤360µmol/L were 
considered to have had reached target SU level, and patients with SU >360µmol/L were 
considered not to have had reached target SU level. 
Cumulative years of allopurinol use 
Previous level of exposure to allopurinol was considered as a time-varying covariate. As this 
covariate was measured in each year of follow-up, it was defined as the cumulative previous 
number of one-year periods in which the patient was exposed to allopurinol; this covariate 
will simply be referred to as cumulative allopurinol use.  
 
4.4.4 Other definitions 
The list of Read codes for gout consultations is shown in Table 4.10. The consultation for gout 
can be for any reason.  
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Table 4.10: Medical codes for gout consultation 
Medical code Read term 
709 Gout 
2857 Gouty arthritis 
3759 H/O: gout 
4440 Gouty tophi of other sites 
9162 Renal stone - uric acid 
9874 Gouty tophi of hand 
10080 Gouty arthropathy 
11462 Idiopathic gout 
12594 Gouty arthritis NOS 
14996 Initial gout assessment 
16475 Gout monitoring 
17284 O/E - auricle of ear -,phi 
21687 Gout due, impairment of renal function 
24153 Gout NOS 
27521 Other specified gouty manifestation NOS 
28999 Other specified gouty manifestation 
29561 Pre-treatment uric acid level 
29658 Joints gout affected 
34006 Date gout treatment started 
34105 Gout treatment changed 
35660 Follow-up gout assessment 
35664 Gouty arthritis of the ankle and foot 
36481 Gouty tophi of ear 
43646 Date gout treatment stopped 
43744 Uric acid nepolithiasis 
44566 Drug-induced gout 
45465 Gouty arthritis of the forearm 
49775 Gouty arthritis of the lower leg 
50067 Gouty iritis 
52101 Gouty arthritis of the hand 
52103 Gout drug side effects 
52117 Gout monitoring NOS 
52969 Gouty nepopathy 
57334 Gouty tophi of heart 
58064 Gouty arthritis of multiple sites 
58746 Gout associated problems 
59344 Gouty neuritis 
60541 Gouty arthritis of other specified site 
61145 Gouty nepopathy NOS 
68209 Date of last gout attack 
72471 Gouty arthritis of the shoulder region 
93677 Gouty arthritis of toe 
93689 Gouty tophi of heart 




Benzbromarone and febuxostat 
As there was no available code list for benzbromarone, Gemscript codes were searched for 
within the CPRD product browser using the search term ‘benzbromarone’. Similarly for 
febuxostat, search terms of ‘febuxostat’ and ‘Adenuric’ identified Gemscript codes.  
Probenecid 
The product codes for probenecid were obtained from Clarson et al. (2015) and in addition, 
the terms ‘probenecid’ and ‘Benemid’ were searched for within the product browser under 
product name and drug substance name. 
Sulfinpyrazone 
The product codes for sulfinpyrazone were obtained from Clarson et al. (2015) and in addition, 
the terms ‘sulfinpyrazone’ and ‘Anturan’ were searched for within the product browser under 
product name and drug substance name. 
 
4.5 Power calculation 
A feasibility count was undertaken to ensure there was sufficient number of patients 
consulting for gout between 1997 and 2002, and there was sufficient sample size and power 
to detect reasonable treatment effect.   
It is assumed that the total CPRD annual registered population is 5.5 million patients and that 
approximately 50% of practices contributing to CPRD have consented to linkage to HES, 
deprivation and ONS mortality. This yields relevant annual population of approximately 2.75 
million. It is estimated that 70,000 of these will have gout, based on the latest figure for 
prevalence of gout as 2.5% (Kuo et al., 2015b). 
111 
 
Between 1st January 1997 and 31st December 2002, 33,538 patients aged 18 years and over 
had a Read code for gout and were registered with their practice for at least two years prior. 
To determine the number of patients prescribed allopurinol, the landmark method described 
in Section 4.3.1 was used. The number of patients prescribed allopurinol is listed in Table 4.11. 
Approximately half these patients would have linkage.  
Table 4.11: Number of patients prescribed allopurinol 
Landmark period Prescribed allopurinol 
N=33,538 
N (%) 




1 year 10,266 (30.61) 5,133 (30.61) 
2 years 11,648 (34.74) 5,824 (34.73) 
 
The primary outcome was SU level ≤360μmol/L. Based on a single small study, 77% of those 
on allopurinol are expected to reach this threshold as opposed to 25% of those not taking 
allopurinol (Roddy et al., 2007b). Secondary outcome of recurrent gout consultations had not 
been compared between treatment groups however, a nationwide population based study 
found 22% of newly diagnosed patients with gout prescribed with allopurinol had a recurrent 
gout attack within a year compared to 14% of non-users, which patients would consult for the 
GP for (Trifiro et al., 2013). Sample size and power calculations could not be performed taking 
into account time to outcome due to lack of studies. Therefore, calculations were based on 
the proportions of outcome between treatment groups.  
Assuming 90% power with 5% significance and allocation ratio of two (as approximately 33% 
of patients were prescribed allopurinol (Table 4.11)), Table 4.12 shows the total number of 
patients required to detect a difference in proportion (percentage) in outcome (target SU level 
and recurrent gout flare) between treatment groups. The proportion of patients having 
outcome in the treatment groups was based on the above figures, which then varied if a 
smaller or larger proportion of outcome was to be observed. A maximum of 1,128 patients 
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were needed assuming proportion of 45% and 36% reached target SU level in allopurinol users 
and non-users respectively; a maximum of 3,753 patients were needed assuming proportion 
of 30% and 35% of recurrent flare in allopurinol users and non-users respectively. 
Table 4.12: Total number of patients required to detect a difference in proportions in 
outcome between treatment groups 
Outcome  
Target SU level Allopurinol non-users 
Allopurinol users 15% 25% 35% 
45% 105 261 1,128 
55% 63 120 288 
65% 42 69 126 
75% 27 42 23 
Recurrent gout flare Allopurinol non-users 
Allopurinol users 5% 15% 25% 
10% 1,278 2,088 306 
20% 216 2,703 3,312 
30% 99 357 3,753 
40% 60 144 453 
 
Across the 1- and 2-year landmark periods, the power to detect a difference of proportion in 
outcome (using the same proportions in Table 4.12) between allopurinol users and non-users 
was almost 100%.   
The five-year period was sufficient to yield sufficient number of consulters for gout and was 
adequate to power analyses potentially across a range of outcomes.  
 
4.6 Summary 
This chapter describes how the retrospective cohort study was set up using primary care 
medical records from CPRD. The study sample was defined, how time-invariant and time-
varying covariates and treatment would be measured over time, definitions of outcomes, 
allopurinol, and covariates, and sample size and power calculations were provided.   
The next chapter aims to describe the statistical models used that will estimate treatment 
effects.   
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5 Propensity scores and marginal structural models 
Observational studies are often used to estimate the causal effect of treatment on outcome. 
In such studies, controlling for confounding can be challenging and is one of the most 
important aspects in estimating valid treatment effect.  
This chapter introduces the conceptual framework and the assumptions required to estimate 
casual effect. An overview of possible approaches to control for time-invariant and time-
varying confounding is discussed, and methods applied to estimate effect of allopurinol on 
outcomes in patients with gout in this PhD project described.  
 
5.1 Causal inference in observational studies 
Neyman (1923) developed a conceptual framework to investigate causality in the context of 
randomised controlled trials (RCTs) which was later extended to observational studies by 
Rubin (1974). 
Consider a binary treatment 𝐴 (1 if treated and 0 if untreated) and binary outcome 𝑌 (1 if 
outcome occurred and 0 if outcome did not occur). Let 𝑌𝑎 denote two potential (or 
counterfactual) outcomes, 𝑌𝑎=1 if treated and 𝑌𝑎=0 if untreated. The idea is to compare the 
same patient under two different treatments at baseline and effect of treatment on outcome 
measured during follow-up; the difference in outcome is attributable to treatment (Equation 
5.1).  
 𝑌𝑎=1 − 𝑌𝑎=0 5.1 
 
In reality, both outcomes cannot be observed as the patient is either treated or untreated 
therefore, patient specific treatment effect cannot be calculated. Instead, the average causal 
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effect is estimated at the population level. Let 𝐸[Ya=1] and 𝐸[Ya=0] be the expected value of 
outcome in treated and untreated patients respectively. The average treatment effect (ATE) 
is then defined in Equation 5.2. For a binary outcome, 𝐸[Y𝑎] represents the probability of 
outcome 𝑝𝑟[𝑌𝑎 = 1] therefore, Equation 5.2 represents the risk difference; alternatively, the 
risk ratio or odds ratio could be derived. For continuous outcome, Equation 5.2 represents the 
average difference in outcome.  
 𝐸[𝑌𝑎=1] − 𝐸[𝑌𝑎=0] 5.2 
 
So far above, treatment at a single time point was considered. In a repeated measures setting 
treatment is measured repeatedly over time. Consider time-varying treatment 𝐴𝑡 measured 
at time 𝑡; 𝑡 can be measured in continuous or discrete time (for example every year). 𝐴𝑡 = 1 
if patient was treated at time 𝑡 and 𝐴𝑡 = 0 if patient was untreated at time 𝑡. Let treatment 
history be denoted as ?̅?𝑡 = (𝐴0, 𝐴1, … . , 𝐴𝑡). The number of treatment histories can become 
large as there can be as many as 2𝑡combinations. Each treatment history has an associated 
outcome measured at the end of follow-up thus there will be 2𝑡 outcomes for each patient of 
which only one will be observed. For simplicity, two treatment histories are often compared 
in practice. For example, never treated history ?̅? = (0, 0, … , 0) is often compared with always 
treated history ?̅? = (1, 1, … , 1). The ATE is defined as the difference in expected outcome 
value between any two treatment histories (Equation 5.3) (Robins et al., 2000). 
 𝐸[𝑌?̅?] − 𝐸[𝑌𝑎′̅̅ ̅] 5.3 
 
On the other hand, outcome can be measured repeatedly at each time point. The difference 
in expected value between treatment groups is measured at time 𝑡 (Equation 5.4) (Robins et 
al., 1999).  
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 𝐸[𝑌𝑎𝑡=1] − 𝐸[𝑌𝑎𝑡=0] 5.4 
 
However, the above definitions (Equations 5.2, 5.3 and 5.4) relies on potential outcomes, i.e., 
only one outcome will be observed by the patient. Causal inference is underpinned by finding 
the best substitute patients who in all ways are similar to the observed patients apart from 
treatment, in an attempt to observe potential outcomes. Randomisation is the gold standard 
approach as each patient is randomly assigned to treatment hence it is due to chance whether 
potential outcomes are observed or not. A key consequence of randomisation is that the 
treatment groups are exchangeable, meaning it does not matter which particular group 
received treatment of interest, the results will be the same regardless. 
Another definition of treatment effect is the average treatment effect for the treated (ATET) 
which restricts attention to the subgroup of the population who received treatment. The 
causal effect in this subpopulation is the average difference in outcome between treated and 
untreated patients (Equation 5.5).        
 𝐸[𝑌𝑎𝑡=1 − 𝑌𝑎𝑡=0] | 𝐴 = 1  5.5 
 
In an RCT, the ATE and ATET estimates coincide as the treated population will on average be 
the same as the overall population due to randomisation. Whereas in an observational study 
in the absence of randomisation, the treated and overall populations on average are likely to 
differ thus the two estimates are unlikely to coincide (Austin, 2011a). In this PhD project the 




5.2 Fundamental assumptions 
In observational studies, assignment of treatment is influenced by patient and other (for 
example, hospital level) covariates. Causal inference is determined by viewing the 
observational study as a ‘conditionally randomised study’ provided the following assumptions 
are met (Hernán and Robins, 2020, Cole and Hernan, 2008): 
Consistency: Treatment is unique and well defined thus has the same effect on the 
patient regardless of how the patient received treatment. Consistency is not met when 
treatment is not well defined, such as having multiple versions of treatment with 
differing effects on outcome e.g., various treatment doses unaccounted for in analysis.  
Exchangeability: Treated and untreated patients are exchangeable if the treated 
patients were instead untreated, they would on average have the same outcome if 
they were treated, and vice versa, conditional on a set of observed covariates. 
Positivity: Patients’ probability of being assigned to each treatment group, conditional 
on observed covariates, is greater than zero. 
Correct model specification: The regression model used to obtain the associations 
between covariates, treatment, and outcome needs to be specified correctly, for 
example, using the correct functional form for continuous covariates.  
The estimated ATE (in Equations 5.2, 5.3 and 5.4) is either considered to be conditional or 
marginal. A conditional effect is the average effect of treatment at the patient level. A 
marginal effect is the average treatment effect at the population level. When observed and 
unobserved confounding effects are absent, the conditional and marginal effects are the 
same. 
The challenge in estimating causal treatment effect is that treatment assignment is not 
random leading to poor exchangeability between treated and untreated patients. The 
117 
 
treatment groups may be dissimilar and some patients may be guaranteed to receive 
treatment, violating the exchangeability and positivity assumptions respectively. 
The lack of exchangeability is otherwise known as confounding that biases treatment effect. 
Within a healthcare setting, confounding may arise from clinical decisions, known as 
confounding by indication. This is where assignment of treatment is based on covariates such 
as patient health status and prognosis, the clinician’s past experience with the treatment, or 
the willingness of the patient to take the medication as prescribed. As a result, patients 
prescribed treatment will often differ (for example be more severely ill or have more 
comorbidities) from patients not prescribed treatment; if these covariates also predict 
outcome, confounding by indication is present.  
The structure of confounding in the simplest case is represented in Figure 5.1 where a single 
covariate and treatment are measured at one time point. Figure 5.1 shows the casual effect 
of 𝐴 on 𝑌 however, this association is confounded by observed covariate 𝑋; this induces 
additional association between 𝐴 and 𝑌 from the confounding effect of 𝑋 on 𝐴 and 𝑌 
(represented by the black arrows). Although covariates can be controlled for in treatment 
effect estimation, unmeasured covariates cannot be controlled for. In practice, assumption of 
no unmeasured confounding is often made, i.e., no association between 𝑈 and 𝐴 illustrated 
by the dashed green arrow in Figure 5.1. 
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Figure 5.1: Illustration of confounding: treatment and covariate measured at a single time 
point  
 
In a repeated measures set-up, confounding is observed at all time points and the strength of 
confounding effect may vary over time, which may be due to, for example, patient attrition, 
missing data, and noncompliance with or changing treatment. A covariate 𝑋𝑡 measured at 
time 𝑡, is a time-varying confounder if its value changes over time and predicts future 
treatment and outcome. If past treatment also predicts 𝑋𝑡, time-varying confounding is 
affected by prior treatment.  
Time-varying associations between covariates and treatment are essentially as depicted in 
Figure 5.1 but repeated over time. Figure 5.2 illustrates an example using three time points 
(𝑡 = 0, 1, 2), but by analogy this can be extended to include further time points. As in Figure 
5.1, the assumption of no unmeasured confounding is illustrated by dashed green arrows. In 
addition, treatment 𝐴𝑡 and a single covariate 𝑋𝑡 at time 𝑡, predict subsequent treatment and 
covariate (represented by the black arrows). Covariate 𝑋1 is a time-varying confounder as it 
predicts treatment 𝐴1 and outcome 𝑌, but is associated with past treatment 𝐴0 thus mediates 
the association between 𝐴0 and 𝑌. Similarly, 𝑋2 is a time-varying confounder as is predicts 𝐴2 
and 𝑌, but is also associated with 𝐴1, thus mediates the association between 𝐴1 and 𝑌. 
X   A   Y 
A: Treatment; X: Observed covariate; U: Unmeasured covariate; Y: Outcome 
          Association between A, X and Y; 




Adjustment for covariates that have a dual role of confounders and mediators in regression 
models will bias the estimated treatment effect as the effect of previous treatment on 
outcome will be adjusted out (Robins et al., 2000).  




5.3 Common methods to control for confounding 
Choice of methodology adopted to control for confounding will depend on different aspects 
of the study, such as the available sample size and number of observed covariates, complexity 
of the data, whether control of time-invariant or time-varying confounding is of interest, 
analyst’s preferences and expertise, and available software.  
𝐴𝑡: Treatment; 𝑋𝑡: Observed covariate; 𝑈𝑡: Unobserved covariate; 𝑌: Outcome 
          Association between 𝑋𝑡, 𝐴𝑡, and 𝑌  
          Association between 𝑈𝑡 and 𝐴𝑡 is assumed not to exist 

















U0 U1 U2 
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This section outlines some of the most common approaches that are used in practice to 
control for confounding, and furthermore, rationale is provided why propensity score (PS) 
subclassification and marginal structural models (MSM) were chosen to estimate treatment 
effectiveness of allopurinol using the Clinical Practice Research Datalink (CPRD). 
 
5.3.1 Subclassification and matching 
Subclassifying involves placing patients into homogenous mutually exclusive subclasses based 
on the values of observed covariates of interest. Difference in outcome between the treated 
and untreated patients is calculated in each subclass, then averaged across all subclasses. 
However, as the number of covariates considered increases the sample size within each 
subclass would decrease rapidly or become zero, depending on the sample size and 
distribution of covariates (Anderson et al., 1980). 
In matching, a treated patient is matched to 𝑛 untreated patients based on them having the 
same values of observed covariates of interest thus ensuring comparability of treatment 
groups. There are several decisions that need to be made in order to perform matching. These 
include choice of covariates to match on; whether to match on the exact same covariate value 
(exact matching) or to match on similar covariate values within a predefined caliper width 
(interval matching); and specifying the number of untreated patients to be matched to a 
treated patient. Treatment effect is subsequently estimated in the matched sample with 
patients who are not matched are excluded from the analysis. An obvious disadvantage is that 
there is an increasing difficulty in finding matches for each of the treated patients as the 
number of covariates included in the matching process increases (Anderson et al., 1980, 




5.3.2 Generalised linear models 
Generalised linear model (GLM) is the most common method used to quantify the effect of 
treatment on outcome adjusting for covariates. GLM refers to a larger class of models 
including linear, logistic, and Poisson regression among others. Let 𝑿 = 𝑋0, 𝑋1, 𝑋2, … , 𝑋𝐾 be a 
vector of covariates with 𝑋0 = 1 and 𝜷 = 𝛽0, 𝛽1, 𝛽2, … , 𝛽𝐾 is a vector of unknown regression 
parameters to be estimated. For treatment 𝐴, the regression parameter to be estimated is 
denoted 𝛼. The GLM consists of two components: (1) the linear predictor (or function) of 
treatment and covariates (Equation 5.6), and (2) the link function 𝑔[. ] that transforms the 
expectation of outcome to the linear predictor (Equation 5.7).  
 










The specification of 𝑔[. ] will depend on the distribution of the outcome; for example, for a 
binary outcome, the link function is a logit function 𝑔[𝐸(𝑌|𝐴, 𝑿)] = 𝑙𝑜𝑔 [
𝐸(𝑌|𝐴,𝑿)
1−𝐸(𝑌|𝐴,𝑿)
] and for a 
Poisson count distributed outcome it is 𝑔[𝐸(𝑌|𝐴, 𝑿)] = 𝑙𝑜𝑔[𝐸(𝑌|𝐴, 𝑿)].  
If the GLM is specified correctly such that all relevant covariates are included in 𝑿, and the 
assumptions associated with the outcome distribution are met, an unbiased conditional 
estimate of the ATE can be obtained (Austin et al., 2007b). 
GLM however may produce unreliable treatment effect estimates in a range of situations. For 
example, issues are encountered when the model is over-fitted, i.e., when the number of 
included covariates is large compared to the number of observations and rate of outcome; 
this can lead to certain combinations of covariates not being observed in the study sample 
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and poor comparability between treatment groups. Consequently, the estimated regression 
parameters are extrapolated. The fact that outcome is always modelled when determining 
which covariates to adjust for increases the risk of model over-fitting. Furthermore, model 
assumptions often go untested in practice, particularly as the number of covariates increases.   
 
5.3.3 Propensity scores 
Rosenbaum and Rubin (1983) introduced the notion of PS. Their seminal paper described the 
theory and application of PS to estimate treatment effect in observational studies accounting 
for confounding effects from observed covariates. Since then, PS methodology has become a 
popular choice for treatment effect estimation, and extensions of the standard PS 
methodology have been examined via both simulation studies and real data, including for 
example comparisons with traditional multivariable regression models (Shah et al., 2005), 
assessment of different PS adjustment methods, choice of covariates for inclusion in PS 
(Austin et al., 2007a), extensions to treatments of non-binary form (Imai and van Dyk, 2004), 
development within Bayesian framework (McCandless et al., 2009), as well as estimation of 
time-varying PS when treatment and confounding variables are time-varying (e.g., risk set 
matching (Li et al., 2001, Lu, 2005)) and although developed separately MSM (Robins et al., 
2000)). 
PS methodology makes two core assumptions, (1) the ignorable treatment assignment 
assumption, and (2) the stable unit treatment value assumption (SUTVA). These two 
assumptions are a mixture of the exchangeability, consistency and positivity assumptions 
described in Section 5.2 above. 
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The ignorable treatment assumption implies that treatment assignment 𝐴 and potential 
outcomes 𝑌𝑎=1 and 𝑌𝑎=0 are conditionally independent given covariates 𝑋 (exchangeability) 
and that each patient has a positive probability of receiving each treatment (positivity). 
SUTVA is made up of two assumptions. Firstly, it is assumed that the potential outcome of a 
patient who received treatment would remain the same regardless of how treatment was 
assigned to that patient and regardless of treatment assignment to other patients, essentially 
ruling out interference between patients and effect of treatment assignment (i.e., association 
between covariates and treatment) on outcome. Secondly, it is assumed that treatment is well 
defined such that there is only one version of treatment; there cannot be various versions of 
treatment, such as different doses of treatment that are unaccounted for in statistical analyses  
(Rubin, 1980, Rubin, 1986). The SUTVA assumption includes the consistency assumption 
above.  
PS is a balancing score 𝑒(𝑿), defined as the probability that lies between 0 and 1 of receiving 
treatment conditional on observed covariates 𝑿 (Equation 5.8).  
 𝑒(𝑿) = 𝑝𝑟(𝐴 = 1 | 𝑿), 0 < 𝑒(𝑿) < 1 5.8 
 
In RCTs the PS is known as it is based on the allocation ratio. Due to randomisation the PS is 
conditional on covariates 𝑽 which consists of both observed (𝑿) and unobserved (𝑼) 
covariates and all patients have a non-zero probability of receiving each treatment. Also, 
treatment assignment 𝐴 is independent of outcome 𝑌 given covariates 𝑽 (Equation 5.9).   
 
 𝑒(𝑽) = 𝑝𝑟(𝐴 = 1 | 𝑽), 0 < 𝑒(𝑽) < 1 
5.9 




These properties do not hold in observational studies hence, at best, 𝑒(𝑿) can be estimated, 
often using logistic regression in the case of a binary treatment. Treatment assignment is 
assumed to be strongly ignorable if 𝑽 = 𝑿, i.e., all relevant covariates are included in 𝑽 and 
there is no unmeasured confounding. It follows that if treatment assignment is strongly 
ignorable given 𝑿 then it is strongly ignorable given the balancing score (i.e., the PS) as it is a 
function of 𝑿. On this basis 𝑌 is independent of treatment assignment given the PS (Equation 
5.10). 
  𝑌 ⫫ A | 𝑒(𝑿) 
5.10 
 0 < 𝑝𝑟[𝐴 = 1| 𝑒(𝑿)] < 1 
 
At a specific PS value, the distribution of PS would be the same amongst treated and untreated 
patients although specific covariate values will differ. Here, the PS balances covariates 
between treated and untreated patients. Consequently, direct adjustment for PS in a 
regression model, subclassification and matching on PS, and inverse probability treatment 
weighting (IPTW) would produce unbiased estimate of the treatment effect. 
The most straightforward method of using estimated PS is to include it as a covariate in the 
regression model estimating the association between treatment and outcome (with 
conditional treatment effect estimated (Austin, 2013, Austin et al., 2007b). Such direct model 
adjustment approach is the only method to model the association between PS and outcome 
and requires that association to be correctly modelled.  
Subclassification on the correctly specified and estimated PS divides treated and untreated 
patients into 𝐽 subclasses based on percentiles of the PS distribution; thus each subclass would 
have equal number of patients. The treatment effect is calculated within each subclass 
generating subclass specific estimates of the treatment effect which can then be pooled 
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generating an overall conditional ATE estimate weighted by the inverse of the treatment 
effect’s standard error. 
PS matching involves matching each treated patient to 𝑛 untreated patients based on having 
the same or similar PS. Consequently, within the matched sample the distribution of 
covariates is similar between the treatment groups. Subsequently comparison of outcomes 
between the treatment groups would yield a marginal ATE estimate that is less biased and 
more precise (i.e., smaller standard error) compared to estimate based on an unmatched 
sample. There are several decisions that need to be made to perform matching and there are 
ample simulation studies providing guidance. These include: choosing the most 
appropriate/suitable matching algorithm, with popular choices including the nearest 
neighbour matching and optimal matching (Austin, 2014); specifying the number of untreated 
patients to be matched to a treated patient (Austin, 2010); specifying caliper width (or the 
range) within which the PS must fall in order to be considered a valid match (Austin, 2009b, 
Austin, 2011b); and choosing whether matching is performed with or without replacement 
(Austin, 2014).   
Rosenbaum (1987) introduced IPTW as a form of model-based direct standardisation. IPTW 
belongs to a larger class of MSM used to estimate treatment effect in the presence of time-
varying treatment and time-varying covariates that are affected by prior treatment (Robins et 
al., 2000). The weight is defined as the inverse of the probability of receiving treatment that 
the patient was given (or observed). For a treated patient, their weight is simply the inverse 













The weight value determines the number of times a patient is represented in the pseudo-
population. Intuitively, untreated patients with high probability of treatment, and treated 
patients with low probability of treatment will be assigned larger weights. Using weights in 
analysis reweights the treated and untreated groups up to the population level making them 
representative of the population, where there is no association between covariates and 
treatment, thus allowing marginal ATE to be estimated.  
Different PS methods have various advantages and disadvantages. Direct adjustment for PS in 
the outcome model is the simplest approach however it is generally not considered in practice 
because it does not allow one to assess comparability nor create comparable treatment 
groups. Matching is a popular approach however, as mentioned above, several decisions need 
to be made during the modelling process and treatment effect estimates may be dependent 
on these different choices. Furthermore, generalisability of findings may be affected if many 
patients are discarded due to lack of good matches. If poor matches are found in matching, 
alternative approaches are IPTW and subclassification that analyses all patients. With 
subclassification on PS, one has to ensure that each subclass has high enough sample size in 
both treatment groups, while considering that bias in treatment effect estimate is reduced 
the greater the number of subclasses used. One methodological consideration of IPTW is the 
estimation of extreme weights from very small PS; such weights may bias and increase the 
variability of the estimated treatment effect. 
These different PS approaches estimate either conditional or marginal treatment effects. 
Direct PS adjustment and PS subclassification allows one to estimate patient-level treatment 
effect conditional on PS (subclasses); whereas PS matching and IPTW allows one to estimate 
a marginal treatment effect at the population level.  
PS methodology is an appealing approach as it is inherently a more natural method of 
mimicking RCT design compared to traditional regression models. PS approaches avoid the 
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use of covariates themselves to achieve comparable treatment groups, thus minimising the 
effect of model selection and over-fitting sometimes seen in regression models.  
 
5.3.4 Controlling for time-varying confounding 
Conventional statistical methods such as time-varying Cox regression (Fisher and Lin, 1999, 
Cox, 1972) and generalised estimating equations (GEE) regression (Zeger et al., 1988) are used 
to model longitudinal data where treatment and covariates (and also outcome) may be 
observed repeatedly over time. The time-varying Cox model compares the risk of outcome 
between treatment groups and re-evaluates that risk with each change to treatment status. 
GEE regression, an extension of GLM, accounts for the correlation between repeated 
measurements within a patient and estimates the population average effect of treatment. To 
naively adjust for time-varying confounding variables and past treatment will estimate biased 
treatment effect (as previously shown in Figure 5.2) (Robins et al., 2000, Cole et al., 2005).  
MSM, parametric G-computation formula and G-estimation, collectively known as G-methods 
(with ‘G’ standing for `generalised’), were specifically developed to estimate time-varying 
treatment effect in the presence of time-varying confounding.   
More direct approaches of utilising PS estimated over time in matching and subclassification 
have also been proposed. 
Some of these different methods are briefly described below, and further outline of the 
associated advantages and disadvantages is provided in Section 5.3.5.  
Marginal Structural models 
Robins et al. (2000) developed a class of casual models known as MSM that directly models 
counterfactual outcomes. MSM are termed “marginal” because they use the joint distribution 
of treatment and covariates via IPTW to estimate a weighted treatment effect on outcome 
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across all time points i.e., treatment effect is unconditional on covariates. They are termed 
“structural”, as they were originally developed within the context of economic and social 
sciences, where historically models estimating causal associations are referred to as 
structural. 
Fitting MSM is a two-step process. The first step involves correctly specifying the PS model 
such that the patient’s probability of receiving observed treatment at time 𝑡, given their 
treatment and covariate history up to that point, is estimated and subsequently used to 
estimate weights. Various weights can be estimated. The simplest are unstabilised weights 
defined in Equation 5.12, where ?̅?𝑡 represents treatment history up to and including time 𝑡 −
1; ?̅?𝑡 represents covariate history (of time-varying and time-invariant covariates) up and 









The second step uses the estimated weights to reweight the study sample to create a pseudo-
population such that the association between covariates and treatment no longer exists thus 
removing effects of confounding from treatment effect estimation. 
G-computation formula 
The G-computation formula, introduced by (Robins, 1986), compares outcomes under 
different treatment histories as if they were derived from a randomised study, i.e., outcome 
that would have been observed if all patients in the study sample followed a particular 
treatment history. G-computation calculates the expectation of outcome for a particular 
treatment history by the sum over all covariates, the probability of outcome conditional on 
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treatment and covariate histories, and the probability of covariate conditional on treatment 
and covariate histories (Equation 5.13). 
 
𝐸[𝑌(?̅?)] = ∑[𝐸(𝑌|?̅?, ?̅?)
𝑋





G-computation is performed in two stages. Firstly, the associations between outcome, 
treatment and covariates are modelled using GLM thus estimating the joint distribution of 
outcome and covariates. Secondly, the estimated joint distributions are then used to simulate 
the risk of outcome at each time point under hypothetical treatments to be compared (Daniel 
et al., 2011, Daniel et al., 2013). 
G-estimation of structural nested models 
Structural nested models (SNM) estimate the effect of treatment conditional on different 
values of a time-varying effect modifier. An effect modifier is when a covariate increases or 
decreases the effect of treatment. Typically, effect modifiers are included in GLM by fitting an 
interaction term between treatment and covariate. SNM estimates the average effects of 
treatment at each time point as a function of effect moderators prior to that time point 
(Robins et al., 1992).  
There are different types of SNM based on the distribution of outcome; for continuous 
outcome there is the structural nested mean models and for time-to-event outcomes the 
structural nested failure time model.  
Risk set matching 
Li et al. (2001) proposed balanced risk set matching that minimises imbalance between 
treatment groups on specified covariates. A patient receiving treatment at time 𝑡 is matched 
to 𝑛 patients with a similar history of covariates but who has not received treatment up to 
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time 𝑡. Rather than matching on several covariates, Lu (2005) proposed matching on the PS 
instead. The PS is estimated via the Cox proportional hazards (PH) model for the instantaneous 
probability of receiving treatment given covariate history. Various matching algorithms exist 
including sequential matching and simultaneous pair matching (Lu, 2005). Matching on the 
prognostic score is another approach (Smith and Schaubel, 2015). Treatment effect estimation 
is subsequently performed on the matched sample. 
Time-varying PS subclassification 
As previously stated in Section 1.3, Leon (2011b) extended PS subclassification to the repeated 
measures setting. Leon (2011b) estimated PS over time by estimating the probability of 
treatment given covariates at each time point using multilevel logistic regression. 
Observations are then stratified into subclasses based on the PS, typically using quintiles, with 
treatment groups comparable within each subclass. As the PS can vary within a patient over 
time, patients may contribute observations to more than one subclass, for example if gout 
becomes worse propensity for treatment may increase. Treatment effects are then estimated 
within each subclass using the complementary log-log model and pooled. More detail on this 
approach is given in Section 5.4.5.1. 
 
5.3.5 Methods used in the PhD project 
Some of the most common approaches used to control for time-varying confounding have 
been described above. The implementation of any of these methods will be complicated by 
the large number of follow-up time points and large sample size, which are likely to be seen 
in studies using CPRD. Furthermore, availability of suitable and easy to use software is also an 
issue that hinders a more widespread application of these approaches in practice. For 
example, Daniel et al. (2013) discuss various limitations of G-methods and report that 
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implementation of these methods computationally intensive and not widely available in 
standard software.  
G-computation models the association between all covariates which can become burdensome 
if the number of covariates is large; CPRD offers the opportunity for large number of covariates 
to be explored. Furthermore, G-computation models the effect of treatment history on 
outcome. Within CPRD, there will be many treatment histories of allopurinol; some patients 
may never start treatment, whilst others may start and remain on treatment, or discontinue 
and restart treatment (Scheepers et al., 2018). Therefore, evaluating effect of all treatment 
histories on outcome may not be feasible or practical. It would be easier if effect of treatment 
was evaluated over a short period of time, say a few years. However in relation to the topic of 
this PhD project, only a small proportion of patients with gout would be prescribed urate-
lowering therapy shortly from diagnosis (Kuo et al., 2014), which may result in a small number 
of patients with distinct treatment histories in the few years post diagnosis. It was only more 
recently that it was shown the length of time patients adhered with allopurinol treatment 
using CPRD data (Scheepers et al., 2018) that may have aided this decision.  
Out of the three G-methods, MSM are the most commonly used method and is considered 
the gold standard for modelling time-varying treatment effect in the presence of time-varying 
confounding. MSM are considered for use in this PhD project as they can be fitted using 
standard software, such as Stata, and the procedure behind them is more intuitive to other G-
methods. Furthermore, the risk of model misspecification is smaller as only two models are 
fitted (one to model the multivariable association between covariates and treatment, and the 
other to model the effect of treatment on outcome), compared with G-computation which 
fits a separate model for each covariate. The disadvantage of MSM is that weights can become 
extremely large due to near violations of the positivity assumption, i.e., PS is close to zero thus 
taking the inverse yields large weights. Large weights often occur if too many covariates are 
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used in the estimation of PS, which may result in combinations of covariates having small PS 
i.e., only a few patients with very low PS actually receive treatment. Large weights can become 
amplified in patients with long follow-up times due to cumulative multiplication of small PS 
over time. Use of stabilised and basic weights, and truncating weights may prevent this 
(described further in Section 5.5.5.1).  
A common issue across GLM, matching and subclassification on the covariates is that they are 
susceptible to poor model fit when the number of covariates is large, the study sample and 
number of outcomes is not large enough for all relevant covariates to be adjusted for. PS 
methodology aims to overcome the most common issues encountered in these three 
approaches. PS methods are easily understood and widely used with matching being the most 
popular method. However, it is currently unclear how straightforward it would be to 
implement any methods based on direct extension of PS to complex electronic health records 
(EHR) data involving repeated measures of treatment and covariates. Risk set matching (Lu, 
2005), as described above, is restricted to the simple setting of comparing patients that were 
never treated to those that initiated treatment, who share similar PS; this approach ignores 
the issue of treatment adherence, and may be impracticable to find valid matches. A less 
restrictive approach would be to use time-varying PS subclassification proposed by Leon 
(2011b). This method is considered for use in this PhD project as it allows patients to 
repeatedly initiate and discontinue treatment over time, stratification attempts to achieve 




5.4 Time-invariant PS subclassification 
This section describes components of the analysis taken to specify, estimate and assess the 
PS, and how it may be used via subclassification and in subsequent estimation of treatment 
effect. 
 
5.4.1 Propensity score estimation 
Logistic (or logit) regression is the most frequently used model to estimate PS in the case of 
binary treatment. A systematic literature review conducted in 2004 found 47 out of 48 
research articles relating to PS used logistic regression (Weitzen et al., 2004). Logistic 
regression is given in Equation 5.14 and allows control for multiple covariates through the 
regression component. The estimated regression coefficients measuring the association 
between treatment 𝐴 and baseline covariates 𝑿 are measured on the logit scale. For each 
patient, their linear prediction on the logit scale is converted into the probability of treatment 
i.e., the PS, that ranges from 0 to 1 (Equation 5.15).  
 𝑙𝑛 [
𝑝𝑟(𝐴 = 1)
1 − 𝑝𝑟(𝐴 = 1)













5.4.2 Covariate specification  
Ideally covariate selection should be pre-specified based on prior clinical knowledge on the 
associations between covariates, treatment, and outcome. In reality this knowledge may be 
limited or unknown. Alternatively, statistical tests on the associations between covariates and 
treatment and outcome are used and covariate selection is based on pre-specified criteria.  
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General consensus is to include all covariates associated with outcome in the PS model (Austin 
et al., 2007a, Cuong, 2013, Rubin and Thomas, 1996). Brookhart et al. (2006) performed a 
simulation study and had shown all covariates associated with outcome, regardless of their 
association with treatment, should be included in the PS model; inclusion of covariates only 
associated with outcome in addition to confounding variables (covariates associated with both 
outcome and treatment) was found to have higher precision of the treatment effect without 
affecting bias. Inclusion of covariates only associated with treatment were found to lower 
precision of the treatment effect although bias was unaffected.  
Consideration of including interaction terms and functional form specification via higher order 
linear or non-linear terms for continuous covariates is needed. Rosenbaum and Rubin (1984) 
and similarly Dehejia and Wahba (1999) suggested including such terms if balance was not 
achieved on the main effects of covariates. Assessment for balance is described further in 
Section 5.4.4. 
Attempts to improve PS prediction are discouraged as goodness-of-fit tests and discrimination 
tests do not necessarily yield the best PS model that improves balance between treatment 
groups, and may lead to lack of common support (Brookhart et al., 2006, Westreich et al., 
2011, Patrick et al., 2011, Weitzen et al., 2005). 
 
5.4.3 Number of subclasses 
Subclassification on the correctly specified estimated PS divides treated and untreated 
patients into 𝐽 subclasses based on percentiles of the PS distribution thus all subclasses would 
have equal number of patients. Patients within each subclass will have similar distribution of 
covariates. There is no general consensus on the optimal number of subclasses. Cochran 
(1968) had shown a 90% reduction in bias in the treatment effect when patients were divided 
into quintiles, i.e., five subclasses on the distribution of a continuous covariate. Rosenbaum 
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and Rubin (1984) showed that this finding is still applicable when patients were spilt into five 
subclasses based on the PS distribution. Thus, it has become standard practice for studies to 
use five subclasses. This is not of course an optimal approach across board, as the number of 
subclasses is dependent on sample size, covariate balance, and associated bias reduction in 
the treatment effect.  
Various simulation studies have shown increasing the number of subclasses reduces bias in 
the treatment effect as the distribution of covariates within subclasses become more 
homogenous (Lunceford and Davidian, 2004, Hullsiek and Louis, 2002, Neuhäuser et al., 2018). 
However, the trade-off is that variance may increase due to smaller sample size in subclasses 
(Lunceford and Davidian, 2004). Hullsiek and Louis (2002) recommend that a large number of 
subclasses as possible should be used (until subclass-specific treatment effects can no longer 
be estimated) in order to achieve maximal bias reduction, this study as well as Neuhäuser et 
al. (2018) demonstrated the use of more than five subclasses led to much smaller reductions 
in bias. 
Note however that despite subclassification removing a significant amount of bias from 
confounding effects, some residual confounding is expected to remain as each subclass would 
contain a range of PS, thus small imbalances in distribution of covariates between the 
treatment groups is expected to remain (Rosenbaum and Rubin, 1983). Lunceford and 
Davidian (2004) suggested to fit regression analysis evaluating the effect of treatment on 
outcome adjusted for covariates within each subclass to further reduce within-subclass 
confounding.   
 
5.4.4 Common support and covariate balance evaluation 
In evaluating covariate balance, two checks are undertaken:  
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1) Common support, to assess whether the distribution of PS overlaps between the 
treated and untreated groups. 
2) Covariate balance, to assess whether the distribution of covariates is similar across the 
treated and untreated groups after PS subclassification. 
If adequate common support and covariate balance has been achieved, the treatment groups 
are assumed comparable. Evaluation of common support and covariate balance can be 
assessed either graphically or descriptively. Austin (2009a) outlines different methods that can 
be used to evaluate covariate balance. 
Common support 
Once PS is estimated, common support is evaluated before and after PS subclassification. This 
involves assessing the amount of non-overlap between treatment groups. This can be 
investigated using box plots with descriptive summaries e.g., minimum, first quartile, median, 
third quartile, and maximum values, or using kernel density plots e.g., histograms. Where 
there is overlap on the PS distribution, this implies similarity of PS between treated and 
untreated patients. Often it is assumed treated patients would have higher PS than untreated 
patients, and untreated patients would have lower PS than treated patients. If there is little 
overlap at the tails (i.e., the lower and upper ends) of the PS distribution, this suggests there 
could be a combination of covariate values that are not shared between treated and untreated 
patients. In case of such poor covariate balance in the tails of the PS distribution, it may be 
sensible to remove these patients, a process known as trimming, prior to outcome analysis 
(Patorno et al., 2013). However, trimming may lead to the study sample no longer being 
representative of the population it was derived from. 
After PS subclassification, each subclass requires a sufficient number of treated and untreated 
patients with outcome occurring in both treatment groups to enable calculation of subclass-
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specific treatment effects. In subclasses that only contain either treated or untreated patients 
there would be no common support and the treatment effect cannot be estimated within that 
subclass. Similarly, treatment effect cannot be estimated if outcome did not occur within a 
treatment group. Common support can be improved by reducing the number of subclasses 
however, covariate balance may decrease within subclasses because the range of PS would 
increase (Stuart, 2010). 
Covariate balance 
Covariate balance is usually evaluated using standardised mean difference (SMD), also known 
as standardised bias. SMD is used to compare means and proportions in units of the pooled 
standard deviation across the treatment groups. SMD is evaluated before and after PS 
subclassification to investigate whether SMD reduces in size for each covariate. SMD is not 
influenced by sample size and allows covariates measured in different units to be compared 
to one another on the same scale. The formula to calculate SMD for continuous covariates is 
shown in Equation 5.16 where ?̅? is the mean and 𝑠 is the standard deviation of the covariate 
in each treatment group.  








SMD for binary covariates can be derived using Equation 5.17 where ?̂? is the proportion of 
covariate of interest in each treatment group (Austin, 2009a).  
 (?̂?𝑡𝑟𝑒𝑎𝑡𝑒𝑑 − ?̂?𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑)







No acceptable size of SMD has been suggested however, a common rule of thumb is SMD 
larger than 0.10 indicates imbalance on the covariate (Austin, 2011a). Other studies have used 
a more relaxed criterion of 0.25 (Stuart, 2010, Stuart and Rubin, 2008). Ho et al. (2017) argued 
covariates with stronger associations with outcome need better balance than covariates with 
weaker associations.  
After PS subclassification, subclass-specific balance should be evaluated for each covariate 
and then averaged across all the subclasses, weighted by the proportion of patients in each 
subclass from the total study sample (Harder et al., 2010). 
There are many other measures of covariate balance such as the variance ratio for continuous 
covariates (Austin, 2009a), and use of prognostic scores to ensure the risk of outcome is similar 
between the treatment groups (Stuart et al., 2013b). The use Kolmogorov-Smirnov test 
statistic and t-tests are discouraged as these measures are dependent on sample size and 
small imbalances are likely to be found statistically significant due to increased power in larger 
datasets (Austin, 2009a, Imai, 2008). If large number of covariates are entered into the PS 
model, multiple testing would be rife and subjected to type I error. Covariate balance was 
assessed using SMD in this PhD project.  
 
5.4.5 Treatment effect estimation 
Once covariate balance has been achieved, treatment effect estimation can proceed. 
Treatment effects are estimated within each subclass by comparing outcome directly between 
the treatment groups. Subclass-specific estimates are derived using GLM which may also 
adjust for covariates to account for residual differences between treatment groups (Equation 
5.6 and Equation 5.7). The subclass-specific treatment estimates 𝑎𝑗 are pooled as the sum of 
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weighted subclass-specific treatment estimates (Equation 5.18). The pooled weighted 
variance 𝑠2 is shown in Equation 5.19.  
 














Two methods are commonly used to weight subclass-specific estimates. Firstly, one could 
weight by the subclass-specific sample size, which involves calculation of subclass-specific 
weight 𝑤𝑗 as shown in Equation 5.20, where 𝑁 is the total number of patients and 𝑁𝑗 is the 








However, given that each subclass would have approximately the same number of patients, 
each subclass would have the same, or very similar, weight (Rosenbaum and Rubin, 1984, 
Cochran, 1968). Note that this may not always be the case, if for example two (or more) 
subclasses are collapsed into one due to low number of treated or untreated patients within 
particular subclasses. 
Secondly, treatment effect estimates may be weighted by the inverse variance, with the 
Mantel-Haenszel (MH) method (Mantel and Haenszel, 1959, Mantel, 1963) being commonly 
used. The weights are represented as the inverse of the estimated variance of the subclass-
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The advantage of using inverse variance weights is that subclass-specific estimates with larger 
variance would have smaller weights thus contributing less to the overall treatment effect 
estimate.  
Rudolph et al. (2016) simulation study had shown that using inverse variance weights 
outperformed weighting by the sample size in PS subclassification but only when treatment 
effects across the subclasses are homogenous. When the treatment effect varied across 
subclasses, the weighting by sample size performed better, especially if over 10 subclasses 
were used. In this PhD project, both approaches were utilised, as appropriate. 
The assumption of constant treatment effects across subclasses can be verified using all 
observations from all subclasses. A GLM model initially regresses outcome on treatment and 
the PS subclasses. The incremental contribution of the interaction term between PS subclasses 
and treatment is then tested using the likelihood ratio test (LRT) by comparing the -2 
difference in log-likelihood of the GLM models with and without the interaction. An 
insignificant test would indicate that the effect of treatment does not vary significantly 
between subclasses, hence results can be pooled. If however the LRT is significant, this would 
indicate that the treatment effect varies across subclasses and the subclass-specific estimates 
should be reported, alongside with the distribution of covariates (Leon, 2011b).  
One should note that differences between treatment groups may remain within PS subclasses 
and may be difficult to achieve balance on particular covariates, even after increasing the 
number of PS and re-estimating PS. One solution would be to adjust for imbalanced covariates 
within subclass-specific treatment effect estimation. However, the number of covariates to 
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adjust for may be restricted by sample size and frequency of outcome (Vittinghoff and 
McCulloch, 2006). One should aim to achieve balance for the majority of covariates prior to 
adjusting for them.  
 
5.4.5.1 Survival analysis 
Survival analysis, the method of interest to estimate treatment effectiveness in this PhD 
project, is the analysis of times from some time origin (such as baseline) to occurrence of 
outcome of interest, for example death.  
Survival data, though inherently continuous, cannot be processed in the usual manner based 
on assumed normality, due to their tendency to follow non-symmetrical distributions and a 
substantial proportion of survival times are usually censored. Censored observations are those 
that have not been fully observed, and this can take the form of right, left or interval censoring. 
Such observations cannot be ignored as they carry potentially important information about 
the effect of treatment and covariates. The form of censoring that is easiest to model, and 
occurs most commonly, is right censoring. An observation is right censored if at the end of 
study, say 𝑡𝑐, the exact survival time, 𝑡 , is not known and all we can state is that 𝑡 > 𝑡𝑐. This 
may occur if, for example, a patient is lost in the follow-up period or the outcome of interest 
has not been observed at the end of the study.  
Left censoring is rare and occurs when the outcome is observed prior to the start of study; 
interval censoring occurs when the outcome is observed between two specified time points.  
Only right censoring was considered in this PhD project. Furthermore, it was assumed that the 
censoring mechanism is non-informative, i.e., the censoring is not related to any factors 
associated with the actual survival time.  
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There are three key functions of interest; the survival function, probability density function, 
and hazard function, which are now defined: Let 𝑇 be a non-negative random variable 
denoting survival time. The survival function 𝑆(𝑡) measures the proportion of patients who 
have not experienced outcome beyond time 𝑡 (Equation 5.22).  
 𝑆(𝑡) = 𝑃(𝑇 ≥ 𝑡) 5.22 
 
The survival function is a monotone, non-increasing function with boundary conditions 
𝑆(0) = 1 and 𝑆(∞) = 0. The probability density function 𝑓(𝑡) is the unconditional probability 




𝑃(𝑡 ≤ 𝑇 ≤ 𝑡 + Δt)
Δt
  5.23 
 
The hazard function ℎ(𝑡) is defined in Equation 5.24 and can be rewritten as the ratio between 









 5.24  
 
So ℎ(𝑡)Δt is approximately the probability that the outcome occurs in the interval (𝑡, 𝑡 + Δt) 
given that the patient has not experienced outcome up to time t. Thus ℎ(𝑡) is a conditional 
function and can also be thought of as the risk of outcome occurring immediately after t. Note 
that ℎ(𝑡) is a rate, not a proportion, so it can take on any value between zero and infinity. 
ℎ(𝑡) can assume many different forms (increasing, decreasing or monotone over time) and is 




5.4.5.2 Cox proportional hazards model 
Cox survival model (Cox, 1972) is used in this thesis and its properties are summarised in this 
section. The hazard rate ℎ(𝑡) is given in Equation 5.25: 𝑿 = 𝑋0, 𝑋1, 𝑋2, … , 𝑋𝐾 is a vector of 
covariates with 𝑋0 = 1, and 𝜷 = 𝛽0, 𝛽1, 𝛽2, … , 𝛽𝐾 is a vector of unknown regression 
parameters to be estimated; for treatment 𝐴, the regression parameter to be estimated is 
denoted 𝛼; and ℎ0(𝑡) > 0 is some arbitrary function of time, also known as the baseline 
hazard function, describing the risk when 𝐴 = 0. ℎ0(𝑡) represents a reference point that 
depends on time, just as the intercept denotes a reference point in other types of regression 
models. Cox regression parameters are estimated using the partial likelihood, which depends 
only on the parameters of interest. 
 





The hazard ratio between two treatment groups when all covariates are fixed is simply 
𝑒𝑥𝑝(α), interpreted as the relative risk of outcome.   
This model is termed PH because the hazard ratio for two patients with time-invariant 
covariates is constant over time and has a relative risk interpretation. The Cox model is 
therefore a semi-parametric model because the exact form of ℎ0(𝑡) is left unspecified and a 
strong assumption of proportionality of hazards is made. It is this semi-parametric property of 
the Cox model that has made it the most popular model used in survival analysis when there 
is doubt about correct parametric specification. Note that specification of ℎ0(𝑡) in Equation 
5.25 would lead to parametric models, such as Weibull.  
It is important that the PH assumption is tested if the Cox model is to be used; there are 
numerous methods of doing this, both numerically and graphically. Schoenfeld residuals, 
defined as the difference between the observed covariate value minus its expected value for 
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that patient at its failure time, are commonly used to assess the PH assumption. The residuals 
are independent of time, therefore plotting the residuals against time would have a random 
pattern. Also, one can test whether the slope is equal to zero in a linear regression model of 
the Schoenfeld residuals on time. If the p-value <0.05, the slope is not equal to zero and 
indicates deviation from PH and the log-hazard ratio changes over time (Grambsch and 
Therneau, 1994).  
Alternatively, the Kaplan-Meier survival curves (or survival times) can be plotted for each 
treatment (or covariate) group (Sedgwick, 2014). If the two survival curves crossover, it 
indicates violation of the PH assumption. Violation of the PH assumption may be resolved by 
including an interaction term between the particular covariate and time in the Cox model.  
 
5.4.5.3 Anderson & Gill method 
The Cox PH model considers time to a single outcome but cannot be used in the case of 
repeated outcome (Andersen and Gill, 1982). The Anderson and Gill model is a common 
method used in the analysis of repeated outcome and is a simple extension of the Cox PH 
model. The Anderson and Gill model assumes repeated outcomes times are independent to 
one another and ignores the order of occurrence of the outcomes. Therefore, the hazard of 
experiencing an outcome at time 𝑡, is the same regardless if outcome occurred previously. 
Each recurrent outcome is assumed to follow the Cox PH model (Equation 5.25).  
 
5.5 Time-varying PS subclassification 
Leon et al. (2001) extended the approach of PS subclassification to the setting of repeated 
treatment and covariates over time. In theory, time-varying covariates and time-varying 
treatment may be measured in continuous time thus it is possible to know the exact date 
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when covariate and treatment status change, such as in EHR where patient observations are 
recorded continuously. This would allow PS to be estimated and updated at each change of 
covariate and treatment status. However, in practice, this set-up may yield an unwieldly large 
dataset; consequently, issues with fitting an effective PS model would arise due to large 
number of repeated measurements for each patient, and potentially high correlations 
between repeated measurements resulting from lack of change between a high proportion of 
time points. Calculating the PS in this way is computationally intensive. As a compromise, 
treatment and covariate values may be ascertained in pre-set time intervals, but the specifics 
would be dependent on the length of follow-up and clinical relevance. Such discrete time 
approach commonly assumes treatment and covariates do not change within an interval. It is 
therefore important, as well as challenging, that both the ease of statistical modelling and 
clinical relevance are considered when making decisions about the width of time intervals.  
Published methods of subclassifying patients on time-dependent PS usually assume such 
discrete time. For example, in Leon et al. (2003) study, patients were followed up semi-
annually for the first five years and annually thereafter up to 20 years. Follow-up was divided 
into intervals of variable length corresponding to which treatment intensity the patient was 
prescribed; median number of intervals of 8 (range 1, 65) per patient. Thus, a patient had a 
mixture of discrete intervals taking various treatment intensity. This created a two-level 
hierarchical data structure with repeated measurements (level 1) clustered within a patient 
(level 2).  
Since their initial paper, subsequent publications by Leon et al. have shown the methodology 
evolve. Various simulations studies have evaluated the performance of time-varying PS 
subclassification in various settings; this method is capable of adjusting for time-varying 
covariates and estimating unbiased treatment effect for survival outcomes (Leon and 
Hedeker, 2005), continuous outcomes (Leon and Hedeker, 2007a) and repeated binary 
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outcomes (Leon, 2011b). Leon et al. (2012b) also proposed full matching, a type of 
subclassification. This involves creating a series of matched sets, where a matched set contains 
at least one treated interval and one untreated interval that have the same PS.    
Application of these methods have commonly been applied to the evaluation of anti-
depressants on outcome (Leon et al., 2001, Leon et al., 2003, Leon et al., 2011, Leon, 2011b) 
but has received little attention elsewhere.  
 
5.5.1 Propensity score estimation 
Following specification of hierarchical data structure as described above, PS needs to be 
estimated in each time interval. 
Use of logistic regression as specified in Section 5.4.1 and Equation 5.14 would be erroneous 
as the model would make an unrealistic assumption that repeated measurements within a 
patient are independent given covariates. Instead, mixed effects (also termed multi-level) 
models can be used to analyse such hierarchical data where the variability in outcome is 
attributable to both repeated measurements within patients and between patients (Rabe-
Hesketh and Skrondal, 2012). Mixed effects models incorporate both fixed and random 
effects. Leon et al. (2001) used such models, specifically random intercept ordinal logistic 
regression model, to estimate PS for each dose of treatment (ordinal treatment dose) over 
time. For binary treatment, random intercept logistic regression would be used. 
Extending Rosenbaum and Rubin (1983) notation to the repeated measures set-up, the PS at 
time 𝑡 is defined in Equation 5.26; 𝑟 is the patient-specific random intercept that is assumed 
to be normally distributed with mean zero and variance 𝜎𝑟
2 and ?̅?𝑡 denotes covariate history 
(that include time-invariant and time-varying covariates) up to and including time 𝑡 − 1 to 
ensure temporal ordering between covariates and treatment.  
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 𝑒(?̅?𝑡, 𝑟) = 𝑝𝑟(𝐴𝑡 = 1 | ?̅?𝑡, 𝑟), 0 < 𝑒(?̅?𝑡, 𝑟) < 1 5.26 
 
The random intercept logistic regression model is specified in Equation 5.27 which is an 
extension of Equation 5.14; it now estimates the probability of treatment at time 𝑡 given the 
random intercept and covariate history. 
 𝑙𝑛 [
𝑃(𝐴𝑡 = 1)
1 − 𝑃(𝐴𝑡 = 1)













Within a patient, PS can change over time due to time-varying covariates included in ?̅?. The 
random intercept can be thought of as patient-specific regression coefficient; inclusion of the 
random intercept in PS estimation allows each patient to have a separate intercept so the PS 
at baseline (𝑡 = 0) would be higher or lower compared to the estimated intercept 𝑏0. 
Measurements within patients may be correlated, which is accounted for in mixed models via 
𝜎𝑟
2. The estimation of the covariance structure is usually performed under certain specific 
structure assumptions. Independent, exchangeable, and unstructured covariance structures 
are commonly used in practice. The independent structure is the most simplistic and assumes 
repeated measurements within a patient are independent. The exchangeable structure 
assumes correlations between subsequent measurements are the same, irrespective of time. 
The least restrictive is the unstructured structure where all correlations are assumed to be 
different. In practice, there is no strict rule on which covariance structure is optimal, and in 




5.5.2 Covariate specification 
As discussed in Section 5.4.2, covariates associated with outcome should be included in 
estimation of the PS at a single time point. However, it is unclear whether the same applies in 
the case of estimation time-varying PS.  
In a repeated treatment and covariates setting, Leon and Hedeker (2007b) performed a 
simulation study on the impact of a misspecified PS model in treatment effect estimation. That 
study found omitting confounding variables from the PS model yielded biased treatment 
effects. Omitting continuous time-varying confounding variable increased bias the most 
followed by time-varying binary confounding variables, and then baseline confounding 
variables. Leon and Hedeker (2007b) also found omitting a confounding variable in PS 
estimation that were highly correlated with other confounding variables yielded less bias 
compared with omitting a confounding variable with lower correlation. Therefore, it was 
suggested to adjust for time in treatment effect estimation to lessen the impact of omitting a 
time-varying confounding variable in PS estimation to the extent that confounding variable is 
associated with time.   
Many of Leon’s research articles hypothesised that the included covariates in the PS were 
associated with treatment however, there was no discussion whether these covariates were 
also associated with outcome (Leon et al., 2003, Leon et al., 2001, Leon, 2011a). This differs 
to time-invariant PS where Brookhart et al. (2006) simulation study suggested all covariates 
associated with outcome should be included in PS estimation (Section 5.4.2).  
As described above, the PS at time 𝑡 is estimated using covariate history, therefore the PS 
should contain lagged covariates representing covariate values in earlier time intervals. For 
example, Leon et al. (2003) included history of disease (e.g., prior number of episodes), 
trajectory of symptom severity prior to treatment (stable, increasing, decreasing), and prior 
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treatment use in the PS model. Leon and Hedeker (2007a) recommended including time as a 
covariate in the PS model if it was hypothesized there was temporal trend in being treated.  
 
5.5.3 Number of subclasses 
Once PS are estimated within intervals, the intervals are then divided into subclasses 𝐽 based 
on the PS distribution leading to equal or very similar number of intervals in each subclass. A 
patient may contribute to multiple subclasses if their PS changes over time.  
Similarly to PS subclassification at a single time point (Section 5.4.3), many studies had used 
quintiles based on the time-varying PS distribution (Leon et al., 2001, Leon et al., 2003, Leon 
and Hedeker, 2005). Later studies by Leon and Hedeker (2007a) and Leon (2011b) performed 
simulation studies and determined that between four and five subclasses were required to 
remove 80-90% of bias in the treatment effect in this repeated measures setting. They noted 
that statistical power decreased as more subclasses were used; these studies did not consider 
more than five subclasses.  
As previously noted in Section 5.4.3, the number of subclasses is dependent on sample size, 
covariate balance, and bias reduction in the treatment effect when PS is performed at 
baseline. Logically the same is assumed here.  
 
5.5.4 Common support and covariate balance evaluation 
Similarly to PS subclassification at a single time point (Section 5.4.4), common support is 
evaluated before and after PS subclassification. It is first necessary to check there is sufficient 
number of treated and untreated intervals with outcome occurring in both treatment groups 
to enable calculation of subclass-specific treatment effects. There is no consensus on the 
minimum number of observations needed within a cell. Leon et al. (2001) and Leon et al. 
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(2003) had a minimum of 4% for each treatment within a subclass in their analyses whilst Leon 
and Hedeker (2007a) suggests a minimum of 5-10 observations in each cell of the PS subclass 
and treatment contingency table. 
Covariate balance was assessed before and after PS subclassification. Leon and Hedeker 
(2007a) and Leon (2011b) assessed balance by using mixed models to regress treatment on 
each covariate (that was included in the PS model) individually; the estimated regression 
coefficient and statistical significance was noted for each covariate. Subsequently, each mixed 
model was adjusted for PS subclasses. If the addition of the PS subclasses to the model 
attenuated the regression coefficient for the covariate towards the null and had become 
statistically insignificant, then it was assumed that balance was achieved on that covariate. If 
balance was not achieved on that covariate, it was adjusted for in the estimation of subclass-
specific treatment effect.  
Note however that as stated above in Section 5.4.4, use of significance testing for covariate 
imbalance is dependent upon sample size and its use is discouraged as small imbalances are 
likely to be found statistically significant due to increased power in larger datasets, for 
example when using CPRD (Austin, 2009a, Imai, 2008); intuitively the same applies here. 
Therefore, assessment of change in the covariate regression coefficient alone is better placed 
to ascertain whether balance was achieved. 
A more appropriate approach to examining the magnitude of imbalance after PS 
subclassification would be to use SMD as described in Section 5.4.4. In the repeated measures 
setting, covariates measured in each interval would contribute to calculating SMD that 
assumed the repeated measurements were independent; ?̅? in Equation 5.16 represents the 
mean covariate across all intervals, and ?̂? in Equation 5.17 represents the proportion of the 
covariate of interest across all intervals. Any covariates which were not successfully balanced 
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across treatment groups should be adjusted for when estimating subclass-specific treatment 
effects. 
 
5.5.5 Treatment effect estimation 
Once balance has been achieved, evaluation of treatment effect can proceed. There are two 
key ways in which PS subclasses can be accounted for in treatment effect estimation. Firstly, 
one could directly adjust for the PS subclasses as covariate in the outcome model that 
estimates the overall association between treatment and outcome (Leon et al., 2001). 
Alternatively, subclass-specific treatment effect estimates could be obtained and pooled via 
the MH method as described in Section 5.4.5 using Equations 5.18, 5.19 and 5.21. To enable 
pooling, the assumption of homogeneity of treatment effects across subclasses would first 
need to be tested, as explained before.  
 
5.5.5.1 Discrete-time survival model 
Discrete time survival models can be used when continuous time line is split into intervals, 
thus several patients would share the same analysis time (Cox, 1972). Each interval contains 
occurrence of outcome which allows one to model the probability that outcome occurred in 
each interval, conditional that the outcome had occurred until then (Rabe-Hesketh and 
Skrondal, 2012).  
The survival function in discrete time at time 𝑡𝑗  is defined as the probability that survival time 









𝑓(𝑡𝑗) = 𝑝𝑟[𝑇 = 𝑡𝑗] 
 5.29 
 
The hazard of failure (outcome) is defined as the probability of failure at time 𝑡𝑗 given that the 
patient has not had outcome to that point (Equation 5.30). 
 
ℎ(𝑡𝑗) = 𝑝𝑟[𝑇 = 𝑡𝑗|𝑇 ≥ 𝑡𝑗] =
𝑓(𝑡𝑗)
𝑆(𝑡𝑗)
  5.30 
 
The survival function can be written in terms of the hazard function of all previous time points 
such that at time 𝑡𝑗, a patient cannot have outcome at time 𝑡1, 𝑡2, up until 𝑡𝑗−1 (Equation 5.31). 
Equation 5.31 is equivalent to the survival function in continuous time (Equation 5.22).  
 𝑆(𝑡𝑗) = [1 − ℎ(𝑡1)][1 − ℎ(𝑡2)], … , [1 − ℎ(𝑡𝑗−1)]  5.31 
 
If continuous time is divided into discrete intervals with constant hazard within each interval, 
the Cox PH model is analogous to the binomial regression model with a complementary log-
log link (Equation 5.32). Complementary log-log regression allows one to estimate the hazard 
ratio in discrete time, and are the same as if the Cox model was fitted in continuous time and 
assumes PH. In the case of time-varying treatment, the PH assumption does not need to be 
satisfied as the hazard function is estimated within each interval. As treatment changes over 
time, the association between treatment and outcome estimated within each interval may 
differ across intervals, therefore the PH assumption may not be satisfied. Interval-specific 









One should note that this particular model does not account for duration of time within an 
interval and simply models whether outcome had occurred in each interval. To account for 
repeated correlated intervals within a patient, one can include patient-specific random 
intercept 𝑟 (as previously described in Section 5.5.1) to Equation 5.32, and shown in Equation 
5.33 (Hedeker et al., 2000, Rabe-Hesketh and Skrondal, 2012, Austin, 2017).  
  





The random intercept complementary log-log regression model has frequently been used to 
estimate subclass-specific treatment effects after time-varying PS subclassification (Leon, 
2011b, Leon, 2011a, Leon et al., 2012a).  
 
5.6 Marginal structural models 
As stated in Section 5.3.4, MSM are used to model the effect of time-varying treatment on 
potential outcomes in the presence of time-varying confounding effects (Robins, 2000). At the 
start of this PhD project (in 2013), very few EHR studies had used MSM to estimate treatment 
effect however, its use has increased since; examples include warfarin use and risk of bleeding 
using GPRD data (Platt et al., 2012), effectiveness of beta-blockers on mortality using GPRD 
data (Delaney et al., 2009), and bisphosphonates use and risk of infection using claims data 
(Xue et al., 2017). 
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Two modelling steps are involved in MSM. The first step requires the correct specification of 
the PS model for estimation of weights; the second step uses the estimated weights to create 
a pseudo-population (where there is no confounding) within which an unbiased treatment 
effect can be estimated. 
Time-varying covariates and treatment can be measured in either continuous or discrete time. 
The same data structure as described for time-varying PS subclassification in Section 5.4.5.1 is 
assumed; treatment and covariates are measured repeatedly in pre-set time intervals creating 
a two-level hierarchical data structure with repeated measurements (level 1) clustered within 
a patient (level 2).  
 
5.6.1 Weight estimation 
The purpose of weights is to balance the distribution of covariates across the treatment 
groups in the pseudo-population in all time intervals. Weights 𝑤𝑡 are assigned to each time 
interval 𝑡 resulting in time-varying weights. As previously described in Section 5.3.3, the 
weights reflect by how much observations are under-represented or over-represented in the 
study sample compared to the pseudo-population in the absence of no confounding. The ideal 
properties of the weight distribution are mean equal to 1, normally distributed, and a narrow 
range at all time points. In practice, this may not be feasible if the number of time points is 
large, therefore the overall weight distribution can be examined instead (Cole and Hernan, 
2008).  
Section 5.3.4 described the estimation of unstabilised weights (Equation 5.12). The 
distribution of unstabilised weights is likely to be skewed, with mean weight is likely to deviate 
from one substantially and have large variance, inflated by the presence of extremely large 
weights. The mean and standard deviation of weights with minimum and maximum weight 
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values should be reported. These issues are indications that the positivity assumption is 
violated (i.e., PS is very close to zero), the PS model could be misspecified (Cole and Hernan, 
2008) or that residual confounding may be present (Jackson, 2016). 
Using the intervals as the unit of analysis, pooled logistic regression is used to estimate PS in 
each interval, given baseline and time-varying covariates (Fewell et al., 2004). Logistic 
regression is ‘pooled’ as a patient contributes multiple times to the model which pools 
treatment and covariates across intervals into a single sample however, the model does not 
account for when treatment and covariates occur within an interval (Ngwa et al., 2016).  
Stabilised weights 
Robins (2000) recommended the use of stabilised weights, a modification of unstabilised 
weights. The formula for stabilised weights is shown in Equation 5.34. The numerator of the 
stabilised weight is the probability of observed treatment conditional on past treatment 
history ?̅?𝑡 (treatment history up to and including time 𝑡 − 1) and time-invariant covariates 𝒁. 
𝒁 is a subset of 𝑿 that includes both time-invariant and time-varying covariates. The 










By including treatment history and baseline covariates in the numerator and denominator, 
the stabilised weights reflect the incremental effect of time-varying covariates on the 
probability of treatment independently of other covariates (Equation 5.34). Therefore, the 
stabilised weights are less variable and skewed, with smaller variance and range, with mean 
weight closer to one, than unstabilised weights. Stabilised weights tend to decrease over time 
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as the denominator accounts for time-varying covariates the probabilities should be on 
average higher (as more recent covariate status would have stronger association with 
treatment than time-invariant covariates) than the probabilities in the numerator for each 
time interval (Xiao et al., 2010). Use of stabilised weights also mean the estimated treatment 
effect would be more precise than using unstabilised weights. The disadvantage of stabilised 
weights is that confounding would remain from baseline covariates and treatment history due 
to its inclusion in the numerator; in the pseudo-population as treatment is only randomised 
within levels of the time-invariant covariates and treatment history, one needs to adjust for 
these covariates in the outcome model estimating treatment effect  (Cole and Hernan, 2008). 
Alternatively, one could estimate basic stabilised weights where the numerator is the 
proportion of treated patients at time 𝑡 (Equation 5.35). Similarly, basic stabilised weights are 
less variable than unstabilised weights and leads to more precision in the estimated treatment 
effect. Use of basic stabilised weights avoids the need to condition on treatment history and 









The PS for the numerator and denominator for all types of weights are estimated separately 
via pooled logistic regression models. 
Normalised weights 
Distribution of stabilised weights may still be undesirable if the mean deviates from one and 
the variance is large. Xiao et al. (2010) proposed normalised weights that ensure the mean 
weight of one in all intervals; weights would be less extreme resulting in reduced variability of 
weights. Both stabilised and unstabilised weights can be normalised. Calculation of normalised 
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unstabilised weights 𝑛𝑤𝑖 is shown in Equation 5.36 where 𝑁(𝑡) is the total number of patients 
in interval 𝑡 and 𝑅(𝑡) is the number of patients at risk of outcome in interval 𝑡. Calculation of 












Xiao et al. (2010) performed a simulation study evaluating effect of different weights on 
treatment effect estimation. Unstabilised weights yielded the largest standard error of the 
treatment effect whilst use of stabilised weights significantly reduced standard error as 
expected. Use of normalised weights (both unstabilised and stabilised) yielded the smallest 
standard errors of the treatment effect. 
Censoring weights 
Longitudinal studies may be susceptible to selection bias due to loss of follow-up. If patients 
were censored prior to outcome occurring, for example if they died, bias in the treatment 
effect is introduced if covariates differ between censored patients and those who remain in 
the study and when these covariates are also associated with outcome. 
Censoring can be viewed as a time-varying confounding variable. Censoring weights are 
defined as the probability of being censored at each time point given time-varying and time-
invariant covariates. Censoring weights reweight the study sample and create a pseudo-
population where censoring did not occur. Multiplying treatment weights with censoring 
weights at each time point creates a pseudo-population where there is no loss of follow-up 





Extreme weights may persist in some situations, regardless of which weight estimation 
approach is used. There are a few approaches that can be adopted to reduce such persistent 
extreme weights. One could remove covariates from the PS model that are weakly associated 
with outcome and cause extreme weights however, this may not always be possible if all 
covariates are strongly associated with outcome. Another approach is exclusion of 
observations that have large weights (known as trimming) however, one would need to define 
a threshold at which weight is considered high enough for an observation to be removed; 
furthermore, generalisability of the sample may be compromised.  
The most common approach is weight truncation. Truncation involves setting the value of 
weights greater than and lower than a certain percentile cut-off to the values of these 
percentiles cut-off points. As the weights are progressively truncated, the treatment effect 
estimate progressively becomes more biased however the standard error reduces. Typically, 
weights are truncated at 1% and 99% of their distribution and typically removes the majority 
of extreme weights (Cole and Hernan, 2008). Cole and Hernan (2008) described weight 
truncation as the trade-off between bias and precision in the treatment effect.  
There is little guidance in the optimal level of truncation. Xiao et al. (2013) suggested the 
optimal level of truncation should be based on minimising the mean squared error (MSE, 
defined as the mean squared difference between the estimated and actual values). A 
simulation study showed truncating weights fixed at 99.5% and 99% percentiles performed 
similarly in terms of bias and variance on the treatment effect with truncation based on MSE 





5.6.2 Intention-to-treat, per-protocol, and as-treated principles 
Weight estimation is dependent on whether treatment effect is estimated under the 
intention-to-treat, per-protocol, or as treated principles. For this PhD project, interest is in 
estimating the actual effect of treatment via as-treated analysis.  
 
5.6.2.1 Intention-to-treat 
Intention-to-treat analysis assumes that once a patient has initiated treatment they remain 
on that treatment throughout the rest of follow-up, therefore the effect of initiating 
treatment is estimated (Cole and Hernan, 2008). Intention-to-treat approach is most 
appropriate in situations where treatment adherence after initiation is low. Weight estimation 
would be simplified as covariates associated with treatment initiation only need to be 
considered as the assumption of exchangeability applies up to treatment initiation; weights 
are estimated up until treatment is initiated, thereafter the probability of treatment is 
assigned a value of one for the remainder of the follow-up.  
 
5.6.2.2 Per-protocol analysis 
The magnitude of the treatment effect estimate and its precision resulting from intention-to-
treat analysis is dependent on whether patients adhered with treatment. Per-protocol 
analysis may be performed by restricting analysis to patients who adhered with treatment by 
censoring patient follow-up time at the point they stop treatment. This artificial censoring may 
be dependent on covariates and outcome and is a type of selection bias. Analysis would have 
to account for both confounding by indication and confounding from selection bias by 
estimating weights separately when patients initiate treatment and when patients continue 




5.6.2.3 As-treated analysis 
As-treated analysis is where patients are analysed according to whether they receive 
treatment or not. This approach estimates the actual treatment effect. Different scenarios 
may occur where patients (1) may never initiate treatment, (2) initiate and remain on 
treatment until the end of follow-up, (3) discontinue treatment once initiated, (4) initiate, 
discontinue and then restart treatment; treatment discontinuation and/or restarting 
treatment may occur repeatedly. This scenario is expected to be seen within CPRD data.  
Weight estimation becomes more complex as weights would need to be estimated separately 
if confounding effects were found to differ for each scenario. Studies rarely consider these 
complexities of as-treated analyses and assume the effect of confounding variables are the 
same for all scenarios (Yang et al., 2014).  
Yang et al. (2014) conducted a systematic review identifying pharmaco-epidemiologic studies 
published in 2012 that attempted to account for patients not adhering with treatment. The 
authors extracted information from 20 eligible studies and found eight studies conducted as-
treated analyses, six intention-to-treat analyses, and three per-protocol analyses. 
Yang et al. (2015b) performed a simulation study comparing impact on treatment effect 
estimate when weight estimation was considered under four different scenarios: (1) 
intention-to-treat analysis, (2) acknowledged confounding effects differed between patients 
initiating treatment and patients continuing treatment, with two separate weights estimated, 
(3) confounding variables had the same effect on initiating treatment and continuing 
treatment, and (4) only time-invariant confounding variables were considered.  
Approach 1 performed poorly in the presence of non-adherence and when treatment effect 
was non null; bias increased approximately by 1% for each 1% increase in the proportion of 
patients discontinuing treatment. Standard error of the treatment effect was larger compared 
with the other approaches. Approach 1 should only be used if adherence to treatment is high.  
161 
 
Incorrectly assuming confounding effects are the same for patients initiating and continuing 
treatment (approach 3), resulted in biased treatment effect due to incomplete control of 
confounding effects. Modelling weights separately for treatment initiation and adherence 
(approach 2) yielded unbiased treatment effect and lower standard errors compared with 
other approaches. Approach 4 was found to estimate biased treatment effect with larger 
standard errors than the other three approaches.   
A limitation of Yang et al. (2015b) study is that it assumed only two time points and only a 
continuous outcome was considered. Graffeo et al. (2018) simulation study focused on 
estimating weights for patients who repeatedly initiated and discontinued treatment with 
time-to-event outcome. Weights were estimated in continuous time using Cox regression 
models. The authors found that bias in the treatment effect reduced when weights were 
modelled separately for treatment initiation and discontinuation compared with an intention-
to-treat analysis.  
 
5.6.3 Covariate specification 
Yang et al. (2014) systematic review of pharmaco-epidemiological studies that used MSM 
found studies generally selected covariates based on either previous knowledge or using 
statistical criterion. Within MSM, Lefebvre et al. (2008) performed a simulation study and 
found the PS model should include covariates that are associated with outcome to increase 
precision in the estimated treatment effect however, including covariates that were only 
associated with treatment increased bias and standard error in the estimated treatment 
effect. These findings were similar to what Brookhart et al. (2006) found in estimating time-
invariant PS (Section 5.4.2) although inclusion of covariates only associated with treatment 
did not affect bias.  
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As discussed for time-varying PS subclassification approach, the PS estimation is conditional 
on covariate history therefore, the PS model should contain lagged covariates representing 
covariate values in earlier time intervals (Robins et al., 2000). Neugebauer et al. (2007) 
proposed history restricted MSM where a shorter history of covariates is considered assuming 
it adequately captures covariate history. The PS model needs to adjust for treatment history; 
this can be achieved by including a counter of previous treatment as a covariate (Graffeo et 
al., 2018).  
The functional form of covariates needs to modelled accurately. Cole and Hernan (2008) found 
modelling continuous covariates as categorical variables affected the bias-variance trade-off 
in the treatment effect. As the number of categories for a continuous covariate increased, this 
led to better control of confounding (as more information on the covariate was available). 
However, the standard error of the treatment effect estimate increased which may have 
resulted from increased range and standard deviation of weights, mean weight deviating from 
one, and a small number of patients that have a certain combination of covariates.  
Instead, one could directly model continuous covariates as a non-linear function as it reduces 
the number of parameters estimated by assuming the intercept is a smooth function thus 
avoiding the need to categorise covariate, and better control for confounding without 
assuming linearity.  
Cole and Hernan (2008) recommended the use of restricted cubic regression splines. 
Regression splines offers a way to examine the functional form of expected treatment with a 
function of the linear predictor, where a spline is a smoothed curve. The amount of 
smoothness is dependent on the number of parameters (or degrees of freedom (df)) used by 
the spline. Estimation of one parameter for the covariate uses up one df thus imposes 
linearity. Estimation of two parameters for the covariate uses up two df and so on. Increasing 
the number of parameters allows one to capture more complicated trends. The number and 
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location of knots need to be specified; a knot is where two regression splines meet; knots are 
commonly placed at the 5% and 95% percentiles of the distribution (Rutherford et al., 2015).  
Alternatively, one could model non-linear functions using fractional polynomials (FP). This is 
where covariate 𝑋 is transformed to 𝑋𝑝 where 𝑝 is chosen from a set of candidates 
{– 2, – 1, – 0.5, 0, 0.5, 1, 2, 3}, where 𝑋0 denotes the logarithm of 𝑋; this is a first degree FP. To 
model more complex non-linear functions, second degree FP where the covariate is 
represented by two power transformations (𝑝 and 𝑞) can be fitted. The linear predictor takes 
the form 𝛽𝑜 + 𝛽1𝑋
𝑝 + 𝛽2𝑋
𝑞 or 𝛽𝑜 + 𝛽1𝑋
𝑝 + 𝛽2𝑋
𝑝log (𝑋) when 𝑝 = 𝑞. The best fitting 
combination of powers is the regression model that has the lowest deviance (defined as twice 
the negative log likelihood). Only a small number of power transformations for 𝑝 was 
considered as they offer considerable flexibility to capture non-linear patterns, and inclusion 
of other powers, for example 𝑝=-3, may yield extreme observations and small improvement 
in model fit (Royston et al., 1999). 
A simulation study had shown that failure to correctly model the functional form of a time-
varying covariate resulted in bias due to imbalance in that covariate between treatment 
groups. Both FP and regression splines performed well yielding small bias in the treatment 
effect (Kyle et al., 2019).  
 
5.6.4 Covariate balance evaluation 
The purpose of weighting is to ensure balance is achieved on history of treatment and 
covariates between treatment groups at each time point. Assessment of balance is often 
ignored in MSM (Vandecandelaere et al., 2016).  
SMD as described in Section 5.4.4 and defined in Equations 5.14 and 5.15 can be used to assess 
balance for covariates included in the PS model between treatment groups at each time point. 
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Various rules of thumb had been used to define imbalance for MSM. Vandecandelaere et al. 
(2016) considered SMD greater than 0.25 as unacceptable imbalance between treatment 
groups; SMD greater than 0.10 has also been used as a cut off to indicate imbalance 
(Lavikainen et al., 2016). Jackson (2016) used trellis plots that illustrated SMD of covariates for 
each pattern of treatment history e.g., SMD between treatment groups at time point 3 is 
evaluated for covariates measured at baseline, first, second and third time points. Assessing 
balance in this way can become cumbersome particularly if the follow-up is long and if there 
are more than two treatment regimes. 
Unlike PS subclassification, common support of weights between treatment groups is not a 
requirement as balance can still be achieved even if there is little overlap in the weight 
distributions of treated and untreated patients.  
 
5.6.5 Treatment effect estimation 
MSM allow one to correctly estimate the effect of time-varying treatment in the presence of 
time-varying confounding variables that are affected by past treatment. They estimate the 
treatment effect that is composed of the direct effect of current treatment on outcome 
(where treatment is not mediated through covariates) and past treatment effect that is 
mediated through covariates on outcome. In this thesis, marginal structural Cox model is used 
to estimate treatment effect. 
 
5.6.5.1 Marginal Structural Cox model 
The marginal structural Cox model is specified in Equation 5.38 where ?̅?𝑡 denotes treatment 
history up to time 𝑡, 𝑇?̅? represents patient time to outcome had they followed a particular 
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treatment history 𝛼 is the regression parameter to be estimated for treatment history, and 
𝑔(. ) is some function of treatment history.  
 ℎ𝑇?̅?(𝑡) = ℎ0(𝑡)𝑒𝑥𝑝 (𝛼𝑔(?̅?𝑡)) 5.38 
 
Specification of 𝑔(. ) allows one to estimate different treatment effect estimates. One can 
evaluate the effect of all treatment histories on outcome; this is known as a saturated MSM. 
There would be 2𝑇 treatment histories, therefore saturated MSM model would be complex to 
fit if the number of intervals is large. Alternatively, the effect of treatment at each time point 
could be estimated, which too may be complex if the number of time points is large. Effects 
of particular treatment regimens (never treated vs. always treated), or a summary measure 
of treatment, for example total number of treatment occurrences over time, could be 
evaluated.  
However, use of summary measures to capture exposure to treatment may not be optimal; 
an assumption would be made that effect of allopurinol among those who are continuously 
treated (without periods of discontinued use) is the same as the effect of allopurinol among 
patients with the same total number of periods they were treated in but who also had periods 
of discontinued treatment. Furthermore, it would also be assumed that total past treatment 
has the same effect on outcome regardless of how long ago that treatment was given.  
Hernan et al. (2000) estimated the effect of current treatment at each time point on outcome 
in intention-to-treat analysis. Equation 5.38 becomes Equation 5.39 to reflect estimation of 
current treatment effect.  




In this thesis, focus was on estimating current treatment use via as-treated analyses thereby 
estimating the effect of actual treatment. However, as allopurinol use is intermittent, this 
approach would  implicitly assume that there is no cumulative effect of treatment on outcome 
i.e., it does not model the effect of past treatment that is mediated through covariates on 
outcome, only the direct effect (not mediated through covariates) is modelled (Yang et al., 
2014).   
Hernan et al. (2000) used weighted pooled logistic regression on discrete time data to 
approximate the weighted Cox model, mainly due to software constraints that did not allow 
for use of time-varying weights with the Cox model. Fitting MSM in this way is popular 
however, fitting the marginal structural Cox model in this way may lead to biased treatment 
effect when outcome is frequent as shown in a simulation study (Xiao et al., 2010). It has been 
shown that marginal structural Cox model should be fit directly using the Cox model, which is 
possible in R software (Xiao et al., 2010, van der Wal and Geskus, 2011).  
Robust standard errors of the treatment effect estimates should be obtained, in order to 
account for repeated measurements within a patient introduced from the weights (Hernan et 
al., 2000).  
 
5.7 Summary 
In summary, this chapter gave an overview of statistical methods that could be used to control 
for confounding. Baseline and time-varying PS subclassification and MSM are the methods of 
choice that will be applied to the estimation of effect of allopurinol on outcome using data 
from CPRD. The next chapter describes how these models were applied to CPRD data 




6 Statistical analysis plan 
This chapter describes the specifics of how PS methods outlined in Chapter 5 were applied to 
CPRD data described in Chapter 4. Four statistical approaches to control for confounding were 
considered: time-invariant (or baseline) propensity score (PS) subclassification (Section 6.2);  
time-varying PS subclassification (Section 6.3); marginal structural models (MSM) assuming 
simple associations between treatment and covariates (Section 6.4); MSM assuming complex 
associations between treatment and covariates (Section 6.5). 
For each method, the main analysis was to evaluate the effectiveness of allopurinol on a range 
of gout outcomes. Various sensitivity analyses were conducted within each method to assess 
robustness of estimated treatment effects.  
Time-invariant PS subclassification 
1) To evaluate whether the effectiveness of allopurinol differs between patients with and 
without renal disease. 
2) To evaluate whether the effectiveness of allopurinol differs between patients with 
severe (>480μmol/L) and non-severe hyperuricaemia. 
3) Assess the impact of missing data, unmeasured confounding and landmark period on 
treatment effect estimation. 
Time-varying PS subclassification 
1) Assess the impact of missing data on treatment effect estimation. 
Simple mechanisms of allopurinol use via MSM 
1) Assess the impact of normalised weights, weight truncation, truncating follow-up, and 




Complex mechanisms of allopurinol use via MSM 
1) Assess the impact of different PS models, weight truncation, missing data, and 
unmeasured confounding on treatment effect estimates.  
 
6.1 Missing data 
As seen in Chapter 4, missing data was present for body mass index (BMI), alcohol 
consumption, smoking status, and serum urate (SU) level. When these covariates were 
assumed time-invariant, the missing indicator method (MIM) was utilised which sets missing 
values to a fixed value (indicating missingness) creating an extra dummy variable.  
When BMI, alcohol consumption, and smoking status were considered time-varying, first, the 
MIM approach was applied from start of follow-up (if missing) until these covariates were 
measured. Secondly, the last observation carried forward (LOCF) approach was used. This 
approach was adopted for primary analysis in favour of complete case analysis to preserve 
sample size. Use of the MIM within PS based methods ensures that the distribution of the 
missingness category is balanced across the treatment groups (Rosenbaum and Rubin, 1984).  
Use of these methods (MIM and LOCF) were used first to understand the data and any issues 
that may arise from modelling that data.  
 
6.2 Time-invariant PS subclassification 
6.2.1 Description of study sample 
The primary analysis utilised a one year-landmark period (Section 4.3.1). The number of 
patients consulting for gout and meeting the inclusion and exclusion criteria were described 
in a flow diagram. Description of baseline covariates, overall and stratified by treatment status 
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were provided. Assessment of covariate balance was determined using standardised mean 
difference (SMD) (Section 5.4.4).  
 
6.2.2 Propensity score model 
Logistic regression was used to estimate the propensity of treatment at baseline. The general 
consensus is to include all covariates into the logistic model if they are associated with 
outcome (Austin et al., 2007a, Cuong, 2013, Rubin and Thomas, 1996) (Section 5.4.2). 
Covariates were chosen based on statistical significance or clinical justification. To determine 
statistical significance, univariable Cox proportional hazards (PH) models were used to 
determine the association between each covariate and time to outcome. Statistical 
significance was achieved when p-value <0.05. Covariates that have previously been shown to 
be associated with outcome were also included in PS estimation, regardless of statistical 
significance: age, sex, deprivation, renal disease, colchicine, non-steroidal anti-inflammatory 
drugs (NSAIDS), diuretics, and SU level. 
The initial PS model included main effects of covariates and assumed continuous covariates 
had a linear trend with the log odds of the PS. The distribution of PS was visually compared 
between the treatment groups to assess overlap in the tails of PS distribution. If there was 
considerable non-overlap, these patients were removed prior to PS subclassification. 
Patients were then stratified into five mutually exclusive subclasses based on the quintiles of 
the PS. Overall SMD for each covariate across the subclasses was calculated. If overall SMD 
>0.10 in any of the covariates indicating imbalance between treatment groups, two 
approaches were considered to improve balance: (1) increasing the number of subclasses 
(Section 5.4.3), (2) re-estimating the PS including interactions between imbalanced covariates 
and/or non-linear terms for continuous imbalanced covariates. A cycle may occur where 
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overall SMD are continually assessed for each additional subclass or change to the PS model. 
Once overall SMD <0.10 across subclasses, covariate balance was considered to be achieved 
overall however, imbalance may remain within subclasses. Therefore, SMD was evaluated for 
all covariates within a subclass and any covariates with SMD >0.10 were adjusted for in the 
outcome analysis.  
 
6.2.3 Estimating treatment effect 
Cox PH regression was used to estimate the effect of allopurinol on time to first outcome. For 
repeated gout consultations, the Anderson & Gill method was used (Section 5.4.5). 
The Cox PH model was fitted within each subclass to obtain subclass-specific hazard ratios 
(HR) and the associated robust standard errors, from which 95% confidence intervals (CI) were 
obtained. The HRs from each subclass were pooled together using the Mantel-Haenszel 
method if subclass-specific HRs were deemed to be homogenous, i.e., not statistically 
significantly different from each other (p-value <0.05), otherwise HRs were weighted by the 
inverse of the subclass-specific sample size if they are non-constant. 
For outcomes where subclass-specific HRs were not homogenous, the estimated pooled HR, 
alongside with subclass-specific HRs and description of subclasses were presented for each 
subclass.  







6.2.4 Sensitivity and stratified analyses 
6.2.4.1 Stratification by renal disease 
The one-year landmark analyses were stratified by presence of renal disease at baseline for 
all outcomes. Patients who did not have renal disease at baseline and went on to develop 
renal disease during the landmark period were removed from analysis. Patients who 
developed renal disease during follow-up had their follow-up censored at that date. The same 
set of covariates (with the exception of renal disease) was used to estimate PS as in the 
primary analysis.   
 
6.2.4.2 Stratification by severity of hyperuricaemia 
The one-year landmark analyses were stratified by severity of hyperuricaemia at baseline for 
all outcomes. Patients had severe hyperuricaemia if SU level was above 480µmol/L. Patients 
had non-severe hyperuricaemia is SU level was between 361-480µmol/L. Patients with SU 
<360µmol/L or no baseline information were removed from analysis. For the analysis of 
secondary outcomes, as SU level was infrequently measured over time, patients were not 
censored when SU level reached target. The same set of covariates (with the exception of SU 
level) was used to estimate PS as in the primary analysis.   
 
6.2.4.3 Two-year landmark period 
The landmark period was extended to two years to evaluate robustness of treatment effect 
estimates when more patients were classified as allopurinol users (Section 4.3.1). Patients 
with less than two years of follow-up were removed from analysis and follow-up commenced 
two years after the index date. Same set of covariates was used to estimate PS as in the 
primary analysis. Patients were classed as an allopurinol user if they had a three-month 
prescription in the first or second year of follow-up during the two-year landmark period.  
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6.2.4.4 Unmeasured confounding 
The core assumption in treatment effect estimation is that there is no unmeasured 
confounding. In practice this is unlikely to be plausible especially with retrospective data 
collection where one cannot choose which covariates to measure. Therefore, there will be 
residual confounding in the treatment effect estimate. There are a large number of 
approaches one could use to evaluate the impact of unmeasured confounding (Streeter et al., 
2017, Uddin et al., 2016).  
For time-invariant PS subclassification, impact of an unmeasured binary covariate (or a vector 
of binary covariates) on treatment effect estimation was assessed for outcomes target SU 
level and mortality. The method by Lin et al. (1998) was used for ease of use and has been 
previously used in other CPRD studies (Blagojevic-Bucknall et al., 2019).  
This is where the association between the unmeasured covariate and outcome was based on 
the hazard ratio (𝑂𝐻𝑅) between observed covariates and outcome. Prevalence of 
unmeasured covariate is (𝑃1) and non-users (𝑃0).  
The estimated adjusted hazard ratio (𝐻𝑅∗) from the one-year landmark analysis was 
corrected for the unmeasured covariate. The formula used for correction is shown in Equation 
6.1. 
 
𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝐻𝑅 = 𝐻𝑅∗ − 𝑙𝑛
𝑂𝐻𝑅 𝑥 𝑃1 + (1 − 𝑃1)




The standard error from the adjusted hazard ratio was assumed to be the same for the 





6.2.4.5 Missing data 
The main analysis was performed using the MIM. Creating a separate category to group all 
observations with missing data on a particular covariate may result in grouping of dissimilar 
measurements; this in turn may lead to incomplete control of confounding effects from 
covariates with missing data. Complete case analysis was performed by restricting analysis to 
patients who had complete data on the lifestyle factors (BMI, smoking status, alcohol 
consumption, and SU level (for secondary outcomes)) excepting a much smaller sample size 
and reduced power although, it does not address the robustness of treatment effect estimates 
against missing data. This sensitivity analysis was performed for the primary outcome target 
SU level and mortality.  
 
6.3 Time-varying PS subclassification 
6.3.1 Descriptive statistics 
Using the repeated measures structure described in Section 4.3.2, covariates were described 
over time by providing descriptive statistics at baseline and in each year of follow-up.  
Using intervals as the unit of analysis, the distribution of covariates was described stratified 
by treatment, and SMD to assess covariate balance was calculated. The following 
characteristics of treatment patterns were described: the proportion of patients prescribed 
allopurinol at each time point, the number of times patients initiated and discontinued 
treatment; year of follow-up in which initiating and discontinuation of treatment occurred in; 





6.3.2 Propensity score model 
The PS for each patient in each interval was estimated using mixed-effects logistic regression 
model with a random intercept (Section 5.5.1). Similarly to time-invariant PS subclassification, 
covariates were included in the PS model if they are associated with outcome based on 
statistical significance or clinical justification. The initial PS model contained main effects of all 
covariates and linear terms for continuous covariates. To determine statistical significance, 
univariable complementary log-log regression model were used to determine the association 
between each covariate and outcome. Statistical significance was achieved when p-value 
<0.05. Covariates that have previously been shown to be associated with outcome were also 
included in PS estimation regardless of statistical significance: age, sex, deprivation, renal 
disease, colchicine, NSAIDS, diuretics, SU level, gout consultation, cumulative allopurinol use, 
and follow-up time were included in the model regardless of significance. 
During PS estimation, lack of common support was identified as an issue for all outcomes. The 
process followed to maximise common support for each outcome is summarised in Figure 6.1. 
With each modification of the PS model, common support was evaluated. Common support 
was assessed by calculating the total of (1) the number of allopurinol intervals for which the 
PS is above the maximum value of PS from the non-allopurinol intervals and (2) the number 
of non-allopurinol intervals for which the PS is below the minimum value of PS from the 
allopurinol intervals.  
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Figure 6.1: Process of selecting the best PS model 
 
FP1: Fractional polynomials of dimension 1; Fractional polynomials of dimension 2 
PS model specification 1 was the initial PS model as described above.  
Non-linear transformations of continuous covariates (age, deprivation, SU level (if applicable), 
cumulative allopurinol use, and follow-up time) via fractional polynomials (FP) were next 
considered. The set of power transformations considered was described in Section 5.6.3. In 
PS model specification 2, all the continuous covariates were replaced with FP1 terms 
(fractional polynomial terms of dimension 1). In PS model specification 3, all the continuous 
covariates were replaced with FP2 terms (fractional polynomial terms of dimension 2). The 
FP1 and FP2 terms that best modelled the association between a continuous covariate and 
outcome was identified and included in the PS model. For each covariate, the best FP1 term 
was identified by fitting a complementary log-log regression model between each FP1 term 
and outcome. The model that yielded the lowest deviance indicated the best FP1 term; 
deviance was defined as twice the negative log-likelihood. Next, the same process was used 
Specification 
1
•Main effects model including linear terms for continuous covariates
Specification 
2
•Replace all continuous covariates with FP1
Specification 
3
•Replace all continuous covariates with FP2
Specification 
4
•Next, for each covariate identify if FP1 or linear terms improves PS estimation more than using FP2 
terms
•Perform backwards selection to identify problematic covariates 
Specification 
5
•Perform forwards selection of two-way and three-way interaction terms to identify any interaction 
terms that improves PS estimation
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to identify the best FP2 terms for each covariate. Restricted cubic splines were initially 
considered however due to high collinearity they were not used. 
In specification 4, for each covariate, it was identified whether its main effect, FP1 term or FP2 
terms improved common support the most. Starting with PS model specification 3, three PS 
models were fitted where age was entered into the PS model as FP2 terms, then FP1 term, 
then as a linear term. The PS model that improved common support the most from model 
specification 3 was retained. This process was then repeated for the remaining continuous 
covariates until common support no longer improved. Next, backwards selection was 
performed removing one covariate from the model at a time to identify if there were 
problematic covariates that caused lack of common support.  
In specification 5, there is the possibility that two-way interaction terms between covariates 
may improve common support. Interaction terms were considered for covariates included in 
the PS model except for non-linear continuous covariates. Interaction terms were only 
included in the PS model if it was associated with outcome. This was determined by fitting a 
complementary log-log model between outcome and any two covariates. The incremental 
contribution of the interaction term between the two covariates is then tested using the 
likelihood ratio test (LRT) by comparing the -2 difference in log-likelihood of the GLM models 
with and without the interaction. An insignificant test would indicate that that the interaction 
term is not associated with outcome thus cannot be included in the PS model. A significant 
test, p-value <0.05, indicates that the interaction term is associated with outcome thus may 
be considered to be included in the PS model. Once the relevant interaction terms were 
identified, each interaction term was fitted to the PS model specification 3, and common 
support was assessed. The interaction term that reduced lack of support the most was 
retained. The process was then repeated finding the next interaction term that reduced the 
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lack of common support the most, and so on. The same process was then repeated for three-
way interaction terms. 
Once this process was completed, the final PS model was estimated and the distribution of 
estimated PS was compared between the treatment groups. 
Observations in each interval were initially stratified into quintiles based on the distribution 
of the PS. Subsequently, overall SMD for each covariate was calculated across the subclasses; 
if overall SMD was >0.10 for any covariate then the number of subclasses was increased until 
overall SMD was achieved. Once the number of subclasses was selected such that overall SMD 
is <0.10 for all covariates, SMD for each covariate was then evaluated within each subclass; 
covariates that had SMD >0.10 were adjusted for in subclass-specific treatment effect 
estimation.  
 
6.3.3 Estimating treatment effect 
The treatment effect was evaluated separately in each subclass by fitting a complementary 
log-log regression model (Section 5.5.5), regressing outcome on allopurinol and follow-up 
time; covariates where imbalance remained between treatment groups were adjusted for as 
well. Treatment effects were presented as HRs and the associated robust standard errors to 
account for clustering of patients within a subclass, from which 95% CI were obtained.  
Subclass-specific hazard ratios were pooled together using the MH method. If the assumption 
of homogenous treatment effect across subclasses could not be verified, the subclass-class 
specific HRs were presented alongside with a summary of covariates of that subclass.  
In case inclusion of random intercept in the complementary log-log model due to non-
convergence of the model, robust standard errors were used to account for repeated 
measurements within patients. 
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6.3.4 Sensitivity analysis: missing data 
Sensitivity analyses to missing data was performed. Similarly to baseline PS subclassification, 
treatment effect estimates from using the MIM and LOCF were compared to treatment effect 
estimates from complete case analysis.. Complete case analysis was restricted to patients who 
had complete data on the lifestyle factors (BMI, smoking status, alcohol consumption, and SU 
level (for secondary outcomes) in all follow-up intervals. This sensitivity analysis was 
performed for the primary outcome target SU level and mortality. 
 
6.4 Simple mechanisms of allopurinol use via MSM 
Initial weight estimation assumed the associations between covariates and treatment 
initiation and continuation were the same. However, the estimated weights were extreme 
and skewed therefore, this analysis was restricted to the outcome mortality to demonstrate 
the difficulty in estimating weights with a reasonable distribution and its impact on treatment 
effect estimation.  
 
6.4.1 Propensity score model 
The pooled logistic regression model was used to estimate PS conditional on treatment history 
and covariates measured in the previous year, assuming it adequately captures covariate 
history; therefore, lagged covariates were not considered. Estimated PS contributed to the 
denominator in the estimation of stabilised weights. Covariates that were statistically 
significantly associated with outcome (previously assessed using the univariable 
complementary log-log model) and associated with treatment (assessed using the univariable 
random intercept logistic model), were included in the PS model if p-value <0.05.   
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The process of selecting a PS model was described in Section 6.3.2, Figure 6.1. Inclusion of 
non-linear terms for continuous covariates via FP and interaction terms were included in the 
PS model if it reduced the standard deviation (SD) of weights. Any problematic covariates that 
cause large weight variability were removed from the PS model.  
For the numerator of the stabilised weight, the PS was conditional on baseline covariates (sex, 
deprivation, baseline SU level) and treatment history i.e., cumulative allopurinol use.   
Covariate balance was assessed for each covariate in each year of follow-up using SMD in the 
weighted study sample; intervals were then pooled together to obtain an overall SMD.  
 
6.4.2 Estimating treatment effect 
The treatment effect on mortality was evaluated using the weighted Cox PH regression model 
(Section 5.6.5). Due to the use of stabilised weights, the Cox model adjusted for baseline 
covariates (SU level, sex and deprivation) and cumulative allopurinol use. HRs with robust 
standard errors, for possible misspecification of the PS model and the Cox model, with 95% CI 
were presented.   
 
6.4.3 Sensitivity analyses 
In addition to the process of finding a suitable PS model, other methods were used to reduce 







6.4.3.1 Normalised weights 
The stabilised weights were normalised such that the mean weight was 1 at each time point. 
Covariate imbalance and treatment effect were re-evaluated weighting the study sample 
using normalised weights. 
 
6.4.3.2 Truncating weights 
Weight truncation was performed on both the stabilised and normalised weights to remove 
extreme weights that may be influential on the estimated treatment effect. The weights were 
truncated at between 1% and 10% percentiles of its distribution. SMD and treatment effect 
were re-evaluated based on the truncated weights.  
 
6.4.3.3 Truncated follow-up 
Due to the long follow-up period that is observed in using EHR data, potentially differences in 
covariate distribution between treatment groups may increase over time (as assessed using 
SMD). Extreme weights may also be present due to cumulatively multiplying large 
probabilities of treatment over time. Follow-up was therefore truncated at the point prior to 
severe covariate imbalance when SMD >0.25. Treatment effect and SMD were re-evaluated. 
 
6.4.3.4 Intention-to-treat analysis 
So far, analyses considered treatment as an intermittent time-varying treatment with weights 
estimated in each year of follow-up, thus estimating the effect of actual treatment. Estimated 
treatment effect was compared with estimates derived under the intention-to-treat principle 
to assess whether the issues encountered in estimating actual treatment effect persisted 
when estimating the effect of initiating treatment.  
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6.5 Complex MSM 
In this analysis, associations between covariates and treatment initiation and continuation 
were allowed to differ in PS estimation.  
 
6.5.1 Revisiting the repeated measures dataset and descriptive statistics 
Previously in Section 6.4, only one PS model (for the denominator of weight) was used to 
estimate the probability of treatment. Here, two PS models were fitted, one that estimated 
the probability of initiating treatment, and the second estimated the probability of continuing 
with treatment. Within the repeated measures dataset, to identify which intervals correspond 
to covariates that were associated with initiating and continuing treatment, intervals were 
stratified by allopurinol use in the previous interval. This approach had previously been used 
by Cook et al. (2012), Xiao et al. (2014), and Yang et al. (2015a). 
Table 6.1 illustrates how this stratification would appear for four hypothetical patients who 
(1) never initiated allopurinol, (2) initiated allopurinol and remained on allopurinol until the 
end of follow-up, (3) initiated allopurinol and then discontinued allopurinol, (4) initiated and 
then discontinued allopurinol, and subsequently restarted and stopped allopurinol. 
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1 1 0 0 0 N/A 
1 2 0 0 0 N/A 
1 3 0 0 0 N/A 
2 1 0 0 0 N/A 
2 2 1 0 1 N/A 
2 3 1 1 N/A 1 
2 4 1 1 N/A 1 
3 1 0 0 0 N/A 
3 2 0 0 0 N/A 
3 3 1 0 1 N/A 
3 4 1 1 N/A 1 
3 5 1 1 N/A 1 
3 6 0 1 N/A 0 
3 7 0 0 0 N/A 
4 1 0 0 0 N/A 
4 2 1 0 1 N/A 
4 3 1 1 N/A 1 
4 4 1 1 N/A 1 
4 5 1 1 N/A 1 
4 6 0 1 N/A 0 
4 7 0 0 0 N/A 
4 8 1 0 1 N/A 
4 9 1 1 N/A 1 
4 10 0 1 N/A 0 
4 11 1 0 1 N/A 
4 12 0 1 N/A 0 
0: No; 1: Yes; N/A: Not applicable 
The example dataset contains patient identifier (first column), year of follow-up (second 
column), prescription of allopurinol (third column), and allopurinol use in the previous year 
(fourth column). The fifth column identifies when non-users initiated treatment. The sixth 
column identifies when on-going allopurinol users discontinued treatment. 
Patient 1 is followed-up for three years and is never prescribed allopurinol, hence only 
contributes to column 5. Patient 2 is followed up for four years, initiates treatment in year 2 
and remains on allopurinol in years 3 and 4; years 1 and 2 contribute to column 5 and years 3 
and 4 contribute to column 6. Patient 3 is followed-up for 7 years, initiates allopurinol in year 
3 and discontinues allopurinol in year 6 for the remainder of the follow-up; years 1-3 and 7 
contribute to column 5 and years 4-6 contribute to column 6. Patient identifier 4 is followed-
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up for 12 years, initiate allopurinol in years 2, 8 and 11 and discontinue allopurinol in years 6, 
10 and 12. 
Covariates were described at the time of allopurinol initiation compared with non-use, and 
allopurinol continuation compared with discontinuation alongside with evaluating SMD of 
covariates between treatment groups. Unadjusted associations of covariates with allopurinol 
initiation and continuation were estimated using the random intercept logistic model.  
 
6.5.2 Propensity score model 
The probability of observing treatment given covariates (denominator of weights) was 
estimated separately for those initiating allopurinol and those continuing with allopurinol.  
The probability of initiating allopurinol was estimated in non-users up to and including the 
year they initiated treatment or until the end of follow-up if they were never treated. Some 
patients initiated treatment multiple times; for simplicity, it was assumed the differences in 
covariates between non-users and those initiating allopurinol for the first time were similar to 
the differences between non-users who may previously have had treatment and those 
restarting allopurinol accepting that some residual confounding may remain; otherwise 
separate PS models would have to be fitted for these scenarios too.  
The probability of continuing with allopurinol (those prescribed allopurinol in the previous 
year), was estimated in allopurinol users up to and including the year they discontinued 
treatment or until the end of follow-up if they remained on treatment. Similarly, it was 
assumed differences in covariates between those continuing allopurinol and those 
discontinuing allopurinol for the first time were similar to the differences between patients 
restarting and remaining on allopurinol and discontinuing treatment again accepting that 
residual confounding may remain.  
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Once PS were estimated, stabilised weights were initially estimated across the whole study 
sample; if the distribution of weights was not skewed, mean weight did not deviate from one, 
and did not have large weights, basic weights were instead estimated.  
The process of selecting a PS model was described in Section 6.3.2, Figure 6.1. Inclusion of 
non-linear terms for continuous covariates via FP and interaction terms were included in the 
PS model if it reduced the SD of weights. Any problematic covariates that caused large weight 
variability were removed from the PS model. The same covariates were included in both PS 
models in estimating probability of initiating and continuing treatment.   
Once PS were estimated weights were derived, SMD for each covariate was evaluated in the 
weighted study sample at each time point and then overall. 
 
6.5.3 Estimating treatment effect 
Treatment effect was estimated using the weighted Cox regression model; HR with 95% CI 
based on robust standard errors were presented.  
Covariate imbalance was assessed between treatment groups in each year of follow-up, and 
then overall. If overall SMD was greater than 0.10, that covariate was adjusted for in the Cox 
model.  
 
6.5.4 Sensitivity analyses 
In addition to the process of finding a suitable PS model, other methods were used to reduce 





6.5.4.1 Weight truncation 
Weights were truncated by 0.5% centile of its distribution. Larger truncation e.g., 1% was not 
considered as 0.5% truncation was sufficient to remove extreme weights. Treatment effects 
were re-estimated using the truncated weights.  
 
6.5.4.2 Unmeasured confounding 
More recently, a different method in measuring the impact of unmeasured confounding on 
treatment effect estimation was introduced, known as E-values (Mathur et al., 2018, 
VanderWeele and Ding, 2017). E-values are attractive to use as they can be applied to various 
situations where treatment estimate can be the HR, odds ratio, rate ratio etc. derived from 
various GLM, and software to estimate E-values is widely available. 
Therefore, E-values were computed for complex MSM. E-values are measured on the risk ratio 
(RR) scale to assess how strong the association between an unmeasured confounding variable 
with treatment and outcome needs to be in order to explain away the treatment effect 
conditional on the observed covariates; therefore, an E-value of 1 indicates there are no 
unmeasured covariates. E-values were computed against the statistically significant treatment 
effects estimated from the main analysis without adjustment for imbalanced covariates. To 
assess the likelihood of such an unmeasured confounding variable to exist, unadjusted RRs 
between observed covariates with outcome, allopurinol initiation and allopurinol 
continuation were estimated using generalised linear models with Poisson distribution and 
log link. If the E-value was outside the range of observed RRs then there is some evidence 
unmeasured confounding is unlikely to explain away the treatment effect. Otherwise, if the E-
value was within the range of observed RRs this suggests there is some evidence unmeasured 
confounding may be present and potentially explain away the treatment effect.  
186 
 
For rare outcomes where the prevalence of outcome is <15% at the end of follow-up, when 
the estimated HR is greater than 1, the formula to estimate E-value is given in Equation 6.2. 
When the HR is less than 1, the formula is given in Equation 6.3. 
 𝐸 𝑣𝑎𝑙𝑢𝑒 = 𝐻𝑅 + √𝐻𝑅(𝐻𝑅 − 1) 6.2 
 
 𝐻𝑅∗ = 1/𝐻𝑅 
𝐸 𝑣𝑎𝑙𝑢𝑒 = 𝐻𝑅∗ + √𝐻𝑅∗(𝐻𝑅∗ − 1) 
6.3 
 
For more common outcomes where the prevalence of outcome is between 15-85% at the end 
of follow-up, the estimated HR is first transformed according to Equation 6.4 before 











This chapter described the statistical analysis plan that addressed the clinical objectives of this 
thesis, and how statistical methods were applied to CPRD data to address confounding by 
indication. 
All analyses were performed in Stata v15 except for the weighted Cox model that was 





7 Effect of allopurinol: time-invariant PS subclassification 
This chapter described the study sample that was obtained from Clinical Practice Research 
Database (CPRD). Allopurinol use and covariates were considered time-invariant, thus 
propensity score (PS) was estimated at baseline.  
 
7.1 Study sample 
Medical records were extracted from CPRD in January 2015. The extract identified 32,814 
patients consulting for gout between the 1st January 1997 and the 31st December 2002, 
registered for at least two years with their practice, and aged at least 18 years. From this initial 
cohort 16,876 patients were eligible. Figure 7.1 shows the number of patients excluded and 
reasons for exclusion.  
Figure 7.1: Study sample flow chart  
 
*Had linkage to either one or two secondary databases (Index of Multiple Deprivation, Hospital Episodes 
Statistics, or the Office of National Statistics mortality data) 
 
Consulted for gout between 1997-2002, registered with 






Missing deprivation score (35)
Less than one year follow-up (1,049)
Urate-lowering and uricosuric drugs 
prescribed two years prior to the gout 
consultation (2,425, of which 2,380 had 
prescription for allopurinol)
Partial linkage* (264)
No linkage (12,165) 
188 
 
Median follow-up was 10.7 years (interquartile range (IQR) 5.7, 13.3 years) contributing 
163,607 person-years of follow-up time. The distribution of follow-up duration is given in 
Figure 7.2. Specific reasons for patient end of follow-up were as follows: last date of practice 
data collection (48%, n=8,141); death (29%, n=4,976); transferred out of practice (21%, 
n=3,583); prescribed either sulfinpyrazone, probenecid, or febuxostat (1%, n=176); none were 
prescribed benzbromarone. 
As seen in Figure 7.2, there were a large number of patients (n=3,763) whose follow-up ended 
between 13 and 16 post index date due to a large number of practices leaving CPRD following 
a change in software systems from Vision to EMIS.  
Figure 7.2: Distribution of follow-up duration 
 
Patients were registered with 275 practices with a median (IQR) 49 (21, 99) patients (with 
gout) per practice. Over half of the patients were registered with practices located in the North 
West (16%, n=2,612), South West (12%, n=2,147), and East (13%, n=2,313) of England, and 
the West Midlands (15%, n=2,652). The least number of patients were registered with 
practices located in the North East of England (3%, n=571) and the East Midlands (4%, n=777). 
The baseline covariates for the study sample are described in Table 7.1. The majority were 
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male (77%) and mean (standard deviation (SD)) age was 62.1 (14.7) years. The three most 
prevalent comorbidities were hypertension (19%), coronary heart disease (13%), and 
osteoarthritis (7%). A small proportion of patients (6%) had an acceptable level of serum urate 
(SU) (360≤µmol/L). Patients were often prescribed pain relief (non-steroidal anti-
inflammatory drugs (NSAIDS) (48%) and analgesics (33%)) and diuretics (36%). At least 30% of 
patients had missing data in lifestyle factors.  
Table 7.1: Baseline covariates of study sample (N=16,876) 
Demographics N (%) 
Age (Mean (SD), range 18, 101) 62.1 (14.7) 
Sex  
   Male 12,995 (77) 
   Female 3,881 (23) 
Deprivation (Mean (SD), range 1, 20) 9.1 (5.5) 
Comorbidities  
Anxiety 672 (4) 
Depression 842 (5) 
Cerebrovascular disease 407 (2) 
Coronary heart disease 2,167 (13) 
Diabetes  1,047 (6) 
Hyperlipidaemia 783 (5) 
Hypertension 3,137 (19) 
Osteoarthritis  1,106 (7) 
Peripheral vascular disease 257 (2) 
Renal disease 217 (1) 
Lifestyle factors  
Alcohol consumption  
   Ever drinker 9,488 (56) 
   Never drinker 856 (5) 
   Missing 6,532 (39) 
Body mass index  
   Normal weight 2,517 (15) 
   Overweight 4,933 (29) 
   Obese 3,219 (19) 
   Missing 6,207 (37) 
Smoking status  
   Ever smoker 6,436 (38) 
   Never smoker 4,847 (29) 
   Missing 5,593 (33) 
SU level  
   ≤360µmol/L 951 (6) 
   >360µmol/L 6,062 (36) 
   Missing 9,863 (58) 
Medication use  
Analgesics 5,578 (33) 
Colchicine 389 (2) 
Diuretics 6,142 (36) 
NSAIDS 8,024 (48) 




Appendix H presents comparison of baseline covariates of the whole study sample with each 
subset of that sample which contains patients who were eligible for each outcome analysis; 
each outcome analysis was restricted to patients who did not have incident outcome during 
the first year of follow-up. Generally, covariates were similar across the subsets with a few 
exceptions. Patients eligible for the analysis of target SU level consisted of 10% (N=1,742) of 
the study sample; this subset of patients was younger and were prescribed analgesics and 
NSAIDS more than the whole study sample.  
The median time to reaching target SU level was 3.5 years. Median time to occurrence of 
outcome is listed in Table 7.2.  
Table 7.2: Median time (years) until occurrence of first outcome 
Outcome Median (Interquartile range) 
Target SU level 3.5 (1.4, 7.1) 
Mortality 5.1 (2.3, 8.4) 
Gout consultation 1.9 (0.7, 4.1) 
Gout hospitalisation 6.8 (3.4, 9.7) 
Joint replacement 5.3 (2.6, 8.2) 
Cerebrovascular disease 4.5 (2.0, 8.2) 
Coronary heart disease 3.3 (1.4, 6.5) 
Peripheral vascular disease 4.3 (1.8, 7.7) 
Renal disease 5.5 (3.7, 7.6) 
SU: Serum urate 
 
7.2 Patient characteristics by allopurinol treatment 
Large differences between the treatment groups were observed where standardised mean 
difference (SMD) was >0.10 (Table 7.3). Allopurinol users had higher prevalence of coronary 
heart disease (SMD=0.11), renal disease (0.12), and were prescribed analgesics (0.19), 
colchicine (0.13), diuretics (0.25), and NSAIDS (0.30) more than non-users. The prevalence of 
missing data between treatment groups were similar for alcohol consumption, body mass 
index (BMI), and smoking status.  
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The largest difference between treatment groups was observed for baseline SU level. 
Allopurinol users had a higher prevalence of having a baseline SU level above target 
(>360μmol/L) (0.39) than non-users however, had lower prevalence of missing data (-0.27).  







Demographics    
Age (Mean (SD)) 61.8 (14.8) 62.9 (14.5) 0.08 
Sex: Female 2,919 (23) 962 (24) 0.04 
Deprivation (Mean (SD)) 9.0 (5.5) 9.6 (5.7) 0.10 
Comorbidities    
Anxiety 529 (4) 143 (4) -0.03 
Depression 654 (5) 188 (5) -0.01 
Cerebrovascular disease 294 (2) 113 (3) 0.04 
Coronary heart disease 1,544 (12) 623 (16) 0.11 
Diabetes  754 (6) 293 (7) 0.06 
Hyperlipidaemia 599 (5) 184 (5) <0.01 
Hypertension 2,362 (18) 775 (20) 0.03 
Osteoarthritis  772 (6) 334 (8) 0.10 
Peripheral vascular disease 179 (1) 78 (2) 0.05 
Renal disease 121 (1) 96 (2) 0.12 
Lifestyle factors    
Alcohol consumption    
   Ever drinker 7,328 (57) 2,160 (55) -0.04 
   Never drinker 663 (5) 193 (5) -0.01 
   Missing 4,928 (38) 1,604 (41) 0.05 
Body mass index    
   Normal 2,021 (16) 496 (13) -0.09 
   Overweight 3,829 (30) 1,104 (28) -0.04 
   Obese 2,358 (18) 861 (22) 0.09 
   Missing 4,711 (36) 1,496 (38) 0.03 
Smoking status    
   Ever smoker 4,945 (38) 1,491 (38) -0.01 
   Never smoker 3,776 (29) 1,071 (27) -0.05 
   Missing 4,198 (32) 1,395 (35) 0.06 
SU level    
   ≤360µmol/L 897 (7) 54 (1) -0.28 
   >360µmol/L 4,064 (31) 1,998 (50) 0.39 
   Missing 7,958 (62) 1,905 (48) -0.27 
Medication use    
Analgesics 3,992 (31) 1,586 (40) 0.19 
Colchicine 232 (2) 157 (4) 0.13 
Diuretics 4,339 (34) 1,803 (46) 0.25 
NSAIDS 5,689 (44) 2,335 (59) 0.30 
N (%) were presented unless otherwise stated; NSAIDS: Non-steroidal anti-inflammatory drugs; SD: Standard 






7.3 Propensity score model 
As previously stated in Section 6.2.2, choice of covariates to be included in the PS model was 
based on clinical justification and a statistically significant association between outcome and 
covariate. Covariates used to estimate PS for each outcome analysis are shown in Table 7.4. 
Age, sex, deprivation, renal disease, colchicine use, NSAIDS, diuretics, and baseline SU level 
were included in the PS model regardless of statistical significance a priori.  
Anxiety was not associated with any of the outcomes and therefore was not included in 
estimation of PS. Depression was only associated with repeated gout consultations. The 
majority of demographics, comorbidities, lifestyle factors and medication usage were 
associated with most outcomes. The least number of covariates were associated with target 
SU level which may be due to a lower sample size than analysis of other outcomes. Alcohol 
consumption was not associated with gout hospitalisation or joint replacement but was 




Table 7.4: Covariates entered into the PS model for each outcome 



























Demographics          
Age X X X X X X X X X 
Sex X X X X X X X X X 
Deprivation  X X X X X X X X X 
Comorbidities          
Anxiety          
Depression   X       
Cerebrovascular disease  X X X X  X X X 
Coronary heart disease X X X X X X  X X 
Diabetes   X X X  X X X X 
Hyperlipidaemia X  X   X X X X 
Hypertension  X  X X X X X X 
Osteoarthritis   X  X X X X X X 
Peripheral vascular disease  X X   X X  X 
Renal disease X X X X X X X X  
Lifestyle factors          
Alcohol consumption X X X X X X X X X 
Body mass index X X X X X X X X X 
Smoking status X X X X  X X X X 
SU level X X X X X X X X X 
Medication use          
Analgesics X X X X X X X X X 
Colchicine X X X X X X X X X 
Diuretics X X X X X X X X X 
NSAIDS X X X X X X X X X 
X: Covariate entered into the PS model; Green cell: Covariate was associated with outcome (p<0.05); Red cell: Covariate was not associated with outcome (p≥0.05); Black cell: Not applicable; 
NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; SU: Serum urate
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7.4 Propensity score distribution 
Across all outcome analyses, there was considerable overlap of PS between the treatment 
groups. For example, in the analysis of target SU level, PS for non-users ranged from 0.08 to 
0.80 and for allopurinol users 0.14 to 0.88; the distribution of PS is illustrated in Figure 7.3. 
Four patients were outside the region of common support therefore the non-overlap of PS 
between treatment groups was considered minimal and these patients were not removed. 
Distribution of PS by treatment for the secondary outcomes is given in (Appendix I). 
Figure 7.3: Distribution of PS by treatment status in the analysis of target SU level 
 
Dotted lines indicate at which value of the PS subclasses were created; PS: Propensity score 
Within all outcome analyses, five PS subclasses were created and within each subclass there 
were sufficient number of patients in both treatment groups. Furthermore, within each 
treatment group, in each subclass, outcome had occurred (Table 7.5).  
Within all outcome analyses, although five subclasses were deemed sufficient to achieve 
overall complete covariate balance between treatment groups across subclasses with SMD 
<0.10 (Table 7.6), imbalance in some covariates remained within subclasses thus these were 
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subsequently adjusted for in treatment effect estimation. For example, in the analysis of 
target SU level, imbalance remained for the following covariates: age (subclass 1, 2, 3), 
deprivation (subclass 4, 5), coronary heart disease (subclass 1, 3, 4, 5), hyperlipidaemia 
(subclass 1, 2), renal disease (subclass 2, 3, 4, 5), alcohol consumption (subclass 3, 4), smoking 
status (subclass 1, 5), BMI (subclass 2, 3, 4), SU level (subclass 1, 2, 5), analgesics (subclass 3), 
colchicine (subclass 1, 2, 3, 4, 5), diuretics (subclass 3, 4, 5).   
For the secondary outcome analyses, subclass 1 had the most number of imbalanced 
covariates (up to a maximum of five covariates including sex, alcohol consumption, BMI, 
NSAIDS, and baseline SU level) whereas balance was achieved on all covariates in subclasses 
4 and 5 (Appendix I).  
Increasing the number of subclasses or including interaction terms between imbalanced 
covariates did not improve balance within subclasses (data not shown).   
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Target SU level 
SU target not met 
N=789 




SU target not met  
N=246 




Subclass 1 193 (24) 99 (26) 292 (25) 23 (9) 34 (11) 57 (10) 
Subclass 2 181 (23) 80 (21) 261 (22) 31 (13) 56 (17) 87 (15) 
Subclass 3 165 (21) 74 (19) 239 (20) 56 (23) 54 (17) 110 (19) 
Subclass 4 130 (16) 75 (19) 205 (17) 61 (25) 82 (26) 143 (25) 














Subclass 1 2,413 (26) 654 (18) 3,067 (24) 236 (9) 73 (6) 309 (8) 
Subclass 2 1,951 (21) 842 (23) 2,793 (22) 404 (15) 178 (14) 582 (15) 
Subclass 3 2,012 (22) 643 (18) 2,655 (21) 540 (20) 180 (14) 720 (18) 
Subclass 4 1,528 (17) 833 (23) 2,361 (18) 642 (24) 372 (28) 1,014 (26) 















Subclass 1 1,744 (30) 1,319 (18) 3,063 (24) 173 (8) 140 (8) 140 (8) 
Subclass 2 1,247 (22) 1,552 (22) 2,799 (22) 320 (15) 256 (15) 256 (15) 
Subclass 3 1,038 (18) 1,610 (23) 2,648 (21) 371 (17) 356 (20) 356 (20) 
Subclass 4 968 (17) 1,416 (20) 2,384 (18) 571 (26) 420 (24) 420 (24) 














Subclass 1 2,370 (25) 198 (15) 2,568 (24) 199 (8) 51 (7) 250 (8) 
Subclass 2 2,065 (22) 267 (21) 2,332 (22) 383 (15) 102 (15) 485 (15) 
Subclass 3 1,928 (20) 284 (22) 2,212 (20) 484 (19) 122 (18) 606 (19) 
Subclass 4 1,726 (18) 269 (20) 1,995 (18) 647 (25) 175 (25) 822 (25) 
Subclass 5 1,457 (15) 265 (21) 1,722 (16) 856 (33) 239 (35) 1,095 (34) 




Table 7.5 continued: 
Outcome No allopurinol Allopurinol 
Joint Replacement No: N=12,008 Yes: N=744 Total: N=12,752 No: N=3,621 Yes: N=271 Total: N=3,892 
Subclass 1 2,876 (24) 151 (20) 3,027 (24) 290 (8) 12 (4) 302 (8) 
Subclass 2 2,607 (22) 152 (20) 2,759 (22) 534 (15) 36 (13) 570 (15) 
Subclass 3 2,462 (21) 150 (20) 2,612 (20) 666 (18) 51 (19) 717 (18) 
Subclass 4 2,185 (18) 151 (20) 2,336 (18) 920 (25) 73 (27) 993 (26) 
Subclass 5 1,878 (16) 140 (19) 2,018 (16) 1,211 (33) 99 (37) 1,310 (34) 
Cerebrovascular disease No: N=11,273 Yes: N=1,195 Total: N=12,468 No: N=3,428 Yes: N=357 Total: N=3,785 
Subclass 1 2,681 (24) 277 (23) 2,958 (24) 268 (8) 25 (7) 293 (8) 
Subclass 2 2,413 (21) 278 (23) 2,691 (22) 501 (15) 59 (17) 560 (15) 
Subclass 3 2,345 (21) 209 (17) 2,554 (20) 652 (19) 44 (12) 696 (18) 
Subclass 4 2,048 (18) 249 (21) 2,297 (18) 861 (25) 93 (26) 954 (25) 
Subclass 5 1,786 (16) 182 (15) 1,968 (16) 1,146 (33) 136 (38) 1,282 (34) 
Coronary heart disease No: N=8,675 Yes: N=2,228 Total: N=10,903 No: N=2,438 Yes: N=722 Total: N=3,160 
Subclass 1 2,086 (24) 475 (21) 2,561 (23) 196 (8) 56 (8) 252 (8) 
Subclass 2 1,864 (21) 501 (22) 2,365 (22) 351 (14) 97 (13) 448 (14) 
Subclass 3 1,778 (21) 436 (20) 2,214 (20) 485 (20) 113 (16) 598 (19) 
Subclass 4 1,555 (18) 459 (21) 2,014 (18) 604 (25) 195 (27) 799 (25) 
Subclass 5 1,392 (16) 357 (16) 1,749 (16) 802 (33) 261 (36) 1,063 (34) 
Peripheral vascular disease No: N=12,186 Yes: N=480 Total: N=12,666 No: N=3,698 Yes: N=155 Total: N=3,853 
Subclass 1 2,910 (24) 92 (19) 3,002 (24) 289 (8) 14 (9) 303 (8) 
Subclass 2 2,636 (22) 102 (21) 2,738 (22) 548 (15) 17 (11) 565 (15) 
Subclass 3 2,494 (20) 92 (19) 2,586 (20) 695 (19) 23 (15) 718 (19) 
Subclass 4 2,238 (18) 102 (21) 2,340 (18) 926 (25) 38 (25) 964 (25) 
Subclass 5 1,908 (16) 92 (19) 2,000 (16) 1,240 (34) 63 (41) 1,303 (34) 
Renal disease No: N=9,867 Yes: N=2,864 Total: N=12,731 No: N=2,716 Yes: N=1,061 Total: N=3,777 
Subclass 1 2,490 (25) 516 (18) 3,006 (24) 232 (9) 64 (6) 296 (8) 
Subclass 2 2,151 (22) 595 (21) 2,746 (22) 432 (16) 124 (12) 556 (15) 
Subclass 3 2,050 (21) 544 (19) 2,594 (20) 544 (20) 163 (15) 707 (19) 
Subclass 4 1,727 (18) 622 (22) 2,349 (18) 660 (24) 293 (28) 953 (25) 
Subclass 5 1,449 (15) 587 (21) 2,036 (16) 848 (31) 417 (39) 1,265 (33) 
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Demographics          
Age 0.02 0.01 0.01 0.01 <0.01 0.01 0.02 0.01 0.01 
Sex: Female 0.01 <0.01 <0.01 <0.01 <0.01 <0.01 0.01 <0.01 <0.01 
Deprivation <0.01 <0.01 <0.01 0.01 <0.01 <0.01 0.01 <0.01 <0.01 
Comorbidities          
Anxiety - - - - - - - - - 
Depression - - <0.01 - - - - - - 
Cerebrovascular disease - <0.01 <0.01 <0.01 <0.01 - 0.01 <0.01 <0.01 
Coronary heart disease 0.02 0.02 0.01 0.01 0.02 0.02 - 0.02 0.02 
Diabetes  - 0.01 <0.01 0.01 - 0.01 0.01 0.01 0.01 
Hyperlipidaemia 0.01 - <0.01 - - <0.01 <0.01 <0.01 <0.01 
Hypertension - <0.01 - <0.01 <0.01 <0.01 0.01 <0.01 <0.01 
Osteoarthritis  - 0.01 - 0.01 <0.01 0.01 0.01 0.01 0.01 
Peripheral vascular 
disease 
- 0.01 0.01 - - 0.01 <0.01 - <0.01 
Renal disease 0.04 0.04 0.04 0.03 0.04 0.04 0.04 0.03 - 
Lifestyle factors          
Alcohol consumptiona 0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
Body mass indexa 0.01 0.01 0.01 0.01 0.01 <0.01 0.01 0.01 0.01 
Smoking statusa -0.01 <0.01 <0.01 <0.01 - -0.01 <0.01 <0.01 <0.01 
SU levela 0.08b -0.09 -0.09 0.02 -0.08 <0.01 -0.08 -0.08 -0.08 
Medication use          
Analgesics 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 
Colchicine 0.03 0.04 0.04 0.04 0.04 0.04 0.05 0.04 0.04 
Diuretics 0.03 0.02 <0.01 0.02 0.02 0.02 0.03 0.02 0.02 
NSAIDS -0.01 0.01 <0.01 0.01 0.01 <0.01 0.01 0.01 0.01 
aFor categorical variables, the largest SMD was presented; bSU level was a continuous covariate; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; SMD: Standardised 
mean difference; SU: Serum urate
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7.5 Treatment effect analysis 
7.5.1 Landmark one-year analysis 
For each outcome analysis, subclass-specific treatment effect estimates were pooled and are 
presented in Table 7.7 alongside with unadjusted treatment effect (hazard ratio (HR) with 95% 
confidence interval (CI)) and distribution of outcome across treatment groups.  
For the majority of outcomes, the subclass-specific treatment effect estimates were 
homogeneous across subclasses as judged by the likelihood ratio test, which showed that 
including an interaction term between allopurinol and PS subclasses in addition to their main 
effects did not improve model fit (p-value >0.05). Allopurinol use was associated with higher 
chance of reaching target SU level (HR 2.32 (95% CI: 1.97, 2.74)), and increased risk of 
premature mortality (1.10 (1.03, 1.17)), coronary heart disease (1.11 (1.02, 1.21)) and renal 
disease (1.19 (1.10, 1.28)) (Table 7.7). 
The subclass-specific treatment effect estimates for repeated gout consultations and gout 
hospitalisation were not homogeneous across subclasses (p<0.001 and p=0.007 respectively). 
The pooled estimates were therefore weighted by the inverse of the sample size and 
presented in Table 7.7, and subclass-specific treatment estimates are presented in Table 7.8 
and Table 7.9 respectively alongside with description of covariates.   
The pooled treatment effect showed that allopurinol was associated with fewer gout 
consultations (0.70 (0.65, 0.75)). Within subclass 5 (highest propensity for allopurinol), 
allopurinol was found to have the strongest protective effect against repeated gout 
consultations (0.60 (0.53, 0.67)); patients in that subclass were older, had higher prevalence 
of females, coronary heart disease, hypertension, obesity, and were also more likely to be 
prescribed analgesics, diuretics and NSAIDS than subclass 2 in which, allopurinol was found to 
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have the weakest protective effect (0.81 (0.68, 0.97)). Most patients in subclass 5 had a 
recorded baseline SU level, which was above 360μmol/L (Table 7.8).  
The pooled treatment effect also showed that allopurinol was associated with increased risk 
of gout hospitalisation (1.82 (1.64, 2.02)). In Table 7.9, the highest risk of gout hospitalisation 
was observed in subclass 1 (2.46 (1.78, 3.40)). Patients in subclass 1 were slightly younger and 
resided in less deprived areas, had lower prevalence of coronary heart disease, osteoarthritis, 
analgesics, diuretics and NSAIDS use, and were more likely to be an ever drinker, never smoker 
and have normal-overweight BMI value, compared with patients in subclass 5 in which 
allopurinol users had the lowest risk of gout hospitalisation (1.46 (1.23, 1.74)). 
Test for proportional hazards (PH) failed for allopurinol in the outcome analyses of target SU 
level, repeated gout consultations and renal disease in unadjusted Cox models. On graphical 
inspection of the Schoenfeld residuals plotted over time (presented in Appendix J), the log-HR 
was constant i.e., had a zero slope, until towards the end of follow-up where its direction 
changed from being constant to either increasing or decreasing. The change in HR may 
indicate that the lessening effect of treatment was due to a small number of patients with the 
longest follow-up times. Given the PH was satisfied for the majority of follow-up, and the 
Kaplan-Meier plots had shown no crossover of survival functions between the two treatment 
groups (graphs not shown), it was assumed overall, that the PH assumption was satisfied.  
After PS subclassification, the PH assumption for allopurinol was met in the majority of 
subclasses for all outcome analyses with the following exceptions. For mortality, the PH 
assumption failed in one subclass; for repeated gout consultations the PH assumption failed 
in three subclasses; for renal disease the PH assumption failed in two subclasses. As above, on 
further inspection of the Schoenfeld residuals the decrease in log-HR towards the end of 
follow-up was due to a small number of patients with the longest follow-up times (Appendix 
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J). Kaplan-Meier plots had shown no crossover of survival functions between the two 
treatment groups (graphs not shown). Therefore, it was assumed the PH assumption was 
satisfied.  







Hazard ratio (95% CI) 
Standard error 
Adjusted 
Hazard Ratio (95% CI) 
Standard error 
SU level     
   Target level not met 789 (67) 246 (43) 2.27 (1.96, 2.64) 
0.17 
2.32 (1.97, 2.74) 
0.19    Target level met 386 (33) 321 (57) 
Mortality     
   Alive 9,260 (72) 2,640 (67) 1.23 (1.15, 1.31) 
0.04 
1.10 (1.03, 1.17) 
0.04    Died 3,659 (28) 1,317 (33) 
Repeated gout consultations     
   Never consulted 5,787 (45) 2,193 (55) 0.75 (0.70, 0.80) 
0.03 
0.70 (0.65, 0.75)* 
0.03    Consulted at least once 7,132 (55) 1,764 (45) 
Gout hospitalisation     
   No 9,546 (88) 2,569 (79) 1.97 (1.80, 2.17) 
0.09 
1.82 (1.64, 2.02)* 
0.10    Yes 1,283 (12) 689 (21) 
Joint replacement     
   No 12,008 (94) 3,621 (93) 1.26 (1.10, 1.45) 
0.09 
1.15 (0.99, 1.32) 
0.08    Yes 744 (6) 271 (7) 
Cerebrovascular disease     
   No 11,273 (90) 3,428 (91) 1.03 (0.91, 1.16) 
0.06 
0.98 (0.87, 1.11) 
0.06    Yes 1,195 (10) 357 (9) 
Coronary heart disease     
   Yes 8,675 (80) 2,438 (77) 1.16 (1.07, 1.26) 
0.05 
1.11 (1.02, 1.21) 
0.05    No 2,228 (20) 722 (23) 
Peripheral vascular disease     
   No 12,186 (96) 3,698 (96) 1.10 (0.92, 1.32) 
0.10 
1.01 (0.84, 1.22) 
0.10    Yes 480 (4) 155 (4) 
Renal disease     
   No 9,867 (78) 2,716 (72) 1.36 (1.27, 1.46) 
0.05 
1.19 (1.10, 1.28) 
0.04    Yes 2,864 (23) 1,061 (28) 





Table 7.8: Estimated treatment effect of allopurinol on repeated gout consultations and 
distribution of covariates within each PS subclass  
 










HR (95% CI) 
Standard error 
0.75 (0.62, 0.92) 
0.08 
0.81 (0.68, 0.97) 
0.07 
0.76 (0.65, 0.88) 
0.06 
0.62 (0.54, 0.71) 
0.04 
0.60 (0.53, 0.67) 
0.03 
Demographics      
Age (Mean (SD)) 59.8 (14.0) 62.0 (15.2) 59.6 (14.4) 64.8 (14.9) 64.1 (14.4) 
Sex: Female 788 (23) 674 (20) 545 (16) 910 (27) 964 (29) 
Deprivation 
(Mean (SD)) 
7.6 (5.1) 8.8 (5.5) 9.2 (5.4) 9.3 (5.5) 10.7 (5.6) 
Comorbidities      
Anxiety 136 (4) 155 (5) 113 (3) 125 (4) 143 (4) 








306 (9) 381 (11) 495 (15) 772 (23) 
Diabetes  143 (4) 155 (5) 176 (5) 211 (6) 362 (11) 
Hyperlipidaemia 155 (5) 171 (5) 122 (4) 167 (5) 168 (5) 
Hypertension 387 (11) 578 (17) 489 (14) 812 (24) 871 (26) 




25 (1) 40 (1) 73 (2) 96 (3) 
Renal disease NA (<1) NA (0) 9 (<1) 42 (1) 162 (5) 
Lifestyle factors      
Alcohol 
consumption 
     
   Ever drinker 2,089 (62) 1,997 (59) 1,838 (54) 1,863 (55) 1,701 (50) 
   Never drinker 194 (6) 192 (6) 123 (4) 203 (6) 144 (4) 
   Missing 1,093 (32) 1,186 (35) 1,414 (42) 1,309 (39) 1,530 (45) 
Body mass 
index 
     
   Normal 772 (23) 659 (20) 382 (11) 433 (13) 271 (8) 
   Overweight 1,107 (33) 1,089 (32) 934 (28) 1,013 (30) 790 (23) 
   Obese 447 (13) 457 (14) 665 (20) 684 (20) 966 (29) 
   Missing 1,050 (31) 1,170 (35) 1,394 (41) 1,245 (37) 1,348 (40) 
Smoking status      
   Ever smoker 1,423 (42) 1,263 (37) 1,158 (34) 1,312 (39) 1,280 (38) 
   Never smoker 1,119 (33) 1,097 (33) 964 (29) 934 (28) 733 (22) 
   Missing 834 (25) 1,015 (30) 1,253 (37) 1,129 (33) 1,362 (40) 
SU level      
   ≤360µmol/L 944 (28) 7 (<1) 0 (0) 0 (0) 0 (0) 
   >360µmol/L 0 (0) 258 (8) 1,073 (32) 1,778 (53) 2,953 (87) 
   Missing 2,432 (72) 3,110 (92) 2,302 (68) 1,597 (47) 422 (13) 
Medication use      
Analgesics 526 (16) 730 (22) 1,011 (30) 1,420 (42) 1,891 (56) 
Colchicine 8 (<1) 12 (<1) 26 (1) 78 (2) 265 (8) 
Diuretics 389 (12) 1,080 (32) 743 (22) 1,952 (58) 2,075 (61) 
NSAIDS 292 (9) 942 (28) 1,765 (52) 2,066 (61) 2,862 (85) 
N (%) presented unless otherwise stated; CI: Confidence interval; NA: Cannot report cell counts with less than 
five events; HR: Hazard ratio; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; SD: 





Table 7.9: Estimated treatment effect of allopurinol on gout hospitalisation and distribution 












HR (95% CI) 
Standard error 
2.46 (1.78, 3.40) 
0.40 
1.98 (1.57, 2.49) 
0.23 
1.60 (1.29, 1.98) 
0.17 
1.75 (1.44, 2.11) 
0.17 
1.46 (1.23, 1.74) 
0.13 
Demographics      
Age (Mean (SD)) 62.5 (13.6) 63.9 (14.8) 62.0 (14.0) 65.3 (14.7) 64.1 (14.2) 
Sex: Female 722 (26) 591 (21) 548 (19) 785 (28) 829 (29) 
Deprivation 
(Mean (SD)) 
7.8 (5.1) 9.0 (5.4) 9.3 (5.4) 9.6 (5.6) 10.5 (5.6) 
Comorbidities      
Anxiety 108 (4) 117 (4) 123 (4) 103 (4) 135 (5) 
Depression 140 (5) 133 (5) 157 (6) 148 (5) 171 (6) 
Cerebrovascular 
disease 31 (1) 58 (2) 66 (2) 88 (3) 126 (4) 
Coronary heart 
disease 213 (8) 301 (11) 354 (13) 441 (16) 627 (22) 
Diabetes  158 (6) 165 (6) 149 (5) 213 (8) 262 (9) 
Hyperlipidaemia 122 (4) 131 (5) 126 (4) 150 (5) 158 (6) 
Hypertension 478 (17) 578 (21) 463 (16) 640 (23) 599 (21) 
Osteoarthritis  107 (4) 99 (4) 178 (6) 246 (9) 381 (14) 
Peripheral 
vascular disease 31 (1) 44 (2) 50 (2) 54 (2) 61 (2) 
Renal disease NA (<1) NA (0) 18 (1) 39 (1) 127 (5) 
Lifestyle factors      
Alcohol 
consumption 
     
   Ever drinker 1,782 (63) 1,615 (57) 1,640 (58) 1,516 (54) 1,440 (51) 
   Never drinker 190 (7) 175 (6) 140 (5) 159 (6) 113 (4) 
   Missing 846 (30) 1,027 (36) 1,038 (37) 1,142 (41) 1,264 (45) 
Body mass index      
   Normal 678 (24) 504 (18) 412 (15) 324 (12) 253 (9) 
   Overweight 927 (33) 884 (31) 858 (30) 821 (29) 695 (25) 
   Obese 381 (14) 423 (15) 519 (18) 618 (22) 803 (29) 
   Missing 832 (30) 1,006 (36) 1,029 (37) 1,054 (37) 1,066 (38) 
Smoking status      
   Ever smoker 1,236 (44) 1,047 (37) 1,074 (38) 1,060 (38) 1,115 (40) 
   Never smoker 961 (34) 904 (32) 844 (30) 760 (27) 569 (20) 
   Missing 621 (22) 866 (31) 900 (32) 997 (35) 1,133 (40) 
SU level      
   ≤360µmol/L 811 (29) NA (<1) 0 (0) 0 (0) 0 (0) 
   >360µmol/L 0 (0) 98 (3) 779 (28) 1,591 (56) 2,555 (91) 
   Missing 2,007 (71) 2,716 (96) 2,039 (72) 1,226 (44) 262 (9) 
Medication use      
Analgesics 544 (19) 727 (26) 972 (34) 1,229 (44) 1,545 (55) 
Colchicine 8 (<1) 8 (<1) 27 (1) 65 (2) 235 (8) 
Diuretics 339 (12) 991 (35) 787 (28) 1,648 (59) 1,714 (61) 
NSAIDS 359 (13) 901 (32) 1,635 (58) 1,564 (56) 2,365 (84) 
N (%) presented unless otherwise stated; CI: Confidence interval; HR: Hazard ratio; NA: Cannot report cell 
counts with less than five events; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity Score; SD: 





7.5.2 Treatment effect stratified by presence of renal disease 
Of the study sample (n=16,876), 217 patients had renal disease at baseline. In patients with 
no renal disease, allopurinol users had higher prevalence of SU being recorded, the SU level 
being ≥360μmol/L, and were more likely to be prescribed analgesics, colchicine, diuretics and 
NSAIDS than non-users (SMD >0.10). In addition to the imbalanced covariates identified in 
patients with no renal disease, in patients with renal disease more differences were observed 
between the treatment groups with SMD >0.10 for BMI distribution, never smokers, and 
cerebrovascular disease, and peripheral vascular disease (Table 7.10). 
PS subclassification was performed in patients with no renal disease. Mean and range of PS 
was similar between treatment groups indicating common support. Five subclasses were 
sufficient to achieve overall covariate balance across subclasses although some imbalance 
remained within subclasses. As in the main analysis, subclass 1 observed the most number of 
imbalanced covariates (Table 7.11).   
PS subclassification could not be performed in patients with renal disease due to insufficient 
sample size and low frequency of occurrence of outcomes. For example, for mortality, five 
subclasses were sufficient to achieve overall balance in covariates across subclasses. However, 
this meant there were approximately 43 patients in each of the five subclasses, there was 
substantial imbalance in the majority of covariates within a subclass, and outcome did not 
occur within treatment groups in certain subclasses. Adjustment for all imbalanced covariates 
in estimating subclass-specific treatment effect was not possible due to small number of 
deaths in that subclass. Therefore, PS subclassification was not used. Instead, multivariable 
Cox regression adjusted for covariates that were originally included in the PS model. Given the 
low frequency of occurrence of outcome for gout hospitalisation, cerebrovascular disease, 
and coronary heart disease, the Cox model only adjusted for age, sex and BMI. Due to an even 
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lower frequency of occurrence of outcome for target SU level, joint replacement, and 
peripheral vascular disease, unadjusted HRs were presented. 
Table 7.10: Baseline covariates stratified by renal disease 
 













Demographics     
Age (Mean (SD)) 61.7 (14.8) 62.5 (14.5) 70.8 (13.4) 72 (12.4) 
Sex: Female 2,860 (22) 892 (24) 40 (33) 36 (38) 
Deprivation (Mean (SD)) 9.0 (5.5) 9.5 (5.7) 10.5 (5.3) 10.4 (5.3) 
Comorbidities     
Anxiety 522 (4) 140 (4) NA (3) NA (2) 
Depression 645 (5) 180 (5) NA (2) NA (4) 
Cerebrovascular disease 291 (2) 105 (3) NA (1) 5 (5) 
Coronary heart disease 1,491 (12) 573 (15) 33 (27) 24 (25) 
Diabetes  715 (6) 252 (7) 25 (21) 20 (21) 
Hyperlipidaemia 580 (5) 164 (4) 9 (7) 9 (9) 
Hypertension 2,301 (18) 726 (19) 42 (35) 32 (33) 
Osteoarthritis  755 (6) 313 (8) 11 (9) 10 (10) 
Peripheral vascular disease 170 (1) 63 (2) 5 (4) 12 (13) 
Lifestyle factors     
Alcohol consumption     
   Ever drinker 7,216 (57) 2,068 (55) 69 (57) 51 (53) 
   Never drinker 650 (5) 179 (5) 8 (7) 6 (6) 
   Missing 4,865 (38) 1,530 (41) 44 (36) 39 (41) 
Body mass index     
   Normal 1,986 (16) 469 (12) 22 (18) 20 (21) 
   Overweight 3,773 (30) 1,052 (28) 38 (31) 27 (28) 
   Obese 2,321 (18) 808 (21) 22 (18) 23 (24) 
   Missing 4,651 (37) 1,448 (38) 39 (32) 26 (27) 
Smoking status     
   Ever smoker 4,863 (38) 1,418 (38) 53 (44) 39 (41) 
   Never smoker 3,717 (29) 1,012 (27) 32 (26) 33 (34) 
   Missing 4,151 (33) 1,347 (36) 36 (30) 24 (25) 
SU level     
   ≤360µmol/L 893 (7) 53 (1) NA (2) NA (1) 
   >360µmol/L 3,990 (31) 1,904 (50) 51 (42) 52 (54) 
   Missing 7,848 (62) 1,820 (48) 68 (56) 43 (45) 
Medication use     
Analgesic 3,891 (31) 1,480 (39) 62 (51) 61 (64) 
Colchicine 224 (2) 143 (4) 8 (7) 8 (8) 
Diuretic 4,207 (33) 1,648 (44) 85 (70) 85 (89) 
NSAIDS 5,613 (44) 2,241 (59) 45 (37) 45 (47) 
N (%) presented unless otherwise stated; Cells highlighted in yellow indicate standardised mean difference >0.10; 
NA: Cannot report cell counts with less than five events; NSAIDS: Non-steroidal anti-inflammatory drugs; SD: 







Table 7.11: Distribution of PS subclasses in patients with no renal disease 
Outcome 





Smallest cellb Imbalanced covariates (SMD >0.10) 
Target SU level 
0.30 (0.08, 0.81) 




S1: Age, sex, coronary heart disease, 
hyperlipidaemia, alcohol consumption, 
smoking status, SU level, analgesics 
S2: Sex, hyperlipidaemia, alcohol 
consumption, BMI, smoking status, SU 
level, diuretics 
S3: Age, coronary heart disease, 
alcohol consumption, BMI, smoking 
status, diuretics 
S4: Coronary heart disease, alcohol 
consumption, BMI, NSAIDS 
S5: Sex, BMI 
Mortality 
0.21 (0.02, 0.71) 




S1: Sex, alcohol consumption, BMI, SU 
level, colchicine 




0.21 (0.03, 0.71) 




S1: Sex, alcohol consumption, BMI, SU 
level 
S2: Deprivation, NSAIDS 
Gout 
hospitalisation 
0.21 (0.02, 0.71) 




S1: Sex, alcohol consumption, BMI, SU 
level,  
S2: Sex, BMI, NSAIDS 




0.21 (0.03, 0.70) 




S1: Sex, alcohol consumption, BMI, 




0.21 (0.02, 0.70) 




S1: Sex, alcohol consumption, BMI, SU 
level, colchicine 
S2: Deprivation 




0.21 (0.02, 0.70) 




S1: Sex, cerebrovascular disease, BMI, 
SU level, colchicine 
S2: Deprivation, BMI 
S3: Alcohol consumption 
Peripheral 
vascular disease 
0.21 (0.02, 0.71) 




S1: Sex, alcohol consumption, BMI, SU 
level, colchicine 
S2: BMI 
S3: SU level 
aNumber of subclasses needed to achieve overall covariate balance across subclasses; bSmallest cell defined as 
the number of allopurinol users within a subclass; BMI: Body mass index; NSAIDS: Non-steroidal anti-







Table 7.12 provides the estimated treatment effect for each outcome stratified by presence 
of renal disease. In patients with no renal disease, allopurinol had a higher chance of reaching 
target SU level (2.26 (1.89, 2.71)), fewer gout consultations (0.71 (0.66, 0.76)), higher risk of 
gout hospitalisation (1.86 (1.65, 2.09)) and undergoing joint replacement (1.24 (1.06, 1.46)).  
Subclass-specific treatment effects estimates are reported in Table 7.13 and Table 7.14 for 
repeated gout consultations and gout hospitalisation respectively, as the subclass-specific 
treatment effect estimates were not homogenous. As in the main analysis (Section 7.5.1), 
within subclass 5, allopurinol was found to have the strongest protective effect against 
repeated gout consultations (0.56 (0.50, 0.63)). Within subclass 1, allopurinol was found to 
have the highest risk of gout hospitalisation (2.96 (2.09, 4.20)).  
In patients with renal disease, allopurinol use was not associated with any of the outcomes. 
Although not statistically significant, adjusted analyses had shown allopurinol may be 
protective against premature mortality (0.83 (0.57, 1.21)) and repeated gout consultations 
(0.58 (0.34, 0.97)), but may have higher risk of gout hospitalisation (1.48 (0.79, 2.80)), 







Table 7.12: Estimated treatment effect of allopurinol stratified by renal disease 






Hazard ratio (95% CI) 
Standard error 
Adjusted 






Hazard ratio (95% CI) 
Standard error 
Adjusted 
Hazard Ratio (95% CI) 
Standard error 
SU level         
   Target SU level not met 743 (69) 233 (46) 2.27 (1.92, 2.67)a 
0.19 
2.26 (1.89, 2.71)a 
0.21 
9 (64) 10 (71) 0.81 (0.22, 2.94) 
0.53 
N/A 
   Target SU level met 333 (31) 273 (54) 5 (36) NA (28) 
Mortality         
   Alive 10,194 (80) 3,000 (79) 1.10 (1.02, 1.19) 
0.05 
1.02 (0.94, 1.11) 
0.04 
41 (34) 27 (28) 1.18 (0.86, 1.63)  
0.19 
0.83 (0.57, 1.21) 
0.16    Dead 2,537 (20) 777 (21) 80 (66) 69 (72) 
Repeated gout 
consultations 
        
   Never consulted 6,022 (47) 2,193 (58) 0.75 (0.70, 0.80)a 
0.03 
0.71 (0.66, 0.76)ab 
0.03 
60 (50) 66 (69) 0.65 (0.40, 1.04)a 
0.16 
0.58 (0.34, 0.97)a 
0.15    Consulted at least once 6,709 (53) 1,584 (42) 61 (50) 30 (31) 
Gout hospitalisation         
   No 9,720 (91) 2,642 (85) 1.95 (1.75, 2.18) 
0.11 
1.86 (1.65, 2.09)ab 
0.11 
95 (83) 59 (78) 1.53 (0.80, 2.94) 
0.51 
1.48 (0.79, 2.80)c 
0.48    Yes 934 (9) 474 (15) 19 (17) 17 (22) 
Joint replacement         
   No 11,938 (95) 3,493 (94) 1.33 (1.14, 1.54) 
0.10 
1.24 (1.06, 1.46) 
0.10 
115 (97) 88 (97) 1.04 (0.24, 4.49) 
0.78 
N/A 
   Yes 628 (5) 227 (6) NA (3) NA (3) 
Cerebrovascular disease         
   No 11,334 (92) 3,357 (93) 1.00 (0.87, 1.14) 
0.07 
0.96 (0.83, 1.11) 
0.07 
103 (879) 71 (83) 1.34 (0.66, 2.73) 
0.42 
1.20 (0.57, 2.53)c 
0.46    Yes 955 (8) 264 (7) 15 (13) 15 (17) 
Coronary heart disease         
   No 8,788 (82) 2,447 (80) 1.13 (1.03, 1.24) 
0.05 
1.10 (1.00, 1.20) 
0.05 
64 (77) 46 (77) 1.17 (0.58, 2.34) 
0.41 
1.16 (0.55, 2.43)c 
0.44    Yes 1,992 (18) 603 (20) 19 (23) 14 (23) 
Peripheral vascular disease         
   No 12,099 (97) 3,582 (97) 0.99 (0.80, 1.23) 
0.11 
0.94 (0.75, 1.17) 
0.11 
107 (93) 76 (93) 1.11 (0.39, 3.15) 
0.59 
N/A 
   Yes 391 (3) 108 (3) 8 (7) 6 (7) 
aStatistical test for the proportional hazards assumption failed, however change in treatment effect was represented by a small number of patients with the longest follow-up times, and 
there was no cross-over of survival functions from treatment groups. Therefore, the proportional hazards assumption was satisfied. bSubclass-specific treatment effects were homogenous; 




Table 7.13: Estimated PS subclass-specific treatment effect of allopurinol on repeated gout 
consultations in those with no renal disease 
 










HR (95% CI) 
Standard error 
0.80 (0.65, 0.98) 
0.08 
0.83 (0.69, 1.00) 
0.08 
0.69 (0.60, 0.81) 
0.05 
0.68 (0.58, 0.79) 
0.05 
0.56 (0.50, 0.63) 
0.03 
Demographics      
Age (Mean (SD)) 59.6 (13.8) 62.9 (15.4) 59.0 (14.1) 64.9 (15.0) 62.9 (14.4) 
Sex: Female 751 (23) 711 (22) 498 (15) 914 (28) 878 (27) 
Deprivation 
(Mean (SD)) 
7.3 (5.0) 9.0 (5.7) 9.0 (5.3) 9.6 (5.6) 10.5 (5.6) 
Comorbidities      
Anxiety 132 (4) 146 (4) 108 (3) 140 (4) 136 (4) 
Depression 190 (6) 191 (6) 139 (4) 160 (5) 145 (4) 
Cerebrovascular 
disease 43 (1) 74 (2) 64 (2) 84 (3) 131 (4) 
Coronary heart 
disease 189 (6) 335 (10) 331 (10) 501 (15) 708 (21) 
Diabetes  142 (4) 170 (5) 153 (5) 210 (6) 292 (9) 
Hyperlipidaemia 163 (5) 172 (5) 107 (3) 168 (5) 134 (4) 
Hypertension 356 (11) 631 (19) 411 (12) 803 (24) 826 (25) 
Osteoarthritis  121 (4) 137 (4) 179 (5) 271 (8) 360 (11) 
Peripheral 
vascular disease 26 (1) 31 (1) 35 (1) 67 (2) 74 (2) 
Lifestyle factors      
Alcohol 
consumption 
     
   Ever drinker 1,790 (54) 1,854 (56) 1,861 (56) 1,862 (56) 1,917 (58) 
   Never drinker 156 (5) 173 (5) 128 (4) 203 (6) 169 (5) 
   Missing 1,356 (41) 1,275 (39) 1,312 (40) 1,237 (37) 1,215 (37) 
Body mass 
index 
     
   Normal 638 (19) 568 (17) 456 (14) 434 (13) 359 (11) 
   Overweight 944 (29) 994 (30) 959 (29) 1,026 (31) 902 (27) 
   Obese 443 (13) 499 (15) 585 (18) 689 (21) 913 (28) 
   Missing 1,277 (39) 1,241 (38) 1,301 (39) 1,153 (35) 1,127 (34) 
Smoking status      
   Ever smoker 1,181 (36) 1,181 (36) 1,175 (36) 1,283 (39) 1,461 (44) 
   Never smoker 988 (30) 1,031 (31) 977 (30) 960 (29) 773 (23) 
   Missing 1,133 (34) 1,090 (33) 1,149 (35) 1,059 (32) 1,067 (32) 
SU level      
   ≤360µmol/L 940 (28) 6 (<1) 0 (0) 0 (0) 0 (0) 
   >360µmol/L 0 (0) 139 (4) 1,095 (33) 1,666 (50) 2,994 (91) 
   Missing 2,362 (72) 3,157 (96) 2,206 (67) 1,636 (50) 307 (9) 
Medication use      
Analgesics 450 (14) 823 (25) 847 (26) 1,487 (45) 1,764 (53) 
Colchicine 7 (<1) 12 (<1) 23 (1) 71 (2) 254 (8) 
Diuretics 255 (8) 1,214 (37) 583 (18) 1,967 (60) 1,836 (56) 
NSAIDS 387 (12) 821 (25) 1,795 (54) 1,970 (60) 2,881 (87) 
N (%) presented unless otherwise stated; CI: Confidence interval; HR: Hazard ratio; NSAIDS: Non-steroidal anti-






Table 7.14: Estimated PS subclass-specific treatment effect of allopurinol on gout 
hospitalisation in those with no renal disease 
 










HR (95% CI) 
Standard error 
2.96 (2.09, 4.20) 
0.53 
1.82 (1.38, 2.40) 
0.26 
1.64 (1.28, 2.10) 
0.21 
1.69 (1.34, 2.13) 
0.20 
1.47 (1.19, 1.82) 
0.16 
Demographics      
Age (Mean (SD)) 62.7 (13.6) 63.6 (14.9) 62.4 (13.8) 64.7 (14.8) 63.6 (14.1) 
Sex: Female 722 (26) 579 (21) 539 (20) 757 (27) 765 (28) 
Deprivation 
(Mean (SD)) 
7.8 (5.2) 9.1 (5.4) 9.1 (5.4) 9.8 (5.6) 10.4 (5.6) 
Comorbidities      
Anxiety 106 (4) 116 (4) 113 (4) 111 (4) 130 (5) 
Depression 139 (5) 129 (5) 149 (5) 148 (5) 169 (6) 
Cerebrovascular 
disease 30 (1) 64 (2) 65 (2) 83 (3) 118 (4) 
Coronary heart 
disease 202 (7) 298 (11) 327 (12) 431 (16) 592 (21) 
Diabetes  158 (6) 166 (6) 140 (5) 190 (7) 226 (8) 
Hyperlipidaemia 119 (4) 128 (5) 120 (4) 144 (5) 144 (5) 
Hypertension 470 (17) 555 (20) 461 (17) 605 (22) 575 (21) 
Osteoarthritis  103 (4) 100 (4) 182 (7) 231 (8) 359 (13) 
Peripheral 
vascular disease 31 (1) 39 (1) 48 (2) 51 (2) 50 (2) 
Lifestyle factors      
Alcohol 
consumption 
     
   Ever drinker 1,741 (63) 1,553 (56) 1,636 (59) 1,457 (53) 1,428 (52) 
   Never drinker 196 (7) 168 (6) 134 (5) 151 (5) 105 (4) 
   Missing 818 (30) 1,032 (37) 984 (36) 1,146 (42) 1,221 (44) 
Body mass 
index 
     
   Normal 678 (25) 483 (18) 405 (15) 305 (11) 246 (9) 
   Overweight 912 (33) 835 (30) 868 (32) 795 (29) 681 (25) 
   Obese 378 (14) 426 (15) 508 (18) 595 (22) 759 (28) 
   Missing 787 (29) 1,009 (37) 973 (35) 1,059 (38) 1,068 (39) 
Smoking status      
   Ever smoker 1,226 (45) 1,005 (37) 1,067 (39) 1,013 (37) 1,086 (39) 
   Never smoker 949 (34) 868 (32) 849 (31) 722 (26) 548 (20) 
   Missing 580 (21) 880 (32) 838 (30) 1,019 (37) 1,120 (41) 
SU level      
   ≤360µmol/L 805 (29) NA (0) 0 (0) 0 (0) 0 (0) 
   >360µmol/L 0 (0) 75 (3) 719 (26) 1,544 (56) 2,541 (92) 
   Missing 1,950 (71) 2,674 (97) 2,035 (74) 1,210 (44) 213 (8) 
Medication use      
Analgesics 528 (19) 722 (26) 927 (34) 1,202 (44) 1,459 (53) 
Colchicine 7 (<1) 8 (0) 28 (1) 64 (2) 220 (8) 
Diuretics 355 (13) 994 (36) 744 (27) 1,569 (57) 1,571 (57) 
NSAIDS 352 (13) 799 (29) 1,684 (61) 1,486 (54) 2,359 (86) 
N (%) presented unless otherwise stated; CI: Confidence interval; HR: Hazard ratio; NA: Cannot report cell 
counts with less than five events; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; SD: 





7.5.3 Treatment effect stratified by severity of hyperuricaemia 
Of the study sample (n=16,876), 3,160 patients had non-severe hyperuricaemia and 2,902 had 
severe hyperuricaemia. Among patients with non-severe hyperuricaemia, allopurinol users 
were older and more likely to be female, reside in a more deprived area, have osteoarthritis, 
and be prescribed analgesics, diuretics and NSAIDS than non-users (SMD >0.10). In patients 
with severe hyperuricaemia, allopurinol users had higher prevalence of osteoarthritis and 
were more likely to be prescribed analgesics, diuretics and NSAIDS than non-users (SMD 
>0.10) (Table 7.15).   
PS subclassification for each outcome in non-severe and severe hyperuricaemic groups was 
performed. Table 7.16 and Table 7.17 shows the mean and range of PS were similar between 
treatment groups indicating common support between treatment groups in non-severe and 
severe hyperuricaemic groups respectively. In both stratified analyses, five subclasses were 
sufficient to achieve overall balance for the majority of covariates however, imbalance 
remained within subclasses. In patients with non-severe hyperuricaemia, there were a greater 
number of imbalanced covariates within subclasses compared with patients with severe 
hyperuricaemia (Table 7.16 and Table 7.17 respectively). In the analysis of peripheral vascular 
disease, in patients with severe hyperuricaemia, use of four or five subclasses led to no 
occurrence of outcome in subclass 1 (the lowest PS), thus this subclass could not be used in 
outcome analysis as treatment effect could not be estimated. Therefore, three PS subclasses 




Table 7.15: Baseline characteristics stratified by severity of hyperuricaemia 
 















Demographics     
Age (Mean (SD)) 61.3 (13.7) 63.0 (13.0) 61.5 (16.0) 63.1 (15.3) 
Sex: Female 443 (18) 195 (27) 385 (24) 322 (25) 
Deprivation (Mean (SD)) 8.6 (5.4) 9.9 (5.8) 9.1 (5.5) 9.6 (5.7) 
Comorbidities     
Anxiety 92 (4) 26 (4) 64 (4) 52 (4) 
Depression 113 (5) 36 (5) 72 (4) 63 (5) 
Cerebrovascular disease 54 (2) 10 (1) 38 (2) 44 (3) 
Coronary heart disease 280 (12) 96 (13) 255 (16) 237 (19) 
Diabetes  118 (5) 37 (5) 116 (7) 122 (10) 
Hyperlipidaemia 107 (4) 29 (4) 85 (5) 73 (6) 
Hypertension 479 (20) 155 (21) 354 (22) 293 (23) 
Osteoarthritis  146 (6) 69 (9) 95 (6) 115 (9) 
Peripheral vascular disease 29 (1) 16 (2) 25 (2) 25 (2) 
Renal disease 14 (1) 10 (1) 37 (2) 42 (3) 
Lifestyle factors     
Alcohol consumption     
   Ever drinker 1,401 (58) 400 (55) 930 (57) 727 (57) 
   Never drinker 82 (3) 31 (4) 80 (5) 54 (4) 
   Missing 949 (39) 297 (41) 622 (38) 489 (39) 
Body mass index     
   Normal 316 (13) 98 (13) 202 (12) 147 (12) 
   Overweight 777 (32) 194 (27) 477 (29) 370 (29) 
   Obese 474 (19) 164 (23) 377 (23) 302 (24) 
   Missing 865 (36) 272 (37) 576 (35) 451 (36) 
Smoking status     
   Ever smoker 1,025 (42) 301 (41) 739 (45) 557 (44) 
   Never smoker 599 (25) 171 (23) 380 (23) 281 (22) 
   Missing 808 (33) 256 (35) 513 (31) 432 (34) 
Medication use     
Analgesic 684 (28) 278 (38) 539 (33) 550 (43) 
Colchicine 47 (2) 26 (4) 48 (3) 53 (4) 
Diuretic 789 (32) 275 (38) 783 (48) 682 (54) 
NSAIDS 1,099 (45) 422 (58) 781 (48) 761 (60) 
N (%) presented unless otherwise stated; Cells highlighted in yellow indicate SMD >0.10; NSAIDS: Non-steroidal 








Table 7.16: Distribution of PS subclasses in patients with non-severe hyperuricaemia  








Imbalanced covariates (SMD>0.10) 
Target SU level 
0.23 (0.05, 0.57) 




S1: Age, deprivation, coronary heart disease, renal disease, alcohol consumption, smoking status, analgesics, 
colchicine, diuretics 
S2: Age, coronary heart disease, hyperlipidaemia, renal disease, alcohol consumption, BMI, SU level, analgesics, 
diuretics 
S3: Age, sex, coronary heart disease, hyperlipidaemia, alcohol consumption, BMI, SU level, diuretics, 
S4: Age, sex, coronary heart disease, alcohol consumption, BMI, smoking status, SU level, analgesics, diuretics 
S5: Age, deprivation, hyperlipidaemia, BMI,  
Mortality 
0.22 (0.07, 0.64) 




S1: Sex, diabetes, hypertension, osteoarthritis, alcohol consumption, smoking status, analgesics, NSAIDS 
S2: Deprivation, coronary heart disease, hypertension, renal disease, alcohol consumption, BMI, analgesics, NSAIDS 
S3: age, osteoarthritis, peripheral vascular disease, BMI, smoking status, analgesics, NSAIDS 




0.22 (0.07, 0.64) 




S1: Sex, diabetes, alcohol consumption, smoking status, analgesics 
S2: Deprivation, depression, coronary heart disease, hyperlipidaemia, renal disease, alcohol consumption, analgesics, 
colchicine 
S3: Peripheral vascular disease, smoking status, analgesics 
S4: Depression, renal disease, BMI, smoking status 
Gout 
hospitalisation 
0.23 (0.07, 0.55) 




S1: Sex, diabetes, hypertension, osteoarthritis, alcohol consumption, smoking status, analgesics, NSAIDS 
S2: Age, deprivation, cerebrovascular disease, coronary heart disease, osteoarthritis, alcohol consumption, BMI, 
analgesics, NSAIDS 
S3: BMI, smoking status, analgesics 
S4: Age, deprivation, cerebrovascular disease, renal disease, alcohol consumption 





Table 7.16 continued: 
Joint 
replacement 
0.22 (0.07, 0.59) 




S1: Sex, osteoarthritis, alcohol consumption, smoking status, analgesics, diuretics 
S2: Deprivation, coronary heart disease, hypertension, osteoarthritis, renal disease, alcohol consumption, BMI, 
analgesics, NSAIDS 





0.22 (0.10, 0.60) 




S1: Sex, hypertension, alcohol consumption, smoking status, analgesics, diuretics, NSAIDS 
S2: Coronary heart disease, alcohol consumption, smoking status, analgesics 
S3: osteoarthritis, alcohol consumption, BMI, smoking status, analgesics, colchicine 
S4: Deprivation, diabetes, renal disease, alcohol consumption, BMI, smoking status 
S5: Hypertension, BMI, analgesics 
Coronary heart 
disease 
0.22 (0.07, 0.60) 




S1: Sex, deprivation, diabetes, hyperlipidaemia, hypertension, peripheral vascular disease, alcohol consumption, 
BMI, smoking status, analgesics, diuretics 
S2: Alcohol consumption, BMI, analgesics 
S3: Sex, cerebrovascular disease, osteoarthritis, renal disease, alcohol consumption, BMI, smoking status, analgesics 




0.22 (0.06, 0.60) 




S1: Sex, deprivation, diabetes, hyperlipidaemia, osteoarthritis, alcohol consumption, smoking status, analgesics, 
NSAIDS 
S2: Sex, coronary heart disease, hypertension, alcohol consumption, smoking status, analgesics 
S3: Coronary heart disease, diabetes, osteoarthritis, alcohol consumption, smoking status, analgesics 
S4: Deprivation, hypertension, smoking status 
S5: Hypertension, analgesics 
Renal disease 
0.22 (0.05, 0.62) 




S1: Sex, deprivation, diabetes, hypertension, osteoarthritis, alcohol consumption, smoking status, analgesics 
S2: Sex, deprivation, coronary heart disease, analgesics, NSAIDS 
S3: Age, analgesics, deprivation, smoking status 
S4: Deprivation, smoking status 
S5: Hypertension, smoking status 
 aNumber of subclasses needed to achieve overall balance across subclasses; bSmallest cell defined as the number of allopurinol users within a subclass; BMI: Body mass index; NSAIDS: 




Table 7.17: Distribution of PS subclasses in patients with severe hyperuricaemia  








Imbalanced covariates (SMD>0.10) 
Target SU level 
0.39 (0.17, 0.82) 




S1: Age, sex, alcohol consumption, BMI, smoking status, SU level, analgesics, colchicine, diuretics,  
S2: Sex, deprivation, smoking status, analgesics, colchicine, diuretics 
S3: Age, hyperlipidaemia, alcohol consumption, smoking status, colchicine 
S4: Deprivation, renal disease, alcohol consumption, BMI, smoking status 
S5: Hyperlipidaemia, renal disease, alcohol consumption, BMI, smoking status 
Mortality 
0.42 (0.24, 0.74) 




S1: osteoarthritis, alcohol consumption, smoking status 
S2: Diabetes, BMI, diuretics, NSAIDS 
S3: Peripheral vascular disease, diuretics 
S4: Smoking status 
S5: BMI, smoking status 
Repeated gout 
consultations 
0.42 (0.24, 0.72) 




S1: Sex, smoking status, diuretics 
S2: Diabetes, BMI, diuretics 
S3: Depression, coronary heart disease 
S4: Smoking status, diuretics  
S5: Smoking status 
Gout 
hospitalisation 
0.42 (0.25, 0.71) 




S1: osteoarthritis, BMI, smoking status, NSAIDS 
S2: Diabetes, renal disease, BMI, NSAIDS 
S3: Cerebrovascular disease, coronary heart disease 
S4: Age, cerebrovascular disease, alcohol consumption 
S5: Deprivation, renal disease 
Joint 
replacement 
0.43 (0.25, 0.71) 




S1: Coronary heart disease, hypertension, alcohol consumption, smoking status, analgesics, NSAIDS 
S2: BMI 
S3: Sex, coronary heart disease 
S4: osteoarthritis, alcohol consumption, smoking status 
S5: Smoking status 
Cerebrovascular 
disease 
0.42 (0.23, 0.73) 




S1: Sex, coronary heart disease, hyperlipidaemia, osteoarthritis, renal disease, smoking status, diuretics 
S2: BMI. Diuretics 
S3: BMI, analgesics  
S4: Alcohol consumption, BMI, Smoking status, diuretics 
S5: BMI, smoking status 
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Table 7.17 continued: 
Coronary heart 
disease 
0.41 (0.21, 0.75) 




S1: Sex, diabetes, hyperlipidaemia, osteoarthritis, peripheral vascular disease, alcohol consumption, BMI, smoking 
status, colchicine 
S2: Renal disease, diuretics 
S3: Age, diabetes, peripheral vascular disease 
S4: Age, sex, cerebrovascular disease, diabetes, alcohol consumption, BMI, colchicine, diuretics, NSAIDS 
S5: Cerebrovascular disease, hyperlipidaemia  
Peripheral 
vascular disease 
0.42 (0.23, 0.74) 




S1: Smoking status, diuretics 
Renal disease 
0.41 (0.24, 0.72) 




S1: osteoarthritis, alcohol consumption, smoking status, diuretics 
S3: Coronary heart disease 
S4: Age, diabetes, BMI, smoking status, diuretics 
S5: NSAIDS 
aNumber of propensity score subclasses needed to achieve overall balance across subclasses; bSmallest cell defined as the number of allopurinol users within a subclass; BMI: Body mass 




Table 7.18 gives the estimated treatment effect for each outcome stratified by severity of 
hyperuricaemia. Treatment effect estimates for target SU level was greater in patients with 
non-severe hyperuricaemia than those with severe hyperuricaemia (HR 2.83 vs. 2.20). In 
patients with non-severe hyperuricaemia, allopurinol had a higher risk of joint replacement 
(1.37 (1.10, 1.84)) and coronary heart disease (1.27 (1.04, 1.55)) than non-users. Pooled effect 
of allopurinol across subclasses had fewer gout consultations with effect sizes that were 
similar across the stratified groups. Risk of gout hospitalisation was higher amongst allopurinol 
users in patients with non-hyperuricaemia (1.61 (1.24, 2.08)) but no association was observed 
in patients with severe hyperuricaemia.    
Table 7.19 and Table 7.20 show subclass specific treatment effect estimates for repeated gout 
consultations in patients with non-severe and severe hyperuricaemia respectively as the 
treatment effect estimates were not homogenous across subclasses. In non-severe 
hyperuricaemic patients, within subclass 2, allopurinol use was found to have the strongest 
protective effect against repeated gout consultations (0.48 (0.35, 0.66)); these patients 
resided in less deprived areas and had lower prevalence of females, coronary heart disease, 
hypertension, osteoarthritis and obesity, had higher prevalence of ever drinker, overweight 
BMI, ever smoker, and prescribed analgesics, colchicine, diuretics and NSAIDS less than 
subclass 5, in which, allopurinol was found to have the least protective treatment effect (0.75 
(0.57, 0.98)). In contrast, among severe hyperuricaemic patients, within subclass 5, allopurinol 
use was found to have the strongest protective effect against repeated gout consultations 
(0.44 (0.34, 0.57)) compared to subclass 2, in which, allopurinol was found to have the least 
protective treatment effect (0.69 (0.51, 0.93)). 
Table 7.21 gives subclass specific treatment effect estimates for gout hospitalisation in 
patients with non-severe hyperuricaemia only as the treatment effect estimates were not 
homogenous across subclasses. No association was observed between allopurinol use and 
218 
 
gout hospitalisation in subclasses 1, 2 and 4. In subclasses 3 and 5, allopurinol use doubled the 
risk of gout hospitalisation (2.08 (1.26, 3.44) and 2.90 (1.86, 4.53) respectively). In patients 
with severe hyperuricaemia, there was no association between allopurinol and gout 




Table 7.18: Treatment effect of allopurinol stratified by severity of hyperuricaemia 
aStatistical test for the proportional hazards assumption failed, however change in treatment effect was represented by a small number of patients with the longest follow-up times, and there was 
no cross-over of survival functions for treatment groups. Therefore, the proportional hazards assumption was satisfied. bSubclass-specific treatment effects were not homogenous; CI: Confidence 
intervals; HR: Hazard ratio; SU: Serum urate






HR ratio (95% CI) 
Standard error 
Adjusted 






HR (95% CI) 
Standard error 
Adjusted 
HR (95% CI) 
Standard error 
SU level         
   Not reached target 419 (67) 74 (38) 2.42 (1.92, 3.05) 
0.28 
2.83 (2.17, 3.68) 
0.38 
370 (68) 172 (46) 2.17 (1.77, 2.66) 
0.23 
2.20 (1.76, 2.75) 
0.25    Reached target 209 (33) 121 (62) 177 (32) 200 (54) 
Mortality         
   Alive 1,880 (77) 543 (75) 1.10 (0.93, 1.29) 
0.09 
0.93 (0.79, 1.11) 
0.08 
1,125 (69) 828 (65) 1.13 (1.00, 1.29) 
0.07 
0.96 (0.84, 1.09) 
0.06    Dead 552 (23) 185 (25) 507 (31) 442 (35) 
Repeated gout consultations         
   Never consulted 1,727 (52) 433 (55) 0.74 (0.65, 0.84)a 
0.05 
0.60 (0.53, 0.69)ab 
0.04 
503 (31) 694 (55) 0.57 (0.51, 0.64)a 
0.03 
0.57 (0.51, 0.64)ab 
0.03    Consulted at least once 1,602 (48) 349 (45) 1,129 (69) 576 (45) 
Gout hospitalisation         
   No 1,784 (89) 505 (81) 1.79 (1.44, 2.24) 
0.20 
1.61 (1.24, 2.08)b 
0.21 
1,103 (81) 816 (79) 1.18 (0.99, 1.42) 
0.11 
1.09 (0.91, 1.31) 
0.10    Yes 223 (11) 121 (19) 251 (19) 220 (21) 
Joint replacement         
   No 2,263 (94) 650 (91) 1.55 (1.15, 2.08) 
0.23 
1.37 (1.01, 1.84) 
0.21 
1,525 (95) 1,177 (94) 1.30 (0.95, 1.78) 
0.21 
1.08 (0.77, 1.51) 
0.18    Yes 142 (6) 65 (9) 78 (5) 77 (6) 
Cerebrovascular disease         
   No 2,151 (91) 631 (89) 1.26 (0.97, 1.63) 
0.17 
1.26 (0.96, 1.65) 
0.17 
1,452 (93) 1,100 (91) 1.26 (0.97, 1.64) 
0.17 
1.04 (0.79, 1.37)a 
0.15    Yes 206 (9) 78 (11) 115 (7) 110 (9) 
Coronary heart disease         
   No 1,663 (81) 455 (76) 1.24 (1.02, 1.50) 
0.12 
1.27 (1.04, 1.55) 
0.13 
1,016 (79) 753 (77) 1.08 (0.90, 1.29) 
0.10 
1.01 (0.83, 1.21) 
0.10    Yes 396 (19) 140 (24) 274 (21) 219 (23) 
Peripheral vascular disease         
   No 2,298 (96) 682 (97) 0.86 (0.55, 1.35) 
0.20 
0.76 (0.48, 1.21)a 
0.18 
1,542 (97) 1,186 (96) 1.22 (0.82, 1.84)a 
0.25 
1.02 (0.67, 1.57) 
0.22    Yes 92 (4) 24 (3) 48 (3) 45 (4) 
Renal disease          
   No 1,847 (77) 516 (72) 1.21 (1.03, 1.43)a 
0.10 
1.06 (0.90, 1.25)a 
0.09 
1,113 (70) 797 (67) 1.15 (1.01, 1.32) 
0.08 
1.05 (0.91, 1.20)a 
0.07    Yes 561 (23) 197 (27) 469 (30) 394 (33) 
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Table 7.19: Estimated PS subclass-specific treatment effect of allopurinol on repeated gout 
consultations in patients with non-severe hyperuricaemia 
 










HR (95% CI) 
Standard error 
0.65 (0.48, 0.89) 
0.11 
0.48 (0.35, 0.66) 
0.08 
0.66 (0.49, 0.89) 
0.10 
0.52 (0.39, 0.68) 
0.07 
0.75 (0.57, 0.98) 
0.10 
Demographics      
Age (Mean (SD)) 56.5 (13.0) 59.8 (13.4) 60.7 (13.5) 63.7 (13.2) 67.8 (12.1) 
Sex: Female 9 (1) 48 (8) 82 (13.0) 158 (25) 341 (54.0) 
Deprivation 
(Mean (SD)) 
4.6 (3.3) 7.9 (4.6) 8.2 (5.5) 10.4 (5.1) 13.3 (4.9) 
Comorbidities      
Anxiety 21 (3) 18 (3) 21 (3) 24 (4) 34 (5) 
Depression 27 (4) 28 (4) 27 (4) 29 (5) 38 (6) 
Cerebrovascular 
disease 37 (6) 12 (2) 7 (1) 8 (1) 0 (0) 
Coronary heart 
disease 42 (7) 60 (9) 83 (13) 80 (13) 111 (18) 
Diabetes  35 (6) 17 (3) 34 (5) 29 (5) 40 (6) 
Hyperlipidaemia 27 (4) 39 (6) 24 (4) 27 (4) 19 (3) 
Hypertension 105 (17) 103 (16) 129 (20) 119 (19) 178 (28) 
Osteoarthritis  8 (1) 21 (3) 30 (5) 55 (9) 101 (16) 
Peripheral 
vascular disease 0 (0) NA (<1) NA (<1) 7 (1) 33 (5) 
Renal disease 0 (0) NA (<1) NA (<1) NA (<1) 21 (3) 
Lifestyle factors      
Alcohol 
consumption 
     
   Ever drinker 434 (69) 376 (59) 343 (54) 328 (52) 320 (51) 
   Never drinker 9 (1) 11 (2) 23 (4) 23 (4) 47 (7) 
   Missing 189 (30) 245 (39) 266 (42) 281 (44) 265 (42) 
Body mass 
index 
     
   Normal 78 (12) 78 (12) 82 (13) 90 (14) 86 (14) 
   Overweight 325 (51) 241 (38) 174 (28) 121 (19) 110 (17) 
   Obese 78 (12) 100 (16) 116 (18) 139 (22) 205 (32) 
   Missing 151 (24) 213 (34) 260 (41) 282 (45) 231 (37) 
Smoking status      
   Ever smoker 276 (44) 284 (45) 270 (43) 253 (40) 243 (38) 
   Never smoker 199 (31) 152 (24) 132 (21) 134 (21) 153 (24) 
   Missing 157 (25) 196 (31) 230 (36) 245 (39) 236 (37) 
Medication use      
Analgesics 32 (5) 85 (13) 163 (26) 257 (41) 425 (67) 
Colchicine 0 (0) NA (<1) 6 (1) 14 (2) 52 (8) 
Diuretics 135 (21) 169 (27) 186 (29) 223 (35) 351 (56) 
NSAIDS 19 (3) 146 (23) 357 (56) 449 (71) 550 (87) 
N (%) presented unless otherwise stated; CI: Confidence interval; HR: Hazard ratio; NA: Cannot report cell 









Table 7.20: Estimated PS subclass-specific treatment effect of allopurinol on repeated gout 
consultations and distribution of covariates in patients with severe hyperuricaemia 
 










HR (95% CI) 
Standard error 
0.64 (0.49, 0.85) 
0.09 
0.69 (0.51, 0.93) 
0.11 
0.49 (0.38, 0.61) 
0.06 
0.65 (0.51, 0.83) 
0.08 
0.44 (0.34, 0.57) 
0.06 
Demographics      
Age (Mean (SD)) 55.8 (14.8) 62.2 (16.0) 60.6 (16.2) 64.2 (15.3) 69.2 (12.9) 
Sex: Female 107 (18) 125 (22) 125 (22) 160 (28) 190 (33) 
Deprivation 
(Mean (SD)) 
7.4 (5.1) 8.6 (5.6) 9.0 (5.4) 10.2 (5.5) 11.2 (5.6) 
Comorbidities      
Anxiety 19 (3) 17 (3) 16 (3) 28 (5) 36 (6) 
Depression 23 (4) 17 (3) 24 (4) 23 (4) 48 (8) 
Cerebrovascular 
disease 0 (0) NA (<1) 14 (2) 20 (3) 46 (8) 
Coronary heart 
disease 36 (6) 84 (14) 80 (14) 116 (20) 176 (30) 
Diabetes  9 (2) 30 (5) 29 (5) 52 (9) 118 (20) 
Hyperlipidaemia 25 (4) 23 (4) 31 (5) 32 (6) 47 (8) 
Hypertension 101 (17) 128 (22) 116 (20) 136 (23) 166 (29) 
Osteoarthritis  11 (2) 18 (3) 41 (7) 55 (9) 85 (15) 
Peripheral 
vascular disease NA (<1) 10 (2) 6 (1) 10 (2) 22 (4) 
Renal disease NA (<1) 12 (2) 5 (1) 16 (3) 45 (8) 
Lifestyle factors      
Alcohol 
consumption 
     
   Ever drinker 327 (56) 318 (55) 364 (63) 313 (54) 335 (58) 
   Never drinker 41 (7) 37 (6) 16 (3) 24 (4) 16 (3) 
   Missing 213 (37) 225 (39) 201 (35) 243 (42) 229 (39) 
Body mass 
index 
     
   Normal 89 (15) 75 (13) 64 (11) 67 (12) 54 (9) 
   Overweight 175 (30) 176 (30) 171 (29) 159 (27) 166 (29) 
   Obese 126 (22) 125 (22) 146 (25) 116 (20) 166 (29) 
   Missing 191 (33) 204 (35) 200 (34) 238 (41) 194 (33) 
Smoking status      
   Ever smoker 285 (49) 277 (48) 255 (44) 248 (43) 231 (40) 
   Never smoker 159 (27) 138 (24) 146 (25) 106 (18) 112 (19) 
   Missing 137 (24) 165 (28) 180 (31) 226 (39) 237 (41) 
Medication use      
Analgesics 11 (2) 134 (23) 174 (30) 267 (46) 503 (87) 
Colchicine NA (<1) 12 (2) 13 (2) 13 (2) 61 (11) 
Diuretics 162 (28) 282 (49) 250 (43) 331 (57) 440 (76) 
NSAIDS NA (<1) 161 (28) 372 (64) 469 (81) 538 (93) 
N (%) presented unless otherwise stated; CI: Confidence interval; HR: Hazard ratio; NA: Cannot report cell 









Table 7.21: Estimated PS subclass-specific treatment effect of allopurinol on gout 
hospitalisation in patients with non-severe hyperuricaemia 
 










HR (95% CI) 
Standard error 
1.69 (0.80, 3.58) 
0.65 
0.83 (0.43, 1.57) 
0.27 
2.08 (1.26, 3.44) 
0.53 
1.27 (0.80, 2.03) 
0.30 
2.90 (1.86, 4.53) 
0.66 
Demographics      
Age (Mean (SD)) 61.1 (12.6) 62.8 (12.9) 62.2 (13.3) 63.8 (12.9) 66.5 (12.9) 
Sex: Female 20 (4) 66 (13) 85 (16) 138 (26) 266 (51) 
Deprivation 
(Mean (SD)) 
5.2 (3.6) 7.9 (4.8) 8.6 (5.4) 10.2 (5.3) 13.6 (4.6) 
Comorbidities      
Anxiety 15 (3) 20 (4) 20 (4) 18 (3) 30 (6) 
Depression 18 (3) 20 (4) 32 (6) 20 (4) 38 (7) 
Cerebrovascular 
disease 34 (6) 14 (3) NA (1) NA (1) NA (0) 
Coronary heart 
disease 46 (9) 61 (12) 67 (13) 81 (15) 92 (17) 
Diabetes  37 (7) 26 (5) 35 (7) 21 (4) 26 (5) 
Hyperlipidaemia 26 (5) 21 (4) 27 (5) 19 (4) 21 (4) 
Hypertension 132 (25) 112 (21) 110 (21) 94 (18) 114 (22) 
Osteoarthritis  5 (1) 13 (2) 27 (5) 41 (8) 110 (21) 
Peripheral 
vascular disease NA (<1) 6 (1) 14 (3) 6 (1) 13 (2) 
Renal disease 0 (0) 0 (0) NA (<1) NA (1) 18 (3) 
Lifestyle factors      
Alcohol 
consumption 
     
   Ever drinker 378 (72) 320 (61) 300 (57) 276 (52) 230 (44) 
   Never drinker 9 (2) 12 (2) 17 (3) 17 (3) 45 (9) 
   Missing 140 (27) 195 (37) 209 (40) 234 (44) 251 (48) 
Body mass 
index 
     
   Normal 50 (9) 74 (14) 73 (14) 64 (12) 83 (16) 
   Overweight 273 (52) 194 (37) 149 (28) 112 (21) 88 (17) 
   Obese 93 (18) 91 (17) 103 (20) 118 (22) 143 (27) 
   Missing 111 (21) 168 (32) 201 (38) 233 (44) 212 (40) 
Smoking status      
   Ever smoker 275 (52) 239 (45) 230 (44) 213 (40) 178 (34) 
   Never smoker 156 (30) 138 (26) 120 (23) 107 (20) 104 (20) 
   Missing 96 (18) 150 (28) 176 (33) 207 (39) 244 (46) 
Medication use      
Analgesics 41 (8) 118 (22) 161 (31) 228 (43) 334 (63) 
Colchicine NA (<1) 7 (1) 10 (2) 15 (3) 32 (6) 
Diuretics 156 (30) 166 (31) 172 (33) 196 (37) 269 (51) 
NSAIDS 9 (2) 119 (23) 286 (54) 396 (75) 487 (93) 
N (%) presented unless otherwise stated; CI: Confidence interval; HR: Hazard ratio; NA: Cannot report cell counts 
with less than five events; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; SD: Standard 







7.6 Sensitivity analyses 
7.6.1 Treatment effect using two-year landmark period 
For this analysis, 15,873 patients had a minimum of two years follow-up. During this period 
28% of patients were prescribed allopurinol. Table 7.22 describes the distribution of baseline 
covariates between treatment groups. Similarly to the one-year landmark analysis (main 
analysis), allopurinol users resided in more deprived areas and had higher prevalence of 
recorded SU level and SU level above target (>360μmol/L), and were prescribed colchicine, 
diuretics, NSAIDS and analgesics more than non-users. 
After PS estimation, the distribution of PS was similar between treatment groups (Table 7.23). 
Within most outcome analyses, five subclasses were sufficient to achieve overall balance for 
all covariates across subclasses although imbalance remained on some covariates within 
subclasses; the number of imbalanced covariates within subclasses were similar to what was 
found in the main analysis. In the analysis of cerebrovascular disease, six subclasses were 
required to achieve overall covariate balance compared with the main analysis that required 












Demographics    
Age (Mean (SD)) 61.4 (14.6) 62.2 (14.4) 0.05 
Sex: Female 2,557 (23) 1,051 (23) 0.02 
Deprivation (Mean (SD)) 8.9 (5.5) 9.5 (5.6) 0.11 
Comorbidities    
Anxiety 452 (4) 163 (4) -0.02 
Depression 554 (5) 225 (5) 0.001 
Cerebrovascular disease 244 (2) 119 (3) 0.03 
Coronary heart disease 1,295 (11) 678 (15) 0.10 
Diabetes  641 (6) 307 (7) 0.05 
Hyperlipidaemia 529 (5) 222 (5) 0.01 
Hypertension 2,078 (18) 888 (20) 0.04 
Osteoarthritis  678 (6) 361 (8) 0.08 
Peripheral vascular disease 150 (1) 74 (2) 0.03 
Renal disease 86 (1) 91 (2) 0.10 
Lifestyle factors    
Alcohol consumption    
   Ever drinker 6,434 (57) 2,495 (55) -0.03 
   Never drinker 570 (5) 221 (5) -0.01 
   Missing 4,356 (38) 1,797 (40) 0.03 
Body mass index    
   Normal 1,790 (16) 554 (12) -0.10 
   Overweight 3,363 (30) 1,303 (29) -0.02 
   Obese 2,081 (18) 955 (21) 0.07 
   Missing 4,126 (36) 1,701 (38) 0.03 
Smoking status    
   Ever smoker 4,330 (38) 1,708 (38) -0.01 
   Never smoker 3,327 (29) 1,224 (27) -0.05 
   Missing 3,703 (33) 1,581 (35) 0.05 
SU level    
   ≤360µmol/L 846 (7) 64 (1) -0.30 
   >360µmol/L 3,505 (31) 2,229 (49) 0.39 
   Missing 7,009 (62) 2,220 (49) -0.25 
Medication use    
Analgesics 3,378 (30) 1,761 (39) 0.20 
Colchicine 177 (2) 179 (4) 0.15 
Diuretics 3,638 (32) 1,963 (43) 0.24 
NSAIDS 4,967 (44) 2,627 (58) 0.29 
N (%) were presented unless otherwise stated; NSAIDS: Non-steroidal anti-inflammatory drugs; SD: Standard 




Table 7.23: Distribution of PS subclasses for the two year landmark period 
Outcome 





Smallest cellb Imbalanced covariates (SMD>0.10) 
Target SU level 
0.33 (0.10, 0.82) 




S1: Age, sex, coronary heart disease, 
renal disease, alcohol consumption, 
BMI, smoking status, analgesics 
S2: SU level, colchicine, NSAIDS 
S3: Coronary heart disease, 
hyperlipidaemia, BMI, SU level, 
colchicine 
S4: Age, hyperlipidaemia, renal 
disease, NSAIDS 
S5: Sex, coronary heart disease, SU 
level, colchicine, NSAIDS 
Mortality 
0.26 (0.03, 0.79) 









0.26 (0.03, 0.77) 




S1: Sex, SU level 
S4: SU level 
Gout 
hospitalisation 
0.26 (0.03, 0.78) 




S1: Sex, SU level 
S2: Sex, NSAIDS 




0.26 (0.03, 0.79) 




S1: Sex, SU level 
S4: SU level  
Cerebrovascular 
disease 
0.26 (0.03, 0.78) 




S1: Sex, SU level, colchicine 




0.25 (0.03, 0.76) 




S1: Sex, SU level 
S3: Alcohol consumption 
S4: Sex, SU level 
Peripheral 
vascular disease 
0.27 (0.03, 0.79) 




S1: Sex, SU level 
Renal disease 
0.26 (0.03, 0.78) 




S1: Sex, SU level 
S2: NSAIDS 
S4: SU level 
aNumber of subclasses needed to achieve overall covariate balance across subclasses; bSmallest cell defined as 
the number of allopurinol users within a subclass; BMI: Body mass index; NSAIDS: Non-steroidal anti-
inflammatory drugs; PS: Propensity score; S: Subclass; SD: Standard deviation; SMD: Standardised mean 
difference; SU: Serum urate 
 
The treatment effect estimate was obtained for each outcome as shown in Table 7.24. 
Allopurinol had greater chance of reaching target SU level (2.15 (1.79, 2.58)), and higher risk 
of premature mortality (1.11 (1.04, 1.18)), and renal disease (1.20 (1.11, 1.29)); these 
treatment effect estimates and standard errors were similar to what was estimated in the 
main analysis. Both this analysis (two-year landmark period) and the main analysis found 
allopurinol increased risk of joint replacement but the effect was greater in the two-year 
landmark period (HR 1.27 vs. 1.15).   
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The subclass-specific treatment effect estimates were not homogenous across subclasses for 
repeated gout consultations and gout hospitalisation; these estimates are presented in Table 
7.25 and Table 7.26 respectively. 
Similarly as the main analysis, all subclasses had shown allopurinol was protective against 
repeated gout consultations, with subclass 5 found to have the strongest protective effect. 
However, the subclass-specific treatment effects were closer to the null than the main 
analysis.  
Within all subclasses, allopurinol increased the risk of gout hospitalisation with the strongest 
effect observed in subclass 1. Compared with the main analysis, the subclass-specific 
treatment effects were greater across all subclasses. Pooled HRs were larger in this analysis 




Table 7.24: Treatment effect of allopurinol using two-year landmark period 
Outcome 
No allopurinol Allopurinol 
Unadjusted 
Hazard ratio (95% CI) 
Standard error 
Adjusted 
Hazard Ratio (95% CI) 
Standard error 
Target SU level     
   Target level not met 655 (69) 265 (49) 2.11 (1.79, 2.49) 
0.18 
2.15 (1.79, 2.58) 
0.20    Target level met 298 (31) 273 (51) 
Mortality     
   Alive 8,353 (74) 3,115 (69) 1.23 (1.15, 1.31) 
0.040 
1.11 (1.04, 1.18) 
0.04    Died 3,007 (26) 1,398 (31) 
Repeated gout 
consultations 
    
   Never consulted 5,428 (48) 2,548 (56) 0.83 (0.79, 0.88) 
0.02 
0.77 (0.73, 0.82)ab 
0.02    Consulted at least once 5,932 (52) 1,965 (44) 
Gout hospitalisation     
   No 8,444 (89) 2,894 (78) 2.23 (2.03, 2.45) 
0.11 
2.05 (1.86, 2.27)ab 
0.11    Yes 1,031 (11) 793 (22) 
Joint replacement     
   No 10,531 (94) 4,111 (93) 1.34 (1.17, 1.53) 
0.09 
1.27 (1.10, 1.46) 
0.09    Yes 615 (6) 306 (7) 
Cerebrovascular disease     
   No 9,904 (91) 3,905 (91) 1.03 (0.91, 1.16) 
0.06 
1.00 (0.87, 1.14) 
0.06    Yes 972 (9) 376 (9) 
Coronary heart disease     
   Yes 7,622 (82) 2,778 (80) 1.12 (1.02, 1.22) 
0.05 
1.10 (1.00, 1.20)a 
0.05    No 1,709 (18) 686 (20) 
Peripheral vascular disease     
   No 10,726 (97) 4,208 (96) 1.25 (1.04, 1.50) 
0.12 
1.16 (0.96, 1.40) 
0.11    Yes 366 (3) 172 (4) 
Renal disease     
   No 8,598 (77) 3,060 (72) 1.34 (1.25, 1.44)a 
0.05 
1.20 (1.11, 1.29)a 
0.04    Yes 2,564 (23) 1,213 (28) 
aStatistical test for the proportional hazards assumption failed, however change in treatment effect was 
represented by a small number of patients with the longest follow-up times, and there was no cross-over of 
survival functions from treatment groups. Therefore, the proportional hazards assumption was satisfied; 





Table 7.25: Estimated PS subclass-specific treatment effect of allopurinol on repeated gout 
consultations and distribution of covariates 
 










HR (95% CI) 
Standard error 
0.85 (0.72, 1.00) 
0.07 
0.83 (0.73, 0.94) 
0.05 
0.83 (0.73, 0.94) 
0.05 
0.69 (0.62, 0.78) 
0.04 
0.68 (0.62, 0.76) 
0.04 
Demographics      
Age (Mean (SD)) 60.3 (13.7) 61.6 (15.0) 59.4 (14.1) 63.7 (14.9) 63.2 (14.4) 
Sex: Female 779 (25) 639 (20) 517 (16) 812 (26) 861 (27) 
Deprivation 
(Mean (SD)) 
7.5 (5.1) 8.6 (5.4) 9.2 (5.4) 9.4 (5.6) 10.8 (5.6) 
Comorbidities      
Anxiety 114 (4) 136 (4) 517 (16) 110 (3) 141 (4) 
Depression 158 (5) 146 (5) 114 (4) 139 (4) 170 (5) 
Cerebrovascular 
disease 46 (1) 54 (2) 166 (5) 86 (3) 115 (4) 
Coronary heart 
disease 191 (6) 273 (9) 62 (2) 455 (14) 713 (22) 
Diabetes  150 (5) 142 (4) 341 (11) 192 (6) 304 (10) 
Hyperlipidaemia 138 (4) 147 (5) 160 (5) 153 (5) 181 (6) 
Hypertension 361 (11) 559 (18) 132 (4) 742 (23) 844 (27) 
Osteoarthritis  123 (4) 131 (4) 460 (14) 254 (8) 360 (11) 
Peripheral 
vascular disease 27 (1) 29 (1) 171 (5) 63 (2) 68 (2) 
Renal disease NA (<1) NA (<1) 37 (1) 24 (1) 143 (5) 
Lifestyle factors      
Alcohol 
consumption 
     
   Ever drinker 1,904 (60) 1,844 (58) 1,746 (55) 1,775 (56) 1,660 (52) 
   Never drinker 172 (5) 170 (5) 122 (4) 179 (6) 148 (5) 
   Missing 1,099 (35) 1,161 (37) 1,306 (41) 1,221 (38) 1,366 (43) 
Body mass 
index 
     
   Normal 756 (24) 616 (19) 362 (11) 369 (12) 241 (8) 
   Overweight 975 (31) 969 (31) 925 (29) 987 (31) 810 (26) 
   Obese 451 (14) 474 (15) 598 (19) 663 (21) 850 (27) 
   Missing 993 (31) 1,116 (35) 1,289 (41) 1,156 (36) 1,273 (40) 
Smoking status      
   Ever smoker 1,297 (41) 1,182 (37) 1,108 (35) 1,219 (38) 1,232 (39) 
   Never smoker 1,057 (33) 1,022 (32) 908 (29) 884 (28) 680 (21) 
   Missing 821 (26) 971 (31) 1,158 (36) 1,072 (34) 1,262 (40) 
SU level      
   ≤360µmol/L 903 (28) 7 (<1) 0 (0) 0 (0) 0 (0) 
   >360µmol/L 0 (0) 281 (9) 1,017 (32) 1,702 (54) 2,734 (86) 
   Missing 2,272 (72) 2,887 (91) 2,157 (68) 1,473 (46) 440 (14) 
Medication use      
Analgesics 473 (15) 617 (19) 925 (29) 1,321 (42) 1,803 (57) 
Colchicine 6 (<1) 7 (<1) 16 (1) 48 (2) 279 (9) 
Diuretics 291 (9) 916 (29) 734 (23) 1,715 (54) 1,945 (61) 
NSAIDS 380 (12) 913 (29) 1,640 (52) 1,988 (63) 2,673 (84) 
N (%) presented unless otherwise stated; CI: Confidence interval; HR: Hazard ratio; NA: Cannot report cell 
counts with less than five events; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; SD: 






Table 7.26: Estimated PS subclass-specific treatment effect of allopurinol on gout 
hospitalisation and distribution of covariates 
 










HR (95% CI) 
Standard error 
2.82 (2.10, 3.79) 
0.42 
2.04 (1.63, 2.56) 
0.24 
1.75 (1.42, 2.16) 
0.19 
2.02 (1.67, 2.45) 
0.20 
1.79 (1.49, 2.16) 
0.17 
Demographics      
Age (Mean (SD)) 63.2 (13.1) 62.9 (14.8) 61.9 (13.7) 64.1 (14.7) 63.4 (14.1) 
Sex: Female 726 (28) 545 (21) 524 (20) 700 (27) 710 (27) 
Deprivation 
(Mean (SD)) 
7.8 (5.1) 8.9 (5.4) 9.3 (5.4) 9.6 (5.6) 10.6 (5.6) 
Comorbidities      
Anxiety 94 (4) 111 (4) 101 (4) 104 (4) 119 (5) 
Depression 128 (5) 123 (5) 135 (5) 136 (5) 163 (6) 
Cerebrovascular 
disease 36 (1) 53 (2) 56 (2) 79 (3) 103 (4) 
Coronary heart 
disease 194 (7) 242 (9) 323 (12) 393 (15) 611 (23) 
Diabetes  159 (6) 150 (6) 154 (6) 176 (7) 216 (8) 
Hyperlipidaemia 116 (4) 126 (5) 121 (5) 138 (5) 153 (6) 
Hypertension 445 (17) 533 (20) 442 (17) 596 (23) 578 (22) 
Osteoarthritis  114 (4) 119 (5) 159 (6) 235 (9) 318 (12) 
Peripheral 
vascular disease 30 (1) 32 (1) 39 (1) 51 (2) 56 (2) 
Renal disease NA (<1) NA (<1) 13 (<1) 26 (1) 106 (4) 
Lifestyle factors      
Alcohol 
consumption 
     
   Ever drinker 1,593 (60) 1,527 (58) 1,504 (57) 1,441 (55) 1,409 (54) 
   Never drinker 160 (6) 157 (6) 118 (4) 160 (6) 119 (5) 
   Missing 881 (33) 947 (36) 1,011 (38) 1,031 (39) 1,104 (42) 
Body mass 
index 
     
   Normal 680 (26) 477 (18) 371 (14) 272 (10) 706 (27) 
   Overweight 812 (31) 821 (31) 795 (30) 810 (31) 210 (8) 
   Obese 359 (14) 407 (15) 498 (19) 580 (22) 725 (28) 
   Missing 783 (30) 926 (35) 969 (37) 970 (37) 991 (38) 
Smoking status      
   Ever smoker 1,112 (42) 982 (37) 991 (38) 1,016 (39) 1,053 (40) 
   Never smoker 886 (34) 869 (33) 763 (29) 713 (27) 538 (20) 
   Missing 636 (24) 780 (30) 879 (33) 903 (34) 1,041 (40) 
SU level      
   ≤360µmol/L 772 (29) 5 (<1) 0 (0) 0 (0) 0 (0) 
   >360µmol/L 0 (0) 141 (5) 714 (27) 1,506 (57) 2,352 (89) 
   Missing 1,862 (71) 2,485 (94) 1,919 (73) 1,126 (43) 280 (11) 
Medication use      
Analgesics 509 (19) 619 (24) 903 (34) 1,111 (42) 1,440 (55) 
Colchicine 5 (<1) 5 (<1) 13 (<1) 45 (2) 241 (9) 
Diuretics 318 (12) 818 (31) 755 (29) 1,441 (55) 1,621 (62) 
NSAIDS 356 (14) 857 (33) 1,512 (57) 1,515 (58) 2,172 (83) 
N (%) presented unless otherwise stated; CI: Confidence interval; HR: Hazard ratio; NA: Cannot report cell 
counts with less than five events; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; SD: 






7.6.2 Impact of omission of confounding variables 
The effect of omission of a single unmeasured binary confounding variable was evaluated for 
target SU level and mortality. The prevalence of the confounding variable amongst allopurinol 
users and non-users, and its strength of association with outcome, are unknown. To obtain 
prevalence and association estimates that can be seen as representing plausible scenarios 
which could be assumed for an unmeasured binary confounding variable, prevalence of each 
observed covariate amongst allopurinol users and non-users and its association (HR) with 
outcome were calculated.  
In the analysis of target SU level, the estimated unadjusted HR between observed covariates 
and target SU level ranged between 0.84 and 1.63, with peripheral vascular disease having the 
largest association thus, it was assumed the association between an unmeasured confounding 
variable and target SU level could be represented by a HR of 1.63. Prevalence of covariates 
ranged from 2% to 66% in allopurinol users, and 1% to 60% in non-users. As seen in Table 7.27 
(and previously in Table 7.7), the effect of allopurinol on target SU level assuming no 
unmeasured confounding was HR 2.32 (1.97, 2.74).  In the presence of an unmeasured 
confounding variable, as the prevalence of the unmeasured confounding variable increased 
amongst allopurinol users but remained fixed in non-users, the estimated HR corrected for 
unmeasured confounding decreased but remained statistically significant; the smallest HR 
observed was 1.95 (1.35, 2.84).  
In the analysis of mortality, the estimated unadjusted HRs between observed covariates and 
mortality ranged from 0.89 to 3.87, with renal disease having the largest association. The 
unmeasured confounding variable was assumed to have a more conservative HR of 1.45, the 
median HR of observed HRs. Prevalence of any covariate ranged from 1% to 59% in allopurinol 
users and 1% to 56% in non-users. As seen in Table 7.28, allopurinol use was associated with 
greater risk of premature mortality assuming no unmeasured confounding (HR (1.10 (1.03, 
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1.17)). As the prevalence of the unmeasured confounding variable increased amongst 
allopurinol users but remained fixed in non-users, the estimated HR corrected for unmeasured 
confounding decreased and lost statistical significance. However, as the difference in 
prevalence of the unmeasured confounding variable had become larger between treatment 
groups, potentially, allopurinol may be protective against premature mortality with the 
smallest HR of 0.83 (0.76, 0.89).  
Table 7.27: Effect of omitted confounding on treatment effect of allopurinol on target SU 
level 




among allopurinol users 
0% 10% 30% 50% 
0% 2.32 (1.97, 2.74)    
10% 2.26 (1.56, 3.28) 2.32 (1.97, 2.74)   
30% 2.15 (1.48, 3.12) 2.21 (1.52, 3.20) 2.32 (1.97, 2.74)  
50% 2.05 (1.41, 2.97) 2.11 (1.45, 3.06) 2.22 (1.53, 3.22) 2.32 (1.97, 2.74) 
70%  1.95 (1.35, 2.84) 2.02 (1.39, 2.93) 2.13 (1.47, 3.09) 2.23 (1.54, 3.23) 
Hazard ratios (95% confidence interval) are presented; SU: Serum urate 
 
Table 7.28: Effect of omitted confounding on treatment effect of allopurinol on mortality 




among allopurinol users 
0% 10% 30% 50% 
0% 1.10 (1.03, 1.17)    
10% 1.06 (0.98, 1.14) 1.10 (1.03, 1.17)   
30% 0.97 (0.90, 1.05) 1.02 (0.94, 1.10) 1.10 (1.03, 1.17)  
50% 0.90 (0.83, 0.97) 0.94 (0.87, 1.02) 1.02 (0.95, 1.11) 1.10 (1.03, 1.17) 
70%  0.83 (0.76, 0.89) 0.87 (0.80, 0.94) 0.95 (0.88, 1.03) 1.03 (0.95, 1.11) 
Hazard ratios (95% confidence interval) are presented 
 
7.6.3 Impact of missing data 
The landmark 1-year analysis was repeated by performing complete case analysis for 
outcomes target SU level and mortality. For target SU level, 52% (N=909) had complete data 
and for mortality 21% (N=3,609) had complete data.  
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Table 7.29 describes the distribution of covariates by treatment. In patients eligible for target 
SU level outcome analysis, allopurinol users were older, had higher prevalence of coronary 
heart disease, renal disease, overweight BMI, prescriptions for analgesics and colchicine, 
different BMI distribution, and had higher mean SU level than non-users where SMD >0.10. 
Compared with the main analysis, this analysis found SMD >0.10 for coronary heart disease, 
renal disease, and BMI that were previously below 0.10. 
For patients eligible for mortality outcome analysis, in addition to the differences identified 
above, allopurinol users resided in more deprived areas, had higher prevalence of 
osteoarthritis, obesity, and were prescribed diuretics and NSAIDS more than non-users. This 
analysis found SMD >0.10 for age, osteoarthritis, and BMI that were not previously seen in the 
main analysis.    
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Table 7.29: Distribution of covariates by treatment for target SU level and mortality 










Demographics     
Age (Mean (SD)) 59.1 (13.7) 61.3 (13.9) 61.3 (14.1) 63.7 (13.9) 
Sex: Female 134 (22) 67 (23) 678 (26) 287 (28) 
Deprivation (Mean (SD)) 9.1 (5.4) 9.3 (6.0) 9.1 (5.5) 9.8 (5.8) 
Comorbidities     
Anxiety 26 (4) 11 (4) 122 (5) 43 (4) 
Depression 34 (5) 20 (7) 131 (5) 66 (6) 
Cerebrovascular disease 12 (2) 10 (3) 62 (2) 28 (3) 
Coronary heart disease 97 (16) 61 (21) 418 (16) 228 (22) 
Diabetes  50 (8) 20 (7) 179 (7) 97 (9) 
Hyperlipidaemia 40 (6) 21 (7) 168 (7) 65 (6) 
Hypertension 168 (27) 75 (26) 625 (24) 275 (27) 
Osteoarthritis  41 (7) 30 (10) 167 (6) 103 (10) 
Peripheral vascular disease 8 (1) 7 (2) 35 (1) 25 (2) 
Renal disease 10 (2) 11 (4) 29 (1) 30 (3) 
Lifestyle factors     
Alcohol consumption     
   Ever drinker 586 (94) 274 (95) 2399 (93) 960 (94) 
   Never drinker 36 (6) 13 (5) 184 (7) 66 (6) 
Body mass index     
   Normal 99 (16) 55 (19) 610 (24) 211 (21) 
   Overweight 313 (50) 128 (45) 1229 (48) 464 (45) 
   Obese 210 (34) 104 (36) 744 (29) 351 (34) 
Smoking status     
   Ever smoker 385 (62) 183 (64) 1619 (63) 654 (64) 
   Never smoker 237 (38) 104 (36) 964 (37) 372 (36) 
SU level 486.0 (13.7)* 526.6 (83.5)*   
   ≤360µmol/L - - 485 (19) 17 (2) 
   >360µmol/L - - 2,098 (81) 1,009 (98) 
Medication use     
Analgesics 219 (35) 126 (44) 829 (32) 465 (45) 
Colchicine 21 (3) 17 (6) 52 (2) 36 (4) 
Diuretics 244 (39) 123 (43) 1,002 (39) 519 (51) 
NSAIDS 377 (61) 178 (62) 1,158 (45) 612 (60) 
N (%) presented unless otherwise stated; Cells highlighted in yellow indicated standardised mean difference 
>0.10; NSAIDS: Non-steroidal anti-inflammatory drugs; SD: Standard deviation; SU: Serum urate 
 
After PS estimation, the mean and range of PS were similar between treatment groups 
indicating adequate common support. Five and six subclasses were required to achieve overall 
balance for all covariates across subclasses for the analyses of target SU level and mortality 
respectively; previously in the main analysis five subclasses were sufficient to achieve overall 
covariate balance for both outcomes.  
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Compared with the main analysis, more covariates were imbalanced within subclasses (Table 
7.30). For example, for mortality, in the main analysis covariate imbalance was observed only 
in subclasses 1 and 2 whereas in this analysis, covariate imbalance was observed across all 
subclasses.  
Table 7.30: Distribution of PS subclasses 
Outcome 






Smallest cellb Imbalanced covariates 
Target SU level 
0.29 (0.09, 0.85) 




S1: Age, deprivation, alcohol 
consumption, BMI, smoking status, SU 
level, analgesics, diuretics, NSAIDS 
S2: Renal disease, alcohol 
consumption, BMI, smoking status, 
colchicine, diuretics 
S3: Age, hyperlipidaemia, BMI, 
smoking status, SU level, analgesics, 
colchicine, diuretics 
S4: Coronary heart disease, renal 
disease, BMI, smoking status, diuretics 
S5: Deprivation, coronary heart 
disease, hyperlipidaemia, renal 
disease, smoking status, SU level, 
diuretics, NSAIDS 
Mortality 
0.35 (0.02, 0.75) 




S1: Sex, deprivation, cerebrovascular 
disease, coronary heart disease, 
hypertension, peripheral vascular 
disease, alcohol consumption, BMI, 
smoking status, SU level, analgesics, 
colchicine, diuretics 
S2: Smoking status, analgesics 
S3: Smoking status, NSAIDS 
S4: Peripheral vascular disease, 
colchicine, NSAIDS 
S5: Deprivation, coronary heart 
disease 
S6: Smoking status 
aNumber of propensity score subclasses needed to achieve overall balance across subclasses; bSmallest cell 
defined as the number of allopurinol users within a subclass; BMI: Body mass index; NSAIDS: Non-steroidal anti-
inflammatory drugs; PS: Propensity score; SD: Standard deviation; S: Subclass; SU: Serum urate 
 
Treatment effect estimated for target SU level and mortality is shown in Table 7.31. For target 
SU level, compared with the main analysis, the estimated treatment effect was lower (2.02 vs. 
2.32), although the HR remained over two and statistical significance persisted. As expected, 
the standard error had increased due to decreased sample size (0.24 vs. 0.19).  
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Treatment effect estimated for mortality was also lower (1.07 vs. 1.10) and lost statistical 
significance which may be due to increased standard error from a reduced sample size (0.08 
vs. 0.04)  








Hazard ratio (95% CI) 
Standard error 
Adjusted 
Hazard Ratio (95% CI) 
Standard error 
SU level     
   Target level not met 398 (64) 126 (44) 
2.15 (1.75, 2.64) 
0.23 
2.02 (1.60, 2.53) 
0.24 
   Target level met 224 (36) 161 (56) 
Mortality     
   Alive 1,953 (76) 698 (68) 
1.36 (1.19, 1.55) 
0.09 
1.07 (0.93, 1.23) 
0.08 
   Died 630 (24) 328 (32) 
CI: Confidence interval; SU: Serum urate 
 
7.7 Summary 
This chapter aimed to estimate the long-term effect of allopurinol, measured at baseline, on 
various outcomes, whilst adjusting for baseline covariates via PS subclassification. Allopurinol 
use had higher chance of reaching target SU level and fewer gout consultations in primary 
care, and had higher risk of premature mortality, gout hospitalisation, coronary heart disease 
and renal disease. The magnitude and direction of treatment effects persisted when extending 
the landmark period to two years. Treatment effect estimate for target SU level was robust to 
unmeasured confounding, and was in the same direction when complete case analysis was 
performed. In contrast, for mortality, treatment effect may potentially be protective of 
premature mortality in the presence of unmeasured confounding, and no association was 





7.7.1 Comparison with published studies 
Target SU level 
As expected, allopurinol users were more likely to reach target SU level than non-users. This 
finding persisted within patients with no renal disease and regardless of severity of 
hyperuricaemia. It was found that SU levels were not frequently measured and patients who 
had SU level measured at baseline and during follow-up differed from the whole study sample.  
No studies using large EHR databases have evaluated the effect of allopurinol on reaching 
target SU level however, few small non-EHR suboptimal studies had done so; general 
consensus across these studies were that allopurinol use (vs. no use) and increasing 
allopurinol dose were associated with reaching target (Dalbeth et al., 2006, Dalbeth et al., 
2012, Pandya et al., 2011). 
A randomised controlled trial (RCT) compared the efficacy of nurse-led care with usual general 
practitioner (GP)-led care on reaching primary outcome, target SU level ≤360µmol/L, with 
urate-lowering therapy (ULT). In nurse-led care, the majority of participants were treated with 
allopurinol and over 90% achieved target compared with only 30% in usual GP-led care 
(Doherty et al., 2018). Findings from this PhD found 57% of allopurinol users (comparable to 
the GP led-care) reached target which was higher than the 30% observed in that RCT. This may 
be due to differing covariate distributions of the study sample, for example, participants 
recruited to the RCT tended to be older, and had a higher prevalence of males, obesity, and 
comorbidities thus may have had more severe gout than the study sample from this PhD.   
Mortality 
Allopurinol use was found to be weakly associated with premature mortality and statistical 




Kuo et al. (2015a) CPRD study had used the one-year landmark period, the same as this PhD. 
They found allopurinol use was not associated with mortality. Key differences between Kuo et 
al. (2015a) and this PhD are adjustment for more covariates within PS estimation, such the 
Charlson comorbidity index (Charlson et al., 1987), and prescriptions for aspirin and lipid 
lowering drugs; covariates being measured over a longer period of five years prior to the index 
date; the study sample was restricted to patients with a new diagnosis of gout; the definition 
of allopurinol use required a six-month prescription rather than three months; use of PS 
matching to create comparable treatment groups resulting in analysing a smaller study sample 
and larger standard error in the treatment effect; a lower prevalence of missing data in 
lifestyle factors. The results from this PhD also differed to a recent systematic review of four 
cohort EHR studies in gout that found no association between allopurinol use and mortality 
(Hay et al., 2020).  
As stated above, there is the possibility that weak unmeasured confounding may nullify the 
treatment effect and thus, results would be similar to the treatment effects obtained from 
Kuo et al. (2015a) CPRD study and the systematic review.  
Repeated gout consultations  
Allopurinol users were less likely to consult for gout in primary care compared to non-users. 
Few case-cross over studies have shown allopurinol use was associated with less flares (Neogi 
et al., 2014, Zhang et al., 2012, Zhang et al., 2014). As allopurinol users were also more 
successful in lowering their SU levels to target, this had likely resulted in the long-term fall in 
the number of gout flares thus leading to fewer consultations.  
A limitation of this analysis was that consultations occurring in the landmark period were 
ignored which may be problematic for patients initiating allopurinol who may have had more 
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consultations in the short term in monitoring SU level and titrating allopurinol dose which may 
have led to a stronger protective HR.  
Doherty et al. (2018) RCT found within nurse-led care, the number of participants reporting 
two or more flares had reduced from 80% at baseline to 8% two years later, whilst in GP-led 
care it had reduced from 80% to 24%. This is the same conclusion obtained in this PhD, that 
the number of primary care gout consultations had reduced over time amongst allopurinol 
users.   
Gout hospitalisation 
Allopurinol was found to be associated with increased risk of gout hospitalisation. One 
possible reason could be that when patients initiate allopurinol or dose increases, they are at 
an increased short-term risk of flares due to partial crystal dissolution that may require 
hospital treatment. Over the long term, risk of flares (and hospitalisations) should decrease as 
allopurinol users reach target SU level and crystal dissolution is complete preventing 
occurrence of flares. Indeed, one small case-control study using hospital records in New 
Zealand found patients who were hospitalised were less likely to be on allopurinol and those 
who were on allopurinol had lower doses. Furthermore, colchicine prophylaxis (to prevent 
flares) was less likely to be used in hospitalised patients compared to non-hospitalised 
patients (Hutton et al., 2009). Similarly, a Swedish study found a small proportion of patients, 
between 19%-27%, received ULT in the six months prior to hospitalisation (Dehlin and 
Jacobsson, 2018).  
Possible reasons why allopurinol users were at increased risk of hospitalisation may be due to 
suboptimal management of ULT and when allopurinol treatment was measured. In the UK, 
prophylactic treatment is often not prescribed and allopurinol dose is inadequate (due to 
failure in titrating allopurinol dose) to lower SU level to target (Roddy et al., 2007b, Cottrell et 
239 
 
al., 2013). As suggested by Hutton et al. (2009), these are factors for greater risk of 
hospitalisation. Patients with a prescription for allopurinol was only captured in the one-year 
landmark period. The analysis did not account for patients whose dose may have increased 
(potentially after the landmark period) thus increasing the risk of flares; patients who were 
prescribed allopurinol after the landmark period potentially attributing protective effects of 
allopurinol to non-users; nor accounted for prophylactic treatment.  
Joint replacement 
No association between allopurinol use and joint replacement at the hip or knee was found. 
Similar findings of no association between cumulative daily dose of ULT with joint replacement 
were observed within CPRD and the Taiwan National Health Insurance Database using a 
nested case-control study amongst incident gout (Kuo et al., 2018). 
Gout is an independent risk factor for joint replacement as irreversible joint damage may 
occur from chronic gouty arthritis, tophi, and bone erosion. Osteoarthritis is the most common 
reason for patients undergoing joint replacement. It has been shown osteoarthritic joints are 
more susceptible to flares (Roddy et al., 2007a) and frequency of osteoarthritis is higher 
amongst patients diagnosed with gout than those without gout (Kuo et al., 2016b). Therefore, 
it was expected allopurinol use would lower SU levels to target and prevent continuing joint 
damage. However, the lack of association may be due to inadequate dose of allopurinol, failing 
to lower SU level to target (Roddy et al., 2007b, Cottrell et al., 2013), and non-adherence to 
allopurinol (Scheepers et al., 2018) which results in continuing flares and joint damage from 
crystal deposition.  
Cerebrovascular disease 
No association between allopurinol use and cerebrovascular disease was found in this thesis. 
The same observation was found in a matched cohort study using insurance claims from 
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Taiwan with a higher estimated HR of 1.18 (0.95, 1.47) (Kok et al., 2014). That study contained 
patients with higher prevalence of comorbidities such as hypertension, diabetes, and 
hyperlipidaemia, and used different methods to control for confounding by matching 
allopurinol users with non-users, and had considered other covariates such as atrial 
fibrillation, uraemia, and gastric ulcer.   
Coronary heart disease 
Allopurinol use was found to be increase the risk of coronary heart disease. Many studies have 
evaluated the risk of allopurinol on cardiovascular disease but definitions of outcome varied. 
An incident user study using American insurance claims records found compared to previous 
allopurinol users, current users were less likely to be hospitalized due to myocardial infarction 
or stroke in patients with both gout and diabetes (Singh et al., 2017). A matched cohort study 
using insurance claims from Taiwan found allopurinol users were at an increased risk of 
coronary heart disease (HR 1.41 (1.10, 1.79)) (Kok et al., 2014). Kok et al. (2014) estimated 
higher HR than this thesis which may be due to using a different data source and control for 
confounding variables. In contrast, a large population-based case-control study using a 
Spanish primary care database, and a cohort study using American insurance claims data had 
found allopurinol use, and longer duration of treatment (over 180 days) were protective of 
myocardial infarction (de Abajo et al., 2015, Singh and Yu, 2016). 
Large RCTs have provided conflicting evidence of the effects of febuxostat vs. allopurinol on 
cardiovascular safety. The CARES trial had shown all-cause and cardiovascular mortality was 
higher amongst febuxostat users (White et al., 2018), whilst the FAST trial had shown there 
was no association (Mackenzie et al., 2020). The differences in study findings could be 
attributed to recruiting from different populations, febuxostat dose, and attrition bias. It is 
unclear why febuxostat increases cardiovascular risk and the observed effect in the CARES trial 
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may be due to allopurinol use having a protective effect (Choi et al., 2018). However, this PhD 
project found allopurinol use (vs. non-use) increased risk of mortality and coronary heart 
disease but did not examine effects of febuxostat. A limitation is that unmeasured 
confounding may be present. An ongoing ALL-HEART RCT will conclusively decide if allopurinol 
vs. non-use increases cardiovascular risk (Mackenzie et al., 2016).        
Peripheral vascular disease 
This thesis had shown there is no association between allopurinol use and peripheral vascular 
disease with the estimated HR close to null. A cohort study using American insurance claims 
found allopurinol use was protective against peripheral arterial disease (HR 0.85 (0.79, 0.93)) 
and those who were on allopurinol for >2 years the HR decreased to 0.75 (0.63, 0.89) 
compared to non-users (Singh and Cleveland, 2018a). Reasons for differing results could be 
due to using data collected in the USA; that study adjusted for confounding variables not 
considered in this thesis (race, Charlson-Romano score, beta blockers, ACE inhibitors, statins) 
but this thesis adjusted for more confounding variables overall.  
Renal disease 
This thesis found allopurinol use increased the risk of renal disease. Few studies have 
evaluated the effect of allopurinol on renal disease. Roughley et al. (2018) employed the one-
year landmark method using data from CPRD. That study found no association between 6-
month use of ULT (99% allopurinol prescription) with chronic kidney disease stage ≥3 (HR 1.09 
(95% CI 0.99, 1.18)). That HR was smaller than the HR estimated in this thesis; this may be due 
to the definition of outcome as that study looked at a more severe renal disease than this 
thesis plus that study adjusted for more confounding variables (myocardial infarction, 
systemic lupus erythematosus, rheumatoid arthritis, heart failure, and hospitalisations). 
Furthermore, that study had higher prevalence of hypertension as they had used prescription 
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data, and higher prevalence of renal disease due to use of estimated glomerular filtration rate 
as opposed to using Read codes to define those comorbidities in this PhD; this suggest using 
Read codes were underused.   
Vargas-Santos et al. (2018) used a time-stratified PS matched cohort study using data from 
THIN. They found allopurinol use of 300mg or more per day was protective against developing 
chronic renal disease stage ≥3 with HR of 0.87 (0.77, 0.97). Sensitivity analysis restricting 
patients not changing treatment status over time yielded lower HR (0.83 (0.72, 0.95). Strong 
assumptions on missing data were made as those with no serum creatinine or no Read code 
for chronic kidney disease stage 2 were considered to have normal kidney function. However, 
after using multiple imputation the protective effect of allopurinol was borderline statistically 
significant (0.92 (0.84, 1.00)). The difference in findings is because that study based allopurinol 
use on higher dose of 300mg which would expect to have more of an effect. In this thesis dose 
was not considered however given that a previous UK primary care study found 58% of 
patients remained on their starting dose of 100mg (Cottrell et al., 2013), it suggests a 
protective effect was not found due to suboptimal dosing.  
 
7.7.2 Strengths and limitations 
Simple strategies were utilised to allow estimation of the effect of allopurinol. Use of the 
landmark method was advantageous in that all patients were allowed a fixed period of time 
to be prescribed allopurinol that was not dependent upon length of follow-up time. PS 
subclassification is a straightforward and intuitive approach that divides patients into 
homogenous subclasses with patients having similar distribution of covariates and allows one 
to estimate subclass-class specific treatment effects. Despite the advantages of these 
approaches, some limitations were encountered.  
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Propensity score subclassification 
PS subclassification performed fairly well ensuring overall balance of covariates between 
treatment groups across subclasses was satisfied. However, within subclasses, balance was 
not achieved on all covariates. Intuitively a greater number of subclasses would create more 
homogenous subclasses however this was not found in this analysis with imbalance remaining 
when up to 10 subclasses were used. Furthermore, one would expect more imbalanced 
covariates to be observed in subclasses containing a wider range of PS, however the opposite 
was found in this analysis.  
PS subclassification was restricted by small sample size as seen when stratifying analyses by 
presence of renal disease. Only a small proportion of patients had renal disease and 
consequently outcome was infrequent. Dividing patients into PS subclasses was not possible 
as outcome had not occurred in some subclasses thus treatment effect could not be 
estimated. Where estimation was possible, corresponding standard errors were large due to 
small sample sizes. Treatment effect estimates were not comparable in patients with and 
without renal disease due to differing baseline covariates and sample size. 
Despite these issues, overall PS subclassification estimated treatment effects that were 
comparable with previous studies.  
Misclassification of treatment status 
Determining landmark period is a balance between retaining sample size by not excluding too 
many patients with short follow-up and capturing patients prescribed allopurinol. A landmark 
period of one year was chosen for the main analysis with a sensitivity analysis extending the 
landmark period to two years. The one- and two- year landmark periods identified 3,957 and 
4,513 allopurinol users, respectively. However, misclassification of treatment was present as 
a total of 7,767 patients were prescribed allopurinol at any time during follow-up. Potentially, 
244 
 
treatment effect estimates may be biased although treatment effect estimates from the one- 
and two- year landmark periods yielded similar HRs.  
Infrequent recording of SU level 
BSR guidelines state SU level should be monitored monthly during allopurinol titration and 
thereafter yearly once SU target has been obtained (Jordan et al., 2007b). Recording of SU 
level was low with nearly 60% of the study sample not having a measurement at baseline, 
although these patients had yet to start allopurinol which may be reason why SU was not 
measured. However, the number of patients having a follow-up SU measurement was low 
(29%). Recording of SU in practice is variable.     
Defining gout hospitalisation 
Gout hospitalisation was defined using inpatient Hospital Episodes Statistics data. Each 
hospitalisation may have up to 20 diagnoses recorded on the same date however, the primary 
reason for hospitalisation was not recorded. Although all patients had a diagnosis of gout 
within primary care, it cannot be differentiated if hospitalisation after diagnosis was attributed 
to gout or was recorded as a comorbidity within the reason for hospitalisation.       
Residual confounding 
This PhD had found allopurinol was associated with increased risk of many poor outcomes 
when it was expected that allopurinol may be protective or to observe no association. This 
may be due to residual confounding from unobserved covariates such as diet and severity of 
gout, but also from incomplete adjustment for covariates with missing data, and 
misclassification of comorbidities, for example basing hypertension solely on Read codes 






PS subclassification with the landmark analysis was a useful method to estimate the long-term 
effect of allopurinol on outcome. The greatest limitation was ignoring changes in treatment 
status after the landmark period. Therefore, advanced modelling strategies was required to 
model changes in allopurinol use over time. The next chapter accommodates this by 
estimating PS scores over time for time-varying allopurinol use and using PS subclassification 




8 Effect of allopurinol: time-varying PS subclassification 
8.1 Study sample 
As shown in Chapter 7, the eligible study sample contained 16,876 patients. After dividing 
follow-up time into one-year intervals (or one-year follow-up periods), resulting in a maximum 
of 18 intervals per patient. Between all patients, there were a total of 155,331 intervals 
(16,876 baseline intervals and 138,544 follow-up intervals). Median (interquartile range (IQR)) 
number of follow-up intervals per patient was 11 (6, 14). 
Table 8.1 describes how the distribution of covariates changed from baseline to the last 
available follow-up interval. Prevalence of comorbidities increased from baseline with the 
largest increases observed in hypertension (+31%), renal disease (+19%), and hyperlipidaemia 
(+18%). Lifestyle factors were more likely to be recorded over time with increased prevalence 
of ever drinkers (+24%), ever smokers (+28%), and across all body mass index (BMI) categories 
(6-10%). There was a small increase in prevalence of prescription for colchicine and analgesics 
but prescription for non-steroidal anti-inflammatory drugs (NSAIDS) had a small decrease. 




Table 8.1: Covariates at baseline and end of follow-up (N=16,876) 
Demographics Baseline End of follow-up 
Age (Mean (SD)) 62.1 (14.7) 70.3 (13.9) 
Sex   
   Male 12,995 (77) 12,995 (77) 
   Female 3,881 (23) 3,881 (23) 
Deprivation (Mean (SD)) 9.1 (5.5) 9.1 (5.5) 
Comorbidities   
Anxiety 672 (4) 2,202 (13) 
Depression 842 (5) 2,838 (17) 
Cerebrovascular disease 407 (2) 1,636 (10) 
Coronary heart disease 2,167 (13) 5,132 (30) 
Diabetes  1,047 (6) 3,391 (20) 
Hyperlipidaemia 783 (5) 3,923 (23) 
Hypertension 3,137 (19) 8,370 (50) 
Osteoarthritis  1,106 (7) 4,204 (25) 
Peripheral vascular disease 257 (2) 826 (5) 
Renal disease 217 (1) 3,449 (20) 
Lifestyle factors   
Alcohol consumption   
   Ever drinker 9,488 (56) 13,472 (80) 
   Never drinker 856 (5) 838 (5) 
   Missing 6,532 (39) 2,566 (15) 
Body mass index   
   Normal weight 2,517 (15) 3,483 (21) 
   Overweight 4,933 (29) 6,011 (36) 
   Obese 3,219 (19) 4,973 (29) 
   Missing 6,207 (37) 2,409 (14) 
Smoking status   
   Ever smoker 6,436 (38) 11,070 (66) 
   Never smoker 4,847 (29) 4,619 (27) 
   Missing 5,593 (33) 1,187 (7) 
SU level   
   ≤360µmol/L 951 (6) 951 (6) 
   >360µmol/L 6,062 (36) 6,062 (36) 
   Missing 9,863 (58) 9,863 (58) 
Medication use   
Analgesics 5,578 (33) 6,644 (39) 
Colchicine 389 (2) 1,030 (6) 
Diuretics 6,142 (36) 6,189 (37) 
NSAIDS 8,024 (48) 5,881 (35) 
Number (%) presented unless otherwise stated; NSAIDS: Non-steroidal anti-inflammatory drugs; SD: Standard 
deviation; SU: Serum urate 
 
 
8.2 Patterns of allopurinol use over time 
Table 8.2 shows the proportion of patients prescribed a total of three months prescription for 
allopurinol in each year of follow-up. The percentage of patients prescribed allopurinol was 











1 12,919 (77) 3,957 (23) 16,876 
2 12,124 (77) 3,749 (24) 15,873 
3 11,175 (75) 3,713 (25) 14,888 
4 10,303 (73) 3,730 (27) 14,033 
5 9,515 (72) 3,692 (28) 13,207 
6 8,783 (71) 3,608 (29) 12,391 
7 8,082 (69) 3,575 (31) 11,657 
8 7,339 (68) 3,438 (32) 10,777 
9 6,644 (67) 3,289 (33) 9,933 
10 6,059 (66) 3,069 (34) 9,128 
11 5,312 (65) 2,814 (35) 8,126 
12 4,437 (64) 2,481 (36) 6,918 
13 2,990 (63) 1,774 (37) 4,764 
14 1,930 (61) 1,229 (39) 3,159 
15 1,180 (58) 839 (42) 2,019 
16 619 (562) 488 (44) 1,107 
17 273 (57) 202 (43) 475 
 
Overall, 7,767 (46%) patients initiated allopurinol and 9,109 (54%) were never prescribed 
allopurinol. Figure 8.1 illustrates the cumulative percentage of patients initiating treatment 
over time. 3,957 (23%) patients initiated allopurinol in the first year of follow-up. This 
cumulatively increased to 4,773 (28%) and 5,328 (32%) by the second and third year, 
respectively.  




Next it was explored whether patients were continuously prescribed allopurinol over time. Of 
all allopurinol users, 60% (n=4,696) remained on treatment until the end of follow-up and 40% 
(n=3,071) discontinued treatment. Of patients who discontinued treatment, 43% (n=1,341) 
resumed treatment. The majority of allopurinol users initiated treatment once (82%, 
n=6,426); and those stopping treatment had only stopped once (82%, n=2,507); a small 
proportion of patients repeatedly initiated and discontinued treatment (Table 8.3). 
Table 8.3: Number of times patients repeatedly initiated and discontinued treatment 






1 6,426 (83) 2,507 (82) 
2 1,078 (14) 452 (15) 
3 218 (3) 98 (3) 
4 38 (<1) 11 (<1) 
5 NA (<1) NA (<1) 
6 NA (<1) NA (<1) 
NA: Cannot report cell counts with less than five events 
 
Table 8.4: Frequency and timing of allopurinol initiation 
 Number of times allopurinol was initiated, N (%) 
Follow-up year 1: N=7,767 2: N=1,341 3: N=263 4: N=45 5: N=7 6: N=NA 
1 3,957 (51) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
2 816 (11) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
3 555 (7) 139 (10) 0 (0) 0 (0) 0 (0) 0 (0) 
4 491 (6) 157 (12) 0 (0) 0 (0) 0 (0) 0 (0) 
5 393 (5) 141 (11) 8 (3) 0 (0) 0 (0) 0 (0) 
6 275 (4) 171 (13) 16 (6) 0 (0) 0 (0) 0 (0) 
7 288 (4) 131 (10) 28 (11) 0 (0) 0 (0) 0 (0) 
8 226 (3) 117 (9) 35 (13) NA (2) 0 (0) 0 (0) 
9 202 (3) 114 (9) 35 (13) NA (4) 0 (0) 0 (0) 
10 136 (2) 84 (6) 26 (9) 9 (20) 0 (0) 0 (0) 
11 133 (2) 90 (7) 27 (10) 8 (18) NA (29) 0 (0) 
12 119 (2) 62 (5) 35 (13) 9 (20) NA (14) 0 (0) 
13 66 (1) 57 (4) 20 (8) 7 (16) NA (14) 0 (0) 
14 53 (1) 38 (3) 13 (5) 5 (11) NA (43) NA (33) 
15 37 (<1) 20 (1) 13 (5) NA (4) 0 (0) 0 (0) 
16 17 (<1) 18 (1) 6 (2) NA (2) 0 (0) NA (33) 
17 NA (<1) NA (<1) NA (<1) NA (2) 0 (0) NA (33) 
NA: Cannot report cell counts with less than five events 
As shown in Table 8.4, 51% (n=3,957) of allopurinol users were prescribed treatment for the 
first time in the first follow-up interval; the proportion of patients initiating allopurinol 
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dwindled over time. 54% (n=739) of allopurinol users who initiated treatment for the second 
time (after discontinuation) were between three and seven years of follow-up.  
From Table 8.5, 25% (n=764) of allopurinol users discontinued treatment for the first time in 
the second year of follow-up. Between 5 and 11 years of follow-up, approximately 10% of 
patients discontinued allopurinol for the second time in each year of follow-up.   
Table 8.5: Frequency and timing of allopurinol discontinuation 















2 764 (25) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
3 455 (15) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
4 351 (11) 31 (6) 0 (0) 0 (0) 0 (0) 0 (0) 
5 285 (9) 62 (11) 0 (0) 0 (0) 0 (0) 0 (0) 
6 238 (8) 79 (14) NA (1) 0 (0) 0 (0) 0 (0) 
7 195 (6) 69 (12) 10 (9) 0 (0) 0 (0) 0 (0) 
8 183 (6) 57 (10) 10 (9) 0 (0) 0 (0) 0 (0) 
9 160 (5) 56 (10) 18 (16) 0 (0) 0 (0) 0 (0) 
10 132 (4) 60 (11) 17 (15) NA (21) 0 (0) 0 (0) 
11 97 (3) 59 (10) 18 (16) NA (21) 0 (0) 0 (0) 
12 88 (3) 36 (6) 11 (10) NA (14) NA (33) 0 (0) 
13 54 (2) 23 (4) 13 (12) NA (21) 0 (0) 0 (0) 
14 30 (1) 16 (3) 5 (4) NA (7) 0 (0) 0 (0) 
15 23 (1) 8 (1) 8 (7) NA (7) NA (33) 0 (0) 
16 11 (<1) NA (1) NA (1) NA (7) NA (33) NA (100) 
17 5 (<1) 5 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
NA: Cannot report cell counts with less than five events 
 
The median (IQR) number of consecutive years patients were prescribed allopurinol for was 









8.3 Patient characteristics by allopurinol treatment 
Table 8.6 describes and compares the distribution of covariates between intervals where 
patients were prescribed and not prescribed allopurinol.   









Demographics    
Age (Mean (SD)) 64.5 (14.0) 65.54 (13.29) 0.08 
Sex: Female 23,908 (22) 8,346 (18) -0.09 
Deprivation (Mean (SD)) 8.9 (5.5) 9.24 (5.61) 0.06 
Comorbidities    
Anxiety 10,965 (10) 4,495 (10) -0.01 
Depression 13,440 (12) 5,448 (12) -0.01 
Cerebrovascular disease 5,861 (5) 2,868 (6) 0.04 
Coronary heart disease 23,046 (21) 12,302 (27) 0.14 
Diabetes  14,337 (13) 7,557 (17) 0.09 
Gout consultation 13,832 (13) 9,338 (20) 0.21 
Hyperlipidaemia 18,126 (17) 9,426 (21) 0.10 
Hypertension 41,426 (38) 21,323 (47) 0.18 
Osteoarthritis  18,931 (17) 9,592 (21) 0.09 
Peripheral vascular disease 3,057 (3) 1,456 (3) 0.02 
Renal disease 8,774 (8) 6,807 (15) 0.22 
Lifestyle factors    
Alcohol consumption    
   Ever drinker 81,194 (74) 35,485 (78) 0.09 
   Never drinker 5,044 (5) 1,911 (4) -0.02 
   Missing 23,446 (21) 8,251 (18) -0.08 
Body mass index    
   Normal 20,361 (19) 6,241 (14) -0.13 
   Overweight 38,511 (35) 16,400 (36) 0.02 
   Obese 28,438 (26) 15,283 (33) 0.17 
   Missing 22,374 (20) 7,723 (17) -0.09 
Smoking status    
   Ever smoker 63,245 (58) 28,277 (62) 0.09 
   Never smoker 31,793 (29) 12,477 (27) -0.04 
   Missing 14,646 (13) 4,893 (11) -0.08 
SU level    
   ≤360µmol/L 8,468 (8) 637 (1) -0.31 
   >360µmol/L 34,192 (31) 20,804 (46) 0.30 
   Missing 67,024 (61) 24,206 (53) -0.16 
Medication use    
Analgesics 32,443 (30) 16,550 (36) 0.14 
Colchicine 4,398 (4) 3,681 (8) 0.17 
Diuretics 29,088 (27) 16,073 (35) 0.19 
NSAIDS 46,698 (43) 20,095 (44) 0.03 
Cumulative allopurinol use, years (Mean (SD)) 0.3 (1.2) 4.0 (3.5) 1.41 
Number (%) presented unless otherwise stated; NSAIDS: Non-steroidal anti-inflammatory drugs; SD: Standard 




Within intervals, large differences between the treatment groups were observed where 
standardised mean difference (SMD) was >0.10 (Table 8.6). Patients within allopurinol 
intervals had higher prevalence of coronary heart disease (SMD=0.14), gout consultation 
(0.21), hypertension (0.18), renal disease (0.22), obese (0.17), serum urate (SU) level above 
target (0.30), and had more prescriptions for analgesics (0.14), colchicine (0.17), and diuretics 
(0.19) than non-users within intervals. Allopurinol users were also previously on allopurinol 
for a longer period of time than non-users (4 years vs. 0.34 years). 
  
8.4 Propensity score model and distribution 
Covariates used to estimate propensity score (PS) for each outcome analysis are shown in 
Table 8.7. Covariates were included in PS estimation regardless of statistical significance: age, 
sex, deprivation, renal disease, colchicine, NSAIDS, diuretics, SU level, gout consultation, 
cumulative allopurinol use and follow-up time.  
Covariates that were significantly associated with outcome, determined via the univariable 
complementary log-log regression model, were also included in the PS model. Gout 
consultation was only associated with outcomes gout hospitalisation, coronary heart disease, 
and renal disease. Generally, the majority of demographics, comorbidities, lifestyle factors 
and medication usage were associated with most outcomes. Cumulative allopurinol use and 




Table 8.7: Covariates entered into the PS model for each outcome analysis 






















Demographics         
Age X X X X X X X X 
Sex X X X X X X X X 
Deprivation X X X X X X X X 
Comorbidities         
Anxiety   X   X   
Depression  X    X  X 
Cerebrovascular disease  X X X  X X X 
Coronary heart disease X X X X X  X X 
Diabetes  X X X  X X X X 
Gout consultation X X X X X X X X 
Hyperlipidaemia X  X  X X X X 
Hypertension  X X X X X X X 
Osteoarthritis  X X X X X X X 
Peripheral vascular disease  X X  X X  X 
Renal disease X X X X X X X  
Lifestyle factors         
Alcohol consumption X X X X X X X X 
Body mass index X X X X X X X X 
Smoking status X X X X X X X X 
SU level X X X X X X X X 
Medication use         
Analgesics X X X X X X X X 
Colchicine X X X X X X X X 
Diuretics X X X X X X X X 
NSAIDS X X X X X X X X 
Cumulative allopurinol use X X X X X X X X 
Follow-up time X X X X X X X X 
X: Covariate was entered into the propensity score model; Green cell: Covariate was associated with outcome (p<0.05); Red cell: Covariate was not associated with outcome (p≥0.05); Black 
cell: Not applicable; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; SU: Serum urate 
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The initial main effects PS model (specification 1) with linear terms for continuous covariates 
was fitted to estimate PS for each outcome analysis. For the analysis of target SU level, 
distribution of PS was skewed and differed between treatment groups (Figure 8.2); median 
(IQR) PS was 0.01 (0.01, 0.10) and 0.87 (0.55, 0.97) for non-allopurinol and allopurinol 
intervals, respectively. 53% (n=3,721) of non-allopurinol intervals and 12% (n=361) of 
allopurinol intervals (total 41%, n=4,082) were outside the PS region of common support 
(Table 8.8). Common support improved by considering fractional polynomial terms of 
dimension 2 (FP2) terms for follow-up time and FP1 terms for age, baseline SU level and 
cumulative allopurinol use (specification 4). Backwards selection identified baseline SU level 
as a potential problematic covariate; omitting this covariate reduced lack of common support 
from 21% to 15% (Table 8.9) however, this covariate was retained as adding two interactions 
to the PS model (colchicine*smoking status and BMI*gout consultation) improved common 
support by approximately the same amount (specification 6) (Table 8.8). Specification 6 was 
chosen as the final PS model as adding another interaction term to the PS model did not 
further improve common support. The distribution of the final estimated PS is shown in Figure 
8.2. Despite the improvement in common support, the distribution of PS by treatment status 
was not similar between treatment groups. 
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Figure 8.2: Distribution of PS by treatment 
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Table 8.8: PS model specification and degree of common support 
Outcome: Target SU level 
Propensity score model specification 
Median propensity score (IQR) 
(Range) 
Number of intervals outside the region of common 
support 








Main effects model 
+ linear terms for age, deprivation, SU level, cumulative allopurinol use, 
follow-up time 
0.01 (0.01, 0.10) 
(<0.01, 0.98) 
0.87 (0.55, 0.97) 
(0.02, 0.99) 
3,721 (53%) 361 (12%) 4,082 (41%) 
2 
Main effects model 
+ FP1 terms for age(-2), deprivation(3), SU level(2), cumulative allopurinol 
use(0.5), follow-up time(3) 
0.02 (0.01, 0.11) 
(0.02, 0.98) 
0.86 (0.55, 0.96) 
(0.02, 0.99) 
3,341 (47%) 300 (10%) 3,641 (36%) 
3 
Main effects model 
+ FP2 terms for age(0.5, 3), deprivation (1, 2), SU level(-2, -2), cumulative 
allopurinol use(0.5, 3), follow-up time(-0.5, 3) 
0.04 (0.02, 0.12) 
(<0.01, 0.95) 
0.83 (0.52, 0.94) 
(0.02, 0.99) 
1,754 (25%) 646 (22%) 2,400 (24%) 
4 
Main effects model 
+ FP2 terms follow-up time(-0.5, 3) 
+ FP1 terms for age(-2), SU level(2), cumulative allopurinol use(0.5) 
+ linear terms deprivation 
0.04 (0.02, 0.12) 
(<0.01, 0.99) 
0.82 (0.52, 0.94) 
(0.02, 0.99) 
2,062 (29%) 82 (3%) 2,144 (22%) 
5 
Main effects model 
+ FP2 terms follow-up time(-0.5, 3) 
+ FP1 terms for age(-2), SU level(2), cumulative allopurinol use(0.5) 
+ linear terms deprivation 
+ colchicine*smoking status 
0.04 (0.02, 0.12) 
(<0.01, 0.99) 
0.82 (0.52, 0.94) 
(0.02, 0.99) 
1,803 (26%) 85 (3%) 1,888 (18%) 
6 
Main effects model 
+ FP2 terms follow-up time(-0.5, 3) 
+ FP1 terms for age(-2), SU level(2), cumulative allopurinol use(0.5) 
+ linear terms deprivation 
+ colchicine*smoking status 
+ BMI*gout consultation 
0.03 (0.02, 0.12) 
(<0.01, 0.99) 
0.83 (0.51, 0.94) 
(0.01, 0.99) 





Table 8.8 continued: 
7 
Main effects model 
+ FP2 terms follow-up time(-0.5, 3) 
+ FP1 terms for age(-2), SU level(2), cumulative allopurinol use(0.5) 
+ linear terms deprivation 
+ colchicine*smoking status 
+ BMI*gout consultation 
+ colchicine use*gout consultation 
0.04 (0.02, 0.12) 
(<0.01, 0.99) 
0.83 (0.52, 0.94) 
(0.01, 0.99) 
1,398 (22%) 55 (3%) 1,453 (16%) 
Specification highlighted in green was the chosen propensity score model; Values in brackets (column 2) indicate which fractional polynomial terms were used; BMI: Body mass index; FP1: 
Fractional polynomials of dimension 1; FP2: Fractional polynomials of dimension 2; IQR: Interquartile range; PS: Propensity score; SU: Serum urate 
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Similar findings were observed for secondary outcomes with relevant results tables presented 
in Appendix L. For all secondary outcome analyses, the initial main effects PS model 
(specification 1) highlighted the distribution of PS differed between treatment groups 
(illustrated in Appendix L). Approximately 50% of intervals were outside the PS region of 
common support. Common support improved considerably when FP terms were considered 
for continuous covariates: for the analysis of mortality, lack of common support reduced from 
49% (based on specification 1) to 19% (based on specification 4); gout hospitalisation (from 
54% to 19%); joint replacement (from 50% to 15%); peripheral vascular disease (from 50% to 
15%); and renal disease (from 54% to 20%). There was a minor improvement in common 
support in the analysis of coronary heart disease when including FP terms for continuous 
covariates in the PS model however, no improvement was observed for cerebrovascular 
disease. Despite these improvements in common support, the distribution of PS remained 
skewed and were different between treatment groups.  
Backwards selection did not identify a single covariate that considerably worsened common 
support. From Table 8.9, in the analysis for mortality, removing SU level from the PS model 
improved lack of common support from 19% to 16%. The largest improvement in common 
support was seen in the analysis for joint replacement, where lack of common support 
reduced from 15% to 6% when SU level was omitted from the PS model. At this stage, no 
covariates were omitted from the PS model as they were deemed strong confounding 
variables based on clinical grounds. 
Inclusion of two-way interaction terms that were associated with outcome and improved 
common support, were included in the PS score model (Appendix L). For example, in the 
analysis for mortality, including four interaction terms (baseline SU level*NSAIDS, baseline SU 
level*hypertension, diuretics*sex, and alcohol consumption*sex) improved lack of common 
support from 19% to 7%. For the other secondary outcomes, up to three interaction terms 
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were included in the PS model with the exception of in the analyses of cerebrovascular disease 
and coronary heart disease, where no interaction terms were found to improve common 
support.  
Although three-way interaction terms were considered in the PS model, none considerably 
improved common support more than using two-way interaction terms, thus they were no 
longer considered.  
Table 8.10 shows which interaction terms and FP terms for continuous covariates were 
included in the final PS model for each outcome analysis. Table 8.11 summarises and 
compares the degree of common support from the main effects model (specification 1) 
compared with the final PS model, which shows despite improvements in lack of common 
support, the distribution of PS remained skewed and differed between treatment groups 
across all outcomes (also shown graphically in Appendix L). 
Table 8.9: Backwards selection to identify problematic covariates 
Outcome 
Number of intervals 
outside the region of 
common support  
(PS model 
specification 4) 
Number of intervals 
outside the region of 
common support after 
omitting problematic 
covariate from the PS 
model 
Omitted covariate 
SU level 2,144 (22%) 1,546 (15%) Baseline SU level 
Mortality 29,137 (19%) 24,565 (16%) Baseline SU level 
Gout hospitalisation 23,075 (19%) 20,459 (17%) Colchicine 
Joint replacement 22,340 (15%) 9,858 (7%) Baseline SU level 
Cerebrovascular disease 72,178 (50%) 72,199 (50%) Follow-up time 
Coronary heart disease 58,791 (50%) 58,490 (50%) Follow-up time 
Peripheral vascular disease 21,827 (15%) 24,574 (16%) Sex 
Renal disease 26,735 (20%) 16,096 (12%) NSAIDS 
PS: Propensity score; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; SU: Serum urate 
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Table 8.10: Addition of fractional polynomial terms and interactions to the main effects PS 
model 
Outcome Fractional polynomial terms Interaction terms 
Target SU level 
age(-2) 
Baseline SU level(2) 
cumulative allopurinol use(0.5) 
follow-up time(-0.5, 3) 












deprivation (3, 3) 
cumulative allopurinol use(-0.5, 0) 
follow-up time(0.5) 
SU level*NSAIDS 




cumulative allopurinol use(0.5) 
follow-up time(-2) 
colchicine*coronary heart disease 
BMI*osteoarthritis  
alcohol consumption*gout consultation 
Cerebrovascular disease N/A N/A 
Coronary heart disease 
age(2, 2) 
deprivation (-2, -2)  
follow-up time(-2, -0.5) 
N/A 
Peripheral vascular disease 
follow-up time(-0.5, 3) 
age(-2) 
cumulative allopurinol use(0.5) 
smoking status*diuretics 
Renal disease 
cumulative allopurinol use(0.5) 
follow-up time(-2) 
SU level*colchicine 









Table 8.11: Comparison of degree of common support between PS models 
Outcome 
Number of intervals outside the region of common 
support: Main effects PS model (Specification 1) 
Number of intervals outside the region of common 
support: Final PS model 
Distribution of propensity scores from the 
final PS model 
Median (IQR) 
(Range) 
 No allopurinol Allopurinol Overall No allopurinol Allopurinol Overall No allopurinol Allopurinol 
Target SU level 3,721 (53%) 361 (12%) 4,082 (41%) 1,405 (20%) 60 (2%) 1,465 (15%) 
0.03 (0.02, 0.12) 
(0.003, 0.99) 
0.83 (0.51, 0.94) 
(0.01, 0.99) 
Mortality 76,177 (69%) 702 (2%) 76,879 (49%) 10,584 (10%) 683 (1%) 11,267 (7%) 
0.01 (0.01, 0.06) 
(2*10-4, 0.99) 
0.92 (0.68, 0.98) 
(0.003, 0.99) 
Gout hospitalisation 63,658 (72%) 2,026 (6%) 65,684 (54%) 7,048 (8%) 2,409 (7%) 9,457 (8%) 
0.01 (0.01, 0.04) 
(2*10-4, 0.99) 
0.92 (0.69, 0.98) 
(0.003, 0.99) 
Joint replacement 72,043 (67%) 2,542 (6%) 74,585 (50%) 15,979 (15%) 771 (2%) 16,750 (11%) 
0.01 (0.007, 0.061) 
(5*10-4, 0.99) 
0.91 (0.69, 0.97) 
(0.005, 0.99) 
Cerebrovascular disease 71,857 (70%) 1,069 (3%) 72,926 (50%) 70,628 (69) 756 (2%) 71,384 (49%) 
0.003 (0.002, 0.05) 
(1*10-5, 0.99) 
0.93 (0.66, 0.99) 
(0.01, 0.99) 
Coronary heart disease 58,716 (70%) 364 (1%) 59,080 (51%) 58,257 (69%) 534 (2%) 58,791 (50%) 
0.003 (0.002, 0.05) 
(7*10-5, 0.99) 
0.92 (0.64, 0.98) 
(0.009, 0.99) 
Peripheral vascular disease 74,245 (70%) 1,079 (2%) 75,324 (50%) 21,456 (20%) 371 (1%) 21,827 (15%) 
0.02 (0.01, 0.07) 
(6*10-4, 0.99) 
0.91 (0.67, 0.97) 
(0.01, 0.99) 
Renal disease 71,622 (73%) 1,871 (5%) 73,493 (54%) 21,211 (22%) 766 (2%) 21,977 (16%) 
0.01 (0.01, 0.05) 
(4*10-4, 0.99) 
0.91 (0.68, 0.97) 
(0.01, 0.99) 
IQR: Interquartile range; PS: Propensity score; SU: Serum urate 
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8.5 Number of propensity score subclasses 
In the analysis of target SU level, four PS subclasses achieved overall covariate balance across 
subclasses, whilst increasing the number the subclasses (≥5) resulted in imbalance for 
cumulative allopurinol use and baseline SU level. As the PS distribution was skewed and 
differed between treatment groups, in the first subclass no outcome was observed within 
allopurinol intervals (Table 8.12 and Table 8.13). However, four PS subclasses were retained 
for treatment effect estimation as 75% of intervals from 99% of patients would be utilised, 
compared with say five subclasses, where a lower number of intervals (60%) from a lower 
number of patients (77%) would be utilised. Within subclasses, there were large differences 
in covariates between treatment groups where SMD >0.10; subclasses 2 and 4 had at least 11 
imbalanced covariates whereas subclass 3 only had two (Table 8.15).  
Within all secondary outcome analyses, use of four PS subclasses resulted in no occurrence of 
outcome within allopurinol intervals in subclass 1. Increasing the number of subclasses up to 
seven, generally resulted in fewer intervals and patients that would be utilised in treatment 
effect estimation (Appendix M). However, for some outcomes, a larger number of subclasses 
were required as overall covariate balance across subclasses was not achieved when using 
four PS subclasses. Choice of number of PS subclasses was based on achieving overall 
covariate balance across subclasses and maximising the number of intervals and patients that 
would be used in treatment effect estimation.  
Four subclasses were sufficient to achieve overall covariate balance across subclasses for the 
analyses of mortality and joint replacement. For the analysis of renal disease, although overall 
covariate balance was achieved using five subclasses, six subclasses were chosen instead as a 
greater number of intervals and patients would be utilised in treatment effect estimation; 
similarly for all other outcome analyses, five subclasses achieved overall covariate balance and 
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would utilise a greater number intervals and patients in treatment effect estimation than 
using four subclasses, or that use of four subclasses did not achieve overall covariate balance. 
In the analysis of cerebrovascular disease, five PS subclasses were created however, outcome 
did not occur in subclasses 1 and 2 within allopurinol intervals. The distribution of outcome 
and treatment across PS subclasses is shown in Table 8.13. Table 8.14 shows the overall SMD 
for each covariate across subclasses, and that overall covariate balance was achieved.  
Covariate imbalance within each subclass were identified and listed in Table 8.15. Generally, 
across all outcome analyses, the subclass with the lowest PS observed the most number of 
imbalanced covariates. The most frequently observed imbalanced covariates within 
subclasses across all outcomes were gout consultation (n=18), age (n=17), diuretics (n=15), 




Table 8.12: Occurrence of outcome within PS subclasses 
Propensity score 
range 
Reached target SU 




Reached target SU 








Intervals N (%) 




4 subclasses     





 2: 0.02, 0.09   108 (44) 16 (3) 
 3: 0.09, 0.53   43 (17) 104 (23) 
 4: 0.53, 0.99   15 (6) 340 (74) 
5 subclasses     





 2: 0.02, 0.05   88 (36) 0 (0) 
 3: 0.05, 0.18   66 (27) 53 (12) 
 4: 0.18, 0.69   26 (11) 142 (31) 
 5: 0.69, 0.99   9 (4) 265 (58) 
6 subclasses     






 2: 0.02, 0.03   73 (30) 0 (0) 
 3: 0.03, 0.09   67 (27) 16 (3) 
 4: 0.09, 0.29   35 (14) 55 (12) 
 5: 0.29, 0.79   20 (8) 169 (37) 
 6: 0.79, 0.99   3 (1) 220 (48) 
7 subclasses     






 2: 0.01, 0.02   53 (21) 0 (0) 
 3: 0.02, 0.05   60 (24) 0 (0) 
 4: 0.05, 0.15   51 (21) 44 (10) 
 5: 0.15, 0.42  23 (9) 42 (9) 
 6: 0.42, 0.85  14 (6) 183 (40) 
 7: 0.85, 0.99   3 (1) 191 (42) 
Propensity score subclassification was performed on 10,027 intervals from 1,742 patients. Results highlighted in 
green indicated the number of subclasses used for treatment effect estimation. aAt least one interval from the 
patient would be included in outcome analysis; bOverall SMD was assessed in subclasses with outcome occurring 





Table 8.13: Distribution of outcome and treatment across PS subclasses 




Target SU level 
SU target not met: 
N=6,805 




SU target not met:  
N=2,515 




Subclass 1 2,424 (36) 81 (33) 2,505 (36) 2 (0) 0 (0) 2 (0) 
Subclass 2 2,305 (34) 108 (44) 2,413 (34) 78 (3) 16 (3) 94 (3) 
Subclass 3 1,791 (26) 43 (17) 1,834 (26) 569 (23) 104 (23) 673 (23) 
Subclass 4 285 (4) 15 (6) 300 (4) 1,866 (74) 340 (74) 2,206 (74) 
Mortality Alive: N=106,338 Died: N=3,346 Total: N=109,684 Alive: N=44,017 Died: N=1,630 Total: N=45,647 
Subclass 1 37,799 (36) 1,029 (31) 38,828 (35) 5 (0) 0 (0) 5 (0) 
Subclass 2 36,748 (35) 1,311 (39) 38,059 (35) 761 (2) 13 (1) 774 (2) 
Subclass 3 29,094 (27) 857 (26) 29,951 (27) 8,537 (19) 345 (21) 8,882 (19) 
Subclass 4 2697 (3) 149 (4) 2,846 (3) 34,714 (79) 1,272 (78) 35,986 (79) 
Gout hospitalisation No: N=87,694 Yes: N=923 Total: N=88,617 No: N=32,402 Yes: N=1,049 Total: N=33,451 
Subclass 1 24,268 (23) 143 (4) 24,411 (22) 3 (0) 0 (0) 3 (0) 
Subclass 2 24,062 (23) 231 (7) 24,293 (22) 120 (0) 1 (0) 121 (0) 
Subclass 3 22,441 (21) 341 (10) 22,782 (21) 1,589 (4) 42 (3) 1,631 (4) 
Subclass 4 16,009 (15) 169 (5) 16,178 (15) 7,999 (18) 237 (15) 8,236 (18) 
Subclass 5 914 (1) 39 (1) 953 (1) 22,691 (52) 769 (47) 23,460 (51) 
Joint replacement No: N=104,135 Yes: N=692 Total: N=104,827 No: N=42,731 Yes: N=323 Total: N=43,054 
Subclass 1 36,770 (35) 194 (28) 36,964 (35) 7 (<1) 0 (0) 7 (<1) 
Subclass 2 36,030 (35) 311 (45) 36,341 (35) 628 (1) 1 (<1) 629 (1) 
Subclass 3 28,456 (27) 161 (23) 28,617 (27) 8,319 (19) 34 (11) 8,353 (19) 





Table 8.13 continued: 




Cerebrovascular disease No: N=101,655 Yes: N=1,114 Total: N=102,769 No: N=41,901 Yes: N=438 Total: N=42,339 
Subclass 1 28,918 (28) 104 (9) 29,022 (28) 0 (0) 0 (0) 0 (0) 
Subclass 2 28,689 (28) 333 (30) 29,022 (28) 0 (0) 0 (0) 0 (0) 
Subclass 3 26,597 (26) 594 (53) 27,191 (26) 1,822 (4) 8 (2) 1,830 (4) 
Subclass 4 16,356 (16) 69 (6) 16,425 (16) 12,494 (30) 103 (24) 12,597 (30) 
Subclass 5 1,095 (1) 14 (1) 1,109 (1) 27,585 (66) 327 (75) 27,912 (66) 
Coronary heart disease No: N=82,268 Yes: N=2,080 Total: N=84,348 No: N=31,438 Yes: N=870 Total: N=32,308 
Subclass 1 23,132 (28) 200 (10) 23,332 (28) 0 (0) 0 (0) 0 (0) 
Subclass 2 22,801 (28) 530 (25) 23,331 (28) 0 (0) 0 (0) 0 (0) 
Subclass 3 21,044 (26) 1,168 (56) 22,212 (26) 1,107 (4) 12 (1) 1,119 (3) 
Subclass 4 14,086 (17) 143 (7) 14,229 (17) 8,916 (28) 186 (21) 9,102 (28) 
Subclass 5 1,205 (1) 39 (2) 1,244 (1) 21,415 (68) 672 (77) 22,087 (68) 
Peripheral vascular disease No: N=105,741 Yes: N=432 Total: N=106,173 No: N=43,775 Yes: N=203 Total: N=43,978 
Subclass 1 29,936 (28) 93 (22) 30,029 (28) 2 (0) 0 (0) 2 (0) 
Subclass 2 29,674 (28) 141 (33) 29,815 (28) 214 (0) 1 (0) 215 (0) 
Subclass 3 27,411 (26) 153 (35) 27,564 (26) 2,454 (6) 12 (6) 2,466 (6) 
Subclass 4 17,503 (17) 40 (9) 17,543 (17) 12,437 (28) 50 (25) 12,487 (28) 
Subclass 5 1,217 (1) 5 (1) 1,222 (1) 28,668 (65) 140 (69) 28,808 (66) 
Renal disease No: N=96,077 Yes: N=2,541 Total: N=98,618 No: N=35,986 Yes: N=1,384 Total: N=37,370 
Subclass 1 22,210 (23) 454 (18) 22,664 (23) 1 (0) 0 (0) 1 (0) 
Subclass 2 21,937 (23) 712 (28) 22,649 (23) 16 (0) 0 (0) 16 (0) 
Subclass 3 21,530 (22) 800 (31) 22,330 (23) 328 (1) 6 (0) 334 (1) 
Subclass 4 19,378 (20) 311 (12) 19,689 (20) 2,888 (8) 88 (6) 2,976 (8) 
Subclass 5 10,417 (11) 227 (9) 10,644 (11) 11,676 (32) 345 (25) 12,021 (32) 
Subclass 6 605 (1) 37 (1) 642 (1) 21,077 (59) 945 (68) 22,022 (59) 





Table 8.14: Overall SMD after PS subclassification 















Demographics         
Age -0.04 0.01a -0.01a 0.01a 0.01 0.03a -0.03 0.06 
Sex: Female 0.01 0.02 0.03 0.02 0.01 0.01 0.02 0.036 
Deprivation -0.02 -0.01a <0.01 <0.01 -0.01 <0.01 <0.01 -0.01 
Comorbidities         
Anxiety - - 0.01 - - 0.02 - - 
Depression - 0.01 - - - 0.02 - 0.01 
Cerebrovascular disease - 0.01 0.01 0.01 - 0.01 0.02 0.01 
Coronary heart disease 0.01 <0.01 <0.01 0.01 <0.01 - 0.01 0.02 
Diabetes  0.02 0.01 <0.01 - 0.01 0.02 0.01 0.02 
Gout consultation -0.03 0.01 0.01 0.02 0.02 0.01 -0.01 -0.03 
Hyperlipidaemia 0.02 - <0.01 - 0.01 0.01 0.01 0.02 
Hypertension - 0.01 -0.01 0.01 0.02 0.02 0.01 0.02 
Osteoarthritis  - <0.01 0.01 0.01 0.01 0.02 0.02 0.02 
Peripheral vascular disease - <0.01 <0.01 - 0.01 0.01 - 0.01 
Renal disease <0.01 <0.01 <0.01 0.01 0.02 0.01 0.02 - 
Lifestyle factors         
Alcohol consumptiona -0.02 0.02 0.01 0.02 -0.03 -0.03 -0.01 -0.02 
Body mass indexa -0.03 0.01 0.02 -0.02 -0.03 -0.03 -0.02 -0.02 
Smoking statusa 0.04 <0.01 -0.01 -0.01 -0.03 -0.04 0.02 -0.02 
SU levela -0.07b 0.04 -0.02 0.04 -0.05 -0.04 0.04 0.04 
Medication use         
Analgesics -0.02 <0.01 0.02 -0.01 <0.01 0.01 0.03 0.02 
Colchicine -0.03 <0.01 0.01 -0.01 0.01 <0.01 <0.01 -0.01 
Diuretics 0.01 0.01 0.01 -0.01 -0.02 <0.01 0.02 0.01 
NSAIDS -0.05 <0.01 -0.01 -0.02 -0.02 <0.01 -0.03 -0.04 
Cumulative allopurinol use -0.05 0.05 -0.04a 0.08 0.08 0.08 0.02 -0.05 
Interaction terms -0.06a -0.03a 0.02 0.01 - - 0.02 -0.01 




Table 8.15: Imbalanced covariates within each PS subclass 
Outcome Imbalanced covariates (SMD >0.10) 
Target SU level S2: Age, coronary heart disease, hyperlipidaemia, alcohol consumption, BMI, 
smoking status, SU level, analgesics, diuretics, NSAIDS, cumulative allopurinol 
use, colchicine*gout consultation 
S3: Smoking status, cumulative allopurinol use 
S4: Age, gout consultation, BMI, SU level, analgesics, colchicine, diuretics, 
NSAIDS, cumulative allopurinol use, colchicine*smoking status, 
colchicine*gout consultation 
Mortality S2: Age, cerebrovascular disease, coronary heart disease, gout consultation, 
hypertension, analgesics, colchicine, diuretics, NSAIDS, cumulative allopurinol 
use, SU level*NSAIDS, diuretics*sex 
S3: Gout consultation 
S4: Age, gout consultation, colchicine, diuretics, NSAIDS, SU level*NSAIDS 
Gout hospitalisation S2: Age, deprivation, cerebrovascular disease, coronary heart disease, gout 
consultation, hypertension, peripheral vascular disease renal disease, 
analgesics, colchicine, diuretics, alcohol consumption, SU level, SU 
level*NSAIDS, diuretics*sex 
S3: Age, coronary heart disease, diuretics, cumulative allopurinol use 
S5: Age, diabetes, gout consultation, renal disease, colchicine, NSAIDS, SU 
level*NSAIDS, renal disease*gout consultation 
Joint replacement S2: Age, sex, cerebrovascular disease, coronary heart disease, gout 
consultation, osteoarthritis, analgesics, diuretics, NSAIDS, alcohol 
consumption, SU level 
S3: Gout consultation 
S4: Age, gout consultation, colchicine, NSAIDS 
Cerebrovascular disease S3: Age, coronary heart disease, diabetes, gout consultation, 
hyperlipidaemia, hypertension, osteoarthritis, renal disease, analgesics, 
colchicine, diuretics, alcohol consumption, smoking status, SU level, BMI 
S4: Gout consultation, smoking status, cumulative allopurinol use 
S5: Gout consultation, osteoarthritis, renal disease, colchicine, NSAIDS, 
cumulative allopurinol use, smoking status 
Coronary heart disease S3: Age, cerebrovascular disease, diabetes, gout consultation, hypertension, 
hyperlipidaemia, osteoarthritis, renal disease, analgesics, colchicine, 
diuretics, smoking status, SU level, BMI 
S4: Cumulative allopurinol use 
S5: Age, gout consultation, colchicine, diuretics, NSAIDS 
Peripheral vascular 
disease 
S3: Sex, deprivation, cerebrovascular disease, coronary heart disease, gout 
consultation, hyperlipidaemia, analgesics, colchicine, diuretics, NSAIDS, 
alcohol consumption, smoking status, SU level, BMI, smoking status*diuretics 
S4: Cumulative allopurinol use 
S5: Age, diabetes, gout consultation, renal disease, colchicine, diuretics, 
NSAIDS, cumulative allopurinol use 
Renal disease S3: Age, depression, cerebrovascular disease, coronary heart disease, gout 
consultation, analgesics, colchicine, diuretics, NSAIDS, alcohol consumption, 
BMI, SU level, smoking status, SU level*colchicine, 
S4: Age, diuretics, cumulative allopurinol use 
S5: Age 
S6: Age, diabetes, gout consultation, colchicine, diuretics, NSAIDS, smoking 
status, cumulative allopurinol use, SU level*colchicine 
BMI: Body mass index; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; S: Subclass; SMD: 
Standardised mean difference; SU: Serum urate 
269 
 
8.6 Treatment effect estimation  
Originally, the complementary log-log model with a random intercept was used to estimate 
subclass-specific treatment effects however, not all models had converged, due to adjustment 
for follow-up time in the model or certain imbalanced covariates. Therefore, the random 
intercept was omitted, and robust standard errors accounting for clustering of repeated 
measurements from patients was utilised.   
For half the outcomes (target SU level, mortality, joint replacement, peripheral vascular disease, 
the subclass-specific treatment effect estimates were homogenous. Allopurinol was associated 
with greater chance of reaching target SU level (4.89 (3.76, 6.37)) and increased risk of peripheral 
vascular disease (2.04 (1.39, 2.99)), however no association was observed for mortality and joint 
replacement (Table 8.16).  
The subclass-specific treatment effect estimates for gout hospitalisation (Table 8.17), 
cerebrovascular disease (Table 8.18), coronary heart disease (Table 8.19), and renal disease 
(Table 8.20) were not homogenous, therefore are presented individually alongside with a 
summary of covariates.  
Allopurinol increased the risk of gout hospitalisation in subclasses 3 and 4. Patients in subclass 4 
had a larger treatment effect estimate (2.70 (2.22, 3.29)), and these patients in these intervals 
had fewer prescriptions for diuretics and was previously on allopurinol for a longer period than 
those in subclass 3 who had a lower treatment effect (1.84 (1.34, 2.51)).  
Within subclass 3, allopurinol was protective against cerebrovascular disease (0.21 (0.11, 0.44)) 
and coronary heart disease (0.21 (0.11, 0.38)), in contrast with subclass 4 where allopurinol had 
increased risk of cerebrovascular disease (1.73 (1.26, 1.38)) and coronary heart disease 1.99 (1.58, 
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2.50)). In both outcomes, the distribution of covariates between subclasses 3 and 4 were similar 
but intervals in subclass 3 were older and had higher prevalence of SU level >360μmol/L, 
prescription for diuretics, and patients were previously on allopurinol for a shorter period of time 
than subclass 4. 
Allopurinol use increased the risk of renal disease in subclass 4 (2.03 (1.61, 1.34)) whereas its use 
was protective in subclass 6 (0.58 (0.42, 0.81)). Subclass 6 contained intervals from patients who 
were older, resided in less deprived areas, and had higher prevalence of coronary heart disease, 
hypertension, ever smokers, ever drinkers, obesity, and fewer prescriptions for NSAIDS, and 
previously prescribed allopurinol for a longer period than intervals in subclass 4.  










Hazard ratio (95% CI) 
Standard error 
PS subclassification 
Hazard ratio (95% CI) 
Standard error 
Target SU level     
   Not reached target 4,381 (96) 2,513 (85) 4.57 (3.80, 5.48) 
0.43 
4.89 (3.76, 6.37) 
0.66    Reached target 166 (4) 460 (15) 
Mortality     
   Alive 68,539 (97) 44,012 (96) 1.15 (1.08, 1.23) 
0.04 
0.97 (0.88, 1.08) 
0.05    Death 2,317 (3) 1,630 (4) 
Gout hospitalisation     
   No 63,426 (99) 32,399 (97) 2.21 (2.01, 2.44) 
0.11 
* 
   Yes 780 (1) 1,049 (3) 
Joint replacement     
   No 67,365 (99) 42,724 (99) 1.01 (0.87, 1.16) 
0.07 
0.77 (0.59, 1.01) 
0.11    Yes 498 (1) 323 (1) 
Cerebrovascular disease     
   No 44,048 (98) 41,901 (99) 0.73 (0.65, 0.83) 
0.05 
* 
   Yes 677 (2) 438 (1) 
Coronary heart disease     
   No 36,335 (96) 31,438 (97) 0.85 (0.78, 0.92) 
0.04 
* 
   Yes 1,350 (4) 870 (3) 
Peripheral vascular disease     
   No 75,805 (99) 43,773 (99) 1.16 (0.97, 1.38) 
0.11 
2.04 (1.39, 2.99) 
0.40   Yes 339 (1) 203 (1) 
Renal disease     
   No 51,930 (97) 35,969 (96) 1.21 (1.12, 1.31) 
0.05 
* 
   Yes 1,375 (3) 1,384 (4) 
*Subclass-specific treatment effects were not homogenous. Therefore they were not pooled; CI: Confidence interval; 
SU: Serum urate 
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Table 8.17: Estimated treatment effect of allopurinol on gout hospitalisation and distribution of 










Hazard ratio (95% CI) 
Standard error 
0.69 (0.11, 4.20) 
0.64 
1.84 (1.34, 2.51) 
0.29 
2.70 (2.22, 3.29) 
0.27 
0.94 (0.61, 1.16) 
0.14 
Demographics     
Age* 66.1 (13.8) 65.9 (13.7) 63.8 (13.6) 67.2 (12.6) 
Sex: Female 5,149 (21) 4,960 (20) 4,291 (18) 4,888 (20) 
Deprivation* 9.1 (5.5) 9.2 (5.5) 9.3 (5.5) 9.3 (5.5) 
Comorbidities     
Anxiety 2,241 (9) 1,712 (7) 2,215 (9) 2,495 (10) 
Depression 2,914 (12) 2,218 (9) 2,638 (11) 3,123 (13) 
Cerebrovascular disease 1,610 (7) 1,127 (5) 1,045 (4) 1,698 (7) 
Coronary heart disease 5,948 (24) 5,324 (22) 5,016 (21) 7,630 (31) 
Diabetes 3,374 (14) 2,550 (10) 2,888 (12) 4,508 (18) 
Gout consultation 2,147 (9) 4,510 (18) 5,876 (24) 4,729 (19) 
Hyperlipidaemia 4,132 (17) 3,000 (12) 3,879 (16) 5,411 (22) 
Hypertension 9,677 (40) 8,580 (35) 9,317 (38) 12,395 (51) 
Osteoarthritis  4,360 (18) 3,521 (14) 4,356 (18) 5,666 (23) 
Peripheral vascular disease 759 (3) 613 (3) 575 (2) 901 (4) 
Renal disease 1,981 (8) 1,447 (6) 2,122 (9) 4,094 (17) 
Lifestyle factors     
Alcohol consumption     
   Ever drinker 18,442 (76) 16,246 (67) 17,998 (74) 19,318 (79) 
   Never drinker 1,207 (5) 1,138 (5) 974 (4) 1,144 (5) 
   Missing 4,765 (20) 7,029 (29) 5,442 (22) 3,951 (16) 
Body mass index     
   Normal  4,467 (18) 3,301 (14) 3,394 (14) 3,310 (14) 
   Overweight 8,714 (36) 8,296 (34) 8,784 (36) 9,137 (37) 
   Obese 6,578 (27) 6,151 (25) 7,035 (29) 8,522 (35) 
   Missing 4,655 (19) 6,665 (27) 5,201 (21) 3,444 (14) 
Smoking status     
   Ever smoker 14,598 (60) 12,525 (51) 13,648 (56) 15,920 (65) 
   Never smoker 6,968 (29) 6,671 (27) 6,974 (29) 6,276 (26) 
   Missing 2,848 (12) 5,217 (21) 3,792 (16) 2,217 (9) 
SU level     
   ≤360µmol/L 304 (1) 248 (1) 388 (2) 294 (1) 
   >360µmol/L 7,268 (30) 10,535 (43) 10,422 (43) 11,575 (47) 
   Missing 16,842 (69) 13,630 (56) 13,604 (56) 12,544 (51) 
Medication use     
Analgesics 7,569 (31) 8,645 (35) 8,172 (33) 9,470 (39) 
Colchicine 469 (2) 1,585 (6) 2105 (9) 1862 (8) 
Diuretics 7,316 (30) 10,049 (41) 7,205 (30) 9,528 (39) 
NSAIDS 9,667 (40) 14,156 (58) 13,767 (56) 9,776 (40) 
Cumulative allopurinol use* 0 (0) 0.1 (0.3) 1.21 (1.65) 4.9 (3.3) 
Number and percentage presented unless otherwise stated; *Mean (Standard deviation) presented for continuous 
covariates; Unit of analysis is intervals; CI: Confidence interval; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: 
Propensity score; SU: Serum urate 
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Table 8.18: Estimated treatment effect of allopurinol on cerebrovascular disease and distribution 








Hazard ratio (95% CI) 
Standard error 
0.21 (0.11, 0.44) 
0.08 
1.73 (1.26, 1.38) 
0.28 
0.80 (0.47, 1.37) 
0.22 
Demographics    
Age* 65.1 (14.1) 61.8 (13.7) 66.1 (12.8) 
Sex: Female 5,099 (18) 4,176 (14) 5,564 (19) 
Deprivation* 9.3 (5.5) 9.1 (5.6) 9.3 (5.6) 
Comorbidities    
Anxiety 2,539 (9) 2,598 (9) 2,789 (10) 
Depression 3,122 (11) 3,153 (11) 3,456 (12) 
Coronary heart disease 6,880 (24) 5,620 (19) 8,159 (28) 
Diabetes 3,791 (13) 3,403 (12) 5,091 (18) 
Gout consultation 6,612 (23) 8,027 (28) 4,981 (17) 
Hyperlipidaemia 4,769 (16) 4,803 (17) 6,240 (22) 
Hypertension 11,728 (40) 11,336 (39) 14,045 (48) 
Osteoarthritis  5,131 (18) 5,101 (18) 6,452 (22) 
Peripheral vascular disease 772 (3) 511 (2) 890 (3) 
Renal disease 2,768 (10) 2,815 (10) 4,516 (16) 
Lifestyle factors    
Alcohol consumption    
   Ever drinker 21,221 (73) 22,248 (77) 22,551 (78) 
   Never drinker 1,144 (4) 1,003 (3) 1,293 (4) 
   Missing 6,656 (23) 5,771 (20) 5,177 (18) 
Body mass index    
   Normal  3,987 (14) 3,901 (13) 3,762 (13) 
   Overweight 10,334 (36) 10,464 (36) 10,331 (36) 
   Obese 8,350 (29) 8,966 (31) 10,230 (35) 
   Missing 6,350 (22) 5,691 (20) 4,698 (16) 
Smoking status    
   Ever smoker 16,605 (57) 16,582 (57) 18,240 (63) 
   Never smoker 8,230 (28) 8,608 (30) 7,815 (27) 
   Missing 4,186 (14) 3,832 (13) 2,966 (10) 
SU level    
   ≤360µmol/L 356 (1) 412 (1) 363 (1) 
   >360µmol/L 14,712 (51) 12,022 (41) 13,859 (48) 
   Missing 13,953 (48) 16,588 (57) 14,799 (51) 
Medication use    
Analgesics 9,530 (33) 8,695 (30) 10,909 (38) 
Colchicine 2,005 (7) 2,840 (10) 2,080 (7) 
Diuretics 10,284 (35) 7,378 (25) 10,938 (38) 
NSAIDS 15,858 (55) 16,510 (57) 11,429 (39) 
Cumulative allopurinol use* 0.2 (0.5) 1.5 (1.7) 5.2 (3.5) 
Number and percentage presented unless otherwise stated; *Mean (Standard deviation) presented for continuous 
covariates; Unit of analysis is intervals; CI: Confidence interval; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: 
Propensity score; SU: Serum urate 
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Table 8.19: Estimated treatment effect of allopurinol on coronary heart disease and distribution 








Hazard ratio (95% CI) 
Standard error 
0.21 (0.11, 0.38) 
0.06 
1.99 (1.58, 2.50) 
0.23 
0.84 (0.61, 1.19) 
0.14 
Demographics    
Age* 63.4 (13.9) 60.1 (13.8) 64.0 (13.0) 
Sex: Female 3,946 (17) 3,099 (13) 4,056 (17) 
Deprivation* 9.1 (5.5) 9.1 (5.6) 9.2 (5.6) 
Comorbidities    
Anxiety 1,998 (9) 2,027 (9) 2,187 (9) 
Depression 2,001 (9) 2,447 (10) 2,601 (11) 
Cerebrovascular disease 997 (4) 701 (3) 1,077 (5) 
Diabetes 2,490 (11) 2,150 (9) 3,293 (14) 
Gout consultation 5,048 (22) 6,315 (27) 4,295 (18) 
Hyperlipidaemia 3,340 (14) 2,928 (13) 3,979 (17) 
Hypertension 8,915 (38) 7,944 (34) 10,369 (44) 
Osteoarthritis  3,694 (16) 3,593 (15) 4,549 (19) 
PVD 256 (1) 322 (1) 436 (2) 
Renal disease 1,698 (7) 1,742 (7) 2,922 (13) 
Lifestyle factors    
Alcohol consumption    
   Ever drinker 16,397 (70) 17,432 (75) 17,317 (74) 
   Never drinker 809 (3) 644 (3) 943 (4) 
   Missing 6,125 (26) 5,255 (23) 5,071 (22) 
Body mass index    
   Normal  2,862 (12) 3,100 (13) 2,821 (12) 
   Overweight 8,013 (34) 8,083 (35) 7,946 (34) 
   Obese 6,638 (28) 6,688 (29) 7,901 (34) 
   Missing 5,818 (25) 5,460 (23) 4,663 (20) 
Smoking status    
   Ever smoker 12,424 (53) 12,410 (53) 13,480 (58) 
   Never smoker 7,079 (30) 7,397 (32) 6,929 (30) 
   Missing 3,828 (16) 3,524 (15) 2,922 (13) 
SU level    
   ≤360µmol/L 241 (1) 329 (1) 290 (1) 
   >360µmol/L 12,078 (52) 9,547 (41) 10,872 (47) 
   Missing 11,012 (47) 13,455 (58) 12,169 (52) 
Medication use    
Analgesics 6,949 (30) 6,110 (26) 7,691 (33) 
Colchicine 1,373 (6) 2,036 (9) 1,642 (7) 
Diuretics 7,069 (30) 4,573 (20) 6,944 (30) 
NSAIDS 12,961 (56) 13,456 (58) 9,855 (42) 
Cumulative allopurinol use* 0.2 (0.4) 1.3 (1.6) 4.9 (3.5) 
Number and percentage presented unless otherwise stated; *Mean (Standard deviation) presented for continuous 
covariates; Unit of analysis is intervals; CI: Confidence interval; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: 
Propensity score; SU: Serum urate 
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Table 8.20: Estimated treatment effect of allopurinol on renal disease and distribution of 










Hazard ratio (95% CI) 
Standard error 
0.46 (0.21, 1.00) 
0.18 
2.03 (1.61, 2.56) 
0.24 
1.14 (0.97, 1.34) 
0.09 
0.58 (0.42, 0.81) 
0.10 
Demographics     
Age* 64.0 (14.2) 61.8 (13.9) 61.0 (13.6) 64.8 (12.3) 
Sex: Female 4,169 (18.4) 3,531 (16) 3,218 (14) 3,695 (16) 
Deprivation* 8.9 (5.5) 9.1 (5.5) 9.3 (5.6) 5.4 (3.3) 
Comorbidities     
Anxiety 1,487 (7) 1,775 (8) 1,844 (8) 2,351 (10) 
Depression 1,624 (7) 1,977 (9) 2,314 (10) 2,719 (12) 
Cerebrovascular disease 979 (4) 781 (3) 803 (4) 1,269 (6) 
Coronary heart disease 4,568 (20) 3,922 (17) 3,850 (17) 6,044 (27) 
Diabetes 2,105 (9) 2,056 (9) 2,121 (9) 3,652 (16) 
Gout consultation 5,009 (22) 3,932 (17) 6,715 (30) 4,076 (18) 
Hyperlipidaemia 2,747 (12) 2,695 (12) 3,134 (14) 4,672 (21) 
Hypertension 7,498 (33) 7,049 (31) 7,630 (34) 10,531 (46) 
Osteoarthritis  2,982 (13) 3,021 (13) 3,245 (14) 4,841 (21) 
Peripheral vascular disease 443 (2) 425 (2) 394 (2) 610 (3) 
Lifestyle factors     
Alcohol consumption     
   Ever drinker 15,547 (69) 15,860 (70) 16,595 (73) 17,997 (79) 
   Never drinker 985 (4) 805 (4) 737 (3) 861 (4) 
   Missing 6,132 (27) 6,000 (26) 5,333 (24) 3,806 (17) 
Body mass index     
   Normal  3,468 (15) 3,073 (14) 2,931 (13) 2,842 (13) 
   Overweight 7,592 (33) 7,561 (33) 7,899 (35) 8,246 (36) 
   Obese 5,576 (25) 5,966 (26) 6,529 (29) 7,974 (35) 
   Missing 6,028 (27) 6,065 (27) 5,306 (23) 3,602 (16) 
Smoking status     
   Ever smoker 11,394 (50) 11,753 (52) 12,034 (53) 14,389 (63) 
   Never smoker 6,721 (30) 6,567 (29) 6,702 (30) 6,192 (27) 
   Missing 4,549 (20) 4,345 (19) 3,929 (17) 2,083 (9) 
SU level     
   ≤360µmol/L 174 (1) 389 (2) 308 (1) 255 (1) 
   >360µmol/L 8,187 (36) 9,885 (44) 9,773 (43) 10,582 (47) 
   Missing 14,303 (63) 12,391 (55) 12,584 (56) 11,827 (52) 
Medication use     
Analgesics 6,720 (30) 6,598 (29) 6,810 (30) 7,841 (35) 
Colchicine 1,059 (5) 1,369 (6) 2,189 (10) 1,532 (7) 
Diuretics 7,411 (33) 6,784 (30) 5,861 (26) 7,306 (32) 
NSAIDS 13,744 (61) 12,600 (56) 13,525 (60) 9,193 (41) 
Cumulative allopurinol use* 0.002 (0.05) 0.3 (0.6) 1.6 (1.8) 5.4 (3.3) 
Number and percentage presented unless otherwise stated; *Mean (Standard deviation) presented for continuous 
covariates; Unit of analysis is intervals; CI: Confidence interval; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: 







8.6.1 Comparison of included and excluded intervals 
As intervals were excluded from outcome analysis due to no occurrence of outcome in the 
subclass(es) with the lowest PS amongst allopurinol intervals, the distribution of covariates were 
compared between these excluded intervals, and intervals that were included in outcome 
analysis. This was performed for target SU level, mortality, and coronary heart disease (as that 
analysis excluded the most number of intervals) (Table 8.21).  
For the analysis of target SU level, 75% of intervals were used in treatment effect estimation. 
Intervals that were excluded from outcome analysis included older patients, less likely to reside 
in poorer areas, and had lower prevalence of gout consultation and prescription for NSAIDS, 
higher prevalence of ever smokers, lower mean baseline SU level and cumulative allopurinol use, 
than intervals that were included for analysis.  
For the analysis of mortality, 75% of intervals were used in treatment effect estimation but in the 
analysis of coronary heart disease fewer intervals were analysed (60%). For both outcomes, 
excluded intervals contained more patients that were female, residing in poorer areas, had higher 
prevalence of normal BMI and SU level <360μmol/L, had lower prevalence of gout consultation, 
and fewer prescriptions for diuretics and NSAIDS, than intervals included for analysis. Similar 
comparisons between excluded and included intervals were also found in the analyses of gout 




Table 8.21: Generalisability of results 














Demographics     ,  
Age (Mean (SD)) 63.1 (13.2) 60.5 (14.0) 65.4 (14.3) 64.6 (13.7) 62.4 (14.3) 62.5 (13.7) 
Sex: Female 559 (22) 1,362 (18) 11,354 (29) 20,900 (18) 12,185 (26) 11,101 (16) 
Deprivation (Mean (SD)) 8.5 (5.1) 9.2 (5.7) 8.1 (5.5) 9.1 (5.5) 8.7 (5.5) 9.1 (5.6) 
Comorbidities       
Anxiety 225 (9) 483 (6) 5,486 (14) 9974 (9) 4,811 (10) 6,212 (9) 
Depression 262 (10) 593 (8) 7,026 (18) 11,862 (10) 6,232 (13) 7,049 (10) 
Cerebrovascular disease 124 (5) 208 (3) 2,481 (6) 6,248 (5) 1,594 (3) 2,775 (4) 
Coronary heart disease 561 (22) 1,456 (19) 8,310 (21) 27,038 (23) - - 
Diabetes 322 (13) 788 (10) 6,304 (16) 15,590 (13) 5,097 (11) 7,933 (11) 
Gout consultation 270 (11) 1,770 (24) 807 (2) 22,363 (19) 1,635 (4) 15,658 (22) 
Hyperlipidaemia 485 (19) 930 (12) 7,935 (20) 19,617 (17) 5,159 (11) 10,247 (15) 
Hypertension 1,036 (41) 2,513 (33) 15,597 (40) 47,152 (40) 13,279 (28) 27,228 (39) 
Osteoarthritis  474 (19) 1,110 (15) 8,105 (21) 20,418 (18) 6,854 (15) 11,836 (17) 
Peripheral vascular disease 65 (3) 142 (2) 1,342 (3) 3,171 (3) 1,019 (2) 1,014 (1) 











Table 8.21 continued: 
Lifestyle factors       
Alcohol consumption       
   Ever drinker 1,878 (75) 5,554 (74) 30,800 (79) 85,879 (74) 32,812 (70) 51,146 (73) 
   Never drinker 134 (5) 305 (4) 2,165 (6) 4,790 (4) 2,508 (5) 2,396 (3) 
   Missing 495 (20) 1,661 (22) 5,868 (15) 25,829 (22) 11,343 (24) 16,451 (24) 
Body mass index       
   Normal  424 (17) 900 (12) 9,980 (26) 16,622 (14) 10,324 (22) 8,783 (13) 
   Overweight 860 (34) 2,565 (34) 14,101 (36) 40,810 (35) 15,225 (33) 24,042 (34) 
   Obese 823 (33) 2,324 (31) 9,474 (24) 34,247 (29) 10,105 (22) 21,227 (30) 
   Missing 400 (16) 1,731 (23) 5,278 (14) 24,819 (21) 11,009 (24) 15,941 (23) 
Smoking status       
   Ever smoker 1,570 (63) 4,242 (56) 25,195 (65) 66,327 (57) 24,863 (53) 38,314 (55) 
   Never smoker 754 (30) 2,050 (27) 11,337 (29) 32,933 (28) 14,717 (32) 21,405 (31) 
   Missing 183 (7) 1,228 (16) 2,301 (6) 17,238 (15) 7,083 (15) 10,274 (15) 
SU level (Mean (SD)) 454.3 (49.8) 504.5 (2.0)     
   ≤360µmol/L - - 7,719 (20) 1,386 (1) 6,147 (13) 860 (1) 
   >360µmol/L - - 5,833 (15) 49,163 (42) 7,701 (17) 32,497 (46) 
   Missing - - 25,281 (65) 65,949 (57) 32,815 (70) 36,636 (52) 
Medication use       
Analgesics 634 (25) 2,393 (32) 10,439 (27) 38,554 (33) 11,132 (24) 20,750 (30) 
Colchicine 36 (1) 712 (9) 254 (1) 7,825 (7) 418 (1) 5,051 (7) 
Diuretics 517 (21) 2,282 (30) 6,330 (16) 38,831 (33) 8,281 (18) 18,586 (27) 
NSAIDS 1,044 (42) 4,306 (57) 9,005 (23) 57,788 (50) 15,510 (33) 36,272 (52) 
Cumulative allopurinol use (Mean (SD)) 0 (0) 1.2 (2.0) 0 (0) 1.9 (3.0) 0 (0) 2.1 (3.0) 




8.7  Sensitivity analysis: impact of missing data 
The main analysis was repeated by performing complete case analysis in the analysis of target SU 
level and mortality. For target SU level, 52% (N=909) had complete data and for mortality 21% 
(N=3,609) had complete data.  
In the analysis of target SU level, allopurinol intervals had higher prevalence of coronary heart 
disease, gout consultation, renal disease, had higher mean baseline SU level, more prescriptions 
for analgesics, diuretics and NSAIDS, and longer mean cumulative allopurinol use than non-
allopurinol intervals, where SMD >0.10 (Table 8.22). This analysis identified the same imbalanced 
covariates as the main analysis but had also found imbalance in coronary heart disease and 
colchicine between treatment groups.  
For mortality, allopurinol intervals contained patients who were older, had higher prevalence of 
coronary heart disease, diabetes, gout consultation, hypertension, renal disease, obesity, SU level 
>360μmol/L, more prescriptions for analgesics, colchicine and diuretics, and longer mean 
previous cumulative allopurinol use than non-allopurinol intervals where SMD >0.10 (Table 8.22). 
Approximately the same number of imbalanced covariates identified here was also observed in 
the main analysis, albeit with larger SMD.   
Distribution of PS between treatment groups is shown in Table 8.23 alongside with the number 
of subclasses required to achieve overall covariate balance across subclasses, and imbalanced 
covariates that remained within subclasses.  
As the main analysis, subclass 1 had no occurrence of either outcome amongst allopurinol 
intervals thus that subclass was excluded from treatment effect estimation. In the analysis of 
target SU level, four PS subclasses were sufficient to achieve overall covariate balance between 
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treatment groups across subclasses. Within subclasses, there were a higher number of 
imbalanced covariates than was observed in the main analysis. For example, in subclass 3, age 
was now imbalanced between treatment groups when previously it was balanced in the main 
analysis.  
For mortality, six subclasses were required to achieve overall covariate balance, whereas in the 
main analysis five subclasses were sufficient. In contrast, this analysis found a fewer number of 
imbalanced covariates between treatment groups within subclasses compared with the main 
analysis. For example, in subclass 2, in this analysis there were 7 imbalanced covariates compared 
with 12 in the main analysis.  
The estimated HRs are presented in Table 8.24. Allopurinol use had higher chance of reaching 
target SU level (5.31 (3.67, 7.67)), and the estimated HR was larger than the HR estimated in the 
main analysis (5.31 vs. 4.89). On the other hand, no association was observed between allopurinol 
and mortality (1.12 (0.89, 1.41)), the same conclusion reached in the main analysis, although 
estimated HR was larger (1.12 vs. 0.97).  
Standard errors were larger in this analysis compared with the main analysis due to smaller 





Table 8.22: Distribution of covariates by treatment for target SU level and mortality 












Demographics     
Age (Mean (SD)) 61.0 (13.5)  61.8 (13.4) 64.4 (13.6) 66.2 (12.9) 
Sex: Female 731 (20) 303 (20) 5,732 (26) 2,466 (23) 
Deprivation (Mean (SD)) 9.0 (5.5) 9.4 (5.9) 9.1 (5.6) 9.5 (5.8) 
Comorbidities     
Anxiety 299 (8) 132 (9) 2508 (11) 1247 (11) 
Depression 365 (10) 117 (8) 2751 (13) 1542 (14) 
Cerebrovascular disease 116 (3) 49 (3) 1123 (5) 784 (7) 
Coronary heart disease 827 (23) 436 (28) 5805 (26) 3608 (33) 
Diabetes  473 (13) 218 (14) 3340 (15) 2164 (20) 
Gout consultation 683 (19) 378 (25) 2949 (13) 2215 (20) 
Hyperlipidaemia 668 (18) 241 (16) 4479 (20) 2554 (23) 
Hypertension 1494 (41) 629 (41) 9484 (43) 5763 (53) 
Osteoarthritis  572 (16) 294 (19) 4260 (19) 2601 (24) 
Peripheral vascular disease 107 (3) 44 (3) 627 (3) 443 (4) 
Renal disease 250 (7) 178 (12) 2097 (10) 1902 (17) 
Lifestyle factors     
Alcohol consumption     
   Ever drinker 3490 (95) 1475 (96) 20811 (95) 10583 (97) 
   Never drinker 184 (5) 59 (4) 1135 (5) 360 (3) 
Body mass index     
   Normal 686 (19) 238 (16) 5074 (23) 1892 (17) 
   Overweight 1663 (45) 695 (45) 9731 (44) 4636 (42) 
   Obese 1325 (36) 601 (39) 7141 (33) 4415 (40) 
Smoking status     
   Ever smoker 2507 (68) 1008 (66) 15765 (72) 8150 (74) 
   Never smoker 1167 (32) 526 (34) 6181 (28) 2793 (26) 
SU level 484.4 (65.3)* 514.2 (76.3)*   
   ≤360µmol/L - - 4477 (20) 324 (3) 
   >360µmol/L - - 17469 (80) 10619 (97) 
Medication use     
Analgesics 1116 (30) 587 (38) 7096 (32) 4474 (41) 
Colchicine 233 (6) 188 (12) 994 (5) 926 (8) 
Diuretics 1032 (28) 550 (36) 6162 (28) 4263 (39) 
NSAIDS 1925 (52) 827 (54) 9083 (41) 4764 (44) 
Cumulative allopurinol use 0.3 (0.8) 2.2 (2.5) 0.4 (1.2) 4.0 (3.4) 
N (%) presented unless otherwise stated; Cells highlighted in yellow indicate SMD >0.10; NSAIDS: Non-steroidal anti-





Table 8.23: Distribution of PS, number of subclasses and imbalanced covariates within PS 
subclasses 
Outcome 





Smallest cellb Imbalanced covariates (SMD >0.10) 
Target SU level 
0.03 (<0.01, 0.97) 





S2: Deprivation, diabetes, 
hyperlipidaemia, renal disease, alcohol 
consumption, BMI, smoking status, SU 
level, analgesics, diuretics, NSAIDS, 
cumulative allopurinol use 
S3: Age, smoking status, cumulative 
allopurinol use 
S4: Age, sex, deprivation, diabetes, 
gout consultation, BMI, smoking 
status, SU level, analgesics, colchicine, 
NSAIDS 
Mortality 
0.35 (0.02, 0.75) 





S2: Age, coronary heart disease, 
diabetes, gout consultation, 
hypertension, diuretics, SU level 
S3: Gout consultation, SU level 
S4: Gout consultation, renal disease, 
analgesics, colchicine, SU level  
N/A: Balance not evaluated as this subclass was not used in treatment effect estimation due to no occurrence of 
outcome within allopurinol intervals; BMI: Body mass index; NSAIDS: Non-steroidal anti-inflammatory drugs; S: 
Subclass; PS: Propensity score; SU: Serum urate 
 







Hazard ratio (95% CI) 
Standard error 
Adjusted 
Hazard Ratio (95% CI) 
Standard error 
SU level     
   Target level not met 2,281 (96) 1,285 (84) 
4.51 (3.51, 5.79) 
0.58 
5.31 (3.67, 7.67) 
1.00 
   Target level met 93 (4) 247 (16) 
Mortality     
   Alive 13,323 (97) 10,554 (96) 
1.25 (1.08, 1.44) 
0.09 
1.12 (0.89, 1.41) 
0.13 
   Died 401 (3) 388 (4) 






Use of time-varying PS subclassification had shown allopurinol increased the chance of reaching 
target SU level and increased risk of peripheral vascular disease. Treatment effect estimates for 
gout hospitalisation, cerebrovascular disease, coronary heart disease, and renal disease differed 
across PS subclasses; allopurinol was either shown to be protective and/or increased the risk of 
adverse outcome in certain subclasses. Although treatment effect estimates for target SU level 
and mortality from complete case analysis and the main analysis had the same conclusions, the 
magnitude of effects differed.  
 
8.8.1 Comparison with baseline PS subclassification 
Compared with treating allopurinol as a time-invariant measure, accounting for its possible 
change in the follow-up resulted in doubling of the HR for target SU level and peripheral vascular 
disease. As allopurinol has a direct effect on SU level, patients who may have reached target SU 
level later on during follow-up may have been due to being prescribed allopurinol near that time, 
which would not have been captured in baseline analysis. Correctly attributing reaching target SU 
to patients prescribed allopurinol later on, may have caused the estimated HR to increase. It is 
less clear why treatment effect had doubled for peripheral vascular disease. Increase in treatment 
effect of this magnitude was not observed for the other outcomes. For both outcomes, standard 
errors were much larger in time-varying PS subclassification than in baseline analysis.  
Treatment effect was almost borderline statistically significant for joint replacement in both 
baseline and time-varying PS subclassification however, the direction of the HRs differed (1.15 in 
baseline analysis vs. 0.77 in time-varying analysis). There is the possibility that over time, as 
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patients continue taking allopurinol, their SU level decreases promoting crystal dissolution and 
tophi clearance, which may prevent further joint damage.  
Time-varying PS subclassification had shown allopurinol use was not associated with premature 
mortality. The estimated HR was closer to the null value than the HR estimated from baseline PS 
subclassification, with both methods yielding similar standard errors. 
A greater number of outcomes (gout hospitalisation, cerebrovascular disease, coronary heart 
disease, and renal disease), had subclass-specific treatment effect estimates that were not 
homogenous across subclasses, unlike baseline analysis where subclass-specific treatment effect 
estimates were not homogenous for gout hospitalisation only. Within time-varying PS 
subclassification, allopurinol was shown to be both protective and increases the risk of coronary 
heart disease and peripheral vascular disease, whereas in baseline analysis allopurinol increased 
the risk of coronary heart disease. Allopurinol was associated with gout hospitalisation in two of 
the four subclasses with estimated HR ranging between 1.84 – 2.70, that had similar magnitude 
as the HRs obtained from baseline analysis that ranged between 1.46 – 2.46.  
 
8.8.2 Strengths and limitations 
The strength of PS subclassification is that in theory it is a straightforward and intuitive approach 
to apply. However, in practice, issues were encountered that were not apparent when baseline 
PS subclassification was performed.  
The main issue was that the positivity assumption was near violated, i.e., the PS were extremely 
close to zero, for the majority of non-users thus the PS distribution was heavily skewed; this was 
not observed for allopurinol users, hence common support was poor. Treatment effect estimation 
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could not be performed in the first subclass (indicating low propensity of treatment) as it 
contained a small number of allopurinol users who did not have any of the outcomes. Use of 
interaction terms and non-linear terms in PS modelling improved common support however, the 
PS distribution remained skewed and dissimilar between treatment groups. Alternative 
approaches to increase the number of outcomes within allopurinol intervals in the first subclass 
by removing patients outside of the regions of common support prior to subclassification, or 
creating PS subclasses based on the PS distribution for allopurinol intervals only, did not work 
(data not shown).  
Use of random intercepts in PS estimation may have been one reason for near violation of the 
positivity assumption. It is known that random effects logistic model has better discrimination 
ability (i.e., higher and lower PS estimated for allopurinol users and non-users respectively) than 
logistic regression omitting random effects (Bouwmeester et al., 2013). This discrimination may 
result in no overlap of PS between treatment groups and lead to large standard errors in 
treatment effect estimation. As an exploratory analysis (data not shown), omitting random 
intercept in PS estimation caused the PS distribution to be normally distributed in both allopurinol 
users and non-users. 
The optimal approach suggested by Leon (2011b) is to account for clustering effects of repeated 
measurements in PS estimation and treatment effect estimation via random effects. However, 
random effects in outcome analysis could not be used as the complementary log-log model did 
not converge. Therefore, random effects were omitted and robust standard errors accounting for 
clustering effects were instead estimated. Omitting random effects from PS estimation as well as 
in outcome analysis may potentially bias treatment effect (Leite, 2016, Li et al., 2013).  
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Due to poor common support and with some subclasses omitted from outcome analysis, 
generalisability of results was affected. Generally, observations excluded from analysis appeared 
to be from healthier patients as they had lower prevalence of gout consultations and 
hypertension, less prescriptions for diuretics and NSAIDS, and SU level was acceptable (<360 
μmol/L). These patients did not all the indications for allopurinol treatment which may be why 
their PS were close to zero.  
 
8.8.3 Conclusions 
To conclude, PS subclassification did not perform well in this dataset. There was poor common 
support resulting in observations removed from outcome analysis affecting generalisability, and 
not all of patient follow-up was modelled in outcome analysis which is far from ideal.  
Alternative methods such as MSM were fitted in the next chapter to see how well fitting these 





9 Modelling simple mechanisms of allopurinol via MSM 
In this chapter, marginal structural models (MSM) were used to model the effect of treatment on 
outcome accounting for treatment and covariate histories. It was assumed the association 
between covariates and treatment were constant regardless of treatment history i.e., whether 
patients were initiating or continuing with treatment. As alluded to in Section 6.4, making this 
assumption led to MSM not performing well. Therefore, analysis approach and results are 
presented, for demonstration purposes, for mortality only. The study sample described in Section 
8.1 was used in this chapter.  
 
9.1 Associations between covariates, allopurinol, and mortality 
Table 9.1 shows the associations between covariates, treatment, and outcome. The majority of 
covariates with the exception of anxiety, gout consultation and hyperlipidaemia were associated 
with mortality. Diuretic use had the strongest association (hazard ratio (HR) 4.13), followed by 
renal disease (3.34), and cerebrovascular and peripheral vascular diseases (3.01). All covariates 
apart from non-steroidal anti-inflammatory drugs (NSAIDS) were strongly associated with 
allopurinol with odds ratios (OR) ranging from 0.25 to 3.93, with serum urate (SU) level having 
the largest association (OR 254.80). Covariates that were associated with both mortality and 
allopurinol were included in the propensity score (PS) model.  
Standardised mean difference (SMD) for covariates between treatment groups in each interval 
and overall are shown in Table 9.2. The majority of covariates were imbalanced between 
treatment groups in at least one follow-up interval (SMD >0.10) with the exception of anxiety, 
depression, cerebrovascular disease and peripheral vascular disease. The largest differences 
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between treatment groups over time was observed for cumulative allopurinol use and baseline 
SU level with SMD >0.25 indicating severe imbalance.  
Table 9.1: Associations between covariates, allopurinol, and outcome 
 Association with  
mortality 
HR (95% CI) 
Association with 
allopurinol 




Demographics    
Age 1.10 (1.10, 1.10) 1.12 (1.12, 1.13) X 
Sex: Female 1.73 (1.63, 1.84) 0.59 (0.50, 0.70) X 
Deprivation 1.02 (1.01, 1.02) 1.03 (1.02, 1.05) X 
Comorbidities    
Anxiety 1.04 (0.95, 1.15) 2.61 (2.31, 2.95)  
Depression 1.27 (1.17, 1.38) 1.91 (1.71, 2.13) X 
Cerebrovascular disease 3.01 (2.78, 3.26) 2.76 (2.39, 3.20) X 
Coronary heart disease 2.31 (2.18, 2.45) 3.52 (3.22, 3.85) X 
Diabetes  1.68 (1.57, 1.80) 2.70 (2.46, 2.98) X 
Gout consultation 1.01 (0.93, 1.09) 2.03 (1.93, 2.13)  
Hyperlipidaemia 1.00 (0.93, 1.08) 3.33 (3.07, 3.62)  
Hypertension 1.25 (1.18, 1.33) 3.56 (3.33, 3.80) X 
Osteoarthritis  1.50 (1.40, 1.60) 3.04 (2.79, 3.31) X 
Peripheral vascular disease 3.01 (2.71, 3.33) 2.44 (1.98, 2.99) X 
Renal disease 3.34 (3.10, 3.59) 3.93 (3.63, 4.27) X 
Lifestyle factors    
Alcohol consumption   X 
   Ever drinker 1.00 1.00  
   Never drinker 1.90 (1.71, 2.11) 0.44 (0.37, 0.54)  
   Missing 1.11 (1.03, 1.19) 0.36 (0.33, 0.39)  
Body mass index   X 
   Normal 1.00 1.00  
   Overweight 0.57 (0.53, 0.62) 1.30 (1.18, 1.42)  
   Obese 0.44 (0.40, 0.48) 2.14 (1.92, 2.40)  
   Missing 0.64 (0.60, 0.70) 0.52 (0.46, 0.58)  
Smoking status   X 
   Ever smoker 1.00 1.00  
   Never smoker 0.84 (0.79, 0.90) 0.47 (0.43, 0.51)  
   Missing 0.84 (0.76, 0.92) 0.25 (0.23, 0.27)  
SU level   X 
   ≤360µmol/L 1.00 1.00  
   >360µmol/L 1.46 (1.26, 1.69) 254.80 (175.30, 370.35)  
   Missing 1.61 (1.41, 1.89) 43.92 (30.53, 63.19)  
Medication use    
Analgesics 2.49 (2.36, 2.63) 1.59 (1.50, 1.68) X 
Colchicine 1.53 (1.38, 1.70) 3.00 (2.76, 3.26) X 
Diuretics 4.13 (3.90, 4.38) 1.94 (1.81, 2.08) X 
NSAIDS 0.66 (0.62, 0.70) 1.01 (0.97, 1.06) X 
Cumulative allopurinol use 1.02 (1.01, 1.04) 1.45 (1.43, 1.46) X 
CI: confidence interval; HR: Hazard ratio; NSAIDS: Non-steroidal anti-inflammatory drugs; OR: Odds ratio; SD: 
Standard deviation; SU: Serum urate; X indicates which covariates were associated with both mortality and 




Table 9.2: SMD for each covariate between treatment groups over time 
Follow-up 
year 









1 0.08 0.04 0.11 -0.02 -0.01 0.04 0.11 0.06  <0.01 
2 0.11 0.02 0.09 -0.01 0.01 0.05 0.15 0.09 0.70 0.05 
3 0.09 -0.02 0.08 -0.03 0.02 0.04 0.16 0.08 0.36 0.05 
4 0.07 -0.04 0.07 -0.02 <0.01 0.02 0.14 0.07 0.29 0.03 
5 0.06 -0.06 0.07 -0.03 -0.03 0.03 0.13 0.08 0.23 0.07 
6 0.06 -0.06 0.05 -0.04 -0.03 0.03 0.11 0.08 0.18 0.06 
7 0.03 -0.09 0.04 -0.04 -0.05 0.01 0.10 0.07 0.16 0.05 
8 0.04 -0.13 0.03 -0.04 -0.08 <0.01 0.12 0.06 0.14 0.06 
9 0.03 -0.14 0.03 -0.05 -0.08 0.04 0.10 0.06 0.13 0.06 
10 0.01 -0.14 0.03 -0.06 -0.09 0.04 0.10 0.07 0.09 0.07 
11 0.01 -0.16 0.02 -0.05 -0.08 <0.01 0.09 0.05 0.09 0.07 
12 -0.02 -0.17 0.02 -0.04 -0.08 0.01 0.09 0.02 0.08 0.07 
13 -0.08 -0.19 0.04 -0.07 -0.07 -0.04 0.04 0.03 0.07 0.07 
14 -0.06 -0.23 0.06 -0.04 -0.05 <0.01 0.07 0.03 0.14 0.07 
15 -0.10 -0.24 0.08 <0.01 -0.04 <0.01 0.09 0.03 0.16 0.07 
16 -0.06 -0.29 0.12 0.02 -0.02 0.09 0.13 0.10 0.17 0.12 
17 -0.11 -0.26 0.29 0.07 -0.06 0.09 0.20 0.14 0.12 0.13 




Table 9.2 continued: 
     Alcohol consumption Body mass index 
Follow-
up year 









Missing Normal Overweight Obese Missing 
1 0.03 0.10 0.05 0.12 0.04 0.02 -0.05 0.01 -0.01 0.09 -0.07 
2 0.08 0.09 0.03 0.17 0.06 0.03 -0.07 0.03 -0.03 0.11 -0.09 
3 0.09 0.08 0.03 0.17 0.10 0.02 -0.10 0.06 -0.05 0.14 -0.13 
4 0.11 0.07 0.01 0.18 0.07 0.02 -0.08 0.05 -0.06 0.12 -0.10 
5 0.13 0.06 <0.01 0.18 0.09 -0.02 -0.08 0.03 -0.09 0.14 -0.09 
6 0.13 0.05 0.02 0.19 0.08 0.01 -0.08 0.03 -0.10 0.16 -0.12 
7 0.15 0.03 0.01 0.20 0.09 <0.01 -0.10 0.03 -0.11 0.15 -0.11 
8 0.17 0.04 <0.01 0.18 0.11 -0.04 -0.09 0.04 -0.13 0.16 -0.12 
9 0.17 0.04 0.01 0.20 0.11 -0.04 -0.10 0.05 -0.16 0.17 -0.12 
10 0.16 0.04 <0.01 0.18 0.11 -0.04 -0.10 0.01 -0.16 0.18 -0.10 
11 0.14 0.04 0.01 0.17 0.12 -0.06 -0.10 0.02 -0.16 0.15 -0.07 
12 0.16 0.03 -0.01 0.17 0.11 -0.05 -0.09 0.01 -0.16 0.15 -0.06 
13 0.14 0.04 -0.01 0.19 0.14 -0.06 -0.12 0.01 -0.20 0.18 -0.06 
14 0.14 0.04 0.02 0.18 0.19 -0.07 -0.17 0.01 -0.25 0.22 -0.08 
15 0.16 0.07 0.06 0.11 0.20 -0.08 -0.18 -0.01 -0.25 0.23 -0.05 
16 0.20 0.10 0.10 0.13 0.21 -0.07 -0.20 0.07 -0.30 0.23 -0.12 
17 0.23 0.14 0.06 0.14 0.40 -0.10 -0.39 <0.01 -0.25 0.32 -0.26 





Table 9.2 continued:  







Missing ≤360µmol/L >360µmol/L Missing Analgesics Colchicine Diuretics NSAIDS 
Cumulative 
allopurinol use 
1 0.03 -0.05 0.02 -0.28 0.39 -0.27 0.19 0.13 0.25 0.30 - 
2 0.08 -0.05 -0.03 -0.29 0.35 -0.23 0.23 0.30 0.28 -0.03 2.12 
3 0.06 -0.02 -0.04 -0.30 0.32 -0.19 0.19 0.25 0.24 0.24 2.35 
4 0.04 -0.03 -0.01 -0.31 0.31 -0.18 0.16 0.20 0.22 0.13 2.29 
5 0.05 -0.02 -0.04 -0.31 0.30 -0.16 0.14 0.20 0.23 0.09 2.32 
6 0.07 -0.04 -0.05 -0.32 0.29 -0.15 0.15 0.18 0.22 0.05 2.38 
7 0.06 -0.02 -0.06 -0.30 0.28 -0.14 0.14 0.14 0.22 0.04 2.31 
8 0.05 -0.02 -0.08 -0.33 0.30 -0.15 0.10 0.12 0.18 0.01 2.31 
9 0.08 -0.04 -0.11 -0.34 0.29 -0.14 0.11 0.14 0.17 -0.02 2.28 
10 0.06 -0.02 -0.12 -0.33 0.30 -0.16 0.07 0.13 0.16 -0.02 2.30 
11 0.07 -0.05 -0.08 -0.33 0.28 -0.13 0.06 0.08 0.18 -0.01 2.26 
12 0.07 -0.05 -0.10 -0.33 0.31 -0.16 0.08 0.13 0.15 -0.01 2.23 
13 0.08 -0.06 -0.10 -0.31 0.29 -0.15 0.12 0.12 0.12 0.02 2.30 
14 0.12 -0.10 -0.09 -0.32 0.30 -0.15 0.10 0.14 0.10 0.02 2.24 
15 0.14 -0.12 -0.11 -0.27 0.27 -0.14 0.04 0.16 0.06 <0.01 2.13 
16 0.18 -0.14 -0.17 -0.15 0.25 -0.18 0.10 0.16 0.06 -0.11 2.05 
17 0.27 -0.21 -0.23 -0.14 0.24 -0.19 <0.01 -0.02 0.07 -0.23 2.13 
Overall 0.13 -0.04 -0.13 -0.31 0.30 -0.16 0.14 0.17 0.19 0.03 1.41 







9.2 Propensity score model and treatment effect estimation 
The PS main effects model initially included main effects of covariates and linear functional form 
of continuous covariates. Unstabilised weights had an extremely skewed distribution with mean 
(standard deviation (SD)) 4.64*1012 (1.16*1015), median (interquartile range (IQR)) 3.04 (1.83, 
26.20), and range 1.03, 3.95*1017. Consequently, stabilised weights were estimated instead. 
Figure 9.1 illustrates the distribution of the stabilised weights that was less skewed than 
unstabilised weights (but was still skewed), with mean (SD) weight 1.60 (55.9), median (IQR) 1.0 
(0.6, 1.2), and range 4*10-5 to 20,893.76. For the first ten years of follow-up, mean weight was 
approximately 1 and SD was constant, but after 10 years of follow-up, mean weight and SD 
increased. In contrast, the median weight was initially approximately 1 for the first few years of 
follow-up, and thereafter decreased over time with the IQR widening (Table 9.3).  




Table 9.3: Distribution of estimated weights over time 
Follow-up 
interval 
Mean (SD) Median (IQR) Range 
1 0.98 (0.21) 1.04 (1.00, 1.09) 0.21, 1.80 
2 1.02 (0.41) 1.09 (0.95, 1.24) 0.06, 3.09 
3 1.03 (0.49) 1.09 (0.86, 1.28) 0.02, 5.47 
4 1.02 (0.54) 1.07 (0.70, 1.27) 0.01, 6.71 
5 1.00 (0.59) 1.03 (0.64, 1.25) 0.01, 11.67 
6 0.98 (0.67) 0.98 (0.61, 1.21) 0.01, 24.61 
7 0.97 (0.70) 0.93 (0.59, 1.16) 0.01, 13.57 
8 0.98 (0.84) 0.86 (0.57, 1.11) 0.01, 14.29 
9 1.01 (1.12) 0.80 (0.53, 1.07) 0.01, 25.43 
10 1.09 (1.70) 0.74 (0.48, 1.02) 0.01, 53.69 
11 1.29 (3.35) 0.67 (0.44, 0.98) 0.01, 194.56 
12 1.68 (5.86) 0.62 (0.39, 0.95) 2.35*10-3, 280.06 
13 2.37 (9.62) 0.57 (0.35, 0.92) 6.00*10-4, 276.42 
14 3.30 (15.04) 0.52 (0.32, 0.91) 1.36*10-4, 369.68 
15 6.75 (38.45) 0.47 (0.30, 1.01) 1.62*10-4, 875.40 
16 17.17 (176.03) 0.43 (0.28, 1.17) 1.89*10-4, 5469.65 
17 73.99 (967.43) 0.39 (0.21, 1.31) 3.50*10-5, 20893.76 
IQR: Interquartile range; SD: Standard deviation 
 
The unadjusted HR in the unweighted study sample was 1.19 (1.12, 1.26) with standard error 
0.03. The treatment effect was then estimated in the weighted study sample and had shown 
allopurinol reduced risk of premature mortality by 22%; treatment effect was then adjusted for 
baseline covariates and cumulative allopurinol use, and there was little change in the estimated 
HR however standard error increased from 0.20 to 0.34 (Table 9.4).  
Weights were re-estimated by restricting the PS model to only include covariates with SMD > 0.10 
in at least half the follow-up intervals (Table 9.2). These covariates were sex, coronary heart 
disease, hypertension, renal disease, body mass index (BMI), baseline SU level, analgesics, 
colchicine, diuretics and cumulative allopurinol use. Compared with the main effects PS model, 
variability of weights was smaller although extreme weights remained; estimated HR was more 
conservative and standard error was smaller.  
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Table 9.4: Distribution of weights and treatment effect of allopurinol 
PS model 
Mean (SD)  
Range  
Median (IQR)  
Unadjusted MSM  
HR (95% CI) 
Standard error 
*Adjusted MSM  
HR (95% CI) 
Standard error 
Main effects model 
1.55 (55.90) 
3.50, 20893.76 
1.00 (0.55, 1.17) 
0.78 (0.52, 1.15) 
0.20 






1.00 (0.56, 1.16) 
0.77 (0.60, 0.97) 
0.12 
0.85 (0.55, 1.31) 
0.22 
Main effects propensity score model included age, sex, deprivation, depression, cerebrovascular disease, coronary 
heart disease, diabetes, hypertension, osteoarthritis, peripheral vascular disease, renal disease, alcohol 
consumption, BMI, smoking status, baseline SU level, analgesics, colchicine, diuretics, NSAIDS, and cumulative 
allopurinol use; Restricted main effects model included sex, coronary heart disease, hypertension, renal disease, BMI, 
baseline SU level, analgesics, colchicine, diuretics and previous cumulative allopurinol use; *Adjusted for cumulative 
allopurinol use and baseline covariates; CI: Confidence interval; HR: Hazard ratio; IQR: Interquartile range; MSM: 
Marginal structural models; SD: standard deviation 
 
Based on the main effects PS model, attempts were made to reduce the variability of weights, 
i.e., reducing standard deviation. Inclusion of fractional polynomial (FP) terms for continuous 
covariates and interaction terms were considered, and whether there were problematic 
covariates that increased weight variability.  
 
9.2.1 Fractional polynomials 
Non-linear functions of continuous covariates were included in the PS model (Table 9.5). Use of 
FP1 terms (model specification 2) lowered weight SD to 4.31 from 55.90 that was obtained from 
the model specification 1 (the main effects PS model with linear terms). Use of FP2 terms (model 
specification 3) yielded higher weight SD of 40.06. Model specification 4 identified cumulative 
allopurinol use with FP2 terms and linear terms for the remaining continuous covariates reduced 
SD of weights the most (3.69). Despite improvements in reducing weight variability, extreme 
weights remained present although they were considerably smaller. 
The estimated HRs differed across the different PS model specifications. Compared with model 
specification 1, model specification 4 estimated a stronger unadjusted HR (0.68 vs. 0.78) and had 
the smallest standard error (0.08 vs. 0.20). Adjustment for baseline covariates and cumulative 
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allopurinol use in the Cox model estimated similar HRs as the unadjusted HR in model 
specifications 1 and 2 however, in model specifications 3 and 4, the HRs had become stronger. 
Model specification 4 was retained (as estimated weights were the least variable) and backwards 
selection was performed to identify problematic covariates in PS estimation.     
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Table 9.5: Distribution of weights and re-estimation of treatment effect of allopurinol 
 






Unadjusted MSM  
HR (95% CI) 
Standard error 
*Adjusted MSM  
HR (95% CI) 
Standard error 
1 Main effects model 
+ linear terms for age, deprivation, cumulative 
allopurinol use, follow-up time 
1.55 (55.90) 1.00 (0.55, 1.17) 3.55*10-5, 20893.76 
0.78 (0.52, 1.15) 
0.20 
0.77 (0.39, 1.51) 
0.34 
2 Main effects model 
+ FP1 terms for deprivation(0), cumulative allopurinol 
use(-2) 
+ linear terms for age, follow-up time 
1.40 (4.31) 0.87 (0.65, 1.16) 9.11*10-7, 437.06 
0.64 (0.53, 0.78) 
0.10 
0.63 (0.52, 0.76) 
0.10 
3 Main effects model 
+ FP2 terms for deprivation(-2, 1), cumulative 
allopurinol use(-2, -1), age(3, 3), follow-up time(-1, 0) 
1.40 (40.06) 0.95 (0.68, 1.15) 8.46*10-5, 13064.98 
0.80 (0.67, 0.97) 
0.09 
0.47 (0.58, 0.94) 
0.13 
4 Main effects model 
+ linear terms for age, deprivation, follow-up time 
+ cumulative allopurinol use(-2, -1) 
1.12 (3.69) 0.97 (0.83, 1.10) 5.07*10-4, 730.51 
0.68 (0.58, 0.79) 
0.08 
0.57 (0.44, 0.72) 
0.13 
*Adjusted for cumulative allopurinol use and baseline covariates. Values in brackets (column 2) indicated the fractional polynomial terms used in PS model specification; CI: 
confidence interval; FP1: fractional polynomial terms of dimension 1; FP2: fractional polynomial terms of dimension 2; HR: Hazard ratio; IQR: Interquartile range; MSM: Marginal 
structural models; SD: Standard deviation
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9.2.2 Problematic covariates 
Backwards selection to identify problematic covariates was next undertaken, which involved by 
first removing covariates one by one from the PS model and identifying which covariate reduced 
weight variability i.e., SD, the most. That covariate was then removed the PS model, and the 
process was repeated to identify the next covariate that reduced weight variability the most, and 
so on.  
The weight distribution and treatment effect estimates are given in Table 9.6. Renal disease was 
identified as the most problematic covariate; omitting renal disease from the PS model resulted 
in a reduction in SD of weights from 3.69 to 2.19; unadjusted treatment effect estimate was closer 
to the null value (0.72 vs. 0.68) and its associated standard error decreased (0.06 vs. 0.08) 
compared with the PS model retaining renal disease; there was little change in the treatment 
effect and standard error when renal disease was adjusted for in the Cox model, and little change 
in HR when further adjusting for baseline covariates and cumulative allopurinol use, although 
standard error did increase.   
Depression was next removed from the PS model and the SD of weights further decreased to 
1.45; there was little change in the unadjusted treatment effect (0.71) but associated standard 
error decreased to 0.05. Once adjusted for depression, baseline covariates and cumulative 
allopurinol use in the Cox model, the estimated HR moved further away from the null value.   
Further removal of covariates from the PS model led to the mean weight moving closer towards 
1 and variability decreased. This resulted in HRs (unadjusted and adjusted) to move closer 
towards the null value and associated standard error decreased.  
The decision was made to retain all covariates in the PS model. Although renal disease improved 
weight estimation, continuing to remove covariates from the PS model still led to large 
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improvements in weight variability and it had become unclear which covariates should be 





Table 9.6: Weight distribution and treatment effect estimation of allopurinol after removing problematic covariates from the PS model 
PS  model 
specification 
Covariates cumulatively 







HR (95% CI) 
Standard error 
*Adjusted MSM 
HR (95% CI) 
Standard error 
**Adjusted MSM  
HR (95% CI) 
Standard error 
Main effects model 
+ linear terms for age, deprivation, follow-up 
time 
+ FP2 terms for cumulative allopurinol use(-2, -1) 
1.12 (3.69) 0.97 (0.83, 1.10) 5.07*10-4, 730.51 
0.68 (0.58, 0.79) 
0.08 
0.57 (0.44, 0.72) 
0.13 
0.57 (0.44, 0.72) 
0.13 
2 Renal disease 1.09 (2.19) 0.97 (0.83, 1.11) 1.91*10-3, 421.29 
0.72 (0.65, 0.81) 
0.06 
0.74 (0.66, 0.82) 
0.06 
0.71 (0.60, 0.85) 
0.10 
3 Depression 1.08 (1.45) 0.97 (0.83, 1.11) 1.91*10-3, 279.98 
0.71 (0.64, 0.79) 
0.05 
0.72 (0.65, 0.80) 
0.05 
0.67 (0.57, 0.80) 
0.09 
4 Analgesic use 1.07 (1.06) 0.97 (0.84, 1.11) 2.56*10-3, 136.42 
0.74 (0.67, 0.81) 
0.05 
0.75 (0.68, 0.82) 
0.05 
0.71 (0.62, 0.83) 
0.08 
5 Diuretic use 1.04 (0.84) 0.99 (0.88, 1.09) 7.70*10-3, 176.94 
0.91 (0.85, 0.98) 
0.04 
0.85 (0.79, 0.91) 
0.04 
0.84 (0.76, 0.93) 
0.05 
6 Colchicine use 1.04 (0.84) 0.99 (0.88, 1.09) 0.01, 176.94 
0.91 (0.85, 0.98) 
0.04 
0.85 (0.79, 0.91) 
0.04 
0.84 (0.76, 0.94) 
0.05 
7 Gout consultation 1.04 (0.56) 0.99 (0.89, 1.08) 0.01, 59.29 
0.93 (0.87, 0.99) 
0.04 
0.86 (0.80, 0.92) 
0.04 
0.86 (0.78, 0.94) 
0.05 
8 Body mass index 1.02 (0.40) 0.99 (0.90, 1.07) 0.02, 39.60 
0.92 (0.86, 0.99) 
0.03 
0.89 (0.83, 0.95) 
0.03 
0.87 (0.79, 0.95) 
0.05 
Values in brackets (column 1) indicated the fractional polynomial terms used; *Adjusted only for covariates that were cumulatively removed from the PS model; **Adjusted 
for covariates that were cumulatively removed from the PS model, cumulative allopurinol use and baseline variables; CI: confidence interval; FP2: fractional polynomial terms 




9.2.3 Interaction terms 
From the previous section, no covariates were removed from the PS model (Table 9.7). Starting 
with the PS model specification 4, two-way interaction terms that improved SD of weights were 
next added to the PS model. Adding an interaction term between hypertension and gout 
consultation reduced SD of weight from 3.69 to 2.73. For each extra interaction term added to 
the PS model, mean weight moved closer to 1 and variability decreased.  
With each additional interaction term to the PS model, the unadjusted HR remained constant 
(0.6) however standard errors decreased from 0.08 to 0.05 after including nine interaction terms. 
The estimated adjusted HRs were lower (0.5) and standard errors were higher than unadjusted 
analyses regardless of which interaction terms were included in the PS model.  
The process was then repeated but including three way interactions to the PS model (specification 
4) (Table 9.8). Similarly, inclusion of a three-way interaction between alcohol consumption, 
diuretic use and colchicine use caused SD of the weights to decrease from 3.69 to 2.73. Further 
inclusion of interaction terms further reduced weight variability. Unadjusted and adjusted HRs 
were similar when adding further interaction terms to the PS model although standard errors did 
decrease. 
It was expected inclusion of one three-way interaction term would reduce weight variability more 
including one two-way interaction term. However, this was not the case as they both reduced SD 
of weights by the same amount. Including four three-way interaction terms yielded a higher SD 
for weight than including nine two-way interaction terms to the PS model (1.20 vs. 1.15). 
Therefore, three-way interaction terms were no longer considered.  
It was clear that regardless of including FP and interaction terms to the PS model, the weight 
distribution will remain skewed with mean deviating from one and presence of extreme weights.  
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The PS model that was next considered in sensitivity analyses included a two-way interaction 
term between hypertension and gout consultation.  
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Table 9.7: Forward selection of two-way interaction terms in PS model 
PS model 
specification 
Two-way interactions cumulatively 






Unadjusted MSM  
HR (95% CI) 
Standard error 
*Adjusted MSM 
HR (95% CI) 
Standard error 
Main effects model 
+ linear terms for age, deprivation, follow-up time 
+ FP2 terms for cumulative allopurinol use(-2, -1) 
1.12 (3.69) 0.97 (0.83, 1.10) 5.07*10-4, 730.51 
0.68 (0.58, 0.79) 
0.08 
0.57 (0.44, 0.72) 
0.13 
2 Hypertension*gout consultation 1.11 (2.73) 0.97 (0.83, 1.11) 4.54*10-4, 481.27 
0.67 (0.58, 0.77) 
0.07 
0.54 (0.43, 0.68) 
0.12 
3 Diuretic use*follow-up time 1.11 (2.36) 0.96 (0.82, 1.13) 7.83*10-4, 407.46 
0.66 (0.58, 0.75) 
0.07 
0.54 (0.44, 0.67) 
0.11 
4 Osteoarthritis *depression 1.10 (1.90) 0.96 (0.82, 1.13) 9.36*10-4, 332.88 
0.67 (0.59, 0.75) 
0.06 
0.55 (0.45, 0.67) 
0.10 
5 Alcohol consumption*colchicine use 1.10 (1.62) 0.96 (0.82, 1.13) 9.34*10-4, 271.55 
0.68 (0.62, 0.76) 
0.05 
0.58 (0.48, 0.69) 
0.09 
6 Body mass index*hypertension 1.10 (1.48) 0.96 (0.82, 1.13) 6.80*10-4, 195.02 
0.67 (0.61, 0.75) 
0.05 
0.56 (0.47, 0.67) 
0.09 
7 Gout consultation*follow-up time 1.09 (1.35) 0.96 (0.81, 1.13) 4.25*10-4, 177.21 
0.69 (0.61, 0.76) 
0.05 
0.59 (0.49, 0.69) 
0.09 
8 Hypertension*coronary heart disease 1.09 (1.25) 0.96 (0.81, 1.13) 6.54*10-4, 135.96 
0.69 (0.62, 0.76) 
0.05 
0.58 (0.49, 0.69) 
0.08 
9 Body mass index*depression 1.09 (1.19) 0.96 (0.81, 1.13) 6.89*10-4, 123.75 
0.69 (0.62, 0.76) 
0.05 
0.58 (0.49, 0.68) 
0.08 
10 Diuretic use*depression 1.09 (1.15) 0.96 (0.81, 1.13) 6.40*10-4, 134.29 
0.69 (0.63, 0.76) 
0.05 
0.58 (0.50, 0.69) 
0.08 
*Adjusted for baseline variables and cumulative allopurinol use; CI: Confidence interval; FP2: Fractional polynomial terms of dimension 2; HR: Hazard ratio; IQR: Interquartile 
range; MSM: Marginal structural models; PS: Propensity score; SD: Standard deviation 
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Table 9.8: Forward selection of three-way interaction terms in PS model 
PS model 
specification 
Three-way interactions cumulatively 






Unadjusted MSM  
HR (95% CI) 
Standard error 
*Adjusted MSM 
HR (95% CI) 
Standard error 
Main effects model 
+ linear terms for age, deprivation, follow-up time 
+ FP2 terms for cumulative allopurinol use(-2, -1) 
1.12 (3.69) 0.97 (0.83, 1.10) 5.07*10-4, 730.51 
0.68 (0.58, 0.79) 
0.08 





1.10 (2.26) 0.96 (0.82, 1.12) 8.34*10-4, 351.34 
0.69 (0.61, 0.77) 
0.06 





1.10 (1.74) 0.96 (0.82, 1.12) 1.76*10-3, 247.41 
0.68 (0.61, 0.76) 
0.06 





1.09 (1.41) 0.96 (0.82, 1.12) 2.89*10-3, 185.45 
0.70 (0.64, 0.78) 
0.05 






1.09 (1.20) 0.96 (0.82, 1.12) 1.46*10-3, 86.92 
0.70 (0.63, 0.77) 
0.05 
0.60 (0.52, 0.70) 
0.08 
*Adjusted for baseline variables and cumulative allopurinol use; CI: Confidence interval; FP2: Fractional polynomial terms of dimension 2; HR: Hazard ratio; IQR: Interquartile 





9.2.4 Assessment of covariate balance 
Covariate balance between treatment groups was evaluated for the PS model that included FP2 
terms for cumulative allopurinol use and one interaction term between hypertension and gout 
consultation. SMD was evaluated for each covariate between treatment groups in each year of 
follow-up and then overall (Table 9.9).  
There were large differences between treatment groups across the majority of covariates with 
SMD >0.25 in at least one interval except for peripheral vascular disease and renal disease. 
Compared with the unweighted study sample (Table 9.2), within many covariates, covariate 
balance between treatment groups had worsened in the weighted study sample when it was 
expected covariate balance would be achieved. For example, for coronary heart disease, SMD 
ranged from 0.04 to 0.20 in the unweighted study sample whereas in the weighted study sample, 
SMD ranged from 0.02 to 0.54. In contrast, for some covariates SMD had improved in the 
weighted study sample. For example, for renal disease, SMD ranged from 0.11 to 0.20 and 
covariate imbalance was present in all intervals in the unweighted study sample however, in the 
weighted study sample, SMD ranged from 0.01 to 0.19 with only four intervals that had 
differences between treatment groups.  
Covariate balance was also assessed by overall pooling intervals together. In the weighted study 
sample, 17 covariates were balanced between treatment groups (SMD<0.10), more than the 
number of balanced covariates in the unweighted study sample (13). There is some indication 





Table 9.9: SMD over time in the weighted study sample 
Follow-up 
year 









1 -0.03 0.01 0.11 -0.02 0.01 0.02 0.02 0.03 - -0.02 -0.05 
2 -0.03 -0.01 0.10 0.00 0.05 0.02 0.03 0.04 0.53 0.02 0.00 
3 -0.06 -0.03 0.09 -0.02 0.06 0.00 0.02 0.02 0.23 0.02 -0.01 
4 -0.08 -0.04 0.08 -0.01 0.05 -0.02 -0.02 -0.01 0.20 0.00 0.01 
5 -0.10 -0.06 0.07 -0.01 0.02 -0.02 -0.05 -0.01 0.12 0.03 0.01 
6 -0.11 -0.05 0.06 -0.01 0.03 -0.02 -0.08 -0.02 0.06 0.00 -0.02 
7 -0.14 -0.07 0.05 0.01 0.04 -0.04 -0.12 -0.06 0.03 -0.02 -0.04 
8 -0.16 -0.10 0.04 0.00 0.03 -0.06 -0.14 -0.07 -0.01 -0.02 -0.06 
9 -0.21 -0.09 0.04 0.04 0.06 -0.03 -0.19 -0.11 -0.05 -0.02 -0.12 
10 -0.21 -0.07 0.03 0.05 0.08 -0.03 -0.23 -0.13 -0.12 -0.02 -0.17 
11 -0.22 -0.01 0.04 0.09 0.17 -0.06 -0.27 -0.18 -0.19 -0.01 -0.25 
12 -0.27 0.08 0.10 0.18 0.26 -0.05 -0.36 -0.24 -0.17 0.01 -0.24 
13 -0.36 0.13 0.18 0.33 0.42 -0.12 -0.48 -0.35 -0.30 -0.08 -0.28 
14 -0.42 0.27 0.03 0.50 0.59 -0.11 -0.41 -0.23 -0.23 -0.07 -0.25 
15 -0.52 0.64 0.00 0.92 0.98 -0.15 -0.29 -0.25 -0.17 0.02 -0.10 
16 -0.29 0.55 0.40 0.83 0.81 0.08 -0.54 -0.21 0.10 0.39 -0.16 
17 -0.38 -0.07 0.29 0.51 0.46 0.42 -0.35 -0.18 0.27 0.03 -0.43 





Table 9.9 continued: 





















1 0.07 0.03 0.05 0.02 -0.06 0.01 0.03 0.03 -0.04 0.06 0.02 -0.07 0.05 
2 0.04 0.01 0.09 0.02 -0.09 0.02 0.04 0.04 -0.07 0.11 0.05 -0.16 0.09 
3 0.03 0.01 0.11 0.02 -0.12 0.05 0.02 0.06 -0.10 0.07 0.08 -0.16 0.11 
4 0.01 -0.02 0.07 0.02 -0.08 0.04 0.01 0.03 -0.06 0.01 0.08 -0.11 0.07 
5 0.00 -0.04 0.08 -0.02 -0.07 0.02 -0.01 0.03 -0.05 0.00 0.09 -0.11 0.08 
6 -0.02 -0.02 0.06 0.01 -0.07 0.03 0.00 0.03 -0.06 0.01 0.07 -0.12 0.06 
7 -0.05 -0.05 0.07 0.00 -0.07 0.02 0.02 0.00 -0.04 -0.02 0.07 -0.11 0.07 
8 -0.06 -0.06 0.07 -0.05 -0.05 0.03 0.05 -0.04 -0.03 -0.05 0.10 -0.11 0.07 
9 -0.08 -0.05 0.06 -0.03 -0.05 0.03 0.05 -0.07 -0.01 -0.07 0.10 -0.11 0.06 
10 -0.08 -0.07 0.05 -0.03 -0.04 -0.01 0.13 -0.10 0.02 -0.11 0.14 -0.13 0.05 
11 -0.10 -0.04 0.02 -0.01 -0.02 0.02 0.18 -0.20 0.05 -0.11 0.13 -0.07 0.02 
12 -0.08 -0.11 0.02 -0.03 -0.01 0.01 0.24 -0.24 0.05 -0.12 0.14 -0.09 0.02 
13 -0.09 -0.10 0.02 0.02 -0.04 -0.08 0.28 -0.21 0.09 -0.14 0.16 -0.08 0.02 
14 0.07 -0.09 -0.04 0.12 -0.05 0.12 0.29 -0.39 0.06 -0.24 0.26 -0.10 -0.04 
15 0.23 -0.06 -0.12 0.26 -0.08 0.14 0.56 -0.62 -0.02 -0.40 0.41 -0.08 -0.12 
16 0.47 -0.13 -0.19 0.46 -0.24 0.39 0.13 -0.46 -0.16 -0.45 0.48 -0.16 -0.19 
17 -0.12 -0.03 0.14 0.07 -0.20 0.53 0.16 -0.58 -0.20 0.00 0.03 -0.16 0.14 




Table 9.9 continued: 









Analgesic Colchicine Diuretic NSAIDS 
Cumulative 
allopurinol use 
(FP2 term 1) 
Cumulative 
allopurinol use 




1 -0.29 0.40 -0.27 0.05 0.07 0.02 0.27    
2 -0.29 0.33 -0.21 0.06 0.16 -0.02 -0.02 2.18 2.18 0.18 
3 -0.29 0.31 -0.18 0.02 0.15 -0.06 0.20 0.95 1.58 0.12 
4 -0.31 0.31 -0.18 0.00 0.11 -0.08 0.10 0.57 1.19 0.09 
5 -0.31 0.29 -0.15 -0.03 0.10 -0.10 0.04 0.39 0.96 0.06 
6 -0.31 0.28 -0.14 -0.04 0.05 -0.15 -0.01 0.29 0.82 0.02 
7 -0.29 0.26 -0.13 -0.07 0.02 -0.21 -0.02 0.14 0.64 0.02 
8 -0.31 0.29 -0.15 -0.15 -0.05 -0.30 -0.08 0.07 0.51 -0.01 
9 -0.31 0.28 -0.14 -0.20 -0.06 -0.40 -0.11 0.00 0.38 -0.08 
10 -0.28 0.25 -0.13 -0.24 -0.15 -0.46 -0.16 -0.06 0.27 -0.11 
11 -0.24 0.22 -0.11 -0.25 -0.24 -0.48 -0.16 -0.14 0.16 -0.20 
12 -0.20 0.27 -0.17 -0.30 -0.27 -0.58 -0.07 -0.22 0.02 -0.16 
13 -0.09 0.23 -0.18 -0.34 -0.35 -0.62 -0.10 -0.28 -0.13 -0.36 
14 -0.31 0.20 -0.08 -0.18 -0.26 -0.90 -0.12 -0.30 -0.22 -0.23 
15 -0.25 0.17 -0.08 -0.39 -0.11 -1.24 -0.12 -0.44 -0.53 -0.14 
16 -0.28 0.06 0.04 0.30 0.12 -0.84 -0.24 -0.37 -0.22 0.17 
17 -0.22 0.39 -0.33 -0.38 0.20 -0.46 -0.55 -0.44 -0.39 0.27 
Overall -0.28 0.24 -0.12 -0.06 -0.01 -0.30 -0.10 0.29 0.61 -0.01 
Yellow cells indicate absolute SMD >0.10; Red cells indicate absolute SMD >0.25; FP2: Fractional polynomial terms of dimension 2; NSAIDS: Non-steroidal anti-inflammatory 






Possible reasons for extreme weights 
A summary of covariates was described for observations with large weights. A small proportion 
of patients had weights larger than 20; 320 intervals from 121 patients had weights larger than 
10; 111 intervals from 43 patients had weights larger than 20.  
The distribution of covariates were compared across observations with: weights <10, weights >10, 
and weights >20 (Table 9.10). Compared to observations with weights <10, those with larger 
weights consisted of older patients, higher percentage of females, comorbidities (depression, 
diabetes, hypertension, osteoarthritis, renal disease), ever drinker, ever smoker, 
normal/overweight BMI, and higher percentage of prescription for analgesics and NSAIDS, as well 
as higher mean duration of cumulative allopurinol use.  
This suggests that larger weights were assigned to patients whose SU level was not measured, in 
worse health and in older females. It may that this combination of covariates has a very small 




Table 9.10: Distribution and comparison of covariates in observations with large versus non-
large weights 










intervals from 43 
patients 
Demographics    
Age (Mean (SD) 64.8 (13.8) 72.2 (10.8) 73.2 (9.5) 
Sex: Female 32,163 (21) 91 (28) 43 (39) 
Deprivation (Mean (SD)) 9.0 (5.5) 10.0 (5.4) 10.4 (5.7) 
Comorbidities    
Anxiety 15,378 (10) 82 (26) 40 (36) 
Depression 18,767 (12) 121 (38) 45 (41) 
Cerebrovascular disease 8,703 (6) 26 (8) 5 (5) 
Coronary heart disease 35,280 (23) 68 (21) 28 (25) 
Diabetes  21,801 (14) 93 (29) 37 (33) 
Gout consultation 23,130 (15) 40 (13) 17 (15) 
Hyperlipidaemia 27,442 (18) 110 (34) 43 (39) 
Hypertension 62,589 (40) 160 (50) 57 (51) 
Osteoarthritis  28,384 (18) 139 (43) 64 (58) 
Peripheral vascular disease 4,501 (3) 12 (4) 2 (2) 
Renal disease 15,469 (10) 112 (35) 45 (41) 
Lifestyle factors    
Alcohol consumption    
   Ever drinker 11,6382 (75) 297 (93) 105 (95) 
   Never drinker 6,942 (4) 13 (4) 6 (5) 
   Missing 31,687 (20) 10 (3) 0 (0) 
Body mass index    
   Normal weight 26,495 (17) 107 (33) 35 (32) 
   Overweight 54,779 (35) 132 (41) 48 (43) 
   Obese 43,646 (28) 75 (23) 27 (24) 
   Missing 30,091 (19) 6 (2) 1 (1) 
Smoking status ,   
   Ever smoker 91,263 (59) 259 (81) 91 (82) 
   Never smoker 44,212 (29) 58 (18) 20 (18) 
   Missing 19,536 (13) 3 (1) 0 (0) 
SU level    
   ≤360µmol/L 9,095 (6) 10 (3) 6 (5) 
   >360µmol/L 54,896 (35) 100 (31) 20 (18) 
   Missing 91,020 (59) 210 (66) 85 (77) 
Medication use    
Analgesic 48,850 (32) 143 (45) 61 (55) 
Colchicine 8,035 (5) 44 (14) 20 (18) 
Diuretic 45,060 (29) 101 (32) 39 (35) 
NSAIDS 66,728 (43) 65 (20) 19 (17) 
Cumulative allopurinol use (Mean (SD)) 1.4 (2.7) 8.6 (4.7) 8.9 (4.9) 
Allopurinol 45,437 (29) 210 (66) 79 (64.23) 




9.3 Sensitivity analyses 
The previous section highlighted that modifying the PS model was unlikely to estimate a 
reasonable distribution of weights without large variability. Therefore, a range of sensitivity 
analyses were performed to assess whether treatment effect estimate was altered by considering 
normalised weights, weight truncation, truncating follow-up time, and performing intention-to-
treat analysis.  
The PS model main effects model with FP2 terms for cumulative allopurinol use and an interaction 
term between hypertension and gout consultation was selected to perform sensitivity analyses 
on.  
 
9.3.1 Normalised weights 
The estimated stabilised weights were normalised, i.e., the mean weight was forced to be one in 
all intervals. The normalised weight distribution was less skewed with decreased variability; 
normalised weights had SD of 1.53 compared with 2.73 from stabilised weights. Large weights 
were still present, although these were not as extreme as stabilised weights (Table 9.11). 
The estimated unadjusted HR was 0.71 (0.63, 0.80) which was closer to the null value and had 
smaller standard error compared with using stabilised weights (0.67 (0.58, 0.67)). The adjusted 





Table 9.11: Distribution of normalised weights 
Mean (SD) 
weight 
Median (IQR) weight Weight range 
Unadjusted MSM 
HR (95% CI) 
Standard error 
*Adjusted MSM 
HR (95% CI) 
Standard error 
1.00 (1.53) 0.94 (0.75, 1.06) 1.97*10-4, 218.04 
0.71 (0.63, 0.80) 
0.06 
0.58 (0.47, 0.71) 
0.10 
*Adjusted for baseline variables and cumulative allopurinol use; CI: Confidence interval; HR: Hazard ratio; IQR: 
Interquartile range; MSM: Marginal structural models; SD: Standard deviation 
 
 
9.3.2 Weight truncation 
In order to visualise the distribution of weights and why they may need to be truncated, the box 
plot of the log transformed stabilised and normalised weights over time is shown in Figure 9.2 
and Figure 9.3 respectively, illustrating the median (IQR) and range. The box plot highlights that 
both stabilised and normalised weights had become more dispersed over time.  





Figure 9.3: Distribution of normalised weights over time 
 
Truncating the stabilised weight distribution at 1% eliminated large weights, with the maximum 
value being 3.85 reduced from 481.27 when no truncation (0%) had taken place; SD of weights 
reduced to 0.49 from 2.73, and mean weight reduced to 1.04 from 1.11. The estimated 
unadjusted HR was closer to the null value (0.77 vs. 0.67) and standard error halved in size (0.04 
vs. 0.07). The estimated adjusted HR and standard error was similar to unadjusted results.  
Similar results were also obtained for normalised weights when distribution was truncated at 1%; 
weight variability decreased, and estimated HRs (unadjusted and adjusted) was closer to the null 
value with smaller standard error compared with no truncation (Table 9.12). 
Progressively increasing percentile at which truncation takes place (2%, 5% and 10%), there were 
small improvements in weight variability for both stabilised and normalised weights, with the 
estimated (unadjusted and adjusted) HRs moving closer towards the null whilst its standard error 
decreased. The estimated treatment effects when weighted by stabilised or normalised weights 
were similar.  
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Unadjusted MSM  
HR (95% CI) 
Standard error 
*Adjusted MSM  
HR (95% CI) 
Standard error 
% of truncated stabilised weights      
0% 1.11 (2.73) 0.97 (0.83, 1.11) 4.53*10-4, 481.27 
0.67 (0.58, 0.77) 
0.07 
0.54 (0.43, 0.68) 
0.12 
1%  1.04 (0.49) 0.97 (0.83, 1.11) 0.20, 3.85 
0.77 (0.72, 0.83) 
0.04 
0.72 (0.66, 0.80) 
0.05 
2% 1.03 (0.41) 0.97 (0.83, 1.11) 0.31, 2.71 
0.80 (0.74, 0.86) 
0.04 
0.76 (0.70, 0.84) 
0.05 
5% 1.00 (0.32) 0.97 (0.83, 1.11) 0.48, 1.84 
0.85 (0.79, 0.91) 
0.03 
0.83 (0.76, 0.91) 
0.04 
10%  0.99 (0.24) 0.97 (0.83, 1.11) 0.63, 1.44 
0.92 (0.86, 0.98) 
0.03 
0.90 (0.83, 0.98) 
0.04 
% of truncated normalised weights      
0% 1.00 (1.53) 0.94 (0.75, 1.06) 1.97*10-4, 218.04 
0.71 (0.63, 0.78) 
0.06 
0.58 (0.47, 0.71) 
0.10 
1% 1.00 (0.45) 0.95 (0.79, 1,08) 0.17, 3.84 
0.78 (0.73, 0.84) 
0.04 
0.73 (0.66, 0.81) 
0.05 
2% 1.00 (0.39) 0.96 (0.80, 1.09) 0.28, 2.70 
0.80 (0.75, 0.86) 
0.04 
0.77 (0.70, 0.84) 
0.05 
5% 1.00 (0.32) 0.97 (0.83, 1.10) 0.47, 1.84 
0.85 (0.79, 0.91) 
0.03 
0.83 (0.76, 0.90) 
0.04 
10%  1.00 (0.24) 0.97 (0.84, 1.12) 0.62, 1.49 
0.91 (0.86, 0.97) 
0.03 
0.90 (0.83, 0.98) 
0.04 




Standardised mean difference 
SMD was evaluated for covariates between treatment groups in each year of follow-up. SMD was 
near identical when evaluated using stabilised and normalised weights, thus SMD was only 
presented for stabilised weights.  
Table 9.13 shows the number of intervals where SMD was greater than 0.25 for each covariate 
when weight truncation was performed at 0%, 1%, 2%, 5%, and 10%. When no truncation had 
taken place (0%), large differences (SMD>0.25) between treatment groups were observed in over 
half the follow-up intervals for baseline SU level, previous cumulative allopurinol use, diuretics, 
and renal disease; all covariates had large imbalance in at least one interval. Performing 1% 
weight truncation reduced the number of intervals in which SMD >0.25, for example, renal 
disease had the number of affected intervals halved (from 8 to 4). Covariates that had a few 
affected intervals when there was no truncation (for example BMI and hypertension) had no large 
differences between treatment groups when 1% weight truncation was performed. However, 
SMD remained persistently high for baseline SU level and previous cumulative allopurinol use 
performing 10% weight truncation. 
Table 9.14 shows for each covariate the number of intervals with SMD >0.10. When no truncation 
had taken place, over half the intervals had imbalance between treatment groups for baseline SU 
level, all medications, smoking status, age, coronary heart disease, gout consultation and renal 
disease. When 1% weight truncation was performed, the number of affected intervals had 
reduced for the majority of covariates (for example gout consultation, BMI, colchicine), however 
imbalance was still present. Weight truncation at 1% had little effect on reducing the number of 
the affected intervals for analgesics, diuretics, previous cumulative allopurinol use, SU level, age, 
and coronary heart disease. Substantial weight truncation at 10% had achieved balance for the 
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majority of covariates within intervals however, weight truncation did not improve balance for 
SU level, diuretics, previous cumulative allopurinol use, age, and sex.    
Table 9.13: Number of follow-up intervals where SMD >0.25 after weight truncation 
 Percentage of weight truncation 
  0% 1% 2% 5% 10% 
Demographics      
Age 6 6 6 5 1 
Sex: Female 3 2 4 2 2 
Deprivation 2 1 1 1 1 
Comorbidities      
Anxiety 5 0 0 0 0 
Depression 6 0 0 0 0 
Cerebrovascular disease 1 0 0 0 0 
Coronary heart disease 7 1 0 0 0 
Diabetes  1 0 0 0 0 
Gout consultation 3 1 1 1 2 
Hyperlipidaemia 1 0 0 0 0 
Hypertension 2 0 0 0 0 
Osteoarthritis  1 0 0 0 0 
Peripheral vascular disease 0 0 0 0 0 
Renal disease 8 4 2 0 0 
Lifestyle factors      
Alcohol consumption      
   Ever drinker 0 0 1 1 1 
   Never drinker 2 0 0 0 0 
   Missing 0 1 1 1 1 
Body mass index      
   Normal 2 0 0 0 0 
   Overweight 3 0 0 0 0 
   Obese 4 0 0 0 0 
   Missing 0 0 0 0 0 
Smoking status      
   Ever smoker 2 0 0 0 0 
   Never smoker 3 0 0 0 0 
   Missing 0 0 0 0 0 
SU level      
   ≤360µmol/L 12 16 15 15 15 
   >360µmol/L 12 17 17 17 17 
   Missing 2 1 1 1 1 
Medication use      
Analgesic 5 2 0 0 0 
Colchicine 3 0 0 0 0 
Diuretic 10 10 10 6 0 
NSAIDS 2 1 1 1 1 
Cumulative allopurinol use FP2 term 1 10 6 6 5 5 
Cumulative allopurinol use FP2 term 2 11 10 10 12 12 
Interactions      
Hypertension*gout consultation 2 0 0 0 0 
FP2: Fractional polynomial terms of dimension 2; NSAIDS: Non-steroidal anti-inflammatory drugs; SMD: 
Standardised mean difference; SU: Serum urate 
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Table 9.14: Number of follow-up intervals where SMD >0.10 after weight truncation 
 Percentage of weight truncation 
  0% 1% 2% 5% 10% 
Demographics      
Age 12 12 12 12 11 
Sex: Female 5 10 10 11 11 
Deprivation 5 4 4 4 3 
Comorbidities      
Anxiety 6 3 2 2 1 
Depression 7 4 3 0 0 
Cerebrovascular disease 4 4 2 1 0 
Coronary heart disease 11 10 10 5 1 
Diabetes  9 7 6 1 0 
Gout consultation 12 4 4 4 6 
Hyperlipidaemia 1 0 0 0 0 
Hypertension 9 9 7 1 0 
Osteoarthritis  3 1 0 0 0 
Peripheral vascular disease 3 0 0 0 0 
Renal disease 9 9 8 6 4 
Lifestyle factors      
Alcohol consumption      
   Ever drinker 4 2 4 5 5 
   Never drinker 3 0 0 0 0 
   Missing 3 4 4 4 5 
Body mass index      
   Normal 4 0 0 0 0 
   Overweight 8 0 0 2 5 
   Obese 8 0 0 1 1 
   Missing 3 2 2 1 2 
Smoking status      
   Ever smoker 8 2 2 2 3 
   Never smoker 9 1 1 1 1 
   Missing 11 11 11 9 7 
SU level      
   ≤360µmol/L 16 17 17 17 17 
   >360µmol/L 16 17 17 17 17 
   Missing 14 17 17 17 17 
Medication use      
Analgesics 10 10 10 6 2 
Colchicine 11 5 5 5 6 
Diuretics 13 13 13 12 10 
NSAIDS 10 8 7 5 5 
Cumulative allopurinol use FP2 term 1 13 12 11 10 10 
Cumulative allopurinol use FP2 term 2 15 13 15 15 15 
Interaction terms      
Hypertension*gout consultation 10 3 2 3 4 
FP2: Fractional polynomial terms of dimension 2; NSAIDS: Non-steroidal anti-inflammatory drugs; SMD: 






Overall, weight truncation at 1% was sufficient to remove large weights and to estimate a more 
precise treatment effect estimate and removed some severe covariate imbalance between 
treatment groups. However, greater weight truncation was required to achieve more 
comparable treatment groups within intervals however, this led to HRs moving closer to the null 
value with smaller standard errors.  
 
9.3.3 Truncating follow-up at 10 years 
For many covariates, differences between treatment groups increased over time particularly, 
after 10 years of follow-up (with SMD >0.25) for covariates such as age, coronary heart disease, 
diuretics etc. in the weighted study sample (Table 9.9). Baseline covariates were compared 
between patients with 10 or less years of follow-up with patients with more than 10 years of 
follow-up to understand if there were possible reasons for this (Table 9.15). Treatment effects 
were then re-estimated with follow-up truncated at 10 years (Table 9.16).  
Patients with ≤10 follow-up years were more likely to female (27% vs. 29%), were older (67 vs. 57 
years) and resided in poorer areas (9.4 vs. 8.9), and had a higher prevalence of coronary heart 
disease (17% vs. 10%), more prescriptions for analgesics (40% vs. 27%) and diuretics (48% vs. 26%) 
than patients with more than 10 years of follow-up.   
Truncating follow-up improved variability in both the stabilised and normalised weights and 
weights were less extreme. Unadjusted HRs of 0.7 were estimated however the adjusted HRs 





Table 9.15: Comparison of baseline covariates of patients with ≤10 years and >10 years of 
follow-up 
 ≤10 years of 
follow-up 
N=7,748 
>10 years of 
follow-up 
N=9,128 
Demographics   
Age (Mean (SD) 67.1 (15.1) 57.8 (13.0) 
Sex: Female 2,117 (27) 1,764 (19) 
Deprivation (Mean (SD)) 9.4 (5.5) 8.9 (5.5) 
Comorbidities   
Anxiety 312 (4) 360 (4) 
Depression 427 (6) 415 (5) 
Cerebrovascular disease 279 (4) 128 (1) 
Coronary heart disease 1,283 (17) 884 (10) 
Diabetes  624 (8) 423 (5) 
Hyperlipidaemia 347 (4) 436 (5) 
Hypertension 1,510 (19) 1,627 (18) 
Osteoarthritis  578 (7) 528 (6) 
Peripheral vascular disease 190 (2) 67 (1) 
Renal disease 164 (2) 53 (1) 
Lifestyle factors   
Alcohol consumption   
   Ever drinker 4,289 (55) 5,199 (57) 
   Never drinker 483 (6) 373 (4) 
   Missing 2,976 (38) 3,556 (39) 
Body mass index   
   Normal weight 1,314 (17) 1,203 (13) 
   Overweight 2,208 (28) 2,725 (30) 
   Obese 1,367 (18) 1,852 (20) 
   Missing 2,859 (37) 3,348 (37) 
Smoking status   
   Ever smoker 3,035 (39) 3,401 (37) 
   Never smoker 2,225 (29) 2,622 (29) 
   Missing 2,488 (32) 3,105 (34) 
SU level   
   ≤360µmol/L 409 (5) 542 (6) 
   >360µmol/L 2,767 (36) 3,295 (36) 
   Missing 4,572 (59) 5,291 (58) 
Medication use   
Analgesics 3,098 (40) 2,480 (27) 
Colchicine 214 (3) 175 (2) 
Diuretics 3,732 (48) 2,410 (26) 
NSAIDS 3,587 (46) 4,437 (49) 
NSAIDS: Non-steroidal anti-inflammatory drugs; SD: Standard deviation; SU: Serum urate 
 
Prior to truncating follow-up, SMD >0.25 was previously observed in the majority of covariates. 
Truncating follow-up improved SMD. Balance was achieved on 13 covariates compared to only 
one covariate beforehand. SMD >0.25 was observed for three covariates compared to 21 
covariates beforehand (Table 9.17). 
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HR (95% CI) 
Standard error 
*Adjusted MSM  
HR (95% CI) 
Standard error 
Stabilised weights      
All follow-up observed 1.11 (2.73) 0.97 (0.83, 1.11) 4.54*10-4, 481.27 
0.67 (0.58, 0.77) 
0.07 
0.54 (0.43, 0.68) 
0.12 
Follow-up truncated at 10 years 1.01 (0.78) 1.0 (0.85, 1.10) 0.03, 108.45 
0.75 (0.64, 0.87) 
0.08 
0.57 (0.42, 0.78) 
0.16 
Normalised weights      
All follow-up observed 1.00 (1.53) 0.94 (0.75, 1.06) 1.97*10-4, 218.04 
0.71 (0.63, 0.80) 
0.06 
0.58 (0.47, 0.71) 
0.10 
Follow-up truncated at 10 years 1.00 (0.72) 1.00 (0.82, 1.10) 0.02, 95.12 
0.76 (0.66, 0.88) 
0.07 
0.59 (0.44, 0.79) 
0.15 





Table 9.17: Number of intervals where SMD was greater than 0.10 or 0.25 
 







All follow-up observed 











Demographics     
Age 13 1 4 0 
Sex: Female 8 3 2 0 
Deprivation 8 2 2 0 
Comorbidities     
Anxiety 4 1 0 0 
Depression 6 3 0 0 
Cerebrovascular disease 2 1 0 0 
Coronary heart disease 7 2 0 0 
Diabetes  3 2 0 0 
Gout consultation 12 3 7 1 
Hyperlipidaemia 3 2 0 0 
Hypertension 4 3 0 0 
Osteoarthritis  2 2 0 0 
Peripheral vascular disease 1 0 0 0 
Renal disease 7 2 0 0 
Lifestyle factors     
Alcohol consumption     
   Ever drinker 2 0 0 0 
   Never drinker 0 0 0 0 
   Missing 2 0 0 0 
Body mass index     
   Overweight 4 1 0 0 
   Normal 4 2 0 0 
   Obese 1 0 0 0 
   Missing 2 0 0 0 
Smoking status     
   Ever smoker 5 3 0 0 
   Never smoker 5 3 0 0 
   Missing 6 0 1 0 
SU level     
   ≤360µmol/L 17 16 9 9 
   >360µmol/L 16 15 9 8 
   Missing 17 4 7 1 
Medication use     
Analgesics 8 2 2 0 
Colchicine 7 4 1 0 
Diuretics 11 6 3 0 
NSAIDS 9 2 5 0 
Cumulative allopurinol use 16 16 8 8 
320 
 
9.3.4 Intention-to-treat analysis 
MSM was modelled under the intention-to-treat principle in that the PS was estimated up to 
when patients first initiated treatment, thereafter the PS was assumed constant for the 
remainder of follow-up. Stabilised weights were estimated only.  
Assuming patients remained on treatment after initiation, the estimated weights had mean 
weight of 1 and variability was small. The unadjusted effect of initiating treatment yielded HR of 
1.06 (0.99, 1.13); the adjusted HR yielded similar HR with larger standard error (Table 9.18). 
Covariate imbalance between treatment groups did persist with differences observed across 
most intervals in gout consultation, target SU level, and cumulative allopurinol use (Table 9.19). 
The issues surrounding weight estimation (in terms of mean weight deviating from 1, presence of 
large weights, and large covariate imbalance between treatment groups) in as-treated analysis 
did not persist when performing intention-to-treat analysis. This suggests that estimating the PS 














HR (95% CI) 
Standard error 
Unadjusted MSM 
HR (95% CI) 
Standard error 
*Adjusted MSM  
HR (95% CI) 
Standard error 
As-treated analysis 1.11 (2.73) 0.97 (0.83, 1.11) 4.54*10-4, 481.27 
1.19 (1.12, 1.26) 
0.03 
0.67 (0.58, 0.77) 
0.07 
0.54 (0.43, 0.68) 
0.12 
Intention-to-treat analysis 1.00 (0.55) 1.00 (0.70, 1.14) 0.12, 16.90 
1.19 (1.12, 1.26) 
0.03 
1.06 (0.99, 1.13) 
0.03 
1.06 (0.96, 1.17) 
0.05 















































Demographics     
Age 13 1 4 0 
Sex: Female 8 3 11 4 
Deprivation 8 2 6 0 
Comorbidities     
Anxiety 4 1 0 0 
Depression 6 3 1 0 
Cerebrovascular disease 2 1 2 0 
Coronary heart disease 7 2 0 0 
Diabetes  3 2 0 0 
Gout consultation 12 3 16 16 
Hyperlipidaemia 3 2 2 0 
Hypertension 4 3 4 0 
Osteoarthritis  2 2 0 0 
Peripheral vascular disease 1 0 0 0 
Renal disease 7 2 4 0 
Lifestyle factors     
Alcohol consumption     
   Ever drinker 2 0 10 0 
   Never drinker 0 0 4 0 
   Missing 2 0 6 0 
Body mass index     
   Normal 4 2 9 0 
   Overweight 4 1 1 0 
   Obese 1 0 10 1 
   Missing 2 0 1 0 
Smoking status     
   Ever smoker 5 3 3 0 
   Never smoker 5 3 1 0 
   Missing 6 0 7 0 
SU level     
   ≤360µmol/L 17 16 17 17 
   >360µmol/L 16 15 17 17 
   Missing 17 4 17 3 
Medication use     
Analgesics 8 2 1 0 
Colchicine 7 4 16 3 
Diuretics 11 6 5 0 
NSAIDS 9 2 12 0 




Application of MSM had shown that allopurinol was strongly protective of premature mortality. 
The HRs estimated via as-treated analyses in this chapter ranged from 0.5 to 0.8. These estimates 
are somewhat lower than what has been reported in the existing literature. A systematic review 
and meta-analysis of three PS matched cohort studies using electronic health records (EHR) (two 
of which used UK primary care data) found no association between allopurinol and mortality in 
gout, reporting an overall HR of 0.80 (0.60, 1.05). Although Dubreuil et al. (2015) had found 
allopurinol use was protective of premature mortality, their reported HR 0.81 (0.70, 0.92) was 
closer to the null value of one.  It is unclear why exactly the analyses in this chapter provided 
lower estimates of allopurinol effect, but a possible reason could be differences in modelling 
approach. 
In this chapter several approaches were taken in an attempt to understand exactly the source of 
issues encountered in estimation of PS modelling. The PS main effects model resulted in the 
distribution of weights that was skewed, mean weight deviated from 1 and extreme weights were 
present. This was an indication the PS model was possibly misspecified. A logical approach was to 
attempt to reduce the extremeness of weights, thus inclusion of non-linear terms and interaction 
terms in the PS model was considered as a mitigation measure suggested by Cole and Hernan 
(2008). However, regardless of which covariates and their composites were included in the PS 
model, distribution of weights remained skewed and extreme weights persisted. The resulting 
HRs were wide ranging, from 0.5 to 0.8, and it remained unclear which, if any, of the PS models 
considered were specified correctly. These large HRs were not expected to be observed as 
treatment of gout is suboptimal in primary care, and patients are generally prescribed low 
dosages of allopurinol; if a protective effect were to be observed, it was expected the HR would 
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be much closer to the null value. Balance of covariates between treatment groups was assessed 
throughout and it was envisaged that there would be little imbalance in the weighted study 
sample. It transpired that this was not the case with imbalance in fact worse in the weighted than 
in the unweighted study sample.  
Various sensitivity analyses were conducted to evaluate how robust the main analysis treatment 
effect estimates were against approaches considered for weight variability reduction. Use of 
normalised weights and weight truncation improved the distribution of weights. The HRs 
remained strongly protective of premature mortality with unadjusted HR is the region of 0.7 and 
adjusted HR in the region of 0.5. Similarly, imbalance of covariates between treatment groups 
remained and only improved when substantial 10% percentile weight truncation was performed 
compared with 1%.  
Truncating follow-up at 10 years drastically improved balance over time although HRs remained 
strongly protective. It appears that in estimating the as-treated treatment effect, the best 
approach was to truncate follow-up prior to differences between treatment groups becoming 
very large in an attempt to achieve covariate balance. This approach is only feasible if one is 
confident that the estimated HR is plausible and estimating the long-term effect of treatment is 
maintained and clinically relevant.  
The HR estimated under the intention-to-treat principle lost statistical significance and was very 
close to the null value. Weight estimation (up to when patients initiated treatment) was more 
satisfactory than estimating weights in all follow-up intervals. This suggests that estimating PS 
after patients initiated treatment may be more complex. There is the possibility that the 
associations between covariates and initiating treatment may be different to the associations 
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between covariates and continuing with treatment which may explain why extreme weights were 
estimated in this analysis.  
To conclude, there are several modelling choices analysts can make while fitting MSM and this 
study has shown that treatment effect estimates and their precision will depend on specific 
choices made. Sensitivity to missing data and unmeasured confounding was not assessed as it is 
believed the associations between covariates and treatment was not modelled correctly.  
The next chapter considers modifications to weight estimation process, by allowing associations 
to differ between covariates and patients initiating allopurinol and between covariates and 




10 Modelling complex mechanisms of allopurinol via MSM 
In Chapter 9, covariates were assumed to have the same association with initiation and 
continuation of allopurinol. However, this led to presence and persistence of extreme weights 
and skewed weight distribution, which in turn may have affected magnitude and precision of 
treatment effect estimates. In this chapter, this assumption was relaxed, and results from 
application of marginal structural models (MSM) when associations were allowed to differ in 
patients initiating and continuing with treatment are presented. 
Chapter 6, Section 6.5 described how the study sample described in Section 8.1 was essentially 
stratified by previous allopurinol use in the last year into two datasets for propensity score (PS) 
estimation; the first dataset contained observations that did not have allopurinol use in the 
previous interval, thus allowing one to estimate the probability of initiating allopurinol; the 
second dataset contained observations that did have allopurinol use in the previous interval, thus 
allowing one to estimate the probability of continuing treatment. After PS estimation, the 
datasets were combined together where weight estimation and treatment effect estimation 
proceeded.  
Analyses were performed for all outcomes.  
 
10.1 Covariates associated with initiation and continuation of 
allopurinol 
Table 10.1 describes the distribution of covariates between allopurinol users and non-users 
stratified by allopurinol use in the previous year; standardised mean difference (SMD) was 
presented that assessed covariate balance between non-users and patients initiating allopurinol 
327 
 
(in intervals that were not prescribed allopurinol in the previous year), and between patients who 
discontinued allopurinol and patients who continued with allopurinol (in intervals that were 
prescribed allopurinol in the previous year).  
In intervals that were not prescribed allopurinol in the previous year, patients initiating 
allopurinol were younger, and had a lower percentage of anxiety, depression, diabetes, gout 
consultation, hyperlipidaemia, hypertension, having baseline serum urate (SU) level ≥360μmol/L, 
lower percentage of ever drinkers, normal body mass index (BMI), ever smokers, and more 
prescriptions for analgesics, colchicine, diuretics, and non-steroidal anti-inflammatory drugs 
(NSAIDS) compared with non-users. 
In intervals that were prescribed allopurinol in the previous year, patients continuing with 
allopurinol were older, and had a higher percentage of coronary heart disease, diabetes, 
hyperlipidaemia, hypertension, osteoarthritis, renal disease, ever drinkers, obesity, ever smokers, 
lower percentage of gout consultation, more prescriptions for diuretics and fewer prescriptions 
for colchicine and NSAIDS, and had higher mean cumulative allopurinol use than patients 
discontinuing with allopurinol.   
The majority of covariates were associated with initiating and continuing allopurinol, although 
the direction of the odds ratio (ORs) differed. Older age, anxiety, cerebrovascular disease, 
diabetes, hyperlipidaemia, hypertension, osteoarthritis, and longer cumulative allopurinol use 
had increased odds of continuing with allopurinol (OR ranged from 1.04 to 2.15); in contrast, 
these same covariates had reduced odds of initiating allopurinol (OR ranged from 0.62 to 0.99).   
On the other hand, gout consultation, never smokers, and NSAID use had decreased odds of 
continuing allopurinol (OR ranged from 0.51 to 0.76) but had increased odds of initiating 
allopurinol (OR ranged from 1.21 to 2.17).  
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Renal disease was only associated with continuing allopurinol. Baseline SU level above target and 
colchicine use were only associated with initiating allopurinol.   
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Table 10.1: Distribution and association of covariates with initiating and continuing with allopurinol (n=16,876 patients) 


























OR (SE) of 
continuing 
allopurinol 
Demographics         
Age (Mean (SD)) 64.5 (14.0) 64.6 (14.0) 62.7 (14.2) 0.99 (<0.01)* 65.9 (13.2) 61.7 (14.7) 66.3 (12.9) 1.04 (<0.01)* 
Sex: Female 25,006 (22) 23,268 (22) 1,738 (18) 0.80 (0.04)* 7,248 (18) 640 (17) 6,608 (18) 1.06 (0.10) 
Deprivation (Mean (SD)) 8.9 (5.5) 8.9 (5.5) 9.3 (5.6) 1.02 (<0.01)* 9.2 (5.6) 9.5 (5.6) 9.2 (5.6) 0.99 (0.01) 
Comorbidities         
Anxiety 11,262 (10) 10,620 (10) 642 (7) 0.62 (0.04)* 4,198 (10) 345 (9) 3,853 (11) 1.27 (0.14)* 
Depression 13,795 (12) 13,008 (12) 787 (8) 0.57 (0.04)* 5,093 (13) 432 (11) 4,661 (13) 1.17 (0.11) 
Cerebrovascular disease 6,049 (5) 5,684 (5) 365 (4) 0.72 (0.06)* 2,680 (7) 177 (5) 2,503 (7) 1.67 (0.22)* 
Coronary heart disease 24,092 (21) 22,310 (21) 1,782 (19) 0.93 (0.04) 11,256 (28) 736 (20) 10,520 (29) 2.03 (0.15)* 
Diabetes  14,814 (13) 13,914 (13) 900 (10) 0.65 (0.04)* 7,080 (18) 423 (11) 6,657 (18) 2.00 (0.17)* 
Gout consultation 13,826 (12) 12,128 (11) 1,698 (18) 1.75 (0.06)* 9,344 (23) 1,704 (45) 7,640 (21) 0.54 (0.03)* 
Hyperlipidaemia 18,677 (16) 17,549 (17) 1,128 (12) 0.69 (0.04)* 8,875 (22) 577 (15) 8,298 (23) 2.04 (0.16)* 
Hypertension 43,002 (37) 40,033 (38) 2,969 (31) 0.76 (0.03)* 19,747 (49) 1,393 (37) 18,354 (51) 2.15 (0.13)* 
Osteoarthritis  19,522 (17) 18,237 (17) 1,285 (14) 0.76 (0.04)* 9,001 (23) 694 (18) 8,307 (23) 1.50 (0.12)* 
Peripheral vascular disease 3,166 (3) 2,964 (3) 202 (2) 0.70 (0.08)* 1,347 (3) 93 (2) 1,254 (3) 1.43 (0.26) 




Table 10.1 continued: 
Lifestyle factors         
Alcohol consumption         
   Ever drinker 84,756 (73) 78,371 (74) 6,385 (68) 1.00 31,923 (80) 2,823 (75) 29,100 (80) 1.00 
   Never drinker 5,283 (5) 4,889 (5) 394 (4) 0.98 (0.09) 1,672 (4) 155 (4) 1,517 (4) 0.82 (0.13) 
   Missing 25,306 (22) 22,659 (21) 2,647 (28) 1.52 (0.06)* 6,391 (16) 787 (21) 5,604 (15) 0.60 (0.04)* 
Body mass index         
   Normal 21,085 (18) 19,818 (19) 1,267 (13) 1.00 5,517 (14) 543 (14) 4,974 (14) 1.00 
   Overweight 40,326 (35) 37,206 (35) 3,120 (33) 1.39 (0.08)* 14,585 (36) 1,305 (35) 13,280 (37) 1.11 (0.10) 
   Obese 29,812 (26) 27,330 (26) 2,482 (26) 1.61 (0.10)* 13,909 (35) 1,108 (29) 12,801 (35) 1.41 (0.14)* 
   Missing 24,122 (21) 21,565 (20) 2,557 (27) 2.00 (0.12)* 5,975 (15) 809 (21) 5,166 (14) 0.66 (0.07)* 
Smoking status         
   Ever smoker 65,783 (57) 61,109 (58) 4,674 (50) 1.00 25,739 (64) 2,136 (57) 23,603 (65) 1.00 
   Never smoker 33,394 (29) 30,683 (29) 2,711 (29) 1.21 (0.05)* 10,876 (27) 1,110 (29) 9,766 (27) 0.76 (0.05)* 
   Missing 16,168 (14) 14,127 (13) 2,041 (22) 1.88 (0.08)* 3,371 (8) 519 (14) 2,852 (8) 0.46 (0.04)* 
SU level         
   ≤360µmol/L 8,547 (7) 8,408 (8) 139 (1) 1.00 558 (1) 60 (2) 498 (1) 1.00 
   >360µmol/L 36,718 (32) 32,497 (31) 4,221 (45) 27.30 (3.84)* 18,278 (46) 1,695 (45) 16,583 (46) 1.72 (0.49) 
   Missing 70,080 (61) 65,014 (61) 5,066 (54) 11.11 (1.53)* 21,150 (53) 2,010 (53) 19,140 (53) 1.61 (0.46) 
Medication use         
Analgesics 34,382 (30) 31,151 (29) 3,231 (34) 1.35 (0.05)* 14,611 (37) 1,292 (34) 13,319 (37) 1.17 (0.06)* 
Colchicine 4,682 (4) 3,864 (4) 818 (9) 2.81 (0.16)* 3,397 (8) 534 (14) 2,863 (8) 0.89 (0.07) 
Diuretics 31,542 (27) 28,114 (27) 3,428 (36) 2.19 (0.08)* 13,619 (34) 974 (26) 12,645 (35) 1.74 (0.11)* 
NSAIDS 50,013 (43) 44,335 (42) 5,678 (60) 2.17 (0.06)* 16,780 (42) 2,363 (63) 14,417 (40) 0.51 (0.02)* 
Cumulative allopurinol use (Mean (SD)) 0.3 (1.0) 0.3 (1.0) 0.4 (1.3) 0.67 (0.01)* 4.8 (3.3) 2.9 (2.5) 4.9 (3.3) 1.21 (0.01)* 
Number (percentage) presented unless otherwise stated; Cells highlighted in yellow indicate SMD>0.10; *Statistically significant p-value <0.05; NSAIDS: Non-steroidal anti-







10.2 Propensity score model 
Across all outcome analyses, the same covariates used to estimate PS in Chapter 8 for time-
varying PS subclassification (Table 8.7) was used to estimate the probability of initiating 
allopurinol and the probability of continuing allopurinol. To briefly recap, age, sex, deprivation, 
renal disease, colchicine, NSAIDS, diuretics, SU level, gout consultation, cumulative allopurinol 
use, and follow-up time were chosen to be in the PS models a priori. Covariates that were 
associated with outcome, by modelling the association between covariate and outcome via the 
complementary log-log model, were also included in the PS model if the p-value<0.05; generally, 
the majority of demographics, comorbidities, lifestyle factors and medication use were associated 
with most outcomes. In estimating the PS for initiating allopurinol and continuing allopurinol, the 
PS models considered main effects of all covariates and continuous covariates had a linear 
functional form, and this was considered as the main analysis. All covariates were entered into 
the PS model as main effects with linear functional form for continuous outcomes.  
Stabilised weights vs. basic weights 
After PS estimation, initially stabilised weights were derived using the whole study sample. The 
distribution of weights across all outcomes was satisfactory with mean close to 1, small standard 
deviation (SD), and narrow range. For example, in the analysis of target SU level, mean (SD) weight 
was 1.00 (0.44) with range 0.05 to 7.18; the distribution was not skewed as median (interquartile 
range (IQR)) was 1.02 (0.72, 1.15). Similar findings were also observed in the analyses of the 
secondary outcomes with the exception for morality, that had a larger weight range of <0.01 to 
188, although mean (SD) was 1 (0.99).  
As the stabilised weight distribution was satisfactory, basic weights were then derived and how it 
compared with stabilised weights. Across all outcomes, the basic weight distribution was 
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satisfactory with mean weight close to one although variability had increased compared with 
stabilised weights. For example, in the analysis of target SU level, basic weights had mean (SD) 
0.99 (0.68) with range <0.01 to 13.05. With the exception of mortality, similar findings were 
observed in secondary outcome analyses that basic weight variability was larger than stabilised 
weights, for example in the analysis of cerebrovascular disease, basic weights had mean (SD) 1.00 
(0.45) whereas for stabilised weights it was 1.00 (0.29). In the analysis of mortality, the opposite 
was found that the variability of basic weights was lower than stabilised weights (mean (SD) 1.00 
(0.81) vs. 1.00 (0.99)).  
The decision was taken to use basic weights for the main analysis. This was because the 
confounding effects of baseline covariates and treatment history were fully adjusted for within 
weight estimation, which was not the case for stabilised weights. Therefore, in treatment effect 
estimation, weighting the study sample using basic weights did not need to adjust for baseline 
covariates and treatment history in the Cox model, which would be required to do so if the study 
sample was weighted using stabilised weights.  
Assessment of covariate balance 
SMD evaluated covariate balance between treatment groups in each year of follow-up and overall 
in the weighted study sample. This was presented for the analysis for mortality (Table 10.2). For 
all other outcomes, overall SMD for each covariate was presented (Table 10.3).  
As observed in Table 10.2, covariate balance was achieved for deprivation and peripheral vascular 
disease across all intervals. Severe imbalance (SMD>0.25) between treatment groups was present 
for gout consultation and cumulative allopurinol use in the majority of intervals; colchicine was 
also imbalanced across the majority of intervals but was not as severe. For the remaining 
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covariates, balance tended to be achieved in the first 12 years of follow-up, with small imbalances 
(SMD≤0.25) appearing thereafter.  
From Table 10.3, overall covariate balance across time found covariate imbalance remained in 
the weighted study sample. Across all outcome analyses, the largest difference between 
treatment groups was observed for cumulative allopurinol use (SMD>0.76). Sex, deprivation, 
anxiety, depression, and NSAIDS were balanced between treatment groups, whereas small 















Table 10.2: SMD over time in the weighted sample in analysis of mortality 
Follow-up 
year 









1 0.13 0.10 0.05 -0.02 0.01 0.06 0.08 0.09 - -0.01 0.03 
2 0.12 0.08 0.05 <0.01 0.03 0.06 0.09 0.09 0.70 0.04 0.07 
3 0.08 0.03 0.04 -0.02 0.04 0.03 0.08 0.07 0.33 0.04 0.06 
4 0.03 0.02 0.04 <0.01 0.04 <0.01 0.06 0.06 0.34 0.02 0.08 
5 0.03 0.02 0.03 0.01 0.01 0.03 0.06 0.07 0.29 0.10 0.10 
6 0.02 0.01 0.01 -0.01 0.02 0.03 0.03 0.06 0.25 0.07 0.08 
7 -0.02 -0.03 <0.01 0.01 0.01 0.02 <0.01 0.04 0.25 0.05 0.07 
8 -0.02 -0.10 -0.02 -0.01 -0.05 <0.01 0.02 0.04 0.26 0.04 0.08 
9 -0.02 -0.10 -0.03 -0.01 -0.06 0.04 0.01 0.03 0.26 0.04 0.10 
10 -0.05 -0.10 -0.03 -0.01 -0.09 0.03 0.01 0.02 0.28 0.06 0.07 
11 -0.06 -0.11 -0.03 -0.03 -0.09 -0.01 <0.01 -0.01 0.21 0.04 0.02 
12 -0.11 -0.11 -0.03 0.02 -0.01 0.03 -0.02 -0.09 0.25 0.07 0.02 
13 -0.17 -0.14 <0.01 0.10 0.08 -0.07 -0.07 -0.08 0.19 0.07 0.05 
14 -0.14 -0.24 0.07 0.19 0.19 -0.05 -0.06 -0.20 0.43 0.12 0.07 
15 -0.14 -0.33 0.03 0.10 0.09 0.04 -0.03 -0.14 0.40 0.04 -0.01 
16 -0.13 -0.35 0.09 0.04 -0.01 0.18 -0.07 -0.09 0.36 0.04 -0.09 
17 -0.29 -0.17 0.03 -0.25 -0.37 -0.06 -0.18 -0.14 0.42 0.06 -0.16 





Table 10.2 continued: 





















1 0.08 0.05 0.05 0.04 0.04 -0.05 0.02 0.04 0.05 -0.06 0.06 0.01 -0.06 
2 0.08 0.02 0.10 0.05 0.05 -0.07 0.02 0.02 0.06 -0.07 0.09 0.02 -0.10 
3 0.08 0.03 0.10 0.06 0.05 -0.08 0.05 <0.01 0.06 -0.09 0.05 0.04 -0.09 
4 0.06 <0.01 0.11 0.03 0.04 -0.05 0.04 -0.01 0.04 -0.06 0.01 0.02 -0.03 
5 0.05 <0.01 0.09 0.07 <0.01 -0.07 0.03 -0.04 0.06 -0.06 0.02 0.03 -0.07 
6 0.03 <0.01 0.07 0.05 0.01 -0.06 0.02 -0.03 0.10 -0.09 0.03 0.01 -0.07 
7 0.01 -0.02 0.09 0.06 0.01 -0.06 0.02 -0.04 0.09 -0.08 0.03 0.01 -0.09 
8 0.01 -0.03 0.06 0.08 -0.06 -0.05 0.04 -0.07 0.09 -0.10 0.02 0.03 -0.11 
9 0.03 -0.02 0.10 0.07 -0.04 -0.06 0.03 -0.09 0.09 -0.07 0.05 -0.01 -0.13 
10 0.02 -0.02 0.05 0.08 -0.03 -0.07 -0.01 -0.07 0.10 -0.06 <0.01 0.03 -0.10 
11 0.01 <0.01 0.01 0.08 -0.06 -0.05 0.02 -0.05 0.02 <0.01 0.03 -0.02 -0.06 
12 0.02 0.01 -0.01 0.06 -0.06 -0.04 <0.01 -0.02 <0.01 0.02 0.02 <0.01 -0.08 
13 -0.01 -0.01 -0.01 0.03 0.10 -0.10 0.03 -0.07 0.01 0.02 0.08 -0.06 -0.10 
14 0.04 -0.03 0.01 0.07 0.13 -0.18 <0.01 -0.13 0.09 0.01 0.07 -0.05 -0.10 
15 0.02 0.06 -0.21 0.24 -0.08 -0.23 0.08 -0.12 -0.03 0.09 0.13 -0.11 -0.12 
16 -0.03 -0.05 -0.23 0.21 0.07 -0.27 0.22 -0.08 -0.12 -0.06 0.18 -0.14 -0.17 
17 -0.08 0.08 -0.31 0.19 0.08 -0.25 -0.01 -0.09 0.07 0.02 0.10 -0.08 -0.14 




Table 10.2 continued: 









Analgesic Colchicine Diuretic NSAIDS 
Cumulative 
allopurinol use 
1 -0.03 0.14 -0.12 0.07 <0.01 0.09 0.02 - 
2 -0.02 0.09 -0.07 0.14 0.22 0.10 -0.08 2.54 
3 <0.01 0.03 -0.03 0.08 0.19 0.05 0.18 2.24 
4 -0.01 0.02 -0.01 0.09 0.17 0.04 0.14 2.04 
5 0.03 -0.02 <0.01 0.04 0.17 0.03 0.09 1.90 
6 0.01 -0.03 0.02 0.07 0.16 0.03 0.07 1.92 
7 0.05 -0.06 0.03 0.05 0.13 0.03 0.05 1.72 
8 -0.04 -0.03 0.05 -0.02 0.12 -0.03 0.06 1.56 
9 -0.09 -0.03 0.07 -0.01 0.13 -0.02 0.04 1.43 
10 -0.07 -0.02 0.05 -0.05 0.14 -0.04 0.10 1.32 
11 -0.06 -0.05 0.08 -0.04 0.10 -0.05 0.09 1.15 
12 -0.05 0.01 0.01 -0.04 0.15 -0.09 0.10 1.00 
13 0.13 -0.03 -0.04 -0.07 0.17 -0.14 0.10 0.90 
14 0.24 -0.08 -0.06 -0.05 0.37 -0.18 0.20 0.72 
15 0.19 -0.10 -0.01 -0.07 0.28 -0.15 0.24 0.41 
16 0.17 -0.12 0.04 -0.09 0.41 -0.24 0.07 0.19 
17 -0.01 -0.30 0.30 -0.38 0.28 -0.55 0.10 <0.01 
Overall <0.01 -0.02 0.02 0.04 0.17 -0.04 <0.01 1.18 























Demographics         
Age 0.01 0.08 0.10 0.14 0.14 0.11 0.14 0.08 
Sex: Female 0.02 -0.07 0.01 0.02 0.01 <0.01 0.01 -0.02 
Deprivation 0.05 0.01 0.04 0.06 0.06 0.06 0.06 0.06 
Comorbidities         
Anxiety 0.06 0.08 0.02 0.02 0.01 0.03 0.02 0.04 
Depression 0.01 0.08 0.01 <0.01 <0.01 0.03 <0.01 0.03 
Cerebrovascular disease 0.04 0.06 0.05 0.13  0.06 0.13 0.09 
Coronary heart disease -0.07 0.09 0.11 0.07 0.13  0.06 0.05 
Diabetes  0.08 0.10 0.10 0.08 0.11 0.09 0.11 0.08 
Gout consultation 0.28 0.29 0.22 0.22 0.22 0.25 0.22 0.24 
Hyperlipidaemia 0.06 0.18 0.06 0.10 0.09 0.09 0.09 0.07 
Hypertension 0.07 0.21 0.14 0.15 0.16 0.16 0.15 0.12 
Osteoarthritis  0.06 0.14 0.09 0.10 0.12 0.10 0.11 0.10 
Peripheral vascular disease -0.01 0.01 0.04 0.03 0.04 0.04  0.03 
Renal disease 0.10 0.19 0.20 0.22 0.22 0.18 0.22  
Lifestyle factors         
Alcohol consumptiona -0.19 -0.29 0.12 0.15 -0.15 0.14 0.15 0.14 
Body mass indexa -0.19 -0.28 0.12 0.15 -0.15 0.14 -0.15 0.13 
Smoking statusa -0.21 -0.29 0.10 0.11 0.12 0.10 0.11 0.10 
SU levela -0.01b 0.02 0.22 0.19 0.19 0.20 -0.13 0.19 
Medication use         
Analgesics 0.01 0.04 0.13 0.16 0.16 0.14 0.15 0.13 
Colchicine 0.12 0.17 0.15 0.16 0.16 0.16 0.15 0.16 
Diuretics -0.04 -0.04 0.15 0.18 0.17 0.12 0.17 0.12 
NSAIDS -0.03 <0.01 0.02 0.02 0.02 0.07 0.02 0.07 
Cumulative allopurinol use 0.76 1.10 1.24 1.24 1.25 1.19 1.26 1.20 
Cells highlighted in red indicate severe covariate balance with SMD>0.25; Cells highlighted in yellow indicate small covariate imbalance with SMD between 0.10 and 0.25; aFor 
categorical variables, the largest SMD was presented; bSU level was a continuous covariate; NSAIDS: Non-steroidal anti-inflammatory drugs; SMD: Standardised mean 
difference; SU: Serum urate. 
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10.3 Treatment effect estimation 
Treatment effect estimates were derived in the weighted study sample using basic weights 
(Table 10.4). Allopurinol use was strongly associated with reaching target SU level (HR 4.73 
(3.89, 5.76)) and increased risk of gout hospitalisation (2.66 (2.40, 2.94)), coronary heart 
disease (1.18 (1.09, 1.29)), and renal disease (1.42 (1.32, 1.53)). No association between 
allopurinol and mortality, joint replacement, cerebrovascular disease, and peripheral vascular 
disease were found.  
All treatment effect estimates were then adjusted for cumulative allopurinol use as there were 
large differences (SMD >0.25) between treatment groups; gout consultation was also adjusted 
for in the analysis of mortality as this covariate was largely imbalanced between treatment 
groups as well (SMD >0.25). Across all outcomes, adjusted HRs estimates either increased or 
decreased but the standard errors increased compared with unadjusted results. For example, 
for target SU level HR increased from 4.73 to 5.01 and standard error increased from 0.47 to 
0.57.  
Treatment effect estimates were then further adjusted for all covariates whose overall SMD 
>0.10. There was no/little change in HR for target SU level and mortality; HRs decreased 
further for gout hospitalisation (2.49 vs. 2.22), cerebrovascular disease (1.07 vs. 1.01), 
coronary heart disease (1.20 vs. 1.11), peripheral vascular disease (1.23 vs. 1.13); and renal 

















HR (95% CI) 
Standard error 
Unadjusted MSM 
HR (95% CI) 
Standard error 
*Adjusted MSM  
HR (95% CI) 
Standard error 
**Adjusted MSM  
HR (95% CI) 
Standard error 
Target SU level   
0.99 (0.68) 
<0.01, 16.13 
4.63 (3.95, 5.42) 
0.37 
4.73 (3.89, 5.76) 
0.47 
5.01 (4.02, 6.25) 
0.57 
5.00 (4.00, 6.23) 
0.56 
   Not reached target 6,805 (96.5) 2,515 (84.5) 
   Reached target 247 (3.5) 460 (15.5) 
Mortality   
1.00 (0.81) 
<0.01, 85.67 
1.19 (1.12, 1.26) 
0.04 
0.96 (0.87, 1.06) 
0.05 
0.91 (0.80, 1.04) 
0.06 
0.93 (0.83, 1.06) 
0.06 
   Alive 106,338 (97.0) 44,017 (96.4) 
   Death 3.346 (3.1) 1.630 (3.6) 
Gout hospitalisation   
1.00 (0.41) 
<0.01, 16.99 
2.92 (2.67, 3.19) 
0.13 
2.66 (2.40, 2.94) 
0.14 
2.49 (2.15, 2.87) 
0.18 
2.22 (1.91, 2.58) 
0.17 
   No 87,694 (99.0) 32,402 (96.9) 
   Yes 923 (1.0) 1,049 (3.1) 
Joint replacement   
1.00 (0.46) 
<0.01, 26.40 
1.14 (0.99, 1.30) 
0.08 
1.14 (0.99, 1.32) 
0.08 
0.98 (0.81, 1.20) 
0.10 
0.93 (0.76, 1.13) 
0.09 
   No 104,135 (99.3) 42,731 (99.3) 
   Yes 692 (0.7) 323 (0.8) 
Cerebrovascular disease   
1.00 (0.45) 
<0.01, 23.86 
0.98 (0.88, 1.10) 
0.06 
1.03 (0.90, 1.19) 
0.07 
1.07 (0.87, 1.31) 
0.11 
1.01 (0.82, 1.25) 
0.11 
   No 101,655 (98.9) 41,901 (99.0) 
   Yes 1,114 (1.1) 438 (1.0) 
Coronary heart disease   
0.99 (0.51) 
<0.01, 31.06 
1.18 (1.09, 1.28) 
0.05 
1.18 (1.09, 1.29) 
0.05 
1.20 (1.08, 1.34) 
0.07 
1.11 (1.01, 1.23) 
0.06 
   No 82,268 (97.5) 31,438 (97.3) 
   Yes 2,080 (2.5) 870 (2.7) 
Peripheral vascular disease   
1.00 (0.45) 
<0.01, 25.55 
1.19 (1.01, 1.41) 
0.10 
1.20 (1.00, 1.44) 
0.11 
1.23 (0.95, 1.58) 
0.16 
1.13 (0.87, 1.46) 
0.15 
   No 105,741 (99.6) 43,775 (99.5) 
   Yes 432 (0.4) 203 (0.5) 
Renal disease   
0.99 (0.45) 
<0.01, 26.43 
1.42 (1.33, 1.52) 
0.05 
1.42 (1.32, 1.53) 
0.05 
1.43 (1.27, 1.61) 
0.08 
1.27 (1.13, 1.43) 
0.07 
   No 96,077 (97.4) 35,986 (96.3) 
   Yes 2,541 (2.6) 1,384 (3.7) 




10.4 Sensitivity analyses 
10.4.1 Various PS model specifications 
As previously seen in Chapter 9, treatment effect estimates may change depending on which 
covariates were included in the PS model. In this analysis, four different PS models were 
considered in addition to the PS model considered above: 
Model specification 1: Main effects PS model with linear terms for continuous covariates (as 
described above). 
Model specification 2: Main effects PS model with fractional polynomial terms of dimension 
2 (FP2) terms for continuous covariates. 
Model specification 3: Main effects PS model with fractional polynomials of dimension 1 (FP1) 
terms for continuous covariates. 
Model specification 4: Main effects PS model with FP terms that reduced weight variability 
the most. 
Model specification 5: Main effects PS model with FP terms and two-way interaction terms 
that reduced weight variability the most.  
Choice of FP terms and interactions terms was based on which terms reduced SD of weights 
the most. Appendix N shows the PS model specification that was used to estimate the 
probability of initiating allopurinol and the probability of continuing with allopurinol. For 
outcomes target SU level, coronary heart disease, gout hospitalisation, no interaction terms 
were identified that reduced the SD of weights.  
Table 10.5 shows the distribution of the weights and the unadjusted treatment effect in the 
weighted study sample for each PS model. In comparison with model specification 1 (the main 
analysis), adding FP terms and/or interaction terms did not cause the mean weight to deviate 
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from one. However, for the majority of outcomes, except for mortality and gout 
hospitalisation, the SD of weight increased for model specification 2, for example for joint 
replacement, SD increased from 0.46 to 1.27.  
Treatment effects were then estimated. Note that these estimates were not adjusted for any 
covariates. For target SU level, estimated treatment effect differed slightly in model 
specifications 2-4 compared with the main analysis; estimated HRs were lower ranging 
between 4.60 and 4.69 compared with 4.73 obtained from the main analysis; standard errors 
were larger in model specifications 2 (SE=0.52) and 3 (SE=0.59) compared with the main 
analysis (SE=0.47), although model specification 4 yielded the same standard error (0.47).  
Similarly, for secondary outcomes, estimated treatment effects in model specifications 2-5 
differed slightly to the main analysis and standard errors were comparable to the main 






Table 10.5: Distribution of weights and treatment effect estimation of allopurinol 
 Model specification 1 Model specification 2 Model specification 3 Model specification 4 Model specification 5 
Target SU level      
Weight (mean (SD)) 0.99 (0.68) 1.00 (0.79) 1.00 (0.85) 0.99 (0.64) - 
MSM Hazard ratio (95% CI) 
Standard error 
4.73 (3.89, 5.76) 
0.47 
4.60 (3.69, 5.74) 
0.52 
4.69 (3.66, 6.00) 
0.59 
4.66 (3.82, 5.69) 
0.47 
 
Mortality      
Weight (mean (SD)) 1.00 (0.81) 1.01 (0.86) 1.01 (0.91) 0.99 (0.75) 0.99 (0.70) 
MSM Hazard ratio (95% CI) 
Standard error 
0.96 (0.87, 1.06) 
0.05 
0.98 (0.89, 1.08) 
0.05 
1.02 (0.92, 1.12) 
0.05 
1.02 (0.93, 1.11) 
0.05 
1.03 (0.95, 1.13) 
0.05 
Gout hospitalisation      
Weight (mean (SD)) 1.00 (0.41) 1.00 (0.42) 1.00 (0.46) 1.00 (0.41) - 
MSM Hazard ratio (95% CI) 
Standard error 
2.66 (2.40, 2.94) 
0.14 
2.70 (2.43, 3.00) 
0.14 
2.70 (2.43, 3.00) 
0.15 
2.67 (2.41, 2.95) 
0.14 
 
Joint replacement      
Weight (mean (SD)) 1.00 (0.46) 1.01 (1.27) 1.00 (0.50) 1.00 (0.45) 1.00 (0.44) 
MSM Hazard ratio (95% CI) 
Standard error 
1.14 (0.99, 1.32) 
0.08 
1.09 (0.93, 1.28) 
0.09 
1.06 (0.91, 1.24) 
0.08 
1.15 (0.99, 1.32) 
0.08 
1.15 (0.99, 1.32) 
0.08 
Cerebrovascular disease      
Weight (mean (SD)) 1.00 (0.45) 1.01 (1.34) 1.00 (0.50) 1.00 (0.45) 1.00 (0.44) 
MSM Hazard ratio (95% CI) 
Standard error 
1.03 (0.90, 1.19) 
0.07 
1.00 (0.87, 1.15) 
0.07 
0.99 (0.87, 1.12) 
0.06 
1.04 (0.91, 1.18) 
0.07 
1.03 (0.91, 1.18) 
0.07 
Coronary heart disease      
Weight (mean (SD)) 0.99 (0.51) 1.01 (1.38) 1.00 (0.53) 0.99 (0.51) - 
MSM Hazard ratio (95% CI) 
Standard error 
1.18 (1.09, 1.29) 
0.05 
1.12 (1.01, 1.23) 
0.06 
1.16 (1.06, 1.26) 
0.05 
1.16 (1.06, 1.26) 
0.05 
 
Peripheral vascular disease      
Weight (mean (SD)) 1.00 (0.45) 1.01 (1.42) 1.00 (0.50) 1.00 (0.45) 1.00 (0.44) 
MSM Hazard ratio (95% CI) 
Standard error 
1.20 (1.00, 1.44) 
0.11 
1.13 (0.94, 1.35) 
0.11 
1.13 (0.94, 1.36) 
0.11 
1.19 (1.00, 1.42) 
0.11 
1.18 (0.98, 1.41) 
0.11 
Renal disease      
Weight (mean (SD)) 0.99 (0.45) 1.01 (1.72) 0.99 (0.49) 0.99 (0.44) 0.99 (0.41) 
MSM Hazard ratio (95% CI) 
Standard error 
1.42 (1.32, 1.53) 
0.05 
1.33 (1.18, 1.49) 
0.08 
1.41 (1.30, 1.52) 
0.06 
1.39 (1.29, 1.51) 
0.06 
1.39 (1.29, 1.51) 
0.06 
CI: Confidence interval; SD: Standard deviation; SU: Serum urate 
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10.4.2 Weight truncation 
Sensitivity analysis was performed truncating weights at 0.5% of its percentile (Table 10.6). A 
low percentile was chosen as weights were not extreme. Across all outcome analyses, mean 
weight remained the same and SD decreased. For example, for mortality, the maximum 
weight value reduced from 85.67 to 4.57 and SD of weights reduced from 0.81 to 0.58. 
Estimated treatment effects using truncated weights changed very little compared to the main 
analysis and standard errors were very similar as well.  
Table 10.6: Distribution of truncated weights and its impact on treatment effect estimation 
of allopurinol 












HR (95% CI) 
Standard error 
Target SU level 
0.99 (0.68) 
<0.01, 16.13 








































1.01 (0.90, 1.14) 
0.06 
Coronary heart disease 
0.99 (0.51) 
<0.01, 31.06 




1.17 (1.07, 1.27) 
0.05 
Peripheral vascular disease 
1.00 (0.45) 
<0.01, 25.55 













1.40 (1.30, 1.50) 
0.05 






10.4.3 Missing data 
Complete case analysis was performed for all outcomes (Table 10.7). Missing data was present 
in alcohol consumption, BMI, smoking status, and SU level (SU level was only missing for 
secondary outcomes). For the analysis of target SU level, 52% of the study sample had 
complete data. For the secondary outcomes, approximately 20% of the study sample had 
complete data.  
Compared with the main analysis, weights estimated in complete case analysis were found to 
have mean weight of 1 although, they were more variable across most outcomes; for joint 
replacement, the weights had become large with the maximum weight value increasing to 
92.57 whilst for other outcomes (mortality, gout hospitalisation, and renal disease), the 
maximum weight value had decreased.  
Compared with the main analysis, the direction of HRs and statistical significance remained 
the same for two outcomes although the magnitude of HRs decreased; for target SU the HR 
reduced from 4.73 to 4.42 and for gout hospitalisation the HR reduced from 2.66 to 2.47.  The 
HR for coronary heart disease had reduced from 1.18 to 1.01 and lost statistical significance 
compared with the main analysis. The HRs for renal disease were similar between the main 
analysis and complete case analysis.  
Although allopurinol was not associated with four outcomes in the main analysis, the direction 
of the HRs changed in complete case analysis but remained insignificant for three of the 
outcomes; for mortality HR had changed from 0.96 to 1.28; for joint replacement the HR 
changed from 1.14 to 0.85; for cerebrovascular disease the HR had increased from 1.03 to 
1.92. In contrast, for peripheral vascular disease, the HR had doubled and had become 
statistically significant (2.44 (1.28, 4.67)).   
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As expected, due to reduced sample size, standard errors of all treatment effect estimates 
were larger compared to the main analysis. The largest increase in standard error was 
observed for target SU level (0.47 vs. 1.00) and cerebrovascular disease (0.07 vs. 0.86). 
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Table 10.7: Impact of missing data on treatment effect estimates of allopurinol 







HR (95% CI) 
Standard error 
Unadjusted MSM 







HR (95% CI) 
Standard error 
Unadjusted MSM 
HR (95% CI) 
Standard error 
Target SU level 1,742 
0.99 (0.68) 
<0.01, 16.13 
4.63 (3.95, 5.42) 
0.37 





4.32 (3.02, 6.18) 
0.79 





1.19 (1.12, 1.26) 
0.04 





1.37 (1.11, 1.70) 
0.15 







2.92 (2.67, 3.19) 
0.13 





2.72 (1.98, 3.74) 
0.44 







1.14 (0.99, 1.30) 
0.08 





0.96 (0.59, 1.57) 
0.24 







0.98 (0.88, 1.10) 
0.06 





1.10 (0.73, 1.65) 
0.23 







1.18 (1.09, 1.28) 
0.05 





1.09 (0.81, 1.46) 
0.16 







1.19 (1.01, 1.41) 
0.10 





2.41 (1.33, 4.39) 
0.74 
2.44 (1.28, 4.67) 
0.81 
Renal disease 16,508 
0.99 (0.45) 
<0.01, 26.43 
1.42 (1.33, 1.52) 
0.05 





1.61 (1.31, 1.97) 
0.17 
1.44 (1.10, 1.89) 
0.20 





10.4.4 Unmeasured confounding variables 
Sensitivity of treatment effect estimates (from the main analysis) against unmeasured 
confounding was assessed. E-values were derived which measures the minimum association 
required between an unmeasured confounding variable with treatment and outcome, to 
explain away (or nullify) the treatment effect; E-values were also calculated such that the 
confidence interval for the treatment effect estimate contains the null value. E-values are 
measured on the risk ratio (RR) scale.  
E-values were computed for target SU level, gout hospitalisation, coronary heart disease, and 
renal disease and are presented in Table 10.8. The largest association on the RR scale between 
a measured covariate with outcome, allopurinol initiation, and allopurinol continuation are 
also presented.  
For target SU level, to nullify the estimated HR of 4.73, an E-value of 5.15 was required and an 
E-value of 4.47 for the confidence interval to contain 1. The largest RR was observed between 
renal disease and outcome (RR 1.53); colchicine and allopurinol initiation (RR 1.61); gout 
consultation and allopurinol continuation (RR 1.61). As the E-values were larger than the 
observed RRs, it is unlikely an unmeasured confounding variable exists that is associated with 
both treatment and outcome with a RR of least 4.47, to cause the treatment effect estimate 
to lose statistical significance.  
Similarly for gout hospitalisation, an E-value of 4.76 was required to nullify the treatment 
effect estimate of 2.66, and an E-value of 4.23 in order for the confidence interval to contain 
1. The largest associations between any covariate with gout hospitalisation, allopurinol 
initiation, and allopurinol continuation ranged from 1.34 to 2.41. Therefore, as the E-value 
was outside of this range, it is unlikely a strong confounding variable exists that could cause 
the treatment effect estimate to lose statistical significance.   
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For coronary heart disease and renal disease, smaller E-values of 1.49 and 1.87 respectively, 
were required to nullify the estimated treatment effects; also, E-values of 1.32 and 1.72 
respectively, would be required to cause the confidence interval to include the null value. The 
RRs observed between covariate and outcome (coronary heart disease/renal disease), 
allopurinol initiation, and allopurinol continuation ranged from 1.39 to 3.31. Therefore, it is 
likely an unmeasured confounding variable exists that could cause the estimated treatment 
effects to lose statistical significance.   
Table 10.8: Assessment of unmeasured confounding using E-values 
Outcome 
MSM 
HR (95% CI) 
E-value 

















































aRR was <1.00 thus the inverse was taken and presented; HR: Hazard ratio; CI: Confidence interval; LCI: Lower 




This chapter aimed to estimate the causal association between allopurinol use and long-term 
outcomes using MSM. In this analysis, the associations between covariates and treatment 
initiation and continuation were modelled separately.  
This analysis had shown allopurinol users had higher chance of reaching target SU level and 
had higher risk of gout hospitalisation, coronary heart disease and renal disease than non-
users. There was no evidence allopurinol use was associated with mortality, joint replacement, 
cerebrovascular disease, and peripheral vascular disease. The estimated treatment effects 
were robust to various PS model specifications and large weights, indicating that the PS 
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models were correctly specified. The treatment effect estimates from complete case analysis 
differed in terms of magnitude, direction, and statistical significance across outcomes, 
although this was primarily due to analysing a much smaller sample and selection bias.  
Treatment estimates for target SU level and gout hospitalisation were likely to be robust 
against unmeasured confounding as strong confounding variables would be required for the 
treatment estimates to lose statistical significance. However, the same cannot be said for 
coronary heart disease and renal disease that will require weak confounding to explain away 
the treatment effect estimates.  
Comparison with previous studies 
Although there are no comparable studies that had evaluated the time-varying effect of 
allopurinol on outcome, one study had evaluated the changes in SU level on outcome in gout 
using MSM (Desai et al., 2018). That study is of interest due to the direct effects of allopurinol 
on lowering SU level that are subsequently expected to lower the risk of poor outcome. Desai 
et al. (2018) found per 3 mg/dL reduction in SU level was not associated with cardiovascular 
disease (coronary heart and cerebrovascular diseases) (HR 1.01 (0.81, 1.27)) but was 
associated with renal function decline (HR 0.89 (95% CI 0.81, 0.98)). The HRs differed to the 
HRs estimated in this analysis but that could be due to differing outcome and exposure 
definitions, different study population (USA), data was obtained from health insurance claims, 
and included more covariates in PS estimation.  
Residual confounding 
In the main analysis, it was found in the weighted study sample covariate balance was not 
achieved for all covariates in all follow-up periods. Some residual confounding was expected 
as the associations between covariates and patients initiating treatment for the first time and 
patients resuming treatment were assumed to be the same when they may instead differ; the 
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same assumption was also made between patients discontinuing treatment for the first time 
versus those discontinuing treatment repeatedly. However, using separate PS models to allow 
these associations to differ may lead to larger standard error in the treatment effects (Platt et 
al., 2013). Other sources of residual confounding will be from incomplete adjustment for 
lifestyle factors due to missing data, unable to model SU level as a time-varying covariate as it 
was infrequently measured, and under reporting of hypertension and renal disease found in 
this dataset.  
Estimating the probability of initiating and continuing with allopurinol separately vastly 
improved the distribution of weights compared with weights estimated in Chapter 9.  
Estimated treatment effects were more in line with treatment effects estimated from baseline 








Electronic health records (EHR) enable real life patterns of drug prescribing and other aspects 
of healthcare to be captured over a long period of time. This in turn allows for the possibility 
of treatment effects to be estimated under conditions of time-varying treatment and 
covariates. However, this may give rise to time-varying confounding as covariates may predict 
future treatment and outcome over time. Controlling for time-varying covariates that are 
affected by past treatment can be challenging in practice as one may inadvertently adjust out 
the effect of treatment that is mediated through covariates, resulting in biased effects.  
The work presented in this thesis employed two advanced propensity score (PS) based 
approaches, namely PS subclassification and marginal structural models (MSM), to complex 
EHR data from the Clinical Practice Research Datalink (CPRD), to accurately estimate effects 
of allopurinol on a range of outcomes in patients with gout. Multiple clinical and statistical 
decisions have had to be made at various stages of data preparation and analysis. Sensitivity 
of the findings to various assumptions was assessed and some important implementation 
challenges have been identified.  
This chapter summarises key findings and highlights the strengths and limitations of this work. 
Potential future research and clinical implications are also discussed.  
 
11.1 Summary of key findings 
Literature review 
The literature review conducted in October 2014 was performed to identify published 
observational studies evaluating the effect of allopurinol on gout outcomes, and to establish 
the range of study designs and statistical methods used to control for confounding variables 
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(Chapter 3). The review highlighted a small number of studies that had used primary care EHR 
to evaluate effects of allopurinol. Studies tended to measure allopurinol and covariates at a 
single time point and the methods used to account for these covariates were generally 
suboptimal. No studies modelled time-varying allopurinol and covariates, nor had considered 
assessing sensitivity of treatment effect estimates to modelling assumptions made, such as 
absence of unobserved confounding. 
Given that considerable time has elapsed since the initial review was conducted and there 
have since been published studies highlighting the benefits of using EHR for research (Herrett 
et al., 2015), the literature review was updated in June 2020. A further 56 studies were 
identified that evaluated effect of allopurinol, of which five studies had used primary care EHR 
data (Abdul Sultan et al., 2017, Sultan et al., 2019, Sultan et al., 2018, Roughley et al., 2018, 
Vargas-Santos et al., 2018). Twenty-two studies analysed EHR from insurance claims. PS 
matching at baseline to create comparable treatment groups was used in 11 studies. One 
study had used inverse probability treatment weights that were estimated using generalised 
boosted regression models to account for confounding (Chung et al., 2019). Some studies had 
reported results for outcomes not considered in earlier similar studies, such as hepatoxicity 
(Lee et al., 2019), dementia (Singh and Cleveland, 2018b), cancer (Shih et al., 2017, Chen et 
al., 2016), erectile dysfunction (Abdul Sultan et al., 2017), and fracture (Sultan et al., 2018, 
Tzeng et al., 2016). Kang et al. (2019) had used competing risk models to account for the 
competing risk of death in the evaluation of non-fatal cardiovascular events. Few studies had 
censored patient follow-up when treatment status had changed (Vargas-Santos et al., 2018, 
Foody et al., 2017, Kang et al., 2019, Kim et al., 2018, Zhang et al., 2018). Although studies had 




No studies were identified that used advanced methods to evaluate the time-varying effect of 
allopurinol on outcome in the presence of time-varying confounding. Hence, new findings 
from this thesis adds to the current literature.  
Baseline PS subclassification 
Chapter 7 estimated the conditional effect of initiating allopurinol on outcome using the one-
year landmark method. Initial descriptive statistics showed allopurinol users more commonly 
had SU level above target, coronary heart disease, and renal disease, and were prescribed 
pain relief and diuretics more compared to non-users. These differences between treatment 
groups suggested confounding by indication could be present. 
Baseline confounding was controlled by creating homogenous subclasses via PS 
subclassification and by adjusting for remaining imbalanced covariates in outcome analysis. 
PS subclassification was relatively straightforward to implement. Estimated PS distribution 
was satisfactory with adequate common support between treatment groups and balance was 
achieved for the majority of covariates within subclasses.  
Allopurinol was shown to be associated with higher chance of reaching target serum urate 
(SU) level ≤360μmol/L and fewer number of primary care gout consultations, while it also 
increased risk of premature mortality, gout hospitalisation, coronary heart disease, and renal 
disease compared with non-use. The magnitude of the effect of allopurinol differed across 
subclasses for gout consultations and gout hospitalisation. No association was observed 
between allopurinol and joint replacement, cerebrovascular disease, and peripheral vascular 
disease.  
Analyses were subsequently stratified by presence of renal disease and severe 
hyperuricaemia. It was not possible to reliably estimate treatment effect estimates among 
those with renal disease due to very low sample size. However, among those without renal 
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disease, allopurinol remained associated with higher chance of reaching target SU level and 
fewer number of primary care gout consultations, and increased risk of gout hospitalisation, 
coronary heart disease, and renal disease than non-use, and now also with a higher risk of 
joint replacement; the direction and magnitude of the hazard ratios were similar to the 
estimated hazard ratios in the whole study sample analysis. 
Allopurinol was associated with reaching target SU level, gout hospitalisation, joint 
replacement, coronary heart disease and fewer gout consultations in those with non-severe 
hyperuricaemia, but only reaching target SU level and fewer gout consultations in those with 
severe hyperuricaemia. 
The key limitation of baseline PS subclassification approach was that PS was estimated as the 
probability of allopurinol at baseline conditional on covariates at baseline, thus assuming that 
these measures remained constant throughout follow-up. These assumptions may be 
unrealistic; the one-year landmark method used for the main analyses did not capture the 
majority of patients consulting for gout that were prescribed allopurinol later on. Using a two-
year landmark period did not change treatment effect estimates substantially, suggesting that 
future similar studies analysing effect of allopurinol initiation following gout diagnosis should 
consider a longer landmark period. However, this simplistic approach provided a base set of 
results, against which estimates based on more elaborate methods could be compared.   
Time-varying PS subclassification 
Chapter 8 extended PS subclassification to a repeated measures setting that captured changes 
in allopurinol status and covariates over time, thus estimating the conditional effect of actual 
treatment. Descriptive analyses showed the prevalence of key comorbidities that are 
indications for allopurinol (renal disease and hypertension) had increased over time and to a 
smaller extent colchicine use although there was a reduction in prescriptions for NSAIDS. The 
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proportion of patients prescribed allopurinol was double that observed in the baseline 
analysis. It was also observed that once patients initiated allopurinol, 40% discontinued 
treatment, with nearly half of those patients subsequently restarting treatment. Differences 
in comorbidities between treatment groups identified in the baseline analysis were more 
pronounced and now included hypertension and obesity; differences in baseline SU level and 
medication use between treatment groups identified in baseline analysis persisted.    
There were several issues encountered during implementation of time-varying PS estimation. 
The initial model estimated PS that near violated the positivity assumption with values close 
to zero in the majority of non-allopurinol intervals in the subclass with the lowest propensity 
for allopurinol. This resulted in poor common support of PS between treatment groups with 
few allopurinol intervals found in the subclass with the lowest PS, and no occurrence of 
outcome in that subclass. Various modifications, such as inclusion of interaction terms and 
non-linear terms, and omission of covariates, were made to the PS model however none 
resolved the issue. Reducing the number of subclasses from five to four and/or removing 
patients outside the region of common support prior to subclassification, still resulted in very 
few allopurinol intervals in the first subclass and no occurrence of outcome. With regards to 
covariate balance, overall balance was achieved across subclasses however within subclasses, 
a number of covariates were not balanced and had to be adjusted for in subclass-specific 
treatment effect estimation. Modifications made to the PS model and increasing the number 
of subclasses did little to improve covariate balance.  
As a result, across all outcomes, the first subclass could not be used and was excluded from 
all outcome analyses. The implication of this was that not all repeated measurements from a 
patient were analysed. Intervals that were excluded contained observations from older 
patients and resided in less deprived areas, were female, had lower SU level, were less likely 
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to consult for gout, had fewer prescriptions for diuretics, and shorter mean duration of 
previous allopurinol use, than intervals that were included in analysis.  
In terms of the findings, allopurinol was found to be associated with increased chance of 
reaching target SU level, and increased risk of gout hospitalisation, coronary heart disease, 
peripheral vascular disease and renal disease.  
Compared with the baseline PS subclassification approach, some findings remained similar, 
however overall the estimated hazard ratios were different and standard errors were larger, 
to varying extent, across all outcomes. For example, the hazard ratios for target SU level and 
peripheral vascular disease doubled; effect of allopurinol on mortality lost statistical 
significance; cerebrovascular disease, coronary heart disease and renal disease now had 
treatment effects that varied across PS subclasses.  
Overall application of time-varying PS subclassification method did not perform well in 
estimating PS, and consequently in the outcome analysis stage. The primary reason is 
suspected to be the use of random intercept (used to account for within patient repeated 
measurements) in the PS estimated model. Use of random effects is known to have better 
discrimination ability (i.e., allopurinol users and non-users have higher and lower estimated 
PS respectively) than logistic regression without random effects (Bouwmeester et al., 2013), 
which may have been the reason for poor common support of PS between treatment groups. 
Random intercept terms had to be omitted from the estimation of subclass-specific treatment 
effects as models failed to converge successfully, potentially because adjustment for time 
component and/or adjustment for imbalanced covariates. Various specifications of variance-
covariance structure were considered, and none resolved the issue of non-convergence. 
Therefore, in the end, robust standard errors were estimated instead to allow for correlated 
repeated measurements of patients within subclasses. 
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Marginal structural models 
MSM were used to estimate the marginal treatment effect accounting for treatment and 
covariate histories. MSM were fitted under two different assumptions.  
In Chapter 9, naïve scenario was considered, where the direction and magnitude of 
associations between covariates and allopurinol initiation and continuation were assumed to 
be the same. Only mortality outcome was considered. The initial PS model yielded extremely 
large stabilised weights with mean weight deviating from one. Consequently, unexpectedly 
low magnitude of the estimated treatment effect was observed, indicating that allopurinol 
use was strongly protective of premature mortality (which was not observed in previous 
chapters), although the standard error was smaller than the corresponding standard error 
derived from time-varying PS subclassification but larger via than baseline PS subclassification.  
Although one primary care EHR study had shown allopurinol use was protective of premature 
mortality (Dubreuil et al., 2015), the estimated hazard ratios in this analysis was considerably 
lower and unexpected, as prescription for allopurinol dose is often low (100-300mg/day) and 
infrequently escalated to the optimal dose within primary care (Cottrell et al., 2013). Similar 
magnitude and direction of treatment effect estimates of allopurinol were also obtained for 
other secondary outcomes, though reporting of the results was restricted to mortality only in 
this analysis.  
Various modifications to PS models were made in an attempt to reduce weight variability. 
Inclusion of non-linear terms for continuous covariates yielded the largest increase in the 
hazard ratio, thus estimating an even stronger protective effect against premature mortality 
although, standard error did reduce. Cumulatively including interaction terms between 
covariates to the PS model resulted in a decrease in hazard ratio towards the null and 
reduction in standard error that was similar to the standard error estimated in baseline PS 
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subclassification approach. Regardless of the choice of PS model, imbalance appeared in all 
covariates and worsened over time; direct adjustment for these imbalanced covariates in 
outcome analysis generally led to the hazard ratio moving further away from the null and 
increased standard error. In all instances, allopurinol use remained protective of premature 
mortality.  
Various common approaches for reducing extremeness of weights were adopted. Using 
normalised weights and weight truncation for both stabilised and normalised weights yielded 
smaller hazard ratios that were closer to the null value, and smaller standard errors than the 
treatment effect estimates obtained from the main analysis. However, despite these remedial 
procedures, the issue of covariate imbalance between treatment groups remained, 
particularly after ten years of follow-up. When follow-up was truncated at 10 years, the 
treatment effect estimate moved closer to the null with a larger standard error compared with 
the main analysis. Notably, covariate balance was achieved over time; this may have been due 
to certain covariate combinations occurring after 10 years that may have been the cause of 
extreme weights initially observed not being captured. Furthermore, extreme weights that 
may have appeared in earlier follow-up were prevented to be cumulatively multiplied over a 
longer period that would have amplified extreme weights. Out of these various approaches 
used, weight truncation estimated the hazard ratios closest to the null and smallest standard 
errors although covariate balance could only be achieved with substantial weight truncation.   
Lastly, intention-to-treat analysis that estimated the effect of initiating allopurinol and 
assumed patients remained on treatment until the end of follow-up was performed. 
Estimated stabilised weights were more satisfactory as there were no extreme weights and 
mean weight did not deviate from one. Estimated treatment effects was comparable with 
baseline PS subclassification although the standard error was slightly larger. This suggests 
estimating weights after treatment initiation may be complex.      
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Overall, it was concluded that the PS model was likely misspecified, primarily because of the 
assumption that the associations between covariates and allopurinol initiation and 
continuation were the same. There appeared to be a trade-off between bias and precision of 
the estimated treatment effect; use of different approaches to reduce extreme weights 
generally led to treatment effect estimates that were close to the null value (indicating 
increase in bias), while standard error decreased (increased precision).  
In Chapter 10, the direction and magnitude of associations between covariates and allopurinol 
initiation and continuation were assumed to differ. This assumption was plausible as the 
associations between covariates and allopurinol continuation and discontinuation differed in 
magnitude, direction, and statistical significance. For example, hyperlipidaemia, hypertension, 
and diabetes had increased odds of continuing allopurinol compared with discontinuing 
allopurinol; in contrast, these same covariates had reduced odds of initiating allopurinol 
compared with non-use.  
Estimating PS separately for patients initiating and continuing allopurinol improved weight 
estimation; the estimated weight distribution was not skewed, mean weight was close to one, 
and extreme weights were not present. Outcome analysis showed that allopurinol was 
associated with higher chance of reaching target SU level, and increased risk of gout 
hospitalisation, coronary heart disease, and renal disease. As a sensitivity analysis, truncating 
weights by a small percentage resulted in very small changes in the hazard ratios and standard 
errors for all outcomes suggesting any larger weights (although not extreme) did not have an 
undue impact on treatment effect estimates. Imbalance remained in some covariates and 
these were adjusted for in the outcome analysis; adjustment for large imbalanced covariates 
caused small changes in treatment effect estimates and small increase in standard errors, 
except for target SU level where hazard ratio and standard error increased by a large amount.  
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Although not statistically significant, treatment effect estimate had shown allopurinol 
generally increased risk of premature mortality in contrast to Chapter 9, where allopurinol 
was protective of mortality and had larger standard error due to larger weight variability.   
Generally, similar conclusions regarding the effectiveness of allopurinol can be made based 
on application of MSM and time-varying PS subclassification approaches; allopurinol 
increased the chance of reaching target SU level, and increased risk of gout hospitalisation, 
coronary heart disease, and renal disease; however, PS subclassification had found allopurinol 
increased the risk of peripheral vascular disease as well. Magnitude of treatment effect 
estimates differed between the two methods; hazard ratios estimated from MSM were 
greater for target SU level and joint replacement, but smaller for peripheral vascular disease 
compared to estimates obtained via time-varying PS subclassification; as PS subclass-specific 
treatment effects could not be pooled for gout hospitalisation, cerebrovascular disease, 
coronary heart disease and renal disease, most estimates were smaller than the estimates in 
MSM, with the exception of one PS subclass that had greater estimates. Precision of treatment 
effect estimates resulting from MSM approach was generally smaller compared with time-
varying PS subclassification.   
Comparison of treatment effect estimates obtained from MSM and baseline PS 
subclassification (Chapter 7) are not comparable; MSM estimated the effect of actual 
treatment, whereas baseline PS subclassification estimate the effect of initiating treatment. 
Regardless, both methods found allopurinol increased the chance of reaching target SU level, 
and increased risk of gout hospitalisation, coronary heart disease, and renal disease. Notably, 
the largest difference observed between the two methods were that estimated hazard ratios 
for target SU level and gout hospitalisation in MSM were double of the hazard ratios obtained 
from baseline analysis, and also had larger standard errors. Overall, no reliable conclusions 
can be made regarding comparison of point and precision estimates between the two 
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methods as similarities and differences were dependent upon frequency of outcome events, 
consideration of time-invariant and time-varying treatment and covariates, and how soon 
outcome occurs after receiving treatment, and how confounding effects were accounted for. 
Missing data 
Missing data were present for body mass index, alcohol consumption, smoking status and 
baseline SU level. For the main analysis, the missing indicator method (MIM) and the last 
observation carried forward (LOCF) were utilised allowing the entire study sample to be 
analysed. Complete case analysis was performed restricting analysis to patients who did not 
have missing data in those covariates across all three methods to assess sensitivity of 
treatment effect estimates regarding target SU level and mortality in (baseline and time-
varying) PS subclassification, and then across all outcomes in MSM.  
In complete case analysis for target SU level, the estimated hazard ratio had reduced in 
baseline PS subclassification whereas in time-varying PS subclassification and MSM, the 
hazard ratios were greater than the hazard ratios obtained from analysing the whole study 
sample. However, significance of estimates of allopurinol effect remained throughout. In 
complete case analysis for mortality, hazard ratio resulting from baseline PS subclassification 
approach, had reduced compared to the hazard ratio estimated from analysing the whole 
study sample, and significance was lost. In contrast, hazard ratios obtained via time-varying 
PS subclassification and MSM increased in complete case analysis. Standard errors of 
treatment effect estimates across all three methods had increased as expected due to smaller 
sample available for analysis; however, the increase in standard error was the greatest in 
MSM, followed by time-varying PS subclassification and then baseline PS subclassification.  
Larger differences in treatment effect estimates obtained from complete case analysis and 
the whole study sample analysis was found in MSM and time-varying subclassification 
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compared with baseline PS subclassification. This may be due to using MIM over time with 
LOCF that may have biased treatment effect estimates more than using MIM at baseline. 
However, treatment effect estimates from complete case analysis may be biased due to 
analysing a more selective group of patients not representative of the whole study sample 
thus introducing selection bias.  
Complete case analysis was performed for the remaining outcomes in MSM only. Allopurinol 
remained associated with greater chance of reaching target SU level and greater risk of gout 
hospitalisation, peripheral vascular disease and renal disease; statistical significance was lost 
for coronary heart disease. Hazard ratios were smaller in complete case analysis for gout 
hospitalisation, joint replacement and coronary heart disease, and were larger for the 
remaining outcomes compared to the hazard ratios estimated in the whole study sample. As 
before, all standard errors were higher in complete case analysis.  
Unmeasured confounding 
PS-based methods make a strong assumption of no unmeasured confounding which in 
practice is unlikely to be satisfied. Impact of confounding was considered for baseline PS 
subclassification, for target SU level and mortality. In MSM, it was considered for outcomes 
that had statistically significant associations with allopurinol. Unmeasured confounding was 
not considered for time-varying PS subclassification as the approach had to exclude some 
repeated measurements within patients from analysis in treatment effect estimation. 
Therefore, differences in the treatment effect obtained in the main analysis compared with 
the revised treatment effect in the presence of unmeasured confounding will be attributed to 
both unmeasured confounding and residual confounding from exclusion of repeated 
measurements from analysis.   
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In baseline PS subclassification, treatment effect estimates were revised in light of an 
unmeasured binary covariate with differing prevalence rates within treatment groups using 
the approach by Lin et al. (1998). Regardless of the distribution of an unmeasured binary 
confounding variable with treatment, allopurinol use remained associated with increased 
chance of reaching target SU level; treatment effect estimate was robust to unmeasured 
confounding as the magnitude of the hazard ratio was smaller but remained large and 
statistically significant. However, for mortality, treatment effect estimate lost significance in 
the assumed presence of an unmeasured binary confounding variable that had small 
difference in prevalence rates between treatment groups. When the difference of prevalence 
rates of the unmeasured confounding variable was large between treatment groups, 
allopurinol was shown it could be protective of premature mortality. The disadvantage of this 
method is that it does not consider the association between an unmeasured confounding 
variable and outcome, and the standard error of treatment effect assumed to be constant.   
Within MSM, E-value approach to assessing unmeasured confounding was used. E-value 
quantifies the association (risk ratio) between an unmeasured confounding variable with 
treatment and outcome that would be required to explain away the treatment effect. As large 
hazard ratios were estimated for target SU level and gout hospitalisation in the main analysis, 
a strong association of at least 4 on the risk ratio scale between an unmeasured confounding 
variable and allopurinol would be required to explain away or nullify the hazard ratios; such 
an unmeasured confounding variable is unlikely to exist as the strongest observed association 
(risk ratio) between any covariate with allopurinol and outcome was 2.4. In contrast, for 
coronary heart disease and renal disease, as the estimated hazard ratios were smaller, a 
weaker association of at least 1.67 (risk ratio) between an unmeasured confounding variable 
with outcome and treatment was required to explain away the treatment effect; thus these 
estimates may be non-robust.  
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Evidently, generally larger estimated treatment effects require stronger unmeasured 
confounding variables to explain away the treatment effect. This thesis had considered strong 
confounding variables such as renal disease and baseline SU level thus finding another strong 
single confounding variable is unlikely; however, in the presence of cumulative confounding 
effects from two or more unmeasured confounding variables could potentially explain away 
small treatment effects.  
Comparison with previous research 
Published literature mostly considered allopurinol use at baseline thus the results are only 
comparable with baseline PS subclassification. As discussed in Section 7.7.1, there are few 
published EHR studies that had used comparable methods that were used in this thesis. 
Compared to published studies that had used EHR from CPRD and the one-year landmark 
method, estimated hazard ratios for mortality and renal disease in this thesis were larger and 
statistically significant although precision was similar (Kuo et al., 2015a, Roughley et al., 2018). 
Kuo et al. (2018) had used a case-control study design with CPRD data and concluded 
allopurinol use was not associated with joint replacement. One study using EHR from a Taiwan 
administrative database had concluded allopurinol increased risk of coronary heart disease 
but not cerebrovascular disease, the same conclusions derived in this thesis albeit with smaller 
hazard ratios and standard errors (Kok et al., 2014). In contrast, a study using EHR from an 
American administrative database had shown allopurinol was protective of peripheral 
vascular disease (Singh and Cleveland, 2018a), which was not verified in this thesis. No existing 
studies using EHR databases have evaluated outcomes target SU level, repeated gout 
consultations and gout hospitalisation. A RCT evaluating efficacy of nurse-led care vs. general 
practitioner (GP)-led care, found nurse-led care achieved greater number of patients achieving 
target SU level and reduced gout flares over two years than GP-led care (Doherty et al., 2018). 
Other smaller studies have shown allopurinol was associated with greater chance of reaching 
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target SU level (Dalbeth et al., 2006, Roddy et al., 2007b) and reduced flares potentially leading 
to fewer consultations (Neogi et al., 2014, Zhang et al., 2012, Zhang et al., 2014) the same 
conclusions as derived in this thesis. However, this thesis found allopurinol use was associated 
with higher risk of gout hospitalisation unlike a small study case-control study in New Zealand 
that found allopurinol use had lower odds of hospitalisation (Hutton et al., 2009).  
As stated above, no studies had evaluated the effect of time-varying allopurinol; few studies 
had censored follow-up when treatment had changed or switched treatment groups (Vargas-
Santos et al., 2018, Kim et al., 2013b). However, one study had evaluated the association 
between changes in SU level and risk of renal disease and cardiovascular disease in people 
with gout using MSM (Desai et al., 2018). This study is of relevance to this thesis as changes in 
SU level due to taking allopurinol were expected to have an effect of outcome. That study 
found reduction in SU level was associated with declining renal function but was not 
associated with cardiovascular disease.  
 
11.2 Strengths, limitations, and future research 
Strengths 
There are several strengths of the work presented in this thesis to note. This was the first 
retrospective cohort study that used complex methods to model time-varying treatment 
effect using a large UK primary care EHR database on a range of clinically important long-term 
outcomes in a heterogeneous group of patients with gout likely to be representative of those 
seen in day-to-day clinical practice. The study sample included incident and prevalent cases of 
gout to maximise generalisability of treatment effect estimates to the UK gout population.  
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Several aspects of how such data could be used for treatment-effectiveness research, 
particularly how to incorporate time dependency of covariates and treatment during data 
preparation, were discussed. Careful consideration was given to ensure temporal ordering 
between covariates, treatment and outcome across all methods employed, by using the 
landmark approach to define baseline period and subsequently splitting the follow-up into 
equally spaced intervals within which these measures can be ascertained. Initial baseline 
analysis employed the one-year landmark period which was extended to two years to capture 
more patients prescribed allopurinol. This extension made little difference to treatment effect 
estimates. Within time-varying PS subclassification, initially time was subdivided into six-
month intervals which were then extended to yearly intervals. Decision to use one-year 
intervals for measurement of covariates and treatment was based on achieving a balance 
between increased computational intensity, that would result from use of small intervals, and 
capturing the real-life frequency of treatment and covariate measurement as accurately as is 
practically feasible. 
The positivity assumption was plausible in the estimation of baseline PS however, was near 
violated when PS was estimated over time. Other core assumptions to infer causal treatment 
effects were generally deemed plausible; for the consistency assumption, i.e., that treatment 
was well defined, patients prescribed urate-lowering or uricosuric drugs in the two years prior 
to gout consultation were excluded to ensure there was no interference from the effect of 
those drugs and the effect of incident allopurinol use could then be evaluated. The plausibility 
of exchangeability and model misspecification were continually assessed. Various PS models 
were fitted to assess sensitivity of estimated treatment effects to these modelling variations.  
Furthermore, sensitivity analyses were conducted to assess robustness of treatments effects 
estimates to missing data and unmeasured confounding.  
Limitations and future work  
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This thesis had defined allopurinol use as a total of three months of allopurinol prescription in 
the landmark period for baseline analysis, and subsequently in each year of follow-up. 
Sensitivity analysis could have been performed using alternative definitions for treatment 
such as classifying allopurinol users as those with six or more months of prescription (Kuo et 
al., 2015a), and/or taking precise allopurinol dosage into account.  
As shown in this thesis, allopurinol use did not lead to protective effects against poor 
outcomes which may be due to suboptimal management of gout, such as patients not 
generally being prescribed a high enough allopurinol dose needed to reach target SU level 
(Cottrell et al., 2013) and discontinuation of treatment (Scheepers et al., 2018). Studies had 
shown higher allopurinol doses were protective of renal disease (Vargas-Santos et al., 2018), 
cardiovascular events (Kok et al., 2014), and greater chance of reaching target SU level (Rees 
et al., 2013). Further research could consider effectiveness of time-varying allopurinol dosages 
on outcome using MSM (Lipkovich et al., 2012).  
Future research could evaluate the direct effect of SU level on outcome to avoid the need to 
model suboptimal allopurinol dose. However, within CPRD, SU level was infrequently 
measured and the majority of patients who did have a recorded SU level was over 360μmol/L. 
If CPRD data was used for such an analysis, future work at the most can only consider SU level 
at baseline.  
Patients adhering with allopurinol for a longer period has been shown to be associated with 
reduced flares (Kim et al., 2013b). Future work could also include evaluation of effectiveness 
of different treatment regimens within MSM, such as continuous use of allopurinol for three 
years versus one year, or comparisons of effectiveness made between patients fully adhering 
with treatment versus those partially adhering versus those not treated. Sophisticated flexible 
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MSM could be used to determined how much cumulative exposure to allopurinol patients are 
required to have in order to see the benefits of treatment on outcome (Xiao et al., 2014).  
Other sensitivity analyses could have been performed to assess robustness of treatment effect 
estimates obtained in this study. For example, length of intervals in which covariates and 
treatment were repeatedly measured in the follow-up could have been varied. However as 
noted above, use of smaller intervals may lead to computational issues such as non-
convergence of regression models. Use of larger intervals on the other hand may be 
inappropriate if covariates are frequently measured, such as prescriptions; using ‘out-of-date’ 
information would have weaker associations with treatment and outcome than more recent 
measurements, thus confounding may not be adequately controlled for. Alternatively, one 
could have used unequal intervals where length of interval is based on the period the patient 
is on treatment, with the interval ending once treatment has changed or discontinued; this 
approach was used by Leon (2011a) and may be a solution to having a large number of 
intervals that may cause modelling issues.  
Correct model specification and positivity assumptions are two of the assumptions that PS 
methods are based on. In considering time-varying PS, estimated PS in non-allopurinol 
intervals were close to zero (in the subclass with the lowest PS) which subsequently led to 
presence of extreme weights in MSM, which indicate that the PS model may have been 
misspecified. In the initial application of MSM, incorrect model specification may have 
stemmed from the assumption that the influence of covariates was the same amongst those 
initiating and continuing with treatment when in fact, they had differed. Yang et al. (2015b) 
simulation study had shown modelling the complex mechanisms of treatment use estimated 
unbiased treatment effects although it was limited to two time points. Further work could 
extend this simulation study to include more time points.  
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Within time-varying PS subclassification, it was difficult to assess whether model 
misspecification had an impact on treatment effect. Attempts to improve common support of 
PS between treatment groups was largely unproductive; patients for whom common support 
improved after modifying the PS model ended up being excluded regardless due to small 
number of allopurinol users and no occurrence of outcome in the subclass corresponding to 
the lowest PS. A possible solution could be to estimate PS estimated separately for patients 
initiating and continuing with allopurinol, as this approach improve PS estimation in MSM. 
Simulation studies would be required to assess how well this approach would adequately 
control for confounding effects.   
In PS models, it was assumed the decision to treat was based on covariate values measured in 
the interval prior to treatment and previous cumulative exposure to treatment, and that 
covariates measured two or more years ago had no influence. In practice, GPs are likely to 
prescribe treatment based on cumulative effects of past treatment, covariate history, and 
patient response to treatment. However, the majority of time-varying covariates only changed 
value once, it was unlikely that adjustment for covariates observed in earlier intervals would 
be strongly associated with treatment. This is more likely to apply to covariates that change 
more frequently over time, such as prescription data; however, this was not explored in this 
thesis.   
PS methods make a strong assumption of no unmeasured confounding which in practice is 
unlikely to be satisfied. In this thesis, effects of confounding were minimised by considering a 
large number of clinically relevant covariates. Covariates that were not considered in this 
thesis may potentially be indications for allopurinol (or urate-lowering therapy more 
generally), include recurrent flares, tophi, chronic gouty arthritis, bone erosion, and 
urolithiasis (Hui et al., 2017, Richette et al., 2017). Patients with these indications are likely to 
have SU level above target, which in turn is associated with outcomes considered in this thesis, 
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for example renal disease (Desai et al., 2018). However, these measures are infrequently 
recorded in primary care (Kuo et al., 2014). Robustness of treatment effect estimates against 
unmeasured confounding was evaluated. An alternative method to account for unmeasured 
confounding is use of instrumental variables (IV). IV are used to remove the correlation of 
treatment with unmeasured covariates in the estimation of causal effects. For a covariate to 
be an IV, it needs to be associated with treatment, act on outcome through treatment, and be 
independent of the unmeasured covariate. Finding a covariate that satisfies the assumption 
of IV may be difficult although directed acyclic graphs may be helpful in identifying such an IV 
(Brookhart et al., 2010a). For example, the IV approach has been used to evaluate the 
associations of hyperuricaemia and gout with myocardial infarction. Multiple IVs were 
considered such as age, renal function, diuretic use, and the metabolic syndrome, which were 
assumed to affect outcome though hyperuricaemia and gout (Krishnan et al., 2006). 
Residual confounding may remain from incomplete adjustment of observed covariates. In this 
thesis the strongest confounding variables were considered to be SU level and renal disease. 
Ideally, SU level should have been treated as a time-varying covariate as it is a strong predictor 
for allopurinol and outcome. BSR and EULAR guidelines state SU levels should be monitored 
in line with titrating allopurinol dose, and ensuring patients reached target SU level (Jordan et 
al., 2007b, Hui et al., 2017). In practice, SU level was only measured at baseline, around the 
time of gout consultation for a small proportion of patients. Consequently, SU level is likely to 
have been imbalanced between treatment groups over time. Renal disease was treated as 
time-varying covariate assuming that once a patient was diagnosed with renal disease, they 
had it for the rest of follow-up. A more accurate measure could have been based on eGFR, a 
measure of renal function, to gauge severity of renal disease; unfortunately, eGFR was not 
measured routinely in clinical practice prior to 2004.  
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A large proportion of patients did not have complete data on lifestyle factors, perhaps due to 
intermitted recording of information when patients consult (Jordan et al., 2007a). This thesis 
had used the MIM and LOCF, however simulation studies have shown that use of these 
methods can bias estimates (Cook et al., 2004, Knol et al., 2010). As described above, complete 
case analysis had shown treatment effect estimates from baseline analysis were more robust 
to missing data than time-varying analyses.  
An alternate approach, multiple imputation (MI) by chained equations, could have been used 
to impute missing data. MI is a frequently used approach to deal with missing data, and has 
been adopted in PS literature; a systematic review of 167 studies that had used PS-based 
methods published between 2010 and 2017, found that found MI was used in 19% of these 
studies (Malla et al., 2018). However, it was only until recently simulation studies had shown 
PS estimation (at a single time point) and treatment effect analysis should be performed 
within each imputed data set separately prior to combining treatment effect estimates 
(Granger et al., 2019, Leyrat et al., 2019); and that MI provided unbiased estimates unlike 
complete case analysis (Leyrat et al., 2019) and MIM (Choi et al., 2019) (within the context of 
PS methods). Similarly, in MSM under the intention-to-treat principle, simulation studies had 
shown MI and inverse probability missing weights performed better than LOCF and complete 
case analysis as estimates were less biased (Vourli and Touloumi, 2015, Mojaverian et al., 
2015). For EHR where the number of follow-up time points is large, further MI approaches 
have been developed to impute missing data over time (Welch et al., 2014, Kontopantelis et 
al., 2017); however further research is required to assess in how well these methods work 
compared with complete case analysis, MIM and LOCF when estimating actual treatment 
effect via time-varying PS subclassification and MSM. Another issue to consider is that MI 
assumes that data are missing at random. This assumption may not hold in EHR databases as 
lifestyle factors are likely to be recorded if particular information is relevant to patient care. 
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Thus, missing data are more likely to be missing not at random. Indeed, one study had shown 
MI for smoking status and alcohol consumption using EHR data from THIN led to a higher 
proportion of current smokers and non-drinkers compared with other external databases, 
suggesting the missing at random assumption was not met (Marston et al., 2010). Due to the 
complexity and time taken fitting PS models in this thesis, MI unfortunately was not 
considered.  
Various sensitivity analyses that tested the assumptions made in outcome analysis could have 
been performed in this thesis. Non-informative censoring, i.e., each patient’s censoring time 
is independent to their outcome time, was assumed when implementing Cox models. 
Competing risks occur when a competing event such as death hinders or changes the risk of 
the outcome of interest being observed. These censored patients may systematically differ to 
uncensored patients introducing bias, for example censored patients due to death may be less 
healthy than uncensored patients. This assumption may not be plausible with an aging study 
sample, where increase in number of comorbidities and increased likelihood of death are 
observed. Competing risks models could have potentially been used with baseline PS 
approach, although it was only until recently a simulation study had shown how the two 
methods could be combined (Austin and Fine, 2019). Within MSM, use of censoring weights 
could be used to balance covariate distribution between censored and uncensored patients 
thus the pseudo-population would contain patients who had complete follow-up data. Future 
work could explore use of these two methods in treatment effect estimation.  
 
11.3 Implications and concluding remarks 
This thesis evaluated the effect of allopurinol in patients with gout on a range of clinically 
important long-term outcomes. Differing complexity of statistical models adjusting for 
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confounding were considered from simple baseline PS subclassification to time-varying PS 
subclassification and MSMs. Choice of statistical models used in this thesis is generally largely 
dependent on whether there is a priori belief that measured covariates are potentially time-
varying confounders affected by past treatment, adherence to treatment, and the type of 
effect one wants to estimate.  
Correctly modelling time-varying covariates that are affected by past treatment can be 
challenging. MSM remove the association between covariates and treatment therefore 
removing confounding effects; covariates are no longer on the causal pathway between past 
treatment and outcome, however the association between treatment history and outcome 
still exists as in the original population. This allows one to specifically estimate the overall 
unbiased marginal (or population average) effect of treatment on outcome i.e., the direct 
effect of current treatment. On the other hand, time-varying PS subclassification assumes past 
treatment and covariates are independent in order to estimate an unbiased treatment effect; 
within a PS subclass it only ensures the distribution of covariates and past treatment are 
balanced across treatment groups. Thus the two methods estimate differing effects of 
treatment that are only equivalent if all confounding has been removed, which is unlikely to 
be the case in practice. 
Studies that want to estimate the actual effect of treatment should be aware of the number 
of assumptions needed to infer casual effect. The largest challenge encountered in this PhD 
project was satisfying the two important assumptions of positivity and correct model 
specification. Incorrect PS model specification, that had led to near violation of the positivity 
assumption, may not necessarily be a result of the choice of covariates included in the PS 
model, but due to inadequately modelling the complex mechanism of the influence of 
covariates on treatment. Although the complexity of treatment use can be modelled within 
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MSM, it has not been shown whether the same can be achieved via time-varying PS 
subclassification.  
It seems plausible to suggest that extensive simulation studies are required to: assess whether 
unbiased estimates of treatment effects can be obtained when influence of covariates on 
treatment use varies over time; provide guidance on the optimal approach to imputation of 
missing time-varying covariates; investigate under which scenarios (considering for example 
sample size, omission of lagged covariates with various associations with treatment and 
outcome) PS model misspecification may lead to biased estimates; understand how accurately 
the time-varying PS subclassification estimates conditional treatment effect in the presence 
of covariates affected by past treatment, particularly if subclasses need to be excluded from 
analysis; assess the impact of length of time intervals used to convert continuous time line 
into discrete time measurements; rigorously compare various methods available for direct 
estimation of time-varying treatment effect, such as G-methods (G-computation and G-
estimation) (Danaei et al., 2013) and regression based models that directly adjust for covariate 
history (Achy-Brou et al., 2010, Keogh et al., 2018).   
Complex models (as described above and used in this thesis) for assessment of time-varying 
treatment effect are worth considering; insight is gained into how the mechanism of 
treatment assignment works in real life which would otherwise be ignored in the common 
intention-to-treat analysis approach. The magnitude of actual treatment effect is generally 
larger than the effect of initiating treatment, reflecting clinical practice that may otherwise be 
under-estimated. In this project, this was particularly found to be the case for target SU level 
and gout hospitalisation where the actual treatment effect was double the effect of initiating 
treatment. More generally, as-treated analysis is more likely to capture small effects of actual 
treatment effect than effects measured from intention-to-treat analysis. These models should 
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be applied in different populations using EHR data to gage how successful they are in practice 
more generally.  
To conclude, PS methodology is a valuable approach to control for confounding at baseline 
and over time. Time-varying PS subclassification is a direct extension of baseline PS 
subclassification and in theory is relatively easy to understand and implement, however in 
practice this was not the case. However, this method was found to be limited if common 
support of PS between treatment groups cannot be achieved. Alternatively, one could use 
MSM however analysts should be mindful that there are considerable practical challenges in 
ensuring correct specification of PS and outcome models, particularly when application is to 
complex EHR data. Use of either of these methods will rely on a large number of decisions that 
have to be based on both statistical and clinical arguments, including defining covariates and 
treatment in time-varying manner, selecting the most appropriate length of follow-up 
intervals and PS covariate selection procedure among others. Despite the number of 
considerations that needed to be made in using EHR for analysis and challenges encountered, 
EHR is valuable resource that is linked to a number of external health care databases, large 
number of covariates and outcomes recorded, and continual supply of patient and healthcare 
information that accurately represents what actually happens in practice which will inform 
what areas of healthcare needs improving.  
Allopurinol use was consistently associated with greater chance of reaching target SU level 
and fewer flares but greater risk of gout hospitalisation, coronary heart disease and renal 
disease. Firstly, these adverse effects of allopurinol could be explained by residual 
confounding by indication from unmeasured covariates, or incomplete adjustment of 
covariates with missing data or covariates that were under-reported. Secondly, the target SU 
level was reached by only 57% of allopurinol users suggesting that allopurinol dosing and/or 
adherence was sub-therapeutic and it is likely that the risk of these adverse outcomes would 
376 
 
have been lower if allopurinol treatment was more optimal. Despite these associations, GPs 
should continue to treat patients with gout should continue with allopurinol for the long-term 
benefits of complete crystal dissolution such as cessation of gout flares and resolution of tophi 
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intranet to help others carrying out reviews in the future and to avoid duplicating work already undertaken in the Centre. Keeping a record 
of all the reviews will also assist in planning the work of the Centre and ensuring adequate methodological support. Not all the information 
will be relevant to every review. However, items can be adapted to fit the type of review that is being undertaken. 
Please complete the form in as much detail as possible for your review and email to Jo Jordan, j.jordan@cphc.keele.ac.uk  
Title of the review 
Statistical methods used to control for confounding in treatment effect estimation of 
allopurinol in gout: a literature review of observational studies 
First reviewer Trishna Rathod 
Team of reviewers N/A 
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1. Background to review 
Brief introduction to the subject of the review, including rationale for undertaking the review and overall aim 
Gout is the most prevalent type of inflammatory arthritis affecting 2.5% of the UK population. It is a chronic and progressive disease 
caused by elevated levels of serum urate in the blood leading to deposits of monosodium urate crystals in and around the joints. Gout 
is characterised as acute flares of severe pain and swelling at the affected joint site. Although there is no cure, current treatment aims 
to treat inflammation of the acute gout flare followed by urate-lowering therapy to prevent recurrent flares. 
The EULAR, BSR, and ACR have all published guidelines on the management of gout. They advocate allopurinol as the first line urate-
lowering drug of choice to treat chronic gout. Although allopurinol has been available since 1963, no randomised controlled trials (RCTs) 
have been conducted to establish its long-term efficacy. In recent RCTs determining the efficacy of newer urate-lowering drugs, 
allopurinol was used as the comparator group. The effect of allopurinol (vs. non- use) has been estimated from cohort studies. Cohort 
studies have established that allopurinol lowers serum urate level, reduces the frequency of gout flares, and is well-tolerated. 
Consequently, although allopurinol is recommended as the first line urate-lowering therapy, further evidence is needed of its long-term 





To infer a causal effect of allopurinol, the ignorable treatment assignment assumption needs to be satisfied i.e., conditional on 
participant characteristics (covariates), the assignment of study participants to binary treatment (allopurinol vs non-allopurinol) is 
independent of the outcome of non-allopurinol treatment and the outcome of the allopurinol treatment. In RCTs, this assumption holds 
as randomisation minimises differences of measured and unmeasured covariates between treatment groups. However, this assumption 
is not satisfied in observational studies as treatment assignment is dependent on measured covariates resulting in differences between 
the treatment groups, introducing confounding hence the causal effect is biased. 
Statistical methods in varying degrees of complexity have been used to control for confounding from measured covariates. Traditional 
methods of multivariable regression models, matching and stratification are commonly used to control for confounding. However, such 
methods are limited to the number to covariates that can be controlled for. Alternatively, propensity score (PS) methodology is not 
constricted by this and aims to estimate the treatment effect by accounting for covariates that predict treatment assignment thus 
balancing the observed covariates between the treatment groups. However, a pitfall of PS methodology (and traditional methods) is 
that not all confounders are known or measured. Instrumental variables, frailty and Bayesian models can account for the heterogeneity 
from unmeasured covariates. 
This literature review aims to identify the statistical methodologies used to model the effect of allopurinol in gout outcomes from 
observational studies. 
 
2. Specific objectives 
1) To describe the range of study designs and statistical methods used to control for confounding in modelling the effect of 
allopurinol on gout outcomes.  
2) To compare and contrast the suitability and the limitations of the statistical methods identified. 
 
3. Criteria for including studies in the review  




conditions of interest 
 
Search terms for gout in title and abstract:  







8) 1 or 2 or 3 or 4 or 5 or 6 or 7 
Interventions or 
exposures 
Search terms for allopurinol in title and abstract: 
9) Allopurinol (Check is mesh term for allopurinol is available) 
10) Xanthine oxidase inhibit* 
11) Urate-lowering 
12) Urate lowering 
13) Uric acid-lowering 
14) Uric acid lowering 
15) Uricostatic 
16) Abburic OR Abopur OR Acepurin OR Acifugan OR Acyprin OR Alfadiman OR Algut OR Alinol OR 
allo* OR Allpargin OR Allupol OR Allura* OR Alluri* OR Aloprim OR Alopur OR Aloral OR Alosfar 
OR Alpur* OR Aluline OR Aluprol OR Aluron OR Alzoprim OR Anurate OR Apnol OR Apo-Tinole 
OR Apronol OR Apulonga OR Apurin OR Apurol OR Arnol OR Arsol OR Artrex OR Arturic OR 
Atisuril OR Aurigen OR Benoxuric OR Be-Uric OR Bionol OR Biuricowas OR Bleminol OR Caplenal 
OR Capurate OR Cellidrin* OR Chinnol OR Ciploric OR Colpuril OR Comburic OR Cosuric OR 
Dabroson OR Darzune OR Desatura OR Docallopu OR Duovitan OR "dura AL" OR Elavil OR 
Embarin OR Epidropal OR Erloric OR Ethipurinol OR Etindrax OR Facilit OR Foligan OR Gealgica 
OR Gewapurol OR Gichtex OR Gotir OR Hamarin OR Harpagin OR Hexanurat OR Hycemia OR 
Isoric OR Jenapurinol OR Labopurinol OR Labypurol OR Lanolone OR Licoric OR Llanol OR Lonol 
OR Lop*ric OR Lopur* OR Loricid OR Lo-Uric OR Lysuron OR Marinol OR Medoric OR Mephanol 
OR Milurit OR Nilapur OR Novo-Purol OR Oloprim OR Petrazyc OR Ponuric OR Prinol OR Pritanol 
OR Progout OR Pureduct OR Puricemia OR Puricin OR Puricos OR Puride OR Purigan OR Purinase 
OR Purinol OR Purispec OR Puristen OR Puritenk OR Pyrazol OR Ranpuric OR Redurate OR Remid 
OR Reucid OR Rimapurinol OR Rinolic OR Sigapurol OR Sinoric OR Soluric OR Stradumel OR 
Suspendol OR Synol OR Synpurinol OR Talol OR Tipuric OR Trianol OR Tylonic OR Unizuric OR 





Urikoliz OR Urinol OR Uriprim OR Uripurinol OR Uritab OR Urobenyl OR Urogotan OR Uroplus 
OR Urosi OR Urosin OR Urozyl-SR OR Urtias OR Valeric OR Xandase OR Xanol OR Xanthomax OR 
Xanturic OR Xanurace OR Xuric-A OR "Z 300" OR Zilopur OR Zurim OR Zygout OR Zylapour OR 
Zylic OR Zylo* 
17)  9 or 10 or 11 or 12 or 13 or 14 or 16 
18) 8 and 17 
Comparisons or control 
groups 
Any comparator that may include:  




• Adrenocorticotrophic hormone 
• Interleukin-1 inhibitors (anakinra, canakinumab) 
• Pegloticase 
• Non-pharmacological intervention 
• Placebo 
• Different dose of allopurinol 
• Allopurinol in combination with another drug 
• Usual care 
• Uricosuric drugs (sulfinpyazone, probenecid, benzbromarone, losartan, fenfibrate, atorvastin, 
lefluomide) 
• No active intervention 
Note, these comparators will not be searched for. 
Outcomes of interest 
 
Any outcome that may include: 
• Pain 
• Joint impairment 
• Joint inflammation 
• Joint damage imaging 
• Serum urate levels 
• Acute gout flares 
• Tophus burden 
• Comorbidities 
• Activity limitations 
• Participation restrictions (e.g., employment) 
• Work disability 
• Healthcare utilisation 
• Cos 
• Patient utility 
• Patient/Physician global assessment 
• Patient global assessment of disease scales 
• Health Related Quality of Life 
• Acute phase markers  
• Adverse effects from allopurinol use: skin and subcutaneous tissue disorders such as rash, severe 
cutaneous adverse reactions (including Stevens-Johnson syndrome, toxic-epidermal necrolysis), 
and eosinophilia  
• Mortality 
• Oxypurinol concentrations 
• Any other medical conditions 
Note, these outcomes will not be searched for. 
Setting All settings   















4. Criteria for excluding studies not covered in inclusion criteria  
Any specific populations excluded, date range, language, whether abstracts or full text available, etc 
• Abstracts from grey literature (e.g., conferences) 
• Papers not written in English 
• Randomised trials 
• Unpublished material 
• Case reports of individual patients 
• Commentaries on articles 
• Letters to the editor 
• Paper is on the diagnosis/strategies/ guidelines in the treatment of gout 
• Prevalence studies 
• Narratives 
Studies on children (<18 years) 
 
5. Search methods 
Electronic databases 
Please list all databases that are to 
be searched and include the 
interface (eg NHS, EBSCO, etc) and 
date ranges searched for each 
Interface: NHS evidence 
https://www.evidence.nhs.uk/about-evidence-services/journals-and-databases 
CINAHL (1981 onwards) 
 
Interface: Ovidsp  
embASE: Excerpta Medica Database (1980 onwards) 
Medline: General medical database (1946 onwards) 
 
Interface: Web of Science 
http://www.keele.ac.uk/healthlibrary/find/medicaldatabaseskeele/Science citation index (1964 
onwards) 









Other methods used for 
identifying relevant research  
ie contacting experts and 
reference checking 
Checking the reference list of the eligible studies identified. 
Journals hand searched 
If any are to be hand searched, 
please list which journals and date 




6. Methods of review 
Details of methods 
Number of reviewers, how 
agreements to be reached and 
disagreements dealt with, etc. 
From each database, conduct the search and save the results into an appropriate file format. 
Import the files into Refworks and save the search results into a folder called ‘1. All studies’. 
Remove duplicates and save the remaining studies into a new folder called ‘2. Studies without 
duplicates’. 
The titles would be screened for eligibility. Eligible titles would be saved into a folder called ‘3. 
Eligible titles’  
Abstracts of the eligible titles would be obtained and screened for eligibility. Eligible abstracts 
would be saved into a folder called ‘4. Eligible abstracts’ 
The papers of the eligible abstracts would be obtained and screened. Eligible papers would be 
saved into a folder called ‘5. Eligible papers’  
Quality assessment 
Tools or checklists used with 
references or URLs 
Hierarchy on the quality of the study: 
• Systematic reviews of observational studies 
• Cohort and case control studies 
• Cross-sectional studies 
 
Hierarchy of statistical methods used to adjust for confounding: 
• Propensity scores and other novel methods (G estimation, instrumental variables, 
frailty models, Bayesian models) 
• Traditional methods (Regression models, stratification, matching) and 
sensitivity/subgroup analysis 
• No adjustment for confounding (descriptive statistics e.g., chi square tests) 
 
Hierarchy of type of outcome/treatment analysed: 
• Repeated measures (time-varying treatment/multiple outcomes) 
• Only analysed a single point in time 
 
Hierarchy of methods used to deal with missing data: 
• Multiple imputation 
• Last observation taken forward/single imputation/missing indicator method 





Data extraction  
What information is to be collected 
on each included study. If databases 
or forms on Word or Excel are used 




Details of what and how synthesis 
will be done 
 
Themes to be identified: 
• Study population (gout/ hyperuricaemia patients/severity of disease) 
• Study design (cohort/cross-sectional/case-control) 
• How data was collected (medical records/self-report questionnaires) 
• Sample size 
• Intervention (drug name, duration, dosage, mode of administration)  
• Comparator pharmacological intervention (drug name, duration, dosage, 
frequency, mode of administration)  
• Comparator of non-pharmacological intervention (description of intervention, 
duration, frequency)  
• Primary and secondary outcomes 
• Length of follow up period 
• Statistical methods used 
• Adjusted covariates to reduce confounding 
• Missing data 
• Any other novel techniques 
• Limitations of study 
This would be recorded in an excel file with the studies listed in a column and the themes across 
the row.  
Meta-analysis  
Details of what and how analysis and 
testing will be done. If no meta-
analysis is to be conducted, please 
give reason. 
The number of studies identified by this search is expected to be low. Combining results across 
the studies would be difficult as there are a wide range of gout outcomes and the statistical 
methods used may vary. 
Grading evidence 
System used, if any, such as GRADE 
N/A 
 
7. Presentation of results 
Additional material  
Summary tables, flowcharts, etc, to 
be included in the final paper 
The PRISMA flow chart would be used showing the total number of studies screened, assessed 
for eligibility, included in the review with reasons why the ineligible studies were excluded. 
In tables, describe the: 
Study characteristics 
Statistical methods 
Outputs from review  
Papers and target journals, 
conference presentations, reports, 
etc 
Results from this review is for the PhD. 
 
8. Timeline for review – when do you aim to complete each stage of the review 
Protocol 18th April 
Literature searching 21st April – 9th May 
Quality appraisal 
12th May – 30th May Data extraction 
Synthesis 







 Search strategy in MEDLINE 
Table B1: MEDLINE search strategy 
Item  Search Terms 
1 exp Gout/ 
2 gout.ab. or gout.ti. 
3 gout$.ab. or gout$.ti. 
4 podagra.ab. or podagra.ti. 
5 artagra.ab. or artagra.ti. 
6 chiragra.ab. or chiragra.ti. 
7 toph$.ab. or,ph$.ti. 
8 1 or 2 or 3 or 4 or 5 or 6 or 7 
9 allopurinol.ab. or allopurinol.ti. 
10 xanthine oxidase inhibit$.ab. or xanthine oxidase inhibit$.ti. 
11 "urate-lowering therap$".ab. or "urate-lowering therap$".ti. 
12 urate lowering therap$.ab. or urate lowering therap$.ti. 
13 "urate-lowering drug$".ab. or "urate-lowering drug$".ti. 
14 urate lowering drug$.ab. or urate lowering drug$.ti. 
15 "uric acid-lowering therap$".ab. or "uric acid-lowering therap$".ti. 
16 uric acid lowering therap$.ab. or uric acid lowering therap$.ti. 
17 "uric acid-lowering drug$".ab. or "uric acid-lowering drug$".ti. 
18 uric acid lowering drug$.ab. or uric acid lowering drug$.ti. 
19 uricostatic.ab. or uricostatic.ti. 
20 (AL or Abburic or Abopur or Acepurin or Acifugan or Acyprin or Adenock or Ailural or Ailurial or Alfadiman or Algut or Aligout or Alinol or Allgoric or Allnol or Allo or Allo$ 
or Allpargin or Allupol or Allura$ or Alluri$ or Aloprim or Alopur or Alopurinol or Aloral or Aloric or Aloriv or Alosfar or Alositol or Alpur$ or Aluline or Aluprol or Alur or 
Alurid or Aluron or Alzoprim or Anoprolin or Anurate or Anzief or Apnol or Apo-Allopurinol or Apo-Tinole or Apronol or Apulonga or Apurin or Apurol or Arnol or Arsol or 
Artrex or Arturic or Atisuril or Aurigen).ab. 
21 (AL or Abburic or Abopur or Acepurin or Acifugan or Acyprin or Adenock or Ailural or Ailurial or Alfadiman or Algut or Aligout or Alinol or Allgoric or Allnol or Allo or Allo$ 
or Allpargin or Allupol or Allura$ or Alluri$ or Aloprim or Alopur or Alopurinol or Aloral or Aloric or Aloriv or Alosfar or Alositol or Alpur$ or Aluline or Aluprol or Alur or 
Alurid or Aluron or Alzoprim or Anoprolin or Anurate or Anzief or Apnol or Apo-Allopurinol or Apo-Tinole or Apronol or Apulonga or Apurin or Apurol or Arnol or Arsol or 






22 (Benoxuric or Be-Uric or Bionol or Biuricowas or Bleminol or Burin or Caplenal or Capurate or Cellidrin or Cellidrin$ or Chinnol or Ciploric or Colpuril or Comburic or 
Cosuric or Dabrosin or Dabroson or Darzune or Dertrifort or Desatura or Docallopu or Duovitan or Dura or Edorin or Elavil or Embarin or Epidropal or Epuric or Erloric or 
Ethipurinol or Etindrax or Facilit or Foligan or Gealgica or Geapur or Gewapurol or Gichtex or Gotax or Gotir or Gurik or Hamarin or Harpagin or Hexanurat or Hexanuret 
or Hycemia or Isoric or Jenapurinol or Ketanrift or Ketobun-A or Labopurinol or Labypurol or Lanolone or Ledopur or Licoric or Linogra or Llanol or Lodiric or Logout-SR or 
Lonol or Loporic or Lopric or Lopur$ or Loricid or Lo-Uric or Lysuron or Marinol or Medoric or Mephanol or Milurit or Miniplanor).ab. 
23 (Benoxuric or Be-Uric or Bionol or Biuricowas or Bleminol or Burin or Caplenal or Capurate or Cellidrin or Cellidrin$ or Chinnol or Ciploric or Colpuril or Comburic or 
Cosuric or Dabrosin or Dabroson or Darzune or Dertrifort or Desatura or Docallopu or Duovitan or Dura or Edorin or Elavil or Embarin or Epidropal or Epuric or Erloric or 
Ethipurinol or Etindrax or Facilit or Foligan or Gealgica or Geapur or Gewapurol or Gichtex or Gotax or Gotir or Gurik or Hamarin or Harpagin or Hexanurat or Hexanuret 
or Hycemia or Isoric or Jenapurinol or Ketanrift or Ketobun-A or Labopurinol or Labypurol or Lanolone or Ledopur or Licoric or Linogra or Llanol or Lodiric or Logout-SR or 
Lonol or Loporic or Lopric or Lopur$ or Loricid or Lo-Uric or Lysuron or Marinol or Medoric or Mephanol or Milurit or Miniplanor).ti. 
24 (Nektrohan or Nilapur or Novo-Purol or Oloprim or Orlu or Petrazyc or Piloric or Ponuric or Prinol or Pritanol or Progout or Pureduct or Puricemia or Puricin or Puricos or 
Puride or Purigan or Purinase or Purinol or Purispec or Puristen or Puritenk or Pyrazol or Ranpuric or Redurate or Remid or Reucid or Riball or Rimapurinol or Rinolic or 
Riva-Purinol or Satric or Sigapurol or Sinoric or Soluric or Stradumel or Suspendol or Swiloric or Synol or Synpurinol or Takanarumin or Talol or Tipuric or Trianol or 
Tylonic or Unizuric or Urbol or Uredimin or Uribenz or Urica or Urica$ or Uricemil or Uricina or Uricnol or Urico$ or Urifugan or Urikoliz or Urinol or Uriprim or Uripurinol 
or Uritab or Uritas or Urlo or Urobenyl or Urogotan or Urolit or Uroplus or Urosi or Urosin or Urozyl-SR or Urtias or Valeric or Xandase or Xanol or Xanthomax or Xanturat 
or Xanturic or Xanurace or Xuric-A or Z 300 or Zilopur or Z-Nol or Zurim or Zygout or Zylapour or Zylic or Zylo$ or Zyprinol or Zytol).ab. 
25 (Nektrohan or Nilapur or Novo-Purol or Oloprim or Orlu or Petrazyc or Piloric or Ponuric or Prinol or Pritanol or Progout or Pureduct or Puricemia or Puricin or Puricos or 
Puride or Purigan or Purinase or Purinol or Purispec or Puristen or Puritenk or Pyrazol or Ranpuric or Redurate or Remid or Reucid or Riball or Rimapurinol or Rinolic or 
Riva-Purinol or Satric or Sigapurol or Sinoric or Soluric or Stradumel or Suspendol or Swiloric or Synol or Synpurinol or Takanarumin or Talol or Tipuric or Trianol or 
Tylonic or Unizuric or Urbol or Uredimin or Uribenz or Urica or Urica$ or Uricemil or Uricina or Uricnol or Urico$ or Urifugan or Urikoliz or Urinol or Uriprim or Uripurinol 
or Uritab or Uritas or Urlo or Urobenyl or Urogotan or Urolit or Uroplus or Urosi or Urosin or Urozyl-SR or Urtias or Valeric or Xandase or Xanol or Xanthomax or Xanturat 
or Xanturic or Xanurace or Xuric-A or Z 300 or Zilopur or Z-Nol or Zurim or Zygout or Zylapour or Zylic or Zylo$ or Zyprinol or Zytol).ti. 
26 exp Allopurinol/ 
27 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 







 Literature review table 
Table C1: Summary of study design characteristics and outcomes considered 









Not stated Recruited from a 
hospital rheumatology 
clinic. Data collected 
via clinical assessment, 
patient interviews or 
the cohort database 
Followed up every six 
months 
90 Renal failure; MSK physical disability 
Azevedo et al. (2014), 
[Brazil] 
Cohort study N/A Medical record review 
from a rheumatology 
clinic 
Followed up every 
three months for 18 
months 
48 SU level 




N/A Medical record review 
of a hospital 
N/A 154 Chronic kidney disease 




N/A Recruited from a 
hospital rheumatology 
clinic. Data collected 
via clinical assessment 
N/A 68 Serum cystatin C concentration 




N/A Medical record review 
of the New York 
Harbor Healthcare 
System from 3 
hospitals 
N/A 1,288 Myocardial infarction 
 
 




N/A Medical record review 
from rheumatology 
clinics 












N/A Recruited from 
community advertising 
and primary and 
secondary care clinics. 
Data collected via 
clinical assessment 
N/A 177 - 273 SU level <360μmol/L 
 




N/A Recruited from 
community advertising 
and primary and 
secondary care clinics. 
Data collected via 
clinical assessment 
N/A 290 Presence of tophi 
 









comorbidity index; statins; 
fibrates; ACE inhibitors; ARBs; 
β blockers; calcium channel 
blockers; aspirin; NSAIDS; 
loop diuretics; 
hydrochlorothiazide; 
losartan; insulin; SU level; 
cholesterol; albumin; GFR; 
no. of primary care visits 
EHR review from THIN  Mean 2.9 years 9,590 
 
Time to all-cause mortality 
Emmerson et al. 




N/A Recruited from a 
hospital. Data 
collected via clinical 
assessment 
N/A 66 Plasma oxypurinol 
Fessel (1979), [USA] Cohort study N/A Medical record review 
from clinics and 
hospitals 






Graham et al. (2013), 
[Australia] 
Cohort study N/A Recruited from 
hospital and 
rheumatology clinics. 
Data collected via 
clinical assessment 
Not stated 46 SU level 
Halpern et al. (2009), 
[USA] 
Cohort study N/A EHR review of an 
administrative claims 
database 
1 year 3,070 Gout flare 
Hatoum et al. (2014), 
[USA] 




6 and 24 months 7,324 – 
10,871 
SU level <6mg/dL (<360μmol/L) 




Age; sex; ethnicity 
 
Medical record review 
from a hospital 
5 years 67 - 96 Two or more unplanned hospital 
admissions for gout management 
Kim et al. (2013b), 
[USA] 
Cohort study N/A EHR review of the 
Innovus InVision Data 
Mart database 
 
Range 30 days to 3 
years. Allopurinol 
cohort, mean follow 
up 0.5 years. 
Febuxostat cohort, 
mean follow up 0.4 
years. 
Colchicine cohort, 
mean follow up 0.2 
years. 
35,577 Frequency of gout flares 
 




Age; sex; index date; 
diabetes; hypertension; 
hyperlipidaemia; atrial 
fibrillation                        
 
 







median (IQR) 5.25 
years (2.81, 7.69).                                             
Non-allopurinol 
cohort, median (IQR) 
5.04 years (2.55, 7.53)   
2,483 – 4,966 Cardiovascular outcome requiring 
hospitalisation; coronary heart 
disease; cerebrovascular disease 
(stroke); hypertensive heart 







Lim et al. (2012), 
[Singapore] 
Cohort study N/A Recruited from a 
hospital rheumatology 
clinic. Data collected 
via clinical assessment 
Median (range): 39.8 
weeks (3.9, 96.6) 
126 
 
Time to reach SU level <360μmol/L; 
attained SU level <360μmol/L 
Mak et al. (2009), 
[Singapore] 
Cohort study N/A Recruited from a 
hospital. Data 
collected via clinical 
assessment and 
medical record review 
15 months 100 Frequency of gout flares 




N/A Medical record review 
from a hospital 
N/A 278 Stone composition (mixed vs. pure) 
Percentage composition of CaOMH, 
CaODH, CaPh, uric acid, struvite, 
cystine. Number of pure stones 
composed of uric acid, CaOMH, 
CaPh, cystine.                 
Meek et al. (2014), 
[Netherlands] 
Cohort study N/A Medical record review 
of the Arthritis Centre 
Twente CardioVascular 
Disease database, GP 
questionnaires, and 
the Dutch national 
death registry 
Median (IQR) 36 
months (30, 41)         
172 Cardiovascular event or death 




Within patient matching of 




collected via online 
self-report 
questionnaires and 
medical record review 
1 year 724 Gout flare 
Pandya et al. (2011), 
[USA] 
Cohort study N/A EHR review of a 
medical claims 
database 
At least one year 
follow-up.                  
Mean (SD) 32 months 
(17.1) 






Perez-Ruiz et al. 
(1998), [Spain] 
Cohort study N/A Recruited from a 
hospital rheumatology 
clinic. Data collected 
via clinical assessment 
Mean 12.5 months 86 SU level; percentage reduction of 
SU level; clearance of creatinine; 
clearance of urate; urinary 
excretion of urate; SU level 
>6mg/dL 
Perez-Ruiz et al. 
(2002), [Spain] 
Cohort study N/A Recruited from a 
hospital gout clinic. 
Data collected via 
clinical assessment 
Not stated 49 SU level; diameter of target tophus; 
time until tophi resolution; velocity 
of tophi reduction 
 
Perez-Ruiz et al. 
(2010), [Spain] 
Cohort study N/A Recruited from a 
hospital. Data 
collected via clinical 
assessment 
At least 12 months 546 Urinary volume; SU level; urinary 
pH; urinary uric acid level; 
undissociated urinary uric acid level; 
24-hr urine uric acid level; 24-hr 
urine dissociated uric acid level; 
clearance of creatinine; clearance of 
uric acid 




N/A Patients recruited 






N/A 145 SU level; SU level >360μmol/L; gout 
flare in preceding year 
Rothenbacher et al. 
(2011), [UK] 
Cohort study N/A EHR review from THIN Mean (range) 3.8 years 
(30 days, 8 years) 
23,857 
 
Time to first gout flare; frequency of 
gout flares 




N/A Medical record review 
from a hospital 
rheumatology clinic 
N/A 31 Plasma oxypurinol 
Stamp et al. (2011a), 
[New Zealand] 
Cohort study N/A Recruited from a 
medical centre. Data 
collected via clinical 
assessment 







Stamp et al. (2011b), 
[New Zealand] 
Cohort study N/A Recruited from a 
hospital rheumatology 
clinic. Data collected 
via clinical assessment 
12 months 35 Percentage reduction in SU level; SU 
level; SU level <360μmol/L 




Age; sex; diuretics; renal 
function 
EHR review of local 
databases, physician 
recall, Centre for 
adverse Reactions 
Monitoring 
Median (Range) 30 
days (1, 1,080) 
211 Allopurinol hypersensitivity 
syndrome; SU level 
 
 




N/A Patients recruited 




records, and clinical 
assessment 
N/A 57 SU level 





Calendar day of admission to 
cohort 




Median (range) 2.1 
years (30 days to 7 
years) 
7,684 Heart failure re-admission or all-
cause mortality                            
Vazquez-Mellado et al. 
(2001), [Mexico] 
Cohort study N/A Medical record review 
from a hospital 
rheumatology clinic. 
Not stated 120 Adverse event including rash, 
allopurinol hypersensitivity 
syndrome, fixed pigmented drug 
eruption, leucocytoclastic vasculitis; 
SU level 




Within person matching of 




collected via online 
self-report 
questionnaires and 
medical record review 
1 year 633 Gout flare 
ACE: Angiotensin-converting enzyme; CaOMH: Calcium oxalate monohydrate; CaODH: Calcium oxalate dihydrate; CaPh: Calcium phosphate; EHR: Electronic health record; GFR: glomerular 
filtration rate; IQR: Interquartile range; MSK: Musculoskeletal; NSAIDS: Non-steroidal anti-inflammatory drugs; PS: Propensity score; SD: Standard deviation; SU: Serum urate; THIN: The Health 





Table C2: Summary of how allopurinol use was defined 
Article 
Treatment comparison group 
vs. allopurinol group 
Was dosage of allopurinol 
taken into account 
How was dosage taken into 
account 
Was duration of 
allopurinol taken into 
account 
How was duration taken 
into account 
Alvarez-Nemegyei et al. 
(2005) 
N/A Yes <300 vs. >300mg/day No N/A 
Azevedo et al. (2014) Benzbromarone vs. allopurinol No N/A No N/A 
Cheyoe et al. (2012) Colchicine vs. allopurinol & 
colchicine 
No N/A No N/A 
Choe et al. (2010) Non-allopurinol vs. allopurinol No N/A No N/A 
Crittenden et al. (2012) Non-allopurinol vs. allopurinol No N/A No N/A 
Dalbeth et al. (2006) Non-allopurinol vs. allopurinol Yes Non-allopurinol use vs. lower 
than recommended dose vs. 
recommended dose vs. higher 
than recommended dose 
No N/A 
Dalbeth et al. (2012) Non-allopurinol or probenecid 
vs. allopurinol 
Yes Mean 235 vs. 194mg/day No N/A 
Dalbeth et al. (2013) Non-allopurinol use vs. 
allopurinol use 
Yes Mean 215 vs. 213mg/day No N/A 
Dubreuil et al. (2015) Non-allopurinol use vs. 
allopurinol use 
No N/A Yes Sensitivity analyses 
truncating follow-up at 1, 2 
and 3 years to address 
treatment discontinuation 
Emmerson et al. (1987) N/A Yes 100 vs. 200 vs. 300 vs. 
400mg/day 
No N/A 
Fessel (1979) Probenecid vs. allopurinol No N/A No N/A 
Graham et al. (2013) N/A Yes Adjusted for dose that ranged 
from 50mg to 600mg/day 
No N/A 
Halpern et al. (2009) Non-allopurinol vs. allopurinol No N/A No N/A 
Hatoum et al. (2014) Febuxostat vs. allopurinol No N/A No N/A 
Hutton et al. (2009) Non-allopurinol vs. allopurinol Yes Distribution of allopurinol 







Kim et al. (2013b) Colchicine vs. allopurinol No No Yes Analysis stratified by no. of 
days taking allopurinol 
(<30, 31-90, 91-120 days)  
Kok et al. (2014) Non-allopurinol vs. allopurinol 
Uricosurics vs. allopurinol 
Yes <100 vs 100 vs. 200 vs. 
≥300mg/day 
No N/A 
Lim et al. (2012) N/A Yes Adjusted for incremental dose 
increase (per 50mg); 
compared distribution of 
doses between those attaining 
and not attaining target SU 
level 
No N/A 
Mak et al. (2009) N/A No N/A Yes Adjusted for duration of 
allopurinol 
Marchini et al. (2013) Non-allopurinol vs. allopurinol No N/A No N/A 
Meek et al. (2014) Non-allopurinol vs. allopurinol No N/A No N/A 
Neogi et al. (2014) Non-allopurinol vs. allopurinol No N/A No N/A 
Pandya et al. (2011) N/A Yes Adjusted for average dose of 
last allopurinol prescription, 
incremental increases of 
50mg/day 
No N/A 
Perez-Ruiz et al. (1998) Benzbromarone vs. allopurinol Yes Analysis stratified by 300mg 
users and 300mg and 450mg 
users 
No N/A 
Perez-Ruiz et al. (2002) Benzbromarone vs. allopurinol No N/A No N/A 
Perez-Ruiz et al. (2010) Benzbromarone vs. allopurinol No N/A No N/A 
Roddy et al. (2007b) Non-allopurinol vs. allopurinol Yes 100 vs. 200 vs. 300 vs. 
>300mg/day 
No N/A 
Rothenbacher et al. (2011) Non-allopurinol vs. allopurinol No N/A No N/A 
Stamp et al. (2000) N/A Yes Recommended dose vs. lower 
than recommended dose vs.  







Stamp et al. (2011a) N/A Yes Adjusted for dose of 
incremental increase of 
100mg/day 
No N/A 
Stamp et al. (2011b) Furosemide vs. allopurinol Yes Incremental increase of 
50mg/day from recommended 
dose 
No N/A 
Stamp et al. (2012) N/A Yes Mean 183.5 vs. 112.2mg/day; 
Starting dose higher than 
recommended vs. same or 
lower dose than 
recommended based on 
creatinine clearance or 
estimated GFR 
No N/A 
Stamp et al. (2013) Non-allopurinol vs. allopurinol No N/A No N/A 
Thanassoulis et al. (2010) Non-allopurinol vs. allopurinol Yes Adjusted for non-allopurinol 
vs. ≤100 vs. >100mg/day 
Yes Adjusted for non-
allopurinol vs. ≤30 days vs. 
>30 days 
Vazquez-Mellado et al. 
(2001) 
N/A Yes Recommended dose vs. higher 
than recommended dose 
No N/A 







Table C3: Summary of how confounding was controlled for 
Article Unadjusted or adjusted 
analysis 
List of covariates Statistical methods Statistical limitations related to 
confounding 
Alvarez-Nemegyei et al. 
(2005) 
Unadjusted N/A Chi square test with yates 
correction 
None stated 
Azevedo et al. (2014) Unadjusted N/A T-test No randomisation; confounding 
by indication; follow-up was not 
blind 
Cheyoe et al. (2012) Adjusted BMI; hypertension; diabetes; dyslipidaemia; 
diuretics; SU level 
Logistic regression Unmeasured covariates 
Choe et al. (2010) Adjusted Stage of renal function; age; HDL-
cholesterol; SU level; benzbromarone; 
erythrocyte sediment reaction; C-reactive 
protein 
Linear regression None stated 
Crittenden et al. (2012) Unadjusted N/A Chi-square test Confounding by indication 
Dalbeth et al. (2006) Unadjusted N/A Chi-square test; T-test Patient compliance to 
allopurinol 
Dalbeth et al. (2012) Unadjusted & adjusted Sex; ethnicity; confidence to keep SU under 
control 
Chi-square test; T-test; 
logistic regression  
Confounding by indication 
Dalbeth et al. (2013) Unadjusted N/A Chi-square test; T-test None stated 
Dubreuil et al. (2015) Adjusted BMI; age; sex; hypertension; cardiovascular 
disease; diabetes; Charlson comorbidity 
index; statins; fibrates; ACE inhibitors; 
ARBs; β blockers; calcium channel blockers; 
aspirin; NSAIDS; loop diuretics; 
hydrochlorothiazide; losartan; insulin; SU 
level; cholesterol; albumin; GFR; no. of 
primary care visits 
Cox regression Residual or unknown 
confounding 
Emmerson et al. (1987) Unadjusted N/A Linear regression None stated 
Fessel (1979) Unadjusted N/A Chi-square test; T-test None stated 






Halpern et al. (2009) Adjusted SU level; age; sex; no. of gout related office 
visits; disorders of lipid metabolism; non-
traumatic joint disorders; hypertension; 
diseases of the heart; diseases of the 
urinary system; diabetes without 
complications               
Logistic regression Missing data 
Hatoum et al. (2014) Adjusted SU level; age; sex; Charlson comorbidity 
index; ethnicity; year of gout diagnosis; 
tophi diagnosis; SU level 
Logistic regression Missing data; compliance with 
treatment and dose adjustment 
Hutton et al. (2009) Unadjusted N/A Odds ratio calculated from 
the Mantel Haenszel 
method; Wilcoxon 
independent groups test 
Adherence to allopurinol 
 
Kim et al. (2013b) Adjusted Age; sex; comorbidity score; hypertension; 
chronic kidney disease; renal stones; heart 
failure; cardiovascular disease; diabetes; 
hyperlipidaemia; stroke; obesity; COPD; 
diuretics; β blockers; ACE inhibitors; ARBs; 
NSAIDS; coxibs; opioids; oral steroids; 
intravenous steroids; intra-articular 
steroids; no. of prescription drugs; no. of 
hospitalisations; no. of ER visits; no. office 
visits; no. of PCP visits; no. of rheumatology 
visits   
Poisson regression Confounding by indication; 
missing data 
Kok et al. (2014) Adjusted Chronic kidney disease, uremia, gastric 
ulcer 
Cox regression Unmeasured covariates; 
Compliance and adherence to 
treatment 
Lim et al. (2012) Unadjusted N/A Cox regression; Mann-
Whitney U test 
No randomization; time 
dependency of the number of 
allopurinol titrations; duration 







Mak et al. (2009) Adjusted Age; sex; ethnicity; duration of gout (years); 
serum creatinine level; SU level; ischaemic 
heart disease; LDL cholesterol; HDL 
cholesterol; triglyceride; creatinine 
clearance; statin use         
Linear regression Unmeasured confounding 
Marchini et al. (2013) Unadjusted N/A T-test; Chi-square test; 
Fisher’s test 
None stated 
Meek et al. (2014) Unadjusted N/A Chi-square test Unmeasured confounding 
Neogi et al. (2014) Adjusted Purine intake, diuretics, colchicine, NSAIDS, 




Pandya et al. (2011) Adjusted Age; sex; stage of chronic kidney disease; 
specialty of prescribing physician 
Logistic regression None stated 
Perez-Ruiz et al. (1998) Unadjusted N/A T-test; Chi-square test None stated 
Perez-Ruiz et al. (2002) Unadjusted N/A T-test None stated 
Perez-Ruiz et al. (2010) Unadjusted N/A T-test None stated 
Roddy et al. (2007b) Unadjusted N/A T-test; Chi-square test; 
ANOVA 
None stated 
Rothenbacher et al. (2011) Adjusted & unadjusted Sex; age; no. of GP visits; smoking status; 
alcohol consumption; BMI; ischaemic heart 
disease; hypertension; hyperlipidaemia; 
diabetes; renal failure               
Cox regression; likelihood 
ratio test 
Unmeasured covariates 
Stamp et al. (2000) Unadjusted N/A Fisher's exact test Compliance with allopurinol; 
unmeasured covariates 
Stamp et al. (2011a) Unadjusted N/A Mixed-effect linear model None stated 
Stamp et al. (2011b) Unadjusted N/A T-test, chi-square test None stated 
Stamp et al. (2012) Unadjusted and adjusted Ethnicity; presence of tophi                        
 
ANOVA; conditional logistic 
regression 
Unmeasured covariates 







Thanassoulis et al. (2010) Adjusted Age; sex; Deyo modified Charlson 
comorbidity score; hypertension; 
myocardial infarction; renal failure; cardiac 
procedures; ACE inhibitors; β blockers; 
antiplatelet agents; anticoagulants; 





confounding by indication; 
compliance 
Vazquez-Mellado et al. 
(2001) 
Unadjusted N/A Chi-square test or Fisher's 
exact test; T-test 
None stated 
Zhang et al. (2012) Adjusted Purine intake; alcohol use; diuretics; 




ANOVA: Analysis of variance; ARB: Angiotensin II receptor blockers; BMI: Body mass index; ER: Emergency room; HDL: High density lipoproteins; LDL: Low density lipoproteins; PCP: 
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Lay Summary (max.200 
words) 
        
Background         
Objective, specific aims 
and rationale 













This will be a hypothesis testing study with the null hypothesis that there is no different in 
outcomes between gout patients prescribed and not prescribed allopurinol. However, the 
study also includes a strong element of methodological research to answer the clinical 
objectives. 
Study Design         
Sample size/power 
calculation  
(Please provide justification 
of  
sample size in the protocol) 
        
Study population  
(including estimate of 
expected number of  







      
Selection of comparison 
group(s) or controls 
        
Exposures, outcomes and 
covariates 
Exposures are clearly 
described  








      
      
Use of linked data  
(if applicable) 
        
Data/ Statistical Analysis 
Plan 
There is plan for 
addressing confounding  
There is a plan for 







      
      
Patient/ user group 
involvement † 
  No PPI was needed in the planning and interpretation of the results for this PhD as it will be 
mostly based on methodological research. 
Limitations of the study 
design, data sources  
and analytic methods 
        
Plans for disseminating and 
communicating study 
results 
        
 
† It is expected that many studies will benefit from the involvement of patient or user groups in their planning and refinement, 
and/or in the interpretation of the results and plans for further work. This is particularly, but not exclusively true of studies with 






Voluntary registration of ISAC approved studies:  
Epidemiological studies are increasingly being included in registries of research around the world, including those primarily set up for clinical trials. 
To increase awareness amongst researchers of ongoing research, ISAC encourages voluntary registration of epidemiological research conducted 
using MHRA databases. This will not replace information on ISAC approved protocols that may be published in its summary minutes or annual 
report. It is for the applicant to determine the most appropriate registry for their study. Please inform the ISAC secretariat that you have 
registered a protocol and provide the location. 
 
Protocol 
Lay Summary (Max 200 words) 
Gout is the most prevalent inflammatory arthropathy and is largely managed in primary care in the UK. The principal risk factor for gout development 
is elevated serum uric acid levels. Long term treatment of gout involves using urate-lowering therapies such as allopurinol, however there is lack of 
high quality evidence on its effectiveness. We aim to use routinely collected data to examine long term effects of allopurinol on different outcomes, 
including uric acid levels. However using such data to determine treatment effect is problematic as there may be differences between treatment 
groups, e.g. certain treatments may be preferred for older patients. The treatment effect may then be due to differences between treatment groups, 
inducing confounding and bias study conclusions. Propensity score (PS) is a statistical approach that we will use to address this. The propensity 
(likelihood) of each patient to receive allopurinol given their measured characteristics is determined, so that the distribution of characteristics for 
patients with similar PS should be the same, enabling valid comparison of treatments. Optimal specification and subsequent adjustment for PS play 
a key role and we aim to explore these aspects of PS approach, and address the potential impact on our findings of patient characteristics not 
measured in CPRD. 
Background 
Gout is the most prevalent inflammatory arthropathy, affecting approximately 2.5% of adults in the UK in 2012; this prevalence increases to over 
14% among men aged over 75 years1. Most gout patients are treated within the primary care setting, with an average general practice having 40 
patients consulting for gout each year2. The principal risk factor for gout development is increased uric acid levels and the definitive long-term 
treatment of gout involves using urate-lowering therapies such as allopurinol. However, only a third of gout sufferers are prescribed allopurinol 
whilst others may be prescribed NSAIDS, analgesics or colchicine. A fifth of allopurinol users fail to lower their uric acid level below the recommended 
target of 360μmol/L3. 
Allopurinol was developed for the treatment of gout over 50 years ago however, only recently have studies investigating its effect been undertaken. 
Most of these have been of experimental nature, with allopurinol used as the comparator in three randomized controlled trials (RCTs) of newer 
urate-lowering drugs such as febuxostat4-6. However these trials were limited to 52 weeks follow-up and employed strict inclusion and exclusion 
criteria which may limit their generalizability to the majority of patients with gout. Therefore an extensive observational study is needed to investigate 
the effect of allopurinol use (Vs. non-allopurinol use), over a longer period of time on range of outcomes. However, in studies drawing on 
observational data a major impediment to valid assessment of treatment effect is the lack of randomization that is inherent in RCTs. This may often 
result in significant differences between treatment groups, with respect to both measured and unmeasured covariates, thus inducing possible 
confounding which may impact on inferences and conclusions. For instance RCTs using allopurinol as the comparator group excluded gout patients 
with poor renal function4-6 in whom gout treatment can be most challenging. A traditional statistical procedure employed to take account of measured 
covariates is multivariable regression. However the issue of covariate imbalance between treatment groups remains. Propensity score methodology, 
formalized by Rosenbaum and Rubin in 19837, is a possible alternative because it enables balance on measured covariates between those receiving 
and nor receiving allopurinol to be achieved thus removing some of the bias inherent in treatment allocation. The process involves collapsing 
information on observed covariates into a single value (the propensity score) which reflects the likelihood of a patient receiving allopurinol given 
these covariates. Once propensity scores have been adjusted for in the analysis of treatment effect, we can then be confident that any differences 
in outcome can be attributed to treatment, at least as far as accountability of observed covariates used in construction of propensity scores is 
concerned. Propensity score methodology has already been applied in studying effect of allopurinol. For example one study found that allopurinol 
users have a slightly reduced risk of mortality compared to non-allopurinol users8 whilst in another study allopurinol users were found to have an 
increased risk of severe cutaneous adverse reactions9. Wei et al10 reported that there was no increased risk in cardiovascular events for allopurinol 
users compared with non-users of urate lowering therapy and that high dose allopurinol users had a significantly lower risk of cardiovascular events 
and mortality than those on a lower dose. However the drawbacks of majority of such studies utilizing propensity score methodology has been the 
restriction to older age groups, consideration of only a few outcomes, not making allowances for recurrence of non-fatal outcomes such as gout 
attacks, renal and cardiovascular disease, assumption of time independence (i.e. they do not change) of certain covariates, and assumption of time 
independence of allopurinol use. For example a patient may be prescribed allopurinol for a couple of months then stop taking the medication until 
a couple of years later and so on. Furthermore, routinely collected observational data typically records only a limited set of covariates, and it is 
possible that some important covariates will remain unmeasured such as family history of gout, purine rich diet, and poor adherence to treatment. 
Propensity score analysis does not balance for such covariates and hence there is a possibility that some bias from lack of randomization will remain. 
This will introduce heterogeneity among patients, ultimately resulting in underestimation of data dispersion and over-optimistic results. Common 
practice is to ignore such heterogeneity. 
This project aims to approach estimation of allopurinol effect in a comprehensive and thorough manner. From a clinical aspect this will be achieved 
by considering a wide range of relevant outcomes among gout patients, relaxing exclusion criteria, specifically in terms of age and possible presence 
of comorbid conditions such as renal disease, and stratifying analyses on severity of gout. From a statistical aspect, allowance will be made for time-
dependent use of allopurinol, time dependence of covariates and recurrence of outcome events, thus giving rise to repeated measures data structure 
within which both propensity scores and subsequently treatment effect will be estimated. Furthermore, robustness of allopurinol effect estimates to 
omission of important covariates will be tested. True propensity score is unknown and we will consider making allowance for such uncertainty by 
modelling propensity score as a latent variable within Bayesian set-up11. 
Objectives, Specific Aims, and Rationale 
The main research objective is to investigate the long term effectiveness of allopurinol among a group of gout patients aged 18 and over.  
To address this, two specific clinical aims are: 
6) Examine effect of allopurinol (Vs. not taking allopurinol) on a range of outcomes: uric acid levels; repeat consultations for gout; hospital 
admissions; NSAID, analgesic and colchicine usage; allopurinol related side effects of hypersensitivity syndrome, rash, liver function, 
bone marrow suppression; gout comorbidities (vascular and renal diseases); joint replacement; mortality. 
7) Repeat objective 1 stratified on baseline levels of uric acid (</> 480 μmol/L)4 and on relevant comorbidities (renal and vascular disease) 
to assess whether effect of allopurinol varies by severity of gout or comorbidity. 





8) On estimation and adjustment for propensity scores: Investigate effect of including different sets of patient characteristics (covariates) 
in propensity score estimation on treatment effect estimate using three different adjustment approaches (stratification, matching, and 
weighting). We will consider inclusion of covariates related to treatment alone, those related to outcome alone, those related to both 
and inclusion of all available information. Extensions will be made to repeated measures setup.  
9) In order to address the impact of unobserved covariates, sensitivity of parameter estimates obtained in 1) to omission of covariates 
(with varying degree of strength of association with outcome and/or treatment) from the propensity score estimation stage will be 
examined.  
10) Investigate modelling propensity score as a latent variable within a Bayesian model, thereby accounting for some of the uncertainty 
inherent in construction of propensity scores.  
Study Type 
This will be a hypothesis testing study with the null hypothesis that there is no different in outcomes between gout patients prescribed and not 
prescribed allopurinol. However, the study also includes a strong element of methodological research to answer the clinical objectives. 
Study design 
This will be a prospective cohort study. The exposure of interest is allopurinol use vs. non usage of allopurinol in those who consulted for gout 
between 1997 and 2002 (see below).   
Study population 
The study sample will consist of all patients aged 18 years and over who had an initial consultation (or Read code) for gout between 1997 and 
2002. The list of Read codes used to identify gout consultations is in appendix 1.  Gout patients will need to have been registered at their practice 
for at least two years prior to their initial gout consultation. 
Patients under the age of 18 years or who have taken any urate lowering drugs (allopurinol, sulfinpyrazone, probenecid and benzbromarone) 
during the two years prior to the initial gout consultation between 1997 and 2002 will be excluded from the analysis. Patients who are prescribed 
other urate lowering drugs (febuxostat, sulfinpyrazone, probenecid and benzbromarone) prior to first prescription of allopurinol will be excluded 
from analysis. Patients prescribed allopurinol who are subsequently prescribed other urate lowering drugs, their follow up will be censored at date 
of prescription of other urate lowering drugs 
Exposures, Outcomes, and Covariates 
Exposure:  
- Prescriptions for allopurinol, including dosage, measured from baseline till end of study or death. 
Patients with an initial consultation for gout between 1997 and 2002 will be identified and will be classified by exposure of allopurinol use 
(allopurinol vs. non-allopurinol). However prescription for allopurinol does not coincide with the initial consultation for gout as it is often prescribed 
a few years later. Defining the follow-up period from the date of the initial consultation for gout would be inappropriate as patients’ exposure 
status would be determined during follow-up. During this time lag between gout consultation and allopurinol prescription, outcomes of interest 
may have occurred thus introducing bias, therefore a landmark method will be used. 
In the landmark method, a fixed time-point (landmark date) would be selected to define the start of the follow-up period after the initial 
consultation for gout. Up to the landmark date, patients would be classified as either allopurinol or non-allopurinol users. Patients would be 
excluded from the sample if they have the outcome of interest prior to the landmark date. Three landmark time-points are selected at one, two 
and three years. 
Primary outcome 
- Occurrence of and time to uric acid levels <360 μmol/L (from blood tests). All records of uric acid level measurements from baseline 
till end of study/death will be needed. 
Secondary outcomes (All records of these outcomes from baseline till end of study/death will be needed) 
- Occurrence of and time to (and between) repeat gout consultations (appendix 1). 
- Gout and non-gout related hospital admissions and related time to event. 
- Occurrence of and time to use of NSAIDs, analgesics and colchicine usage and allopurinol related side effects of hypersensitivity 
syndrome, rash, liver function, bone marrow suppression. 
- Occurrence of and time to vascular and renal diseases, and joint replacement (appendix 1). 
- Occurrence of and time to death and cause of death. 
Covariates (measured from baseline till death or end of study) 
Socio-demographic and lifestyle 
- Gender 
- Year of birth 
- Date and cause of death  
- General practice 
- Index of multiple deprivation  
- Alcohol consumption 
- Smoking status 
General health  
- Body Mass Index 
Comorbidity 
- Depression 





- Hypertension  
- Hyperlipidaemia 
- Diabetes mellitus 
- Osteoarthritis 
- Diuretic use 
- Vascular disease 
- Renal disease 
Covariates will be collected 2 years before gout consultation and 10 years after or until death or no longer contribute to CPRD. Possible time 
dependent nature of allopurinol use will be explored. In analysis of outcomes where their recurrence is not of interest or not possible (for example 
joint replacement), covariate information after the date of such an event will be ignored.  
Sample size/power calculation 
Restriction is made to population of patients registered at general practices that have consented to HES, deprivation and ONS mortality linkage. It 
is assumed that the total CPRD annual registered population is 5.5 million patients and that approximately 50% of practices contributing to CPRD 
have consented to linkage. This yields relevant annual population of approximately 2.75 million.  It is estimated that 70,000 of these will have 
gout, based on the latest figure for prevalence of gout as 2.5%.  
A feasibility count was performed using CPRD. Between 1997 and 2002, 33,538 individuals aged 18 years and over had a Read code for gout and 
were registered with their practice for at least two years prior. The table below shows the proportion of patients who were prescribed allopurinol 
up to each landmark date. 
Landmark date Number (%) prescribed allopurinol 
1 year 10,266 (30.61) 
2 years 11,648 (34.74) 
3 years 12,671 (37.78) 
 
Adequate power is required to yield reasonable estimates of treatment effect of allopurinol across a wide range of outcomes. 
The first primary outcome is uric acid level <360 μmol/L. Based on a single small recent study3, 77% of those on allopurinol are expected to reach 
this threshold as opposed to 25% of those not taking allopurinol. Secondary outcomes of recurrent gout attacks and allopurinol hypersensitivity 
syndrome have been evaluated. A nationwide population based study found 22% of newly diagnosed gout patients prescribed with allopurinol had 
a recurrent gout attack within a year compared to 14% of non-allopurinol users12. The proportion of hypersensitivity syndrome cases amongst 
allopurinol users is known to be 0.4%13 compared to 0% amongst non-allopurinol users. 
Using a significance level of 0.01, the power to detect a difference in proportion in each outcome outlined above between allopurinol and non-
allopurinol users is almost 1. 
Use of linked data 
Deprivation is a risk factor for increased consultation, morbidity and all-cause mortality which would have an impact on resource allocation to 
general practices. In England, gout prevalence increases with worsening occupational socio-economic status and gout is associated with 
inadequate income. The long term effects of allopurinol vs. alternative treatments are unknown and any difference arising between treatment 
groups could potentially partly be explained by deprivation.  
Gout has a strong association with the metabolic syndrome in particular hypertension, hyperlipidaemia, insulin resistance and obesity. This 
increases the risk of diabetes, vascular events and renal diseases which may result in hospitalization. Admissions to hospital would indicate 
whether gout patients using allopurinol are hospitalised more often than those on alternative treatments. 
Knowing the exact cause of death would identify gout patients whose cause of death is gout comorbidity related. 
Data /Statistical Analysis 
It is aimed that the project starts with the most basic models aimed at estimating effect of allopurinol on various outcomes. Extensions will then be 
made to more complex analysis in terms of accounting for data structure and type and using propensity score methodology to account for 
confounding due to observed covariates. Comparisons of the estimated effects of allopurinol will be made between models. Specific phases of model 
development, starting with the simplest model are: 
Phase 1 (Descriptive statistics) 
The baseline characteristics and demographics of allopurinol and non-allopurinol users will be described using proportions and means. The 
association between allopurinol use and outcomes will be described as incidence rates and relative risks. 
Phase 2 (Allopurinol at baseline, unadjusted effect) 
(a) All outcomes will initially be considered as single binary occurrences. Cox regression model will be used to estimate association 
between allopurinol at baseline and time to first occurrence of a particular event of interest. Proportionality of hazards assumption will be 
appropriately tested throughout and adjustments to the Cox model made or alternative non-PH models used. Right censoring will be taken into 
account, defined as the end of study or death (where death is not outcome of interest) and the censoring mechanism will be assumed non-
informative. Time will be treated as a continuous variable. 
(b) Extend (a) to recurrent times to event analyses. We will use Andersen-Gill model, an extension of Cox model, and Cox model with 
shared frailty component (an unobserved patient specific component aimed at accounting for correlation of times to a particular event within a 
patient) to analyse effect of allopurinol at baseline on recurrent times to event of interest. This will not be applicable to all outcomes. Note that 
considerations of other models will be made in case of violation of assumptions of these models. 
Phase 3 (Allopurinol at baseline, multivariable and propensity score adjustment) 
(c) Multivariable adjustment. Extend (a)-(b) by including observed covariates measured at baseline (i.e. closest to the time point leading up to 
prescription of allopurinol) directly in the model of allopurinol effect on time to event of interest. This is the most common way of adjusting treatment 





(d) Propensity scores. Estimate probability to use allopurinol (i.e. propensity score) at baseline via logistic regression. Different choices of 
covariates at baseline to be included in this process will be investigated (baseline for allopurinol and covariates as defined above): 
(i) all observed covariates 
(ii) all observed covariates related to allopurinol use only 
(iii) all observed covariates related to outcome of interest only 
(iv) all observed covariates related to both allopurinol use and outcome of interest 
Subsequently three methods of incorporating propensity scores in analyses (a)-(b): will be used during estimation of effect of allopurinol on time to 
event of interest  
- Stratification (patients will be ranked according to their propensity score and then split into strata (i.e. probability of using allopurinol based on 
quintiles of the propensity score). Within each stratum the effect of allopurinol will be calculated and then pooled across strata to get an overall 
allopurinol effect. 
- Matching (Matched pairs between allopurinol and non-allopurinol users who share similar (definition of “similar” dependent on matching algorithm) 
propensity score will be created. Allopurinol effect can then be estimated by directly comparing the outcomes between allopurinol users and non-
users. There are different algorithms to form a matched sample, most popular are greedy, optimal, nearest neighbour and caliper matching 
algorithms. 
- Inverse probability weighting (allopurinol effect e weighted by using the inverse of the propensity score. This approach ensures the distribution of 
covariates will be independent of allopurinol use). 
Phase 4 (Bayesian modelling) 
e) By considering allopurinol use at baseline and a single event occurrence, a fully Bayesian model for the joint distribution of data and parameters 
will be developed, treating propensity score as a latent variable. Then the treatment effect marginal posterior distribution will incorporate uncertainty 
in propensity scores as it integrates over the latent variable 11. A comparison will then be made between the Bayesian credible intervals for treatment 
effect and the intervals obtained using the standard propensity score approaches. In construction of the Bayesian model, we will initially consider 
non-informative priors only, followed by prior information based on expert opinion and existing research.   
Phase 5 (Incorporating allopurinol use over time (i.e. all periods of allopurinol prescription and non-prescription), multivariable 
and propensity score adjustment) 
f) Use of allopurinol may change on multiple occasions over time. Allopurinol use/non-use for each patient will therefore be defined for the entire 
study duration. Based on the number of allopurinol tablets and the frequency the patient needs to take them for, an estimate of how long the 
patient was taking allopurinol will be derived. Care will be taken to account for covariates appropriately by taking the covariate measurement closest 
in time prior to each occurrence of allopurinol prescription. For periods of non-use of allopurinol the midpoint in time will be taken for covariate 
measures. Timings of repeated events, in relation to allopurinol use, will be taken into account in the model of effect of allopurinol. 
g) Propensity score adjustment. Analysis f) above will be repeated, but using time-varying propensity scores, rather than time-varying covariate 
adjustment. Essentially two approaches will be considered to estimate such propensity scores, firstly they could be estimated at each time point 
when a treatment is received and secondly using a random effects model.   
Phase 6 (estimating effect of omitting important unobserved covariates) 
h) In all analyses pertaining to propensity score methodology above, the covariate found to be most influential (i.e. in terms of being strongly 
related to treatment and outcome, or to outcome alone) will be omitted from the propensity score estimation stage and resulting allopurinol effects 
compared to findings using a more correct specification of propensity score.  
Phase 7 (subgroup analyses) 
Stratification of all analyses above will be made on baseline uric acid levels </> 480 μmol/L and on relevant comorbidities (renal and vascular 
disease) to assess whether effect of allopurinol varies by severity of gout or comorbidity. 
Other considerations: 
Missing data 
During a consultation, all the patient’s symptoms and GP’s diagnoses may not be recorded therefore it will be assumed that all problems considered 
by the GP to be of importance at the time will be recorded and those things not recorded were not of importance. Hence, if a symptom or diagnosis 
is not recorded, this will not be considered ‘missing’ data. Missing information on patient socio-demographic, lifestyle and general health 
characteristics will be treated as true missing and will initially be ignored. Subsequently, we will consider multiple imputation, taking into account 
the repeated measures structure of the data where appropriate.   
Data will be managed and analysed in in Stata v13, R (v3.0.2+) and SAS.   
It has been noted to preserve confidentiality at the reporting stage and that cells with less than <5 events will not be reported. 
Patient or user group involvement 
It was not envisaged PPI is required to aid development of this protocol.   
Limitations of the study design, data sources, and analytic methods 
There is possibility patients may be misclassified as having gout however, a recent systematic review had validated 183 different diagnoses and 
had shown the median 89% of cases were confirmed using additional internal or external information14. With regards to gout, a study had taken a 
small subsample and had shown patients with a Read code for gout, a high urate level and prescribed anti-gout medication were all confirmed as 
having gout whereas those with a read code for gout and prescribed anti-gout medication 86% were confirmed as having gout15. We can be 90% 





Observational studies evaluating the effectiveness of drug effects will be biased due to residual confounding. The methodology outlined in this 
study attempts to minimise residual confounding. Firstly propensity score analysis will minimise the effect of confounding by indication. Although 
residual confounding may persist due to unmeasured covariates, the Bayesian methodology described will model the propensity scores as a latent 
variable taking into account the uncertainty in the estimation of propensity scores.  
Plans for disseminating and communicating study results, including the presence or absence of any restrictions on the extent 
and timing of publication 
The CPRD data will be used for a PhD. Results will be written into a thesis and findings will be presented at internal and external meetings and 




List of Read codes of consultation for gout 
Read Code Read Term 
C34 Gout 
N023 Gouty arthritis 
EGTON 227 Gout NOS 
OX2740G Gout Acute /ox 
1443 H/O: gout 
EMISR4QG01 Gouty tophi + Gout NOS 
2D52 O/E - auricle of ear – tophi 
669 Gout monitoring 
 
List of read codes of joint replacement 
The appropriate Read codes for joint replacement will be identified from the Read code chapter 7. An example read code list has been provided as 
follows:  
• hip replacement: 7K2..  
• knee replacement: 7K3.. 
• humerus/shoulder replacement: 7K4..  
• other joint replacement: 7K6.. 
• elbow replacement: 7K7.. 
• ankle replacement: 7K8.. 
List of read codes of renal disease 
Read 
Code 
Read Term Read 
Code 
Read Term 
K032600 Berger's IgA or IgG nephropathy K07..00 Renal sclerosis unspecified 
K0A0500 Acute neph syn, diffuse mesangiocapillary 
glomerulonephritis 
K00..00 Acute glomerulonephritis 
K03y.00 Other nephritis and nephrosis unspecified K08y500 Acute interstitial nephritis 
K0A0200 Acute nephritic syn, diffuse membranous 
glomerulonephritis 
SP01500 Mechanical complication of dialysis catheter 
1Z12.00 Chronic kidney disease stage 3 K0A4200 Isolatd proteinur/specfd morphlgcl les df membrn 
glomneph 
K02..00 Chronic glomerulonephritis K016.00 Nephrotic syndrome, diffuse membranous 
glomerulonephritis 
K032.00 Membranoproliferative nephritis unspecified K0A0300 Acut neph syn, diffuse mesangial prolifrative 
glomnephritis 
K132.00 Acquired cyst of kidney B91z111 Renal neoplasm of uncertain behaviour 
K040.00 Acute renal tubular necrosis K0A0600 Acute nephritic syndrome, dense deposit disease 
K0C1.00 Nephropathy induced by other drugs meds and biologl 
substncs 
K019.00 Nephrotic syn,diffuse mesangiocapillary 
glomerulonephritis 
K017.00 Nephrotic syn difus mesangial prolifertiv 
glomerulonephritis 
C341z00 Gouty nephropathy NOS 
G22..11 Nephrosclerosis G22z.11 Renal hypertension 
C104.11 Diabetic nephropathy K01x300 Nephrotic syndrome in polyarteritis nodosa 
7L1B100 Removal of ambulatory peritoneal dialysis catheter K072.00 Glomerulosclerosis 
K0A2300 Recur+persist haemuria df mesangial prolif 
glomerulnephritis 
K0A4500 Isoltd prteinur+specfd morph les df mesangiocap 
glomnephr 
K0z..00 Nephritis, nephrosis and nephrotic syndrome NOS K08z.00 Impaired renal function disorder NOS 
K013.11 Lipoid nephrosis PD3D.00 Enlarged kidney 
K030.00 Proliferative nephritis unspecified D310100 Henoch-Schonlein nephritis 
K032300 Anaphylactoid glomerulonephritis K0D..00 End-stage renal disease 
K043.00 Acute drug-induced renal failure K03X.00 Unsp nephrit synd, diff mesang prolif glomerulonephritis 
K02y200 Chronic focal glomerulonephritis K0A3700 Chronic nephritic syn diffuse crescentic 
glomerulonephritis 





K05..11 Chronic uraemia K0A3100 Chronic nephritic syndrm focal+segmental glomerular 
lesions 
K0A4300 Isoltd prteinur/spcfd morph lesn df mesngl prolf 
glomneph 
K0A2800 IgA nephropathy 
K00y300 Acute diffuse nephritis K0A2200 Recur+persist haematuria difus membranous 
glomerulonephritis 
K08yz11 Renal acidaemia C109C00 Non-insulin dependent diabetes mellitus with 
nephropathy 
TB11.00 Kidney dialysis with complication, without blame K03..12 Nephropathy, unspecified 
K0A0400 Ac neph syn difus endocaplry prolifrative 
glomerulonephritis 
K032y00 Nephritis unsp+OS membranoprolif glomerulonephritis 
lesion 
K01x400 Nephrotic syndrome in systemic lupus erythematosus C109C11 Type II diabetes mellitus with nephropathy 
7L1A500 Continuous ambulatory peritoneal dialysis K03W.00 Unsp nephrit synd, diff endocap prolif glomerulonephritis 
C10ED00 Type 1 diabetes mellitus with nephropathy K00..11 Acute nephritis 
K032y13 Mesangioproliferative glomerulonephritis NEC K041.00 Acute renal cortical necrosis 
K0A0700 Acute nephrotic syndrm diffuse crescentic 
glomerulonephritis 
K0A2700 Recur+persist haematuria difus crescentic 
glomerulonephritis 
9Ot3.00 Chronic kidney disease monitoring verbal invite K034.00 Renal cortical necrosis unspecified 
K0A1200 Rapid progres neph syn diffuse membranous 
glomerulonephritis 
K0C4.00 Toxic nephropathy, not elsewhere classified 
SP08300 Kidney transplant failure and rejection K0C2.00 Nephropathy induced by unspec drug medicament or 
biol subs 
K032y11 Hypocomplementaemic persistent glomerulonephritis 
NEC 
K022.00 Chronic membranoproliferative glomerulonephritis 
C10FC00 Type 2 diabetes mellitus with nephropathy 7L1A400 Automated peritoneal dialysis 
C354711 Renal calcinosis K04..00 Acute renal failure 
4519 Deteriorating renal function K060.00 Renal impairment 
9Ot4.00 Chronic kidney disease monitoring telephone invite S760111 Renal haematoma without mention of open wound into 
cavity 
K08..00 Impaired renal function disorder K138z11 Renal infarction 
A786.00 Haemorrhagic nephrosonephritis C108D11 Type I diabetes mellitus with nephropathy 
K01A.00 Nephrotic syndrome, dense deposit disease 9Ot1.00 Chronic kidney disease monitoring second letter 
K00y100 Acute exudative nephritis C341.00 Gouty nephropathy 
K060.11 Impaired renal function K03yz00 Other nephritis and nephrosis NOS 
K00yz00 Other acute glomerulonephritis NOS K071.00 Renal fibrosis 
C373600 Nephropathic amyloidosis K0A0100 Acute nephritic syndrome, focal+segmental glomerular 
lesions 
K050.00 End stage renal failure TB00111 Renal transplant with complication, without blame 
K023.00 Chronic rapidly progressive glomerulonephritis K042.00 Acute renal medullary necrosis 
K090.00 Unilateral small kidney SP15400 Renal failure as a complication of care 
K0C0.00 Analgesic nephropathy 7L1B000 Insertion of ambulatory peritoneal dialysis catheter 
7L1A.11 Dialysis for renal failure K01x100 Nephrotic syndrome in diabetes mellitus 
7B00z00 Transplantation of kidney NOS K020.00 Chronic proliferative glomerulonephritis 
K021.00 Chronic membranous glomerulonephritis 9Ot0.00 Chronic kidney disease monitoring first letter 
K0A3500 Chronic neph syn difus mesangiocapillary 
glomerulonephritis 
K014.00 Nephrotic syndrome, minor glomerular abnormality 
K138.11 Renal vascular disorders K0A3.00 Chronic nephritic syndrome 
K0A1300 Rpd prog neph syn df mesangial prolifratv 
glomerulonephritis 
K0A1700 Rapid progres nephritic syn df crescentic 
glomerulonephritis 
66i..00 Chronic kidney disease monitoring 7L1A100 Peritoneal dialysis 
1Z13.00 Chronic kidney disease stage 4 K08y000 Hypokalaemic nephropathy 
K0A3300 Chron neph syn difus mesangial prolifrtiv 
glomerulonephritis 
TB11.11 Renal dialysis with complication, without blame 
1Z11.00 Chronic kidney disease stage 2 K00y000 Acute glomerulonephritis in diseases EC 
9Ot..00 Chronic kidney disease monitoring administration 1Z10.00 Chronic kidney disease stage 1 
K032z00 Nephritis unsp+membranoprolif glomerulonephritis 
lesion NOS 
K0A0.00 Acute nephritic syndrome 
K02z.00 Chronic glomerulonephritis NOS K01x200 Nephrotic syndrome in malaria 
K01x411 Lupus nephritis K032y14 Mesangiocapillary glomerulonephritis NEC 
K01x000 Nephrotic syndrome in amyloidosis K138.00 Vascular disorders of kidney 
K03V.00 Unspecified nephritic syndrome, dense deposit disease K07z.00 Renal sclerosis NOS 
K02y300 Chronic diffuse glomerulonephritis K01B.00 Nephrotic syndrome, diffuse crescentic 
glomerulonephritis 






K02y000 Chronic glomerulonephritis + diseases EC K00y200 Acute focal nephritis 
K0...00 Nephritis, nephrosis and nephrotic syndrome K0A1600 Rapid progressive nephritic syndrome, dense deposit 
disease 
7L1A600 Peritoneal dialysis NEC 7L1A000 Renal dialysis 
K0A0000 Acute nephritic syndrome, minor glomerular abnormality 7B00100 Transplantation of kidney from live donor 
K070.00 Atrophy of kidney K001.00 Acute nephritis with lesions of necrotising glomerulitis 
K0y..00 Other specified nephritis, nephrosis or nephrotic 
syndrome 
K03y000 Other nephritis and nephrosis in diseases EC 
K0A1100 Rapid progres nephritic syn focal+segmental glomerulr 
lesion 
K015.00 Nephrotic syndrome, focal and segmental glomerular 
lesions 
K0A1.00 Rapidly progressive nephritic syndrome   
K02..12 Nephropathy - chronic 7L1C000 Insertion of temporary peritoneal dialysis catheter 
K03U.00 Unspecif nephr synd, diff concentric glomerulonephritis K01..00 Nephrotic syndrome 
7B00200 Transplantation of kidney from cadaver K018.00 Nephrotic syn,difus endocapilary proliftv 
glomerulonephritis 
K081.00 Nephrogenic diabetes insipidus K08y400 Renal tubular acidosis 
K13yz11 Salt-losing nephritis K000.00 Acute proliferative glomerulonephritis 
K032y15 Mixed membranous and proliferative glomerulonephritis 
NEC 
K010.00 Nephrotic syndrome with proliferative glomerulonephritis 
K00z.00 Acute glomerulonephritis NOS K0A3600 Chronic nephritic syndrome, dense deposit disease 
K03y200 Other interstitial nephritis K03..11 Nephritis and nephropathy unspecified 
K06..00 Renal failure unspecified K031.00 Membranous nephritis unspecified 
K013.12 Steroid sensitive nephrotic syndrome K03T.00 Tubulo-interstit nephritis, not specif as acute or chron 
TB00100 Kidney transplant with complication, without blame K02..11 Nephritis - chronic 
7L1A200 Haemodialysis NEC K01y.00 Nephrotic syndrome with other pathological kidney 
lesions 
1Z1..00 Chronic renal impairment K033.00 Rapidly progressive nephritis unspecified 
K13z000 Non-functioning kidney SP15411 Kidney failure as a complication of care 
K03z.00 Unspecified glomerulonephritis NOS C108D00 Insulin dependent diabetes mellitus with nephropathy 
1Z14.00 Chronic kidney disease stage 5 C354700 Nephrocalcinosis 
K02y.00 Other chronic glomerulonephritis K0A2500 Recur+persist hmuria df mesangiocapilary 
glomerulonephritis 
K01z.00 Nephrotic syndrome NOS K0A3000 Chronic nephritic syndrome, minor glomerular 
abnormality 
K013.00 Nephrotic syndrome with minimal change 
glomerulonephritis 
K04z.00 Acute renal failure NOS 
G222.00 Hypertensive renal disease with renal failure PDz0.00 Unspecified anomaly of kidney 
9Ot2.00 Chronic kidney disease monitoring third letter K032000 Focal membranoproliferative glomerulonephritis 
7B00.00 Transplantation of kidney K0A7.00 Glom disordr in blood diseas+disordr invlvg imun 
mechansm 
K0A3200 Chron nephritic syndrom difuse membranous 
glomerulonephritis 
K012.00 Nephrotic syndrome+membranoproliferative 
glomerulonephritis 
K02yz00 Other chronic glomerulonephritis NOS K00y.00 Other acute glomerulonephritis 
K035.00 Renal medullary necrosis unspecified K138z00 Renal vascular disorders NOS 
 
List of read codes for vascular disease 
Cardiovascular, cerebrovascular and peripheral vascular Read codes will be identified.  
List of cardiovascular Read codes 
Read 
Code 
Read Term Read 
Code 
Read Term 
14A..00 H/O: cardiovascular disease 32B..00 ECG: Q wave 
14A..12 H/O: myocardial problem 32B2.00 ECG: Q wave abnormal 
14A4.00 H/O: myocardial infarct >60 44p2.00 Cardiac troponin positive 
14A5.00 H/O: angina pectoris 5543 Coronary arteriograph.abnormal 
14AH.00 H/O: Myocardial infarction in last year 662..00 Cardiac disease monitoring 
14AJ.00 H/O: Angina in last year 662K000 Angina control - good 
14AL.00 H/O: Treatment for ischaemic heart disease 662K100 Angina control - poor 
14AZ.00 H/O: CVS disease NOS 662K200 Angina control - improving 
14N6.00 H/O: cardiac surgery 662K300 Angina control - worsening 





3213100 Exercise ECG abnormal 66f..00 Cardiovascular disease monitoring 
3213111 Positive exercise ECG test 6A2..00 Coronary heart disease annual review 
322..00 ECG: myocardial ischaemia 6A4..00 Coronary heart disease review 
3222 ECG:shows myocardial ischaemia 790H300 Revascularisation of wall of heart 
322Z.00 ECG: myocardial ischaemia NOS 792..00 Coronary artery operations 
323..00 ECG: myocardial infarction 792..11 Coronary artery bypass graft operations 
3232 ECG: old myocardial infarction 7920 Saphenous vein graft replacement of coronary artery 
3233 ECG: antero-septal infarct. 7920.11 Saphenous vein graft bypass of coronary artery 
3234 ECG:posterior/inferior infarct 7920000 Saphenous vein graft replacement of one coronary 
artery 
3235 ECG: subendocardial infarct 7920100 Saphenous vein graft replacement of two coronary 
arteries 
3236 ECG: lateral infarction 7920200 Saphenous vein graft replacement of three coronary 
arteries 
323Z.00 ECG: myocardial infarct NOS 7920300 Saphenous vein graft replacement of four+ coronary 
arteries 
7920y00 Saphenous vein graft replacement of coronary artery OS 7926 Connection of other thoracic artery to coronary artery 
7920z00 Saphenous vein graft replacement coronary artery NOS 7926000 Double anastom thoracic arteries to coronary arteries 
NEC 
7921 Other autograft replacement of coronary artery 7926200 Single anastomosis of thoracic artery to coronary artery 
NEC 
7921.11 Other autograft bypass of coronary artery 7926300 Single implantation thoracic artery into coronary artery 
NEC 
7921000 Autograft replacement of one coronary artery NEC 7926z00 Connection of other thoracic artery to coronary artery 
NOS 
7921100 Autograft replacement of two coronary arteries NEC 7927 Other open operations on coronary artery 
7921200 Autograft replacement of three coronary arteries NEC 7927000 Repair of arteriovenous fistula of coronary artery 
7921300 Autograft replacement of four of more coronary arteries 
NEC 
7927100 Repair of aneurysm of coronary artery 
7921y00 Other autograft replacement of coronary artery OS 7927300 Transposition of coronary artery NEC 
7921z00 Other autograft replacement of coronary artery NOS 7927400 Exploration of coronary artery 
7922 Allograft replacement of coronary artery 7927500 Open angioplasty of coronary artery 
7922.11 Allograft bypass of coronary artery 7927y00 Other specified other open operation on coronary artery 
7922000 Allograft replacement of one coronary artery 7927z00 Other open operation on coronary artery NOS 
7922100 Allograft replacement of two coronary arteries 7928 Transluminal balloon angioplasty of coronary artery 
7922200 Allograft replacement of three coronary arteries 7928.11 Percutaneous balloon coronary angioplasty 
7922300 Allograft replacement of four or more coronary arteries 7928000 Percut transluminal balloon angioplasty one coronary 
artery 
7922y00 Other specified allograft replacement of coronary artery 7928100 Percut translum balloon angioplasty mult coronary 
arteries 
7922z00 Allograft replacement of coronary artery NOS 7928200 Percut translum balloon angioplasty bypass graft 
coronary a 
7923 Prosthetic replacement of coronary artery 7928300 Percut translum cutting balloon angioplasty coronary 
artery 
7923.11 Prosthetic bypass of coronary artery 7928y00 Transluminal balloon angioplasty of coronary artery OS 
7923000 Prosthetic replacement of one coronary artery 7928z00 Transluminal balloon angioplasty of coronary artery NOS 
7923100 Prosthetic replacement of two coronary arteries 7929 Other therapeutic transluminal operations on coronary 
artery 
7923200 Prosthetic replacement of three coronary arteries 7929000 Percutaneous transluminal laser coronary angioplasty 
7923300 Prosthetic replacement of four or more coronary arteries 7929100 Percut transluminal coronary thrombolysis with 
streptokinase 
7923z00 Prosthetic replacement of coronary artery NOS 7929111 Percut translum coronary thrombolytic therapy- 
streptokinase 
7924 Revision of bypass for coronary artery 7929200 Percut translum inject therap subst to coronary artery 
NEC 
7924000 Revision of bypass for one coronary artery 7929300 Rotary blade coronary angioplasty 
7924100 Revision of bypass for two coronary arteries 7929400 Insertion of coronary artery stent 
7924200 Revision of bypass for three coronary arteries 7929500 Insertion of drug-eluting coronary artery stent 
7924y00 Other specified revision of bypass for coronary artery 7929600 Percutaneous transluminal atherectomy of coronary 
artery 
7925 Connection of mammary artery to coronary artery 7929y00 Other therapeutic transluminal op on coronary artery OS 
7925.11 Creation of bypass from mammary artery to coronary 
artery 
7929z00 Other therapeutic transluminal op on coronary artery 
NOS 
7925000 Double anastomosis of mammary arteries to coronary 
arteries 
792A.00 Diagnostic transluminal operations on coronary artery 
7925011 LIMA sequential anastomosis 792A000 Percutaneous transluminal angioscopy 





7925100 Double implant of mammary arteries into coronary 
arteries 
792Ay00 Diagnostic transluminal operation on coronary artery OS 
7925300 Single anastomosis of mammary artery to coronary 
artery NEC 
792Az00 Diagnostic transluminal operation on coronary artery 
NOS 
7925311 LIMA single anastomosis 792B.00 Repair of coronary artery NEC 
7925312 RIMA single anastomosis 792B000 Endarterectomy of coronary artery NEC 
7925400 Single implantation of mammary artery into coronary 
artery 
792B100 Repair of rupture of coronary artery 
7925y00 Connection of mammary artery to coronary artery OS 792B200 Repair of arteriovenous malformation of coronary artery 
7925z00 Connection of mammary artery to coronary artery NOS 792By00 Other specified repair of coronary artery 
792Bz00 Repair of coronary artery NOS 9Ob5.00 Coronary heart disease monitoring 3rd letter 
792C.00 Other replacement of coronary artery 9Ob6.00 Coronary heart disease monitoring verbal invitation 
792C000 Replacement of coronary arteries using multiple 
methods 
G3...00 Ischaemic heart disease 
792Cy00 Other specified replacement of coronary artery G3...11 Arteriosclerotic heart disease 
792Cz00 Replacement of coronary artery NOS G3...12 Atherosclerotic heart disease 
792D.00 Other bypass of coronary artery G3...13 IHD - Ischaemic heart disease 
792Dy00 Other specified other bypass of coronary artery G30..00 Acute myocardial infarction 
792Dz00 Other bypass of coronary artery NOS G30..11 Attack - heart 
792y.00 Other specified operations on coronary artery G30..12 Coronary thrombosis 
792z.00 Coronary artery operations NOS G30..13 Cardiac rupture following myocardial infarction (MI) 
7932z00 Open operation on heart NOS G30..14 Heart attack 
7938000 Angiocardiography of both right and left sides of heart G30..15 MI - acute myocardial infarction 
7938100 Angiocardiography of right side of heart NEC G30..16 Thrombosis - coronary 
7938200 Angiocardiography of left side of heart NEC G30..17 Silent myocardial infarction 
7938300 Coronary arteriography using two catheters G300.00 Acute anterolateral infarction 
7938400 Coronary arteriography using single catheter G301.00 Other specified anterior myocardial infarction 
7938500 Coronary arteriography NEC G301000 Acute anteroapical infarction 
7938600 Coronary arteriography using three catheters G301100 Acute anteroseptal infarction 
7939.11 Cardiac catheterisation G301z00 Anterior myocardial infarction NOS 
7939000 Catheterisation of both right and left sides of heart NEC G302.00 Acute inferolateral infarction 
7939100 Catheterisation of right side of heart NEC G303.00 Acute inferoposterior infarction 
7939200 Catheterisation of left side of heart NEC G304.00 Posterior myocardial infarction NOS 
7939y00 Other specified catheterisation of heart G305.00 Lateral myocardial infarction NOS 
7939z00 Catheterisation of heart NOS G306.00 True posterior myocardial infarction 
793G.00 Perc translumin balloon angioplasty stenting coronary 
artery 
G307.00 Acute subendocardial infarction 
793G000 Perc translum ball angio insert 1-2 drug elut stents cor 
art 
G307000 Acute non-Q wave infarction 
793G100 Perc tran ball angio ins 3 or more drug elut stents cor 
art 
G307100 Acute non-ST segment elevation myocardial infarction 
793G200 Perc translum balloon angioplasty insert 1-2 stents cor 
art 
G308.00 Inferior myocardial infarction NOS 
793G300 Percutaneous cor balloon angiop 3 more stents cor art 
NEC 
G309.00 Acute Q-wave infarct 
793Gy00 OS perc translumina balloon angioplast stenting 
coronary art 
G30A.00 Mural thrombosis 
793Gz00 Perc translum balloon angioplasty stenting coronary art 
NOS 
G30B.00 Acute posterolateral myocardial infarction 
793K.00 Transluminal operations internal mammary artery side 
branch 
G30X.00 Acute transmural myocardial infarction of unspecif site 
793K000 Translum occlusion left internal mammary artery side 
branch 
G30X000 Acute ST segment elevation myocardial infarction 
88A8.00 Thrombolytic therapy G30y.00 Other acute myocardial infarction 
8B3k.00 Coronary heart disease medication review G30y000 Acute atrial infarction 
8B63.11 Aspirin prophylaxis - IHD G30y100 Acute papillary muscle infarction 
8H2V.00 Admit ischaemic heart disease emergency G30y200 Acute septal infarction 
9Ob..00 Coronary heart disease monitoring administration G30yz00 Other acute myocardial infarction NOS 
9Ob0.00 Attends coronary heart disease monitoring G30z.00 Acute myocardial infarction NOS 
9Ob2.00 Coronary heart disease monitoring default G31..00 Other acute and subacute ischaemic heart disease 
9Ob3.00 Coronary heart disease monitoring 1st letter G34yz00 Other specified chronic ischaemic heart disease NOS 





G310.00 Postmyocardial infarction syndrome G34z000 Asymptomatic coronary heart disease 
G310.11 Dressler's syndrome G35..00 Subsequent myocardial infarction 
G311.00 Preinfarction syndrome G350.00 Subsequent myocardial infarction of anterior wall 
G311.11 Crescendo angina G351.00 Subsequent myocardial infarction of inferior wall 
G311.13 Unstable angina G353.00 Subsequent myocardial infarction of other sites 
G311.14 Angina at rest G35X.00 Subsequent myocardial infarction of unspecified site 
G311100 Unstable angina G36..00 Certain current complication follow acute myocardial 
infarct 
G311200 Angina at rest G360.00 Haemopericardium/current comp folow acut myocard 
infarct 
G311300 Refractory angina G361.00 Atrial septal defect/curr comp folow acut myocardal 
infarct 
G311400 Worsening angina G362.00 Ventric septal defect/curr comp fol acut myocardal 
infarctn 
G311500 Acute coronary syndrome G363.00 Ruptur cardiac wall w'out haemopericard/cur comp fol 
ac MI 
G311z00 Preinfarction syndrome NOS G364.00 Ruptur chordae tendinae/curr comp fol acute myocard 
infarct 
G312.00 Coronary thrombosis not resulting in myocardial 
infarction 
G365.00 Rupture papillary muscle/curr comp fol acute myocard 
infarct 
G31y.00 Other acute and subacute ischaemic heart disease G366.00 Thrombosis atrium,auric append&vent/curr comp foll 
acute MI 
G31y000 Acute coronary insufficiency G37..00 Cardiac syndrome X 
G31y100 Microinfarction of heart G38..00 Postoperative myocardial infarction 
G31y200 Subendocardial ischaemia G380.00 Postoperative transmural myocardial infarction anterior 
wall 
G31y300 Transient myocardial ischaemia G381.00 Postoperative transmural myocardial infarction inferior 
wall 
G31yz00 Other acute and subacute ischaemic heart disease NOS G384.00 Postoperative subendocardial myocardial infarction 
G32..00 Old myocardial infarction G38z.00 Postoperative myocardial infarction, unspecified 
G32..11 Healed myocardial infarction G3y..00 Other specified ischaemic heart disease 
G32..12 Personal history of myocardial infarction G3z..00 Ischaemic heart disease NOS 
G33..00 Angina pectoris G5...00 Other forms of heart disease 
G330.00 Angina decubitus G5y..00 Other specified heart disease 
G330000 Nocturnal angina G5y1.00 Myocardial degeneration 
G330z00 Angina decubitus NOS G5y2.00 Cardiovascular arteriosclerosis unspecified 
G331.00 Prinzmetal's angina G5yy.00 Other ill-defined heart disease 
G331.11 Variant angina pectoris G5yyz00 Other ill-defined heart disease NOS 
G332.00 Coronary artery spasm G5yz.00 Other heart disease NOS 
G33z.00 Angina pectoris NOS G5z..00 Heart disease NOS 
G33z000 Status anginosus Gyu3.00 [X]Ischaemic heart diseases 
G33z100 Stenocardia Gyu3000 [X]Other forms of angina pectoris 
G33z200 Syncope anginosa Gyu3200 [X]Other forms of acute ischaemic heart disease 
G33z300 Angina on effort Gyu3300 [X]Other forms of chronic ischaemic heart disease 
G33z400 Ischaemic chest pain Gyu3400 [X]Acute transmural myocardial infarction of unspecif 
site 
G33z500 Post infarct angina Gyu3600 [X]Subsequent myocardial infarction of unspecified site 
G33z600 New onset angina ZV45800 [V]Presence of coronary angioplasty implant and graft 
G33z700 Stable angina ZV45K00 [V]Presence of coronary artery bypass graft 
G33zz00 Angina pectoris NOS ZV45K11 [V]Presence of coronary artery bypass graft - CABG 
G34..00 Other chronic ischaemic heart disease ZV45L00 [V]Status following coronary angioplasty NOS 
G340.00 Coronary atherosclerosis G340000 Single coronary vessel disease 
G340.11 Triple vessel disease of the heart G340100 Double coronary vessel disease 
G340.12 Coronary artery disease G342.00 Atherosclerotic cardiovascular disease 
G343.00 Ischaemic cardiomyopathy G34y000 Chronic coronary insufficiency 
G344.00 Silent myocardial ischaemia G34y100 Chronic myocardial ischaemia 
G34y.00 Other specified chronic ischaemic heart disease   
 
 







Read term Read 
code 
Read term 
1477 H/O: cerebrovascular disease 7A20311 Carotid endarterectomy and patch 
14A7.00 H/O: CVA/stroke 7A20400 Endarterectomy of carotid artery NEC 
14A7.11 H/O: CVA 7A20700 Intracranial bypass from carotid artery NEC 
14A7.12 H/O: stroke 7A21200 Open embolectomy of carotid artery 
14AF.00 H/O sub-arachnoid haemorrhage 7A22300 Percutaneous transluminal insertion stent carotid artery 
14AK.00 H/O: Stroke in last year 7A24600 Open embolisation of cerebral artery 
5513 Carotid A angiogram abnormal 7A25100 Percutaneous transluminal embolisation of circle of Willis 
5C10.00 Carotid artery doppler abnormal 7A25600 Percutaneous transluminal insertion of stent cerebral 
artery 
662M.00 Stroke monitoring 8HBJ.00 Stroke / transient ischaemic attack referral 
662e.00 Stroke/CVA annual review 8HTQ.00 Referral to stroke clinic 
662o.00 Haemorrhagic stroke monitoring 9N0p.00 Seen in stroke clinic 
7A20.00 Reconstruction of carotid artery 9Om..00 Stroke/transient ischaemic attack monitoring 
administration 
7A20000 Replacement of carotid artery using graft 9Om0.00 Stroke/transient ischaemic attack monitoring first letter 
7A20100 Intracranial bypass to carotid artery 9Om1.00 Stroke/transient ischaemic attack monitoring second 
letter 
7A20300 Endarterectomy and patch repair of carotid artery 9Om2.00 Stroke/transient ischaemic attack monitoring third letter 
F11x200 Cerebral degeneration due to cerebrovascular disease 9Om3.00 Stroke/transient ischaemic attack monitoring verbal 
invitati 
G6...00 Cerebrovascular disease 9Om4.00 Stroke/transient ischaemic attack monitoring telephone 
invte 
G60..00 Subarachnoid haemorrhage G640000 Cerebral infarction due to thrombosis of cerebral arteries 
G600.00 Ruptured berry aneurysm G641.00 Cerebral embolism 
G601.00 Subarachnoid haemorrhage from carotid siphon and 
bifurcation 
G641.11 Cerebral embolus 
G602.00 Subarachnoid haemorrhage from middle cerebral artery G641000 Cerebral infarction due to embolism of cerebral arteries 
G603.00 Subarachnoid haemorrhage from anterior 
communicating artery 
G64z.00 Cerebral infarction NOS 
G604.00 Subarachnoid haemorrhage from posterior 
communicating artery 
G64z.11 Brainstem infarction NOS 
G605.00 Subarachnoid haemorrhage from basilar artery G64z.12 Cerebellar infarction 
G606.00 Subarachnoid haemorrhage from vertebral artery G64z000 Brainstem infarction 
G60X.00 Subarachnoid haemorrh from intracranial artery, 
unspecif 
G64z100 Wallenberg syndrome 
G60z.00 Subarachnoid haemorrhage NOS G64z111 Lateral medullary syndrome 
G61..00 Intracerebral haemorrhage G64z200 Left sided cerebral infarction 
G61..11 CVA - cerebrovascular accid due to intracerebral 
haemorrhage 
G64z300 Right sided cerebral infarction 
G61..12 Stroke due to intracerebral haemorrhage G64z400 Infarction of basal ganglia 
G610.00 Cortical haemorrhage G65..00 Transient cerebral ischaemia 
G611.00 Internal capsule haemorrhage G65..12 Transient ischaemic attack 
G612.00 Basal nucleus haemorrhage G65..13 Vertebro-basilar insufficiency 
G613.00 Cerebellar haemorrhage G650.00 Basilar artery syndrome 
G614.00 Pontine haemorrhage G650.11 Insufficiency - basilar artery 
G615.00 Bulbar haemorrhage G651.00 Vertebral artery syndrome 
G616.00 External capsule haemorrhage G651000 Vertebro-basilar artery syndrome 
G617.00 Intracerebral haemorrhage, intraventricular G652.00 Subclavian steal syndrome 
G618.00 Intracerebral haemorrhage, multiple localized G653.00 Carotid artery syndrome hemispheric 
G61X.00 Intracerebral haemorrhage in hemisphere, unspecified G654.00 Multiple and bilateral precerebral artery syndromes 
G61X000 Left sided intracerebral haemorrhage, unspecified G655.00 Transient global amnesia 
G61X100 Right sided intracerebral haemorrhage, unspecified G656.00 Vertebrobasilar insufficiency 
G61z.00 Intracerebral haemorrhage NOS G65y.00 Other transient cerebral ischaemia 
G62..00 Other and unspecified intracranial haemorrhage G65z.00 Transient cerebral ischaemia NOS 
G62z.00 Intracranial haemorrhage NOS G65z100 Intermittent cerebral ischaemia 
G63..00 Precerebral arterial occlusion G65zz00 Transient cerebral ischaemia NOS 
G63..11 Infarction - precerebral G66..00 Stroke and cerebrovascular accident unspecified 
G63..12 Stenosis of precerebral arteries G66..11 CVA unspecified 





G631.00 Carotid artery occlusion G66..13 CVA - Cerebrovascular accident unspecified 
G631.11 Stenosis, carotid artery G660.00 Middle cerebral artery syndrome 
G631.12 Thrombosis, carotid artery G661.00 Anterior cerebral artery syndrome 
G632.00 Vertebral artery occlusion G662.00 Posterior cerebral artery syndrome 
G633.00 Multiple and bilateral precerebral arterial occlusion G663.00 Brain stem stroke syndrome 
G634.00 Carotid artery stenosis G664.00 Cerebellar stroke syndrome 
G63y.00 Other precerebral artery occlusion G665.00 Pure motor lacunar syndrome 
G63y000 Cerebral infarct due to thrombosis of precerebral arteries G666.00 Pure sensory lacunar syndrome 
G63y100 Cerebral infarction due to embolism of precerebral 
arteries 
G667.00 Left sided CVA 
G63z.00 Precerebral artery occlusion NOS G668.00 Right sided CVA 
G64..00 Cerebral arterial occlusion G67..00 Other cerebrovascular disease 
G64..11 CVA - cerebral artery occlusion G670.00 Cerebral atherosclerosis 
G64..12 Infarction - cerebral G670.11 Precerebral atherosclerosis 
G64..13 Stroke due to cerebral arterial occlusion G671.00 Generalised ischaemic cerebrovascular disease NOS 
G640.00 Cerebral thrombosis G671000 Acute cerebrovascular insufficiency NOS 
G673300 Vertebral artery dissection G671100 Chronic cerebral ischaemia 
G674.00 Cerebral arteritis G671z00 Generalised ischaemic cerebrovascular disease NOS 
G674000 Cerebral amyloid angiopathy G672.00 Hypertensive encephalopathy 
G676.00 Nonpyogenic venous sinus thrombosis G673.00 Cerebral aneurysm, nonruptured 
G676000 Cereb infarct due cerebral venous thrombosis, 
nonpyogenic 
G673000 Dissection of cerebral arteries, nonruptured 
G677.00 Occlusion/stenosis cerebral arts not result cerebral 
infarct 
G673100 Carotico-cavernous sinus fistula 
G677000 Occlusion and stenosis of middle cerebral artery G673200 Carotid artery dissection 
G677100 Occlusion and stenosis of anterior cerebral artery G70y000 Carotid artery atherosclerosis 
G677200 Occlusion and stenosis of posterior cerebral artery G70y011 Carotid artery disease 
G677300 Occlusion and stenosis of cerebellar arteries G72y000 Aneurysm of common carotid art 
G677400 Occlusion+stenosis of multiple and bilat cerebral arteries G72y100 Aneurysm of external carotid artery 
G679.00 Small vessel cerebrovascular disease G72y200 Aneurysm of internal carotid artery 
G67y.00 Other cerebrovascular disease OS G755000 Cranial arteritis 
G67z.00 Other cerebrovascular disease NOS Gyu6.00 [X]Cerebrovascular diseases 
G68..00 Late effects of cerebrovascular disease Gyu6300 [X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl 
artrs 
G680.00 Sequelae of subarachnoid haemorrhage Gyu6400 [X]Other cerebral infarction 
G681.00 Sequelae of intracerebral haemorrhage Gyu6500 [X]Occlusion and stenosis of other precerebral arteries 
G682.00 Sequelae of other nontraumatic intracranial 
haemorrhage 
Gyu6600 [X]Occlusion and stenosis of other cerebral arteries 
G683.00 Sequelae of cerebral infarction Gyu6A00 [X]Other cerebrovascular disorders in diseases CE 
G68W.00 Sequelae/other + unspecified cerebrovascular diseases Gyu6F00 [X]Intracerebral haemorrhage in hemisphere, 
unspecified 
G68X.00 Sequelae of stroke,not specfd as h'morrhage or 
infarction 
Gyu6G00 [X]Cereb infarct due unsp occlus/stenos precerebr 
arteries 
G6W..00 Cereb infarct due unsp occlus/stenos precerebr arteries ZLEP.00 Discharge from stroke serv 
G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs ZV12511 [V]Personal history of stroke 
G6y..00 Other specified cerebrovascular disease ZV12512 [V]Personal history of cerebrovascular accident (CVA) 
G6z..00 Cerebrovascular disease NOS   
 
List of peripheral vascular Read codes 
Read 
code 
Read term Read 
code 
Read term 
662U.00 Peripheral vascular disease monitoring 7A41C00 Bypass leg artery by aorta/deep femoral art anastomosis 
NEC 
7A10300 Axillo-unifemoral PTFE bypass graft 7A41D00 Bypass iliac artery by iliac/iliac artery anastomosis NEC 
7A26A00 Endarterectomy and patch repair of vertebral artery 7A41F00 Ilio-femoral prosthetic cross over graft 
7A28000 Percutaneous transluminal angioplasty of subclavian 
artery 
7A41y00 Other specified other bypass of iliac artery 
7A28200 Percutaneous transluminal angioplasty of vertebral 
artery 
7A41z00 Other bypass of iliac artery NOS 





7A32000 Percutaneous transluminal angioplasty of renal artery 7A42011 Endarterectomy and patch repair of common iliac artery 
7A32400 Percutan transluminal balloon angioplasty stenting renal 
art 
7A42012 Iliac endarterectomy and patch 
7A32500 Percutaneous transluminal insertion stent into renal 
artery 
7A42100 Endarterectomy of iliac artery NEC 
7A33100 Bypass of superior mesenteric artery NEC 7A42111 Endarterectomy of common iliac artery NEC 
7A35300 Percutaneous transluminal angioplasty suprarenal artery 
NEC 
7A44400 Percutaneous transluminal insertion of iliac artery stent 
7A41000 Emerg bypass iliac art by iliac/femoral art anastomosis 
NEC 
7A47.00 Other emergency bypass of femoral artery or popliteal 
artery 
7A41100 Bypass iliac artery by iliac/femoral artery anastomosis 
NEC 
7A47.11 Other emerg bypass femoral or popliteal art by 
anastomosis 
7A41200 Emerg bypass iliac artery by femoral/femoral art anast 
NEC 
7A47.12 Other emergency bypass of common femoral artery 
7A41211 Emergency femoro-femoral prosthetic cross over graft 7A47.13 Other emergency bypass of deep femoral artery 
7A41300 Bypass iliac artery by femoral/femoral art anastomosis 
NEC 
7A47.14 Other emergency bypass of popliteal artery 
7A41311 Femoro-femoral prosthetic cross over graft 7A47.15 Other emergency bypass of superficial femoral artery 
7A41400 Emerg bypass comm iliac art by aorta/com iliac art anast 
NEC 
7A47.16 Other emergency bypass of femoral artery 
7A41600 Emerg bypass leg artery by aorta/com fem art 
anastomosis NEC 
7A47000 Emerg bypass femoral art by fem/pop art anast c prosth 
NEC 
7A41900 Bypass common iliac artery by aorta/com iliac art anast 
NEC 
7A47100 Emerg bypass popliteal art by pop/pop art anast c 
prosth NEC 
7A41B00 Bypass leg artery by aorta/com femoral art anastomosis 
NEC 
7A47200 Emerg bypass femoral art by fem/pop a anast c vein 
graft NEC 
7A48C00 Bypass femoral artery by femoral/femoral art 
anastomosis NEC 
7A47300 Emerg bypass pop art by pop/pop art anast c vein graft 
NEC 
7A48D00 Bypass popliteal artery by pop/fem artery anastomosis 
NEC 
7A47400 Emerg bypass femoral art by fem/tib art anast c prosth 
NEC 
7A48E00 Femoro-femoral prosthetic cross over graft 7A47600 Emerg bypass femoral art by fem/tib a anast c vein graft 
NEC 
7A48y00 Other bypass of femoral artery or popliteal artery OS 7A47700 Emerg bypass pop art by pop/tib art anast c vein graft 
NEC 
7A48z00 Other bypass of femoral artery or popliteal artery NOS 7A47800 Emerg bypass femoral art by fem/peron art anast c 
prosth NEC 
7A49100 Endarterectomy and patch repair of popliteal artery 7A47B00 Emerg bypass pop art by pop/peron art anast c vein 
graft NEC 
7A49300 Endarterectomy of popliteal artery NEC 7A47C00 Emerg bypass femoral artery by fem/fem art 
anastomosis NEC 
7A49400 Profundoplasty femoral artery & patch repair deep fem 
artery 
7A47D00 Emerg bypass popliteal artery by pop/fem art 
anastomosis NEC 
7A49500 Profundoplasty and patch repair of popliteal artery 7A47y00 Other emergency bypass of femoral or popliteal artery 
OS 
7A49600 Profundoplasty of femoral artery NEC 7A47z00 Other emergency bypass of femoral or popliteal artery 
NOS 
7A49700 Profundoplasty of popliteal artery NEC 7A48.00 Other bypass of femoral artery or popliteal artery 
7A4B000 Percutaneous transluminal angioplasty of femoral artery 7A48.11 Other bypass of femoral or popliteal artery by 
anastomosis 
7A4B100 Percutaneous transluminal angioplasty of popliteal artery 7A48.12 Other bypass of common femoral artery 
7A4B900 Percutaneous transluminal insertion of stent femoral 
artery 
7A48.15 Other bypass of popliteal artery 
7A56600 Percutaneous transluminal placement peripheral stent 
artery 
7A48.16 Other bypass of superficial femoral artery 
9N4h.00 DNA - Did not attend peripheral vascular disease clinic 7A48000 Bypass femoral artery by fem/pop art anast c prosthesis 
NEC 
G701.00 Renal artery atherosclerosis 7A48100 Bypass popliteal artery by pop/pop a anast c prosthesis 
NEC 
G702.00 Extremity artery atheroma 7A48200 Bypass femoral artery by fem/pop art anast c vein graft 
NEC 
G702z00 Extremity artery atheroma NOS 7A48300 Bypass popliteal artery by pop/pop a anast c vein graft 
NEC 
G703.00 Acquired renal artery stenosis 7A48400 Bypass femoral artery by fem/tib art anast c prosthesis 
NEC 
G73..00 Other peripheral vascular disease 7A48600 Bypass femoral artery by fem/tib art anast c vein graft 
NEC 
G73..11 Peripheral ischaemic vascular disease 7A48700 Bypass popliteal artery by pop/tib a anast c vein graft 
NEC 
G73..12 Ischaemia of legs 7A48800 Bypass femoral artery by fem/peron a anast c prosthesis 
NEC 
G73..13 Peripheral ischaemia 7A48A00 Bypass femoral artery by fem/peron a anast c vein graft 
NEC 
G731000 Buerger's disease 7A48B00 Bypass popliteal art by pop/peron art anast c vein graft 
NEC 
G731100 Presenile gangrene G73yz00 Other specified peripheral vascular disease NOS 
G732.00 Peripheral gangrene G73z.00 Peripheral vascular disease NOS 





G732100 Gangrene of foot G73zz00 Peripheral vascular disease NOS 
G733.00 Ischaemic foot G763.00 Hyperplasia of renal artery 
G73y.00 Other specified peripheral vascular disease G768000 Fibromuscular hyperplasia of arteries NOS 
G73y000 Diabetic peripheral angiopathy G768100 Arterial fibromuscular dysplasia 
G73y100 Peripheral angiopathic disease EC NOS Gyu7400 [X]Other specified peripheral vascular diseases 
SP12.00 Peripheral vascular complications of care   
 
Glossary of Acronyms 
CONSORT    Consolidated Standards of Reporting Trials 
CPRD           Clinical Practice Research Datalink 
EQUATOR     Enhancing the Quality and Transparency of health research network 
GP               General Practitioner  
ISAC            Independent Scientific Advisory Committee for MHRA database research 
MREC           Multi-centre NHS Research Ethic Committee 
MHRA           Medicines and Healthcare products Regulatory Agency  
NHS             National Health Service 
NRR             National Research Register 
OXMIS          Oxford Medical Information Systems (codes) 
REC              NHS Research Ethics Committee 
STROBE        Strengthening the Reporting of Observational studies in Epidemiology 
UK               United Kingdom 
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 Cleaning of SU levels 
The UK frequently measures serum urate (SU) in μmol/L however, SU level was found to be 
recorded inconsistently with various other units of measurement used, for example mg/dL, 
which is commonly used in the US, and mmol/L which is used in mainland Europe. To convert 
measurements to μmol/L, measurements recorded as mg/dL was multiplied by 59.48; mmol/L 
measurements were divided by 1000; measurements per dL were multiplied by 10 to obtain 
L; international units were assumed to be mmol/L (Taylor, 2013).  
For each observed unit, the distribution of SU level was checked and then split into groups 
based on the gaps in the distribution; the gaps in the distribution indicate the incorrect units 
were recorded. For each group, if it was believed the wrong unit was recorded a more 
appropriate unit was allocated based on the SU distribution and if necessary, converted to 
µmol/L.  
Table E1 shows how measurements were standardised. For example, 2,107 measurements 
did not have units recorded; 2 measurements equalled 0.04 thus assumed the units were 
mmol/dL; 1,195 measurements ranged between 0.1 and 0.95 thus assumed units were 





Table E1: Standardising SU level to µmol/L 
Unit of measurement recorded (in grey) 
Range of serum urate level 
Number of measurements 
Assumption of the unit of measurement and the action taken to convert to µmol/L 
Any other notes 
Unknown 2,107  
     0.04 2 Assume units were mmol/dL and multiplied by 10000. 
     0.1 – 0.95 1,195 Assume units were mmol/L and multiplied by 1000. 
     1.06 – 9.3 7 
Assume units were mg/dL and multiplied by 59.48. 
Two measurements were removed as the patient had a more plausible measurement on the same 
date. 
     41 – 56 5 Assume units were µmol/dL and multiplied by 10.  
     106 – 928 897 Assume units were µmol/L. 
     5141 1 Cannot assume what the unit was thus measurement was removed. 
IU/L (international units per litre) 3,962  
     0.04 – 0.05 3 Assume units were mmol/dL and multiple by 10000. 
     0.15 – 0.96 2,371 Assume units were mmol/L and multiplied by 1000. 
     3.9 – 11.4 20 
Assume units were mg/dL and multiplied by 59.48. 
One measurement was removed as there was a more plausible measurement 4 days later. 
One measurement was removed as there was a more plausible measurement one day earlier. 
     28 – 60 8 Assume units were µmol/dL and multiplied by 10. 
     107 – 946 1,560 Assume units were µmol/L. 
mg/L (milligrams per litre) 1  
     66.6 1 Assume units were mg/L and divide by 10 and multiplied by 59.48. 
mL/min (millilitre per minute) 2  
     36 – 49 2 Assume units were µmol/dL and multiplied by 10. 
mmol/d (millimole per day) 1   
     0.43 1 Assume units were mmol/L and multiplied by 1000 
mmol/L (millimole per litre) 13,851  
     0.08 1 Assume units were mmol/dL and multiplied by 10000. 
     0.1 – 0.97 13,473 Assume units were mmol/L and multiplied by 1000. 
     1.01 - 7.1 7 
Assume units were mg/dL and multiplied by 59.48. 





     43 – 53 2 Assume units were µmol/dL and multipled by 10. 
     153 – 774 368 Assume units were µmol/L. 
mol/L (mol per litre) 57  
     0.33 – 0.76 12 
Assume units were mmol/L and multiplied by 1000. 
One measurement was removed as it was entered twice on the same date. 
     206 – 627 45 Assume units were µmol/L. 
mosmol/L (osmoles per litre) 1  
     685 1 Assume units were µmol/L. 
nmol/L (nano moles per litre) 3  
     0.46 – 0.47 2 
Assume units were mmol/L and multiplied by 1000. 
One measurement was removed as it was entered twice on the same date. 
     369 1 Assume units were µmol/L. 
pmol (picomole) 1  
      358 1 Assume units were µmol/L. 
pmol/L (picomole per litre) 9  
     227 – 577 9 Assume units were µmol/L. 
U (unit) 1  
     639 1 Assume units were µmol/L. 
U/L (units per litre) 1  
365 1 Assume units were µmol/L. 
μg/L (microgram per litre) 1  
     1 1 Cannot assume what the unit was thus remove reading. 
μmol (micro mole) 20  
     168 -773 20 Assume units were µmol/L. 
μmol/L (micromole per litre) 15,890  
     0.19 – 0.78 202 Assume units were mmol/L and multiplied by 1000. 
     43 – 93 5 The reading 43 was assumed, be µmol/dL and then multiplied by 10. 
The readings 89, 93, 80, and 87 were assumed, be µmol/L. 
     102 – 995 15,680 Assume units were µmol/L. 
     1046 – 3070 3 One measurement should be 307.  
Otherwise assume units were µmol/L. 





     363 – 532 2 Assume units were µmol/L. 
microU/L (micro unit per litre) 19  
     275 – 592 19 Assume units were µmol/L. 
mmol (millimole) 8  
     0.37 – 0.5 6 Assume units were mmol/L and multiplied by 1000. 
     308 – 401 2 Assume units were µmol/L. 
mmol/mmol (micromole per micromole) 1  
     0.51 1 Assume units were mmol/L and multiplied by 1000. 
M 1  
     526 1 Assume units were µmol/L. 










 Cleaning of allopurinol prescription data 
Table F1 and Table F2 describes the distribution of numeric daily dose and quantity of drugs before and after imputing missing data.  
Table F1: Distribution of numeric daily dose by quantity of drugs prior to imputing missing data 
 Numeric daily dose 
Quantity 0.5 1 1.5 2 2.5 3 4 5 6 Missing Total 
7 7 12,943 0 0 0 5 0 0 0 1,522 14,477 
14 79 180 0 1,246 0 0 0 0 0 1,128 2,633 
28 504 146,493 2 411 0 152 5 0 0 9,438 157,005 
30 3 6,854 2 10 0 2 0 0 0 231 7,102 
56 36 74,214 187 27,154 0 217 30 0 0 9,641 111,479 
60 0 8,316 25 1,486 0 5 0 0 0 562 10,394 
84 26 15,033 49 1,341 29 2,827 0 0 3 1,627 20,935 
90 0 779 0 45 0 53 9 0 0 77 963 
100 3 4,485 39 1,270 7 152 4 0 3 971 6,934 
112 0 518 6 12,671 0 84 312 0 0 2,201 15,792 
120 0 117 2 878 0 6 3 0 0 159 1,165 
140 0 2 0 4 0 0 0 5 0 2 13 
150 0 2 0 0 0 0 0 0 0 5 7 
168 0 237 2 1,252 2 495 4 0 25 290 2,307 
180 0 28 0 89 0 15 0 0 0 4 136 
Missing 12 1,760 30 759 6 88 85 0 1 507 3,248 






Table F2: Distribution of numeric daily dose by quantity of drugs after imputing missing data 
 Numeric daily dose 
Quantity 0.5 1 1.5 2 2.5 3 4 5 6 Missing Total 
7 7 13,971 0 0 0 5 0 0 0 498 14,481 
14 80 196 0 2,379 0 0 0 0 0 1 2,656 
28 517 153,425 2 498 0 152 5 0 0 3,861 158,460 
30 3 7,046 2 12 0 2 0 0 0 101 7,166 
56 36 80,137 217 27,522 0 217 30 0 0 3,948 112,107 
60 0 8,862 25 1,505 0 5 0 0 0 73 10,470 
84 26 16,396 48 1,397 35 2,921 0 0 3 388 21,213 
90 0 859 0 46 0 53 9 0 0 2 969 
100 3 5,422 39 1,452 7 152 4 0 3 225 7,307 
112 0 532 6 14,401 0 84 397 0 0 536 15,956 
120 0 119 2 988 0 6 3 0 0 55 1,173 
140 0 2 0 6 0 0 0 5 0 0 13 
150 0 2 0 5 0 0 0 0 0 0 7 
168 0 238 2 1,483 2 495 4 0 26 116 2,368 
180 0 29 0 93 0 15 0 0 0 0 137 
Missing 0 0 0 0 0 0 0 0 0 107 107 





 Cleaning of BMI measurements 
The process of removing implausible height, weight and body mass index (BMI) values was 
described below (Bhaskaran et al., 2013). 
Weight measurements below 20kg and height measurements below 121cm were removed as 
they were deemed implausible values. Bhaskaran et al. (2013) removed height measurements 
above 214 cm however this cut off was increased in this thesis to 219cm as one patient had a 
height of 218cm which was recorded multiple times thus appeared to be plausible. 
BMI was then calculated for patients who had height and weight recorded on the same day. 
If patients had different values of BMI on one day, it was checked if the BMI values were 
plausible by comparing it to previous recordings; if a decision could not be made on which 
BMI was plausible, a value was chosen at random.  
For the remaining weight measurements that had no height recorded on the same day, if 
weight was recorded multiple times on the same day, then it was checked if the weight 
measurements were plausible and if it could not be decided which measurement was the most 
plausible then one was picked at random. The process was repeated for the height 
measurements.  
BMI was then calculated using the most recent height record prior to recording of weight. For 
the remaining weight records, BMI was calculated using height that was recorded afterwards. 
Next, BMI that was automatically generated in Vision software was used.  







 Distribution of baseline covariates 
Table H1: Distribution of baseline covariates of eligible patients for each outcome analysis 
Baseline covariates Whole study 
sample* 




Number of patients 16,876 1,742 14,087 16,644 
Demographics     
Age (Mean (SD)) 18-101 62.1 (14.7) 59.4 (14.3) 63.6 (14.3) 61.9 (14.8) 
Sex: Female 3,881 (23) 361 (21) 3,475 (25) 3,796 (23) 
Deprivation (Mean (SD)) 9.1 (5.5) 9.0 (5.6) 9.3 (5.5) 9.1 (5.5) 
Comorbidities     
Anxiety 672 (4) 58 (3) 586 (4) 663 (4) 
Depression 842 (5) 84 (5) 749 (5) 826 (5) 
Cerebrovascular disease 407 (2) 40 (2) 1,936 (14) 2,136 (13) 
Coronary heart disease 2,167 (13) 236 (14) 369 (3) 399 (2) 
Diabetes  1,047 (6) 107 (6) 947 (7) 1,024 (6) 
Hyperlipidaemia 783 (5) 83 (5) 687 (5) 768 (5) 
Hypertension 3,137 (19) 371 (21) 2,758 (20) 3,064 (18) 
Osteoarthritis  1,106 (7) 129 (7) 1,011 (7) 1,011 (6) 
Peripheral vascular disease 257 (2) 22 (1) 240 (2) 252 (2) 
Renal disease 217 (1) 28 (1) 190 (1) 210 (1) 
Lifestyle factors     
Alcohol consumption     
   Ever drinker 9,488 (56) 1,048 (60) 7,993 (57) 9,343 (56) 
   Never drinker 856 (5) 61 (4) 777 (6) 841 (5) 
   Missing 6,532 (39) 633 (36) 5,317 (38) 6,460 (39) 
Body mass index     
   Normal weight 2,517 (15) 183 (11) 2,171 (15) 2,487 (15) 
   Overweight 4,933 (29) 535 (31) 4,185 (30) 4,861 (29) 
   Obese 3,219 (19) 416 (24) 2,744 (19) 3,160 (19) 
   Missing 6,207 (37) 608 (35) 4,987 (35) 6,136 (37) 
Smoking status     
   Ever smoker 6,436 (38) 773 (44) 5,532 (39) 6,349 (38) 
   Never smoker 4,847 (29) 423 (24) 4,038 (29) 4,767 (29) 
   Missing 5,593 (33) 546 (31) 4,517 (32) 5,528 (33) 
SU level     
   ≤360µmol/L 951 (6) N/A 814 (6) 937 (6) 
   >360µmol/L 6,062 (36) 497.6 (74.3)a 5,023 (36) 5,977 (36) 
   Missing 9,863 (58) 0 (0.00) 8,250 (59) 9,730 (58) 
Medication use     
Analgesics 5,578 (33) 603 (65) 5,017 (36) 5,402 (32) 
Colchicine 389 (2) 70 (4) 343 (2) 387 (2) 
Diuretics 6,142 (36) 638 (37) 5,479 (39) 5,998 (36) 
NSAIDS 8,024 (48) 1,078 (62) 6,824 (48) 7,843 (47) 
*The study sample was eligible for analysis of outcomes mortality and repeated gout consultations; aMean (SD) 
presented and ranged from 361 to 905; NSAIDS: Non-steroidal anti-inflammatory drugs; SD: Standard deviation; 













Number of patients 16,253 14,063 16,519 16,508 
Demographics     
Age (Mean (SD)) 61.6 (14.7) 60.5 (14.9) 61.9 (14.8) 61.9 (14.7) 
Sex: Female 3,687 (23) 3,137 (22) 3,784 (23) 3,752 (23) 
Deprivation (Mean (SD)) 9.1 (5.5) 9.0 (5.5) 9.1 (5.5) 9.1 (5.5) 
Comorbidities     
Anxiety 634 (4) 540 (4) 661 (4) 662 (4) 
Depression 788 (5) 678 (5) 823 (5) 825 (5) 
Cerebrovascular disease  271 (2) 2,064 (12) 2,064 (13) 
Coronary heart disease 2,015 (12)  385 (2) 396 (2) 
Diabetes  972 (6) 742 (5) 986 (6) 967 (6) 
Hyperlipidaemia 732 (5) 483 (3) 749 (5) 744 (5) 
Hypertension 2,939 (18) 2,281 (16) 3,039 (18) 3,027 (18) 
Osteoarthritis  1,057 (7) 867 (6) 1,059 (6) 1,068 (6) 
Peripheral vascular disease 231 (1) 160 (1)  233 (1) 
Renal disease 204 (1) 143 (1) 197 (1)  
Lifestyle factors     
Alcohol consumption     
   Ever drinker 9,140 (56) 7,662 (54) 9,278 (56) 9,284 (56) 
   Never drinker 813 (5) 642 (5) 828 (5) 829 (5) 
   Missing 6,300 (39) 5,759 (41) 6,413 (39) 6,395 (39) 
Body mass index     
   Normal weight 2,402 (15) 2,058 (15) 2,444 (15) 2,455 (15) 
   Overweight 4,751 (29) 3,928 (28) 4,813 (29) 4,825 (29) 
   Obese 3,113 (19) 2,541 (18) 3,169 (19) 3,129 (19) 
   Missing 5,987 (37) 5,536 (39) 6,093 (37) 6,099 (37) 
Smoking status     
   Ever smoker 6,170 (38) 5,079 (36) 6,219 (38) 6,281 (38) 
   Never smoker 4,669 (29) 4,029 (29) 4,786 (29) 4,729 (29) 
   Missing 5,414 (33) 4,955 (35) 5,514 (33) 5,498 (33) 
SU level     
   ≤360µmol/L 915 (6) 830 (6) 931 (6) 946 (6) 
   >360µmol/L 5,843 (36) 4,916 (35) 5,917 (36) 5,894 (36) 
   Missing 9,495 (58) 8,317 (59) 9,671 (59) 9,668 (59) 
Medication use     
Analgesics 5,259 (32) 4,260 (30) 5,366 (32) 5,371 (33) 
Colchicine 368 (2) 295 (2) 376 (2) 367 (2) 
Diuretics 5,725 (35) 4,382 (31) 5,938 (36) 5,855 (35) 
NSAIDS 7,749 (48) 6,661 (47) 7,840 (47) 7,854 (48) 
The whole study sample was eligible for analysis of outcomes mortality and repeated gout consultations; NSAIDS: 






 Distribution of baseline PS and imbalanced covariates within subclasses 
Figure I1: Mortality 
 
Dotted lines indicate at which propensity scores subclasses (S) were created. 
Standardised mean difference >0.10 was observed in covariates;  
S1: Sex, alcohol consumption, BMI, and NSAIDS 




Figure I2: Gout consultation 
 
Dotted lines indicate at which propensity scores subclasses (S) were created. 
Standardised mean difference >0.10 was observed in covariates;  









Figure I3: Gout hospitalisation 
 
Dotted lines indicate at which propensity scores subclasses (S) were created. 
Standardised mean difference >0.10 was observed in covariates;  
S1: Sex, alcohol consumption, BMI, and SU level 




Figure I4: Joint replacement 
 
Dotted lines indicate at which propensity scores subclasses (S) were created. 
Standardised mean difference >0.10 was observed in covariates;  
S1: Sex, alcohol consumption, and SU level 









Figure I5: Cerebrovascular disease 
 
Dotted lines indicate at which propensity scores subclasses (S) were created. 
Standardised mean difference >0.10 was observed in covariates;  
S1: Sex, alcohol consumption, smoking status, and SU level 





Figure I6: Coronary heart disease 
 
Dotted lines indicate at which propensity scores subclasses (S) were created. 
Standardised mean difference >0.10 was observed in covariates;  
S1: Sex, cerebrovascular disease, BMI, SU level, and colchicine  










Figure I7: Peripheral vascular disease 
 
Dotted lines indicate at which propensity scores subclasses (S) were created. 
Standardised mean difference >0.10 was observed in covariates;  
S1: Sex, alcohol consumption, BMI, and SU level 





Figure I8: Renal disease 
 
Dotted lines indicate at which propensity scores subclasses (S) were created. 
Standardised mean difference >0.10 was observed in covariates;  
S1: Sex, alcohol consumption, BMI, SU level, and colchicine  
S2: Sex 








 Assessment for proportional hazards 
Figure J1: Target serum urate level (unadjusted Cox model) 
 









Figure J3: Renal disease (unadjusted Cox model) 
 
 























 Distribution of covariates over time  
















0 (N=16,876) 62.1 (14.7) 3,881 (23) 9.1 (5.5) 672 (4) 842 (5) 407 (2) 2,167 (13) 1,047 (6) 0 (0) 
1 (N=15,873) 62.6 (14.5) 3,608 (23) 9.1 (5.5) 862 (5) 1,106 (7) 550 (3) 2,569 (16) 1,239 (8) 5,541 (35) 
2 (N=14,888) 63.2 (14.3) 3,314 (22) 9.1 (5.5) 1,005 (7) 1,259 (8) 622 (4) 2,805 (19) 1,369 (9) 2,571 (17) 
3 (N=14,033) 63.7 (14.1) 3,068 (22) 9.1 (5.5) 1,137 (8) 1,384 (10) 677 (5) 2,950 (21) 1,531 (11) 2,342 (17) 
4 (N=13,207) 64.2 (13.9) 2,837 (21) 9.0 (5.5) 1,216 (9) 1,473 (11) 730 (6) 3,025 (23) 1,659 (13) 2,159 (16) 
5 (N=12,391) 64.7 (13.7) 2,602 (21) 9.0 (5.5) 1,274 (10) 1,547 (12) 734 (6) 3,019 (24) 1,728 (14) 1,853 (15) 
6 (N=11,657) 65.3 (13.6) 2,404 (21) 9.0 (5.5) 1,303 (11) 1,598 (14) 744 (6) 3,003 (26) 1,788 (15) 1,688 (14) 
7 (N=10,777) 65.8 (13.4) 2,173 (20) 9.0 (5.5) 1,294 (12) 1,577 (15) 715 (7) 2,852 (26) 1,815 (17) 1,499 (14) 
8 (N=9,933) 66.3 (13.2) 1,965 (20) 8.9 (5.5) 1,281 (13) 1,578 (16) 692 (7) 2,720 (27) 1,849 (19) 1,307 (13) 
9 (N=9,128) 66.8 (13.0) 1,764 (19) 8.9 (5.5) 1,247 (14) 1,557 (17) 688 (8) 2,560 (28) 1,836 (20) 1,177 (13) 
10 (N=8,126) 67.3 (12.7) 1,521 (19) 8.9 (5.6) 1,177 (14) 1,462 (18) 645 (8) 2,316 (29) 1,743 (21) 960 (12) 
11 (N=6,918) 67.8 (12.4) 1,255 (18) 8.8 (5.6) 1,055 (15) 1,279 (18) 561 (8) 1,985 (29) 1,552 (22) 824 (12) 
12 (N=4,764) 68.0 (12.2) 812 (17) 9.0 (5.6) 767 (16) 889 (19) 386 (8) 1,412 (30) 1,116 (23) 550 (12) 
13 (N=3,159) 68.3 (11.9) 517 (16) 9.1 (5.6) 539 (17) 598 (19) 260 (8) 918 (29) 758 (24) 346 (11) 
14 (N=2,019) 68.9 (11.6) 302 (15) 9.1 (5.6) 342 (17) 405 (20) 179 (9) 591 (29) 489 (24) 218 (11) 
15 (N=1,107) 69.4 (11.5) 165 (15) 8.9 (5.6) 193 (17) 229 (21) 101 (9) 321 (29) 258 (23) 93 (8) 






      Alcohol consumption 
Follow-up 
year 




Renal disease Ever-drinker Never drinker Missing 
0 (N=16,876) 783 (5) 3,137 (19) 1,106 (7) 257 (2) 217 (1) 9,488 (56) 856 (5) 6,532 (39) 
1 (N=15,873) 1,171 (7) 3,922 (25) 1,584 (10) 315 (2) 310 (2) 9,882 (62) 784 (5) 5,207 (33) 
2 (N=14,888) 1,493 (10) 4,420 (30) 1,876 (13) 348 (2) 359 (2) 9,959 (67) 728 (5) 4,201 (28) 
3 (N=14,033) 1,765 (13) 4,802 (34) 2,090 (15) 379 (3) 404 (3) 9,984 (71) 677 (5) 3,372 (24) 
4 (N=13,207) 2,020 (15) 5,077 (38) 2,253 (17) 377 (3) 550 (4) 9,892 (75) 608 (5) 2,707 (20) 
5 (N=12,391) 2,248 (18) 5,275 (43) 2,360 (19) 377 (3) 970 (8) 9,634 (78) 560 (5) 2,197 (18) 
6 (N=11,657) 2,403 (21) 5,372 (46) 2,459 (21) 390 (3) 1,334 (11) 9,347 (80) 506 (4) 1,804 (15) 
7 (N=10,777) 2,475 (23) 5,263 (49) 2,470 (23) 366 (3) 1,559 (14) 8,850 (82) 462 (4) 1,465 (14) 
8 (N=9,933) 2,528 (25) 5,107 (51) 2,417 (24) 364 (4) 1,756 (18) 8,329 (84) 409 (4) 1,195 (12) 
9 (N=9,128) 2,499 (27) 4,933 (54) 2,333 (26) 338 (4) 1,886 (21) 7,762 (85) 373 (4) 993 (11) 
10 (N=8,126) 2,364 (29) 4,561 (56) 2,180 (27) 319 (4) 1,858 (23) 7,027 (86) 319 (4) 780 (10) 
11 (N=6,918) 2,109 (30) 3,997 (58) 1,930 (28) 268 (4) 1,633 (24) 6,081 (88) 257 (4) 580 (8) 
12 (N=4,764) 1,507 (32) 2,813 (59) 1,373 (29) 170 (4) 1,130 (24) 4,258 (89) 180 (4) 326 (7) 
13 (N=3,159) 1,023 (32) 1,893 (60) 940 (30) 117 (4) 749 (24) 2,858 (90) 116 (4) 185 (6) 
14 (N=2,019) 662 (33) 1,227 (61) 629 (31) 72 (4) 480 (24) 1,847 (91) 72 (4) 100 (5) 
15 (N=1,107) 352 (32) 665 (60) 360 (33) 40 (4) 264 (24) 1,032 (93) 34 (3) 41 (4) 







 Body mass index Smoking status 
Follow-up 
years 
Normal weight Overweight Obese Missing Ever smoker Never smoker Missing 
0 (N=16,876) 2,517 (15) 4,933 (29) 3,219 (19) 6,207 (37) 6,436 (38) 4,847 (29) 5,593 (33) 
1 (N=15,873) 2,482 (16) 4,967 (31) 3,364 (21) 5,060 (32) 7,047 (44) 4,479 (28) 4,347 (27) 
2 (N=14,888) 2,427 (16) 4,914 (33) 3,416 (23) 4,131 (28) 7,424 (50) 4,236 (28) 3,228 (22) 
3 (N=14,033) 2,383 (17) 4,813 (34) 3,495 (25) 3,342 (24) 7,747 (55) 4,050 (29) 2,236 (16) 
4 (N=13,207) 2,290 (17) 4,670 (35) 3,541 (27) 2,706 (20) 7,894 (60) 3,766 (29) 1,547 (12) 
5 (N=12,391) 2,166 (17) 4,528 (37) 3,560 (29) 2,137 (17) 7,827 (63) 3,538 (29) 1,026 (8) 
6 (N=11,657) 2,089 (18) 4,338 (37) 3,565 (31) 1,665 (14) 7,667 (66) 3,371 (29) 619 (5) 
7 (N=10,777) 1,942 (18) 4,104 (38) 3,426 (32) 1,305 (12) 7,304 (68) 3,113 (29) 360 (3) 
8 (N=9,933) 1,797 (18) 3,818 (38) 3,291 (33) 1,027 (10) 6,851 (69) 2,856 (29) 226 (2) 
9 (N=9,128) 1,633 (18) 3,529 (39) 3,125 (34) 841 (9) 6,378 (70) 2,599 (28) 151 (2) 
10 (N=8,126) 1,478 (18) 3,130 (39) 2,874 (35) 644 (8) 5,719 (70) 2,313 (28) 94 (1) 
11 (N=6,918) 1,252 (18) 2,676 (39) 2,527 (37) 463 (7) 4,917 (71) 1,946 (28) 55 (1) 
12 (N=4,764) 891 (19) 1,858 (39) 1,751 (37) 264 (6) 3,425 (72) 1,310 (27) 29 (1) 
13 (N=3,159) 576 (18) 1,236 (39) 1,183 (37) 164 (5) 2,270 (72) 874 (28) 15 (0) 
14 (N=2,019) 375 (19) 795 (39) 764 (38) 85 (4) 1,461 (72) 550 (27) 8 (0) 
15 (N=1,107) 213 (19) 423 (38) 428 (39) 43 (4) 805 (73) 298 (27) 4 (0) 






 SU level     
Follow-up 
years (N) 
≤360μmol/L >360μmol/L Missing Analgesics Colchicine Diuretics NSAIDS 
0 (N=16,876) 951 (6) 6,062 (36) 9,863 (58) 5,578 (33) 3,881 (23) 6,142 (36) 8,024 (48) 
1 (N=15,873) 910 (6) 5,734 (36) 9,229 (58) 4,908 (31) 3,608 (23) 4,874 (31) 12,340 (78) 
2 (N=14,888) 879 (6) 5,372 (36) 8,637 (58) 4,207 (28) 3,314 (22) 4,286 (29) 6,178 (41) 
3 (N=14,033) 844 (6) 5,066 (36) 8,123 (58) 4,026 (29) 3,068 (22) 4,103 (29) 5,849 (42) 
4 (N=13,207) 808 (6) 4,786 (36) 7,613 (58) 3,931 (30) 2,837 (21) 3,897 (30) 5,471 (41) 
5 (N=12,391) 763 (6) 4,514 (36) 7,114 (57) 3,798 (31) 2,602 (21) 3,625 (29) 4,975 (40) 
6 (N=11,657) 710 (6) 4,250 (36) 6,697 (57) 3,684 (32) 2,404 (21) 3,387 (29) 4,557 (39) 
7 (N=10,777) 659 (6) 3,913 (36) 6,205 (58) 3,461 (32) 2,173 (20) 3,050 (28) 4,059 (38) 
8 (N=9,933) 605 (6) 3,577 (36) 5,751 (58) 3,252 (33) 1,965 (20) 2,757 (28) 3,544 (36) 
9 (N=9,128) 542 (6) 3,295 (36) 5,291 (58) 3,109 (34) 1,764 (19) 2,428 (27) 3,167 (35) 
10 (N=8,126) 484 (6) 2,885 (36) 4,757 (59) 2,729 (34) 1,521 (19) 2,098 (26) 2,710 (33) 
11 (N=6,918) 412 (6) 2,401 (35) 4,105 (59) 2,367 (34) 1,255 (18) 1,743 (25) 2,261 (33) 
12 (N=4,764) 252 (5) 1,469 (31) 3,043 (64) 1,641 (34) 812 (17) 1,161 (24) 1,540 (32) 
13 (N=3,159) 158 (5) 862 (27) 2,139 (68) 1,103 (35) 517 (16) 779 (25) 1,009 (32) 
14 (N=2,019) 87 (4) 497 (25) 1,435 (71) 692 (34) 302 (15) 484 (24) 630 (31) 
15 (N=1,107) 31 (3) 226 (20) 850 (77) 356 (32) 165 (15) 249 (22) 343 (31) 
16 (N=475) 10 (2) 87 (18) 378 (80) 151 (32) 66 (14) 98 (21) 136 (29) 






 Time-varying PS model specification and distribution 
Table L1: PS model specification for mortality analysis 
PS model specification 
Median PS (IQR) 
(Range) 
Number of intervals outside the region of common 
support 








Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, 
follow-up time 
0.003 (0.002, 0.06) 
(8*10-5, 0.99) 
0.93 (0.66, 0.99) 
(0.01, 0.99) 
76,177 (69%) 702 (2%) 76,879 (49%) 
2 
Main effects model 
+ FP1 terms for deprivation(0), cumulative allopurinol use(0.5), follow-
up time(3) 
+ linear term for age 
0.01 (0.01, 0.06) 
(3*10-4, 0.99) 
0.92 (0.67, 0.98) 
(0.01, 0.99) 
48,406 (44%) 1,132 (2%) 49,538 (32%) 
 
3 
Main effects model 
+ FP2 terms for age(3, 3), deprivation(-2, -1), cumulative allopurinol 
use(1, 2), follow-up time(3, 3) 
0.01 (0.004, 0.06) 
(2*10-4, 0.99) 
0.93 (0.70, 0.98) 
(0.01, 0.99) 
61,767 (56%) 6,797 (15%) 68,564 (44%) 
4 
Main effects model 
+ FP2 term for age(3, 3), deprivation(-2, -1) 
+ FP1 term for cumulative allopurinol use(0.5) 
+ linear terms for follow-up time 
0.01 (0.01, 0.06) 
(2*10-4, 0.99) 
0.92 (0.67, 0.98) 
(0.01, 0.99) 
28,739 (26%) 398 (1%) 29,137 (19%) 
5 
Main effects model 
+ FP2 term for age(3, 3), deprivation(-2, -1) 
+ FP1 term for cumulative allopurinol use(0.5) 
+ linear terms for follow-up time  
+ SU level*NSAIDS 
0.01 (0.01, 0.06) 
(2*10-4, 0.99) 
0.92 (0.67, 0.98) 
(0.01, 0.99) 
22,520 (21%) 395 (1%) 22,915 (15%) 
6 
Main effects model 
+ FP2 term for age(3, 3), deprivation(-2, -1) 
+ FP1 term for cumulative allopurinol use(0.5) 
+ linear terms for follow-up time  
+ SU level*NSAIDS 
+ SU level*hypertension 
0.01 (0.01, 0.06) 
(2*10-4, 0.99) 
0.92 (0.67, 0.98) 
(0.01, 0.99) 






Main effects model 
+ FP2 term for age(3, 3), deprivation(-2, -1) 
+ FP1 term for cumulative allopurinol use(0.5) 
+ linear terms for follow-up time  
+ SU level*NSAIDS 
+ SU level*hypertension 
+ diuretics*sex 
0.01 (0.01, 0.06) 
(1*10-4, 0.99) 
0.92 (0.67, 0.98) 
(0.004, 0.99) 
13,152 (12%) 457 (1%) 13,609 (9%) 
8 
Main effects model 
+ FP2 term for age(3, 3), deprivation(-2, -1) 
+ FP1 term for cumulative allopurinol use(0.5) 
+ linear terms for follow-up time  
+ SU level*NSAIDS 
+ SU level*hypertension 
+ diuretics*sex 
+ alcohol consumption*sex 
0.01 (0.01, 0.06) 
(2*10-4, 0.99) 
0.92 (0.68, 0.98) 
(0.003, 0.99) 
10,584 (10%) 683 (1%) 11,267 (7%) 
9 
Main effects model 
+ FP2 term for age(3, 3), deprivation(-2, -1) 
+ FP1 term for cumulative allopurinol use(0.5) 
+ linear terms for follow-up time  
+ SU level*NSAIDS 
+ SU level*hypertension 
+ diuretics*sex 
+ alcohol consumption*sex 
+ analgesic*sex 
0.01 (0.01, 0.06) 
(1*10-4, 0.99) 
0.92 (0.67, 0.98) 
(0.003, 0.99) 
10,217 (9%) 436 (1%) 10,653 (7%) 
Specification highlighted in green is the chosen PS model; Values in brackets indicate which fractional polynomial terms were used; FP1: Fractional polynomials of dimension 1; FP2: 

















Table L2: PS model specification for gout hospitalisation analysis 
PS model specification 
Median PS (IQR) 
(Range) 
Number of intervals outside the region of common 
support 
 








Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-up 
time 
0.002 (0.001, 0.04) 
(9*10-5, 0.99) 
0.94 (0.67, 0.99) 
(0.01, 0.99) 
63,658 (72%) 2,026 (6%) 65,684 (54%) 
2 
Main effects model 
+ FP1 terms for age(3), deprivation(3), cumulative allopurinol use(0.5), 
follow-up time(0.5) 
0.01 (0.01, 0.05) 
(3*10-4, 0.99) 
0.92 (0.67, 0.98) 
(0.01, 0.99) 
26,608 (30%) 2,671 (8%) 29,279 (24%) 
 
3 
Main effects model 
+ FP2 terms for age(-2, 3), deprivation(3, 3), cumulative allopurinol use(-0.5, 0), 
follow-up time(3, 3) 
0.01 (0.01, 0.04) 
(3*10-4, 0.99) 
0.92 (0.71, 0.98) 
(0.01, 0.99) 
23,549 (27%) 3,301 (10%) 26,850 (22%) 
4 
Main effects model 
+ FP2 terms for age(-2, 3), deprivation (3, 3), cumulative allopurinol use(-0.5, 0) 
+ FP1 term for follow-up time(0.5) 
0.01 (0.01, 0.04) 
(20*10-4, 0.98) 
0.92 (0.69, 0.98) 
(0.003, 0.99) 
17,771 (20%) 5,304 (16%) 23,075 (19%) 
5 
Main effects model 
+ FP2 terms for age(-2, 3), deprivation (3, 3), cumulative allopurinol use(-0.5, 0) 
+ FP1 term for follow-up time(0.5) 
+ SU level*NSAIDS 
0.01 (0.01, 0.04) 
(2*10-4, 0.98) 
0.92 (0.69, 0.98) 
(0.003, 0.99) 
9,541 (11%) 5,203 (16%) 14,744 (12%) 
6 
Main effects model 
+ FP2 terms for age(-2, 3), deprivation(3, 3), cumulative allopurinol use(-0.5, 0) 
+ FP1 term for follow-up time(0.5) 
+ SU level*NSAIDS 
+ renal disease*gout consultation 
0.01 (0.01, 0.04) 
(20*10-4, 0.99) 
0.92 (0.69, 0.98) 
(0.003, 0.99) 
9,076 (10%) 2,875 (9%) 11,951 (10%) 
7 
Main effects model 
+ FP2 terms for age(-2, 3), deprivation(3, 3), cumulative allopurinol use(-0.5, 0) 
+ FP1 term for follow-up time(0.5) 
+ SU level*NSAIDS 
+ renal disease*gout consultation 
+ diuretics*sex 
0.01 (0.01, 0.04) 
(2*10-4, 0.99) 
0.92 (0.69, 0.98) 
(0.003, 0.99) 








Main effects model 
+ FP2 terms for age(-2, 3), deprivation(3, 3), cumulative allopurinol use(-
0.5, 0) 
+ FP1 term for follow-up time(0.5) 
+ SU level*NSAIDS 
+ renal disease*gout consultation 
+ diuretics*sex 
+ diuretics*hyperlipidaemia  
0.01 (0.01, 0.04) 
(2*10-4, 0.99) 
0.92 (0.69, 0.98) 
(0.002, 0.99) 
6,639 (7%) 2,002 (6%) 8,641 (7%) 
Specification highlighted in green is the chosen PS model; Values in brackets indicate which fractional polynomial terms were used; FP1: Fractional polynomials of dimension 1; FP2: 













Table L3: PS model specification for joint replacement analysis 
PS model specification 
Median PS (IQR) 
(Range) 
Number of intervals outside the region of common 
support 








Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-
up time 
0.003 (0.002, 0.05) 
(1*10-4, 0.99) 
0.93 (0.67, 0.99) 
(0.01, 0.99) 
72,043 (69%) 2,542 (6%) 74,585 (50%) 
2 
Main effects model 
+ FP1 terms for age(-2), deprivation(3), cumulative allopurinol use(0.5), 
follow-up time(-2) 
0.01 (0.01, 0.06) 
(7*10-4, 0.99) 
0.91 (0.69, 0.98) 
(0.01, 0.99) 
22,985 (22%) 954 (2%) 23,939 (16%) 
 
3 
Main effects model 
+ FP2 terms for age(2, 3), deprivation(-2, 3), cumulative allopurinol use(1, 2), 
follow-up time(1, 1) 
0.01 (0.004, 0.05) 
(3*10-4, 0.99) 
0.92 (0.70, 0.98) 
(0.01, 0.99) 
56,524 (54%) 4,812 (11%) 61,336 (41%) 
4 
Main effects model 
+ FP2 terms for age(2, 3) 
+ FP1 terms for cumulative allopurinol use(0.5), follow-up time(-2) 
+ linear term for deprivation 
0.01 (0.01, 0.06) 
(50*10-4, 0.99) 
0.91 (0.69, 0.98) 
(0.01, 0.99) 
21,510 (21%) 830 (2%) 22,340 (15%) 
5 
Main effects model 
+ FP2 terms for age(2, 3) 
+ FP1 terms for cumulative allopurinol use(0.5), follow-up time(-2) 
+ linear term for deprivation 
+ colchicine*coronary heart disease 
0.01 (0.01, 0.06) 
(5*10-4, 0.99) 
0.91 (0.69, 0.98) 
(0.01, 0.99) 
19,283 (18%) 851 (2%) 20,134 (14%) 
6 
Main effects model 
+ FP2 terms for age(2, 3) 
+ FP1 terms for cumulative allopurinol use(0.5), follow-up time(-2) 
+ linear term for deprivation 
+ colchicine*coronary heart disease 
+ body mass index*osteoarthritis  
0.01 (0.01, 0.06) 
(5*10-4, 0.99) 
0.91 (0.6, 0.98) 
(0.01, 0.99) 









Main effects model 
+ FP2 terms for age(2, 3) 
+ FP1 terms for cumulative allopurinol use(0.5), follow-up time(-2) 
+ linear term for deprivation 
+ colchicine*coronary heart disease 
+ body mass index*osteoarthritis  
+ alcohol consumption*gout consultation 
0.01 (0.007, 0.061) 
(5*10-4, 0.99) 
0.91 (0.69, 0.97) 
(0.005, 0.99) 
15,979 (15%) 771 (2%) 16,750 (11%) 
8 
Main effects model 
+ FP2 terms for age(2, 3) 
+ FP1 terms for cumulative allopurinol use(0.5), follow-up time(-2) 
+ linear term for deprivation 
+ colchicine*coronary heart disease 
+ body mass index*osteoarthritis  
+ alcohol consumption*gout consultation 
+ diuretic*analgesic 
0.01 (0.01, 0.06) 
(4*10-4, 0.99) 
0.91 (0.69, 0.98) 
(0.01, 0.99) 
14,548 (14%) 617 (1%) 15,165 (10%) 
Specification highlighted in green is the chosen PS model; Values in brackets indicate which fractional polynomial terms were used; FP1: Fractional polynomials of dimension 1; FP2: 























Table L4: PS model specification for cerebrovascular disease analysis 
PS model specification 
Median PS (IQR) 
(Range) 
Number of intervals outside the region of common support 








Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-
up time 
0.003 (0.002, 0.05) 
(1*10-5, 0.99) 
0.93 (0.66, 0.99) 
(0.01, 0.99) 
70,628 (69) 756 (2%) 71,384 (49%) 
2 
Main effects model 
+ FP1 terms for age(-1), deprivation(-1), cumulative allopurinol use(0), 
follow-up time(0) 
0.003 (0.002, 0.05) 
(8*10-5, 0.99) 
0.93 (0.66, 0.99) 
(0.01, 0.99) 
72,162 (70%) 6,364 (15%) 78,526 (54%) 
3 
Main effects model 
+ FP2 terms for age(2, 3), deprivation(-1, 3), cumulative allopurinol use(0, 3), 
follow-up time(-2, -2) 
0.003 (0.002, 0.05) 
(6*10-5, 0.99) 
0.93 (0.68, 0.99) 
(0.01, 0.99) 
72,073 (70%) 10,061 (24%) 82,134 (57%) 
4 
Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-
up time 
+ sex*follow-up time 
0.003 (0.002, 0.05) 
(9*10-5, 0.99) 
0.93 (0.65, 0.99) 
(0.01, 0.99) 
71,439 (70%) 739 (2%) 72,178 (50%) 
Specification highlighted in green is the chosen PS model; Values in brackets indicate which fractional polynomial terms were used; FP1: Fractional polynomials of dimension 1; FP2: 






















Table L5: PS model specification for coronary heart disease analysis 
PS model specification 
Median PS (IQR) 
(Range) 
Number of intervals outside the region of common support 








Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-
up time 
0.003 (0.002, 0.049) 
(8.00*10-5, 0.999) 
0.914 (0.638, 0.984) 
(0.010, 0.999) 
58,716 (67%) 364 (1%) 59,080 (51%) 
2 
Main effects model 
+ FP1 terms for age(-2), deprivation(-1), follow-up time(0.5) 
+ linear term cumulative allopurinol use 
0.003 (0.002, 0.049) 
(9.00*10-5, 0.999) 
0.914 (0.638, 0.984) 
(0.009, 0.999) 
58,611 (69%) 375 (1%) 58,986 (51%) 
3 
Main effects model 
+ FP2 terms for age(2, 2), deprivation(-2 -2), cumulative allopurinol use(0, 1), 
follow-up time(-2, -0.5) 
0.003 (0.002, 0.047) 
(9.00*10-5, 0.997) 
0.917 (0.647, 0.983) 
(0.010, 0.999) 
58,687 (70%) 2,194 (7%) 60,881 (52%) 
4 
Main effects model 
+ FP2 terms for age(2, 2), deprivation(-2, -2), follow-up time(-2, -0.5) 
+ linear term for cumulative allopurinol use 
0.003 (0.002, 0.05) 
(7*10-5, 0.99) 
0.92 (0.64, 0.98) 
(0.009, 0.99) 
58,257 (69%) 534 (2%) 58,791 (50%) 
5 
Main effects model 
+ FP2 terms for age(2, 2), deprivation(-2, -2), follow-up time(-2, -0.5) 
+ linear term for cumulative allopurinol use 
+ smoking status*diuretics 
0.003 (0.002, 0.05) 
(8*10-5, 0.99) 
0.92 (0.64, 0.98) 
(0.008, 0.99) 
57,508 (68%) 498 (2%) 58,006 (50%) 
Specification highlighted in green is the chosen propensity model; Values in brackets indicate which fractional polynomial terms were used; FP1: Fractional polynomials of dimension 1; 




















Table L6: PS model specification for peripheral vascular disease analysis 
PS model specification 
Median PS (IQR) 
(Range) 
Number of intervals outside the region of common support 








Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-
up time 
 0.003 (0.002, 0.05) 
(9*10,5, 0.99)   
 0.93 (0.65, 0.99) 
(0.01, 0.99)    74,245 (70%)    1,079 (2%)    75,324 (50%)   
2 
Main effects model 
+ FP1 terms for age(-2), deprivation(0.5), cumulative allopurinol use(0.5), 
follow-up time(0) 
 0.02 (0.01, 0.07) 
(5*10,4, 0.99)   
 0.92 (0.66, 0.98) 
(0.01, 0.99)  2,616 (25%)    384 (1%)    27,100 (18%)   
3* 
Main effects model 
+ FP2 terms for age(1, 2), deprivation(0, 2), cumulative allopurinol use(-0.5, 
3), follow-up time(-0.5, 3) 
- - - - - 
4 
Main effects model 
+ FP2 terms for follow-up time(-0.5, 3) 
+ FP1 terms for age(-2), cumulative allopurinol use(0.5) 
+ linear terms for deprivation 
0.02 (0.01, 0.07) 
(5*10-4, 0.99) 
0.91 (0.66, 0.98) 
(0.01, 0.99) 
24,750 (23%) 569 (1%) 25,319 (17%) 
5 
Main effects model 
+ FP2 terms for follow-up time(-0.5, 3) 
+ FP1 terms for age(-2), cumulative allopurinol use(0.5) 
+ linear terms for deprivation 
+ smoking status*diuretics 
0.02 (0.01, 0.07) 
(6*10-4, 0.99) 
0.91 (0.67, 0.97) 
(0.01, 0.99) 
21,456 (20%) 371 (1%) 21,827 (15%) 
6 
Main effects model 
+ FP2 terms for follow-up time(-0.5, 3) 
+ FP1 terms for age(-2), cumulative allopurinol use(0.5) 
+ linear terms for deprivation 
+ smoking status*diuretics 
+ SU level*hypertension 
0.02 (0.01, 0.07) 
(5*10-4, 0.99) 
0.91 (0.66, 0.98) 
(0.01, 0.99) 
21,086 (20%) 342 (1%) 21,428 (14%) 
*Propensity score model did not converge; Specification highlighted in green is the chosen propensity model; Values in brackets indicate which fractional polynomial terms were used; FP1: 














Table L7: PS model specification for renal disease analysis 
PS model specification 
Median PS (IQR) 
(Range) 
Number of intervals outside the region of common support 








Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-
up time 
0.002 (0.001, 0.04) 
(9*10-5, 0.99) 
0.93 (0.66, 0.99) 
(0.01, 0.99) 
71,622 (73%) 1,871 (5%) 73,493 (54%) 
2 
Main effects model 
+ FP1 terms for age(0), deprivation(-1), cumulative allopurinol use(0.5), 
follow-up time(-2) 
0.01 (0.01, 0.05) 
(40*10-4, 0.99) 
0.91 (0.68, 0.97) 
(0.01, 0.99) 
22,481 (23%) 792 (2%) 23,273 (17%) 
3 
Main effects model 
+ FP2 terms for age(3, 3), deprivation(0.5, 2), cumulative allopurinol use(1, 
2), follow-up time(1, 1) 
0.01 (0.003, 0.04) 
(2*10-4, 0.99) 
0.92 (0.69, 0.98) 
(0.01, 0.99) 
53,895 (55%) 4,216 (11%) 58,111 (43%) 
4 
Main effects model 
+ FP1 terms for cumulative allopurinol use(0.5), follow-up time(-2) 
+ linear terms for age, deprivation 
0.01 (0.01, 0.05) 
(5*10-4, 0.99) 
0.91 (0.68, 0.97) 
(0.01, 0.99) 
25,972 (26%) 763 (2%) 26,735 (20%) 
5 
Main effects model 
+ FP1 terms for cumulative allopurinol use(0.5), follow-up time(-2) 
+ linear terms for age, deprivation 
+ SU level*colchicine 
0.01 (0.01, 0.05) 
(4*10-4, 0.99) 
0.91 (0.68, 0.97) 
(0.01, 0.99) 
21,211 (22%) 766 (2%) 21,977 (16%) 
6 
Main effects model 
+ FP1 terms for cumulative allopurinol use(0.5), follow-up time(-2) 
+ linear terms for age, deprivation 
+ SU level*colchicine 
+ SU level*body mass index 
0.01 (0.01, 0.05) 
(3*10-4, 0.99) 
0.91 (0.68, 0.97) 
(0.01, 0.99) 
20,998 (21%) 730 (2%) 21,728 (16%) 
Specification highlighted in green is the chosen propensity model; Values in brackets indicate which fractional polynomial terms were used; FP1: Fractional polynomials of dimension 1; 
















 Varying number of time-varying PS subclasses 
Table M1: PS and outcome distribution, imbalanced covariates in mortality analysis 
PS range  








Number to be 
analysed in 
outcome analysis 
Intervals N (%) 
Patients N (%)a 
Imbalanced 
covariatesb 
4 subclasses     




 2: 0.01, 0.04   1311 (39) 13 (1) 
 3: 0.04, 0.60   857 (26) 345 (21) 
 4: 0.60, 0.99 149 (4) 1272 (78) 
5 subclasses     




 2: 0.01, 0.02   870 (26) 0 (0) 
 3: 0.02, 0.14   1285 (38) 78 (5) 
 4: 0.14, 0.79   302 (9) 445 (27) 
 5: 0.79, 0.99  77 (2) 1107 (68) 
6 subclasses     




 2: 0.01, 0.01   670 (20) 0 (0) 
 3: 0.01, 0.04   988 (30) 13 (1) 
 4: 0.04, 0.28   716 (21) 116 (7) 
 5: 0.28, 0.89   246 (7) 503 (31) 
 6: 0.89, 0.99  44 (1) 998 (61) 
7 subclasses     





 2: 0.01, 0.01   592 (18) 0 (0) 
 3: 0.01, 0.02   660 (20) 2 (0) 
 4: 0.02, 0.10   1075 (32) 49 (3) 
 5: 0.10, 0.43   231 (7) 136 (8) 
 6: 0.44, 0.93   193 (6) 577 (35) 
 7: 0.93, 1.00   24 (1) 866 (53) 
Propensity score subclassification was performed on 155,331 intervals from 16,876 patients; Results highlighted 
in green indicated the number of subclasses used for outcome analysis; aAt least one interval from the patient 
would be included in outcome analysis; bOverall SMD >0.10 and assessed in subclasses with outcome occurring 















Number to be 
analysed in 
outcome analysis 
Intervals N (%) 
Patients N (%)a 
Imbalanced 
covariatesb 
4 subclasses     




 2: 0.01, 0.02   308 (33) 2 (0) 
 3: 0.02, 0.52   343 (37) 145 (14) 
 4: 0.52, 0.99 78 (8) 902 (86) 
5 subclasses     




 2: 0.01, 0.01   231 (25) 1 (0) 
 3: 0.01, 0.09   341 (37) 42 (4) 
 4: 0.09, 0.75   169 (18) 237 (23) 
 5: 0.75, 0.99   39 (4) 769 (73) 
6 subclasses     




 2: 0.01, 0.01   178 (19) 0 (0) 
 3: 0.01, 0.02   203 (22) 2 (0) 
 4: 0.02, 0.20   262 (28) 72 (7) 
 5: 0.20, 0.86   141 (15) 305 (29) 
 6: 0.86, 0.99   18 (2) 670 (64) 
7 subclasses     





 2: 0.01, 0.01   131 (14) 0 (0) 
 3: 0.01, 0.02   185 (20) 1 (0) 
 4: 0.02, 0.06   255 (28) 25 (2) 
 5: 0.06, 0.35   142 (15) 74 (7) 
 6: 0.35, 0.91   106 (11) 360 (34) 
 7: 0.91, 0.99 8 (1) 589 (56) 
Propensity score subclassification was performed on 122,068 intervals from 14,087 patients; Results highlighted 
in green indicated the number of subclasses used for outcome analysis; aAt least one interval from the patient 
would be included in outcome analysis; bOverall SMD >0.10 and assessed in subclasses with outcome occurring 















Number to be 
analysed in 
outcome analysis 
Intervals N (%) 
Patients N (%)a 
Imbalanced 
covariatesb 
4 subclasses     




 2: 0.01, 0.04   311 (45) 1 (0) 
 3: 0.04, 0.60   161 (23) 34 (11) 
 4: 0.60, 1.00   26 (4) 288 (89) 
5 subclasses     




 2: 0.01, 0.02   247 (36) 0 (0) 
 3: 0.02, 0.13   218 (32) 8 (2) 
 4: 0.13, 0.79   64 (9) 73 (23) 
 5: 0.80, 1.00   19 (3) 242 (75) 
6 subclasses     




 2: 0.01, 0.01   184 (27) 0 (0) 
 3: 0.01, 0.04   207 (30) 1 (0) 
 4: 0.04, 0.26   136 (20) 13 (4) 
 5: 0.26, 0.88   40 (6) 93 (29) 
 6: 0.88, 1.00   11 (2) 216 (67) 
7 subclasses     




 2: 0.01, 0.01   132 (19) 0 (0) 
 3: 0.01, 0.02   203 (29) 0 (0) 
 4: 0.02, 0.09   157 (23) 7 (2) 
 5: 0.09, 0.43   66 (10) 10 (3) 
 6: 0.43, 0.92   32 (5) 113 (35) 
 7: 0.92, 1.00   8 (1) 193 (60) 
Propensity score subclassification was performed on 147,881 intervals from 16,644 patients; Results highlighted 
in green indicated the number of subclasses used for outcome analysis; aAt least one interval from the patient 
would be included in outcome analysis; bOverall SMD >0.10 and assessed in subclasses with outcome occurring 


















Number to be 
analysed in 
outcome analysis 
Intervals N (%) 
Patients N (%)a 
Imbalanced 
covariatesb 
4 subclasses     





 2: 0.002, 0.02   820 (74) 0 (0) 
 3: 0.03, 0.60   118 (11) 67 (15) 
 4: 0.60, 0.99  27 (2) 371 (85) 
5 subclasses     




 2: 0.002, 0.004   333 (30) 0 (0) 
 3: 0.004, 0.14   594 (53) 8 (2) 
 4: 0.14, 0.79   69 (6) 103 (24) 
 5: 0.79, 0.99  14 (1) 327 (75) 
6 subclasses     




 2: 0.002, 0.003   199 (18) 0 (0) 
 3: 0.003, 0.02   680 (61) 0 (0) 
 4: 0.02, 0.30   82 (7) 27 (6) 
 5: 0.30, 0.89   54 (5) 149 (34) 
 6: 0.89, 1.00   9 (1) 262 (60) 
7 subclasses     




 2: 0.002, 0.003   127 (11) 0 (0) 
 3: 0.003, 0.005   321 (29) 0 (0) 
 4: 0.005, 0.10   482 (43) 4 (1) 
 5: 0.010, 0.46   63 (6) 42 (10) 
 6: 0.46, 0.94   36 (3) 157 (36) 
 7: 0.94, 1.00   4 (0) 235 (54) 
Propensity score subclassification was performed on 145,108 intervals from 16,253 patients; Results highlighted 
in green indicated the number of subclasses used for outcome analysis; aAt least one interval from the patient 
would be included in outcome analysis; bOverall SMD >0.10 and assessed in subclasses with outcome occurring 


















Number to be 
analysed in 
outcome analysis 
Intervals N (%) 
Patients N (%)a 
Imbalanced 
covariatesb 
4 subclasses     





 2: 0.002, 0.01   1258 (60) 0 (0) 
 3: 0.01, 0.54   495 (24) 124 (14) 
 4: 0.54, 0.99 68 (3) 746 (86) 
5 subclasses     




 2: 0.002, 0.004   530 (25) 0 (0) 
 3: 0.004, 0.11   1168 (56) 12 (1) 
 4: 0.11, 0.74   143 (7) 186 (21) 
 5: 0.74, 0.99 39 (2) 672 (77) 
6 subclasses     




 2: 0.002, 0.003  283 (14) 0 (0) 
 3: 0.003, 0.01   1065 (51) 0 (0) 
 4: 0.01, 0.25   437 (21) 50 (6) 
 5: 0.25, 0.85   107 (5) 268 (31) 
 6: 0.85, 0.99 19 (1) 552 (63) 
7 subclasses     




 2: 0.001, 0.002   167 (8) 0 (0) 
 3: 0.002, 0.004   530 (25) 0 (0) 
 4: 0.004, 0.07   1023 (49) 4 (0) 
 5: 0.07, 0.40   115 (6) 78 (9) 
 6: 0.40, 0.91   81 (4) 348 (40) 
 7: 0.91, 0.99 9 (0) 440 (51) 
Propensity score subclassification was performed on 116,656 intervals from 14,063 patients; Results highlighted 
in green indicated the number of subclasses used for outcome analysis; aAt least one interval from the patient 
would be included in outcome analysis; bOverall SMD >0.10 and assessed in subclasses with outcome occurring 



















Number to be 
analysed in 
outcome analysis 
Intervals N (%) 
Patients N (%)a 
Imbalanced 
covariatesb 
4 subclasses     




 2: 0.01, 0.05   166 (38) 4 (2) 
 3: 0.05, 0.59   132 (31) 40 (20) 
 4: 0.59, 0.99  14 (3) 159 (78) 
5 subclasses     




 2: 0.01, 0.02   141 (33) 1 (0) 
 3: 0.02, 0.13   153 (35) 12 (6) 
 4: 0.13, 0.78   40 (9) 50 (25) 
 5: 0.78, 0.99 5 (1) 140 (69) 
6 subclasses     




 2: 0.007, 0.01   102 (24) 0 (0) 
 3: 0.01, 0.05   107 (25) 4 (2) 
 4: 0.05, 0.27   115 (27) 17 (8) 
 5: 0.27, 0.88   26 (6) 61 (30) 
 6: 0.88, 0.99 5 (1) 121 (60) 
7 subclasses     




 2: 0.01, 0.01   76 (18) 0 (0) 
 3: 0.01, 0.03   107 (25) 1 (0) 
 4: 0.03, 0.09   125 (29) 8 (4) 
 5: 0.09, 0.43   37 (9) 18 (9) 
 6: 0.43, 0.92   18 (4) 69 (34) 
 7: 0.92, 0.99 4 (1) 107 (53) 
Propensity score subclassification was performed on 150,151 intervals from 16,519 patients; Results highlighted 
in green indicated the number of subclasses used for outcome analysis; aAt least one interval from the patient 
would be included in outcome analysis; bOverall SMD >0.10 and assessed in subclasses with outcome occurring 



















Number to be 
analysed in 
outcome analysis 
Intervals N (%) 
Patients N (%)a 
Imbalanced 
covariatesb 
4 subclasses     





 2: 0.01, 0.03   1216 (48) 6 (0) 
 3: 0.03, 0.52   445 (18) 152 (11) 
 4: 0.52, 0.99 130 (5) 1226 (89) 
5 subclasses     




 2: 0.01, 0.01   1021 (40) 0 (0) 
 3: 0.01, 0.09   587 (23) 49 (4) 
 4: 0.09, 0.75   313 (12) 291 (21) 
 5: 0.75, 0.99 59 (2) 1044 (75) 
6 subclasses     




 2: 0.01, 0.01   712 (28) 0 (0) 
 3: 0.01, 0.03   800 (31) 6 (0) 
 4: 0.03, 0.21   311 (12) 88 (6) 
 5: 0.21, 0.85   227 (9) 345 (25) 
 6: 0.85, 0.99 37 (1) 945 (68) 
7 subclasses     




 2: 0.01, 0.01   537 (21) 0 (0) 
 3: 0.01, 0.02   814 (32) 2 (0) 
 4: 0.02, 0.06   371 (15) 27 (2) 
 5: 0.06, 0.36   263 (10) 88 (6) 
 6: 0.36, 0.90   158 (6) 416 (30) 
 7: 0.90, 0.99 20 (1) 851 (61) 
Propensity score subclassification was performed on 135,988 intervals from 16,508 patients; Results highlighted 
in green indicated the number of subclasses used for outcome analysis; aAt least one interval from the patient 
would be included in outcome analysis; bOverall SMD >0.10 and assessed in subclasses with outcome occurring 







 PS model specification 
Table N1: Specification of the PS score model for each outcome analysis 
Outcome PS model specification 
Target SU level  
1 
Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-up time, SU 
level 
2 
Main effects model 
+ FP1 terms for age(-2), deprivation (3), cumulative allopurinol use(0.5), follow-up time(-2), 
SU level(-0.5) 
3 
Main effects model 
+ FP2 terms for age(-2, -2), deprivation (1, 2), cumulative allopurinol use(-0.5, 0.5), follow-up 
time(-2, 0.5), SU level(-2 -2) 
4 
Main effects model 
+ FP2 terms for age(-2, -2), cumulative allopurinol use(-0.5, 0.5) 
+ FP1 terms for deprivation (3), SU level(-0.5) 
+ linear terms for follow-up time 
Mortality  
1 
Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-up time 
2 
Main effects model 
+ FP1 terms for age(3), deprivation (2), cumulative allopurinol use(0.5), follow-up time(-2) 
3 
Main effects model 
+ FP2 terms for age(3, 3), deprivation (2, 3), cumulative allopurinol use(-1, 0), follow-up 
time(-2, -2) 
4 
Main effects model 
+ FP2 terms for age(3, 3), deprivation (2, 3), cumulative allopurinol use(-1, 0) 
+ linear terms for follow-up time 
5 
Main effects model 
+ FP2 terms for age(3, 3), deprivation (2, 3), cumulative allopurinol use(-1, 0) 
+ linear terms for follow-up time 
+ interaction terms between SU level*hypertension 











Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-up time 
2 
Main effects model 
+ FP1 terms for age(3), cumulative allopurinol use(-0.5), follow-up time(-1) 
+ linear terms for deprivation 
3 
Main effects model 
+ FP2 terms for age(-2, 2), deprivation (3, 3), cumulative allopurinol use(-1, -0.5), follow-up 
time(0.5, 3) 
4 
Main effects model 
+ FP2 terms for deprivation (3, 3) 
+ FP1 terms for age(3), follow-up time(-1) 
+ linear terms for cumulative allopurinol use 
Joint replacement  
1 
Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-up time 
2 
Main effects model 
+ FP1 terms for age(3), cumulative allopurinol use(-0.5), follow-up time(-1) 
+ linear term for deprivation 
3 
Main effects model 
+ FP2 terms for age(-2, 3), deprivation (-0.5, 0), cumulative allopurinol use(-1, -0.5), follow-up 
time(0.5, 3) 
4 
Main effects model 
+ FP2 terms for deprivation (-0.5, 0) 
+ FP1 terms for follow-up time(-1) 
+ linear terms for age, cumulative allopurinol use 
5 
Main effects model 
+ FP2 terms for deprivation (-0.5, 0) 
+ FP1 terms for follow-up time(-1) 
+ linear terms for age, cumulative allopurinol use 













Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-up time 
2 
Main effects model 
+ FP1 terms for age(3), cumulative allopurinol use(-0.5), follow-up time(-2) 
+ linear term for deprivation 
3 
Main effects model 
+ FP2 terms for age(-2, 3), deprivation (3, 3), cumulative allopurinol use(-1, -0.5), follow-up 
time(-1, 3) 
4 
Main effects model 
+ FP2 terms for deprivation ( 3, 3) 
+ FP1 terms for cumulative allopurinol use(-0.5), follow-up time(-2) 
+ linear terms for age 
5 
Main effects model 
+ FP2 terms for deprivation ( 3, 3) 
+ FP1 terms for cumulative allopurinol use(-0.5), follow-up time(-2) 
+ linear terms for age  





Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-up time 
2 
Main effects model 
+ FP1 terms for age(3), deprivation (2), cumulative allopurinol use(-0.5), follow-up time(-1) 
3 
Main effects model 
+ FP2 terms for age(-2, 2), deprivation (0, 0), cumulative allopurinol use(-1, -0.5), follow-up 
time(-1, 3) 
4 
Main effects model 
+ FP2 terms for age(-2, 2), deprivation (0, 0), cumulative allopurinol use(-1, -0.5) 













Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-up time 
2 
Main effects model 
+ FP1 terms for age(3), cumulative allopurinol use(-0.5), follow-up time(-2) 
+ linear terms for deprivation 
3 
Main effects model 
+ FP2 terms for age(-2, 3), deprivation (3, 3), cumulative allopurinol use(-1, -0.5), follow-up 
time(-0.5, 3) 
4 
Main effects model 
+ FP2 terms for deprivation (3, 3) 
+ FP1 terms for follow-up time(-2) 
+ linear terms for age, cumulative allopurinol use 
5 
Main effects model 
+ FP2 terms for deprivation (3, 3) 
+ FP1 terms for follow-up time(-2) 
+ linear terms for age, cumulative allopurinol use 
+ interaction term SU level*cumulative allopurinol use 
Renal disease  
1 
Main effects model 
+ linear terms for age, deprivation, cumulative allopurinol use, follow-up time 
2 
Main effects model 
+ FP1 terms for age(3), deprivation (2), cumulative allopurinol use(-0.5), follow-up time(-2) 
3 
Main effects model 
+ FP2 terms for age(-2, 2), deprivation (0, 0.5), cumulative allopurinol use(-2, -0.5), follow-up 
time(0, 3) 
4 
Main effects model 
+ FP2 terms for deprivation (0, 0.5) 
+ FP1 terms for cumulative allopurinol use(-0.5), follow-up time(-2) 
+ linear terms for age 
5 
Main effects model 
+ FP2 terms for deprivation (0, 0.5) 
+ FP1 terms for cumulative allopurinol use(-0.5), follow-up time(-2) 
+ linear terms for age 
+ interaction term coronary heart disease*sex 
+ interaction term diabetes*sex 
Values in brackets indicate the fractional polynomials used; PS: Propensity score; SU: Serum urate 
 
 
